CREMA TRATTAMENTO PSORIASI OFFERTA -50% !

Home Blog Page 212

Psorilax:a cosa serve |crema psoriasi senza cortisone

0

Psorilax: prezzo, funziona, recensioni, opinioni, composizione

AbbVie Inc  (NYSE: ABBV) Q4 2019 Earnings Conference Call

February 07, 2020

Corporate Participants:

Liz SheaVice President of Investor Relations

Richard A. GonzalezChairman of the Board and Chief Executive Officer

Michael E. SeverinoVice Chairman and President

Robert A. MichaelExecutive Vice President and Chief Financial Officer

Analysts:

Geoffrey PorgesSVB Leerink — Analyst

Steve ScalaCowen — Analyst

Navin JacobUBS — Analyst

Terence FlynnGoldman Sachs — Analyst

Vamil DivanMizuho — Analyst

Randall StanickyRBC Capital Markets — Analyst

Tim AndersonWolfe Research — Analyst

Andrew BaumCiti — Analyst

David RisingerMorgan Stanley — Analyst

Presentation:

Operator

Good morning and thank you for standing by. Welcome to the AbbVie Fourth Quarter 2019 Earnings Conference Call. (Operator Instructions) I would now like to introduce Ms. Liz Shea, Vice President of Investor Relations.

Liz SheaVice President of Investor Relations

Good morning and thanks for joining us. Also on the call with me today are Rick Gonzalez, Chairman of the Board and Chief Executive Officer; Michael Severino, Vice Chairman and President; and Rob Michael, Executive Vice President and Chief Financial Officer.

Before we get started, I remind you that some statements we make today may be considered forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Additional information about these risks and uncertainties is included in our 2018 Annual Report and on Form 10-K, and in our other SEC filings. AbbVie undertakes no obligation to update these forward-looking statements, except as required by law.

On today’s conference call, as in the past, non-GAAP financial measures will be used to help investors understand AbbVie’s ongoing business performance. These non-GAAP financial measures are reconciled with comparable GAAP financial measures in our earnings release and regulatory filings from today, which can be found on our website. Please note that we have also posted a set of slides to our website to supplement some of the content we’ll be covering this morning. Following our prepared remarks, we’ll take your questions.

So with that, I’ll now turn call over to Rick.

Richard A. GonzalezChairman of the Board and Chief Executive Officer

Thank you, Liz. Good morning, everyone, and thank you for joining us today. I’ll discuss our fourth quarter and full year 2019 performance as well as our 2020 expectations for AbbVie on a standalone basis. We will provide combined AbbVie and Allergan guidance after the close of the planned transaction. Mike will then provide an update on recent advancements across our R&D programs, and Rob will discuss last year’s performance and our 2020 guidance in more detail. Following our remarks, we will take your questions.

We delivered another strong quarter with adjusted earnings per share exceeding the midpoint of our guidance. Our adjusted EPS of $2.21 represents growth of more than 16% versus the fourth quarter of 2018. Total adjusted operational sales growth of 5.3% was also ahead of our expectations for the quarter, driven by continued strong performance in both immunology and hematological oncology.

Our performance this quarter tops off another strong year for AbbVie. For the full year 2019, we delivered adjusted earnings per share growth of 13%. We have driven strong commercial, operational and R&D execution, which has allowed us to substantially grow through the impact of international biosimilar competition. We saw excellent performance in our hematological oncology business, which drove operational growth of more than 39% in the year.

We have built a substantial franchise with IMBRUVICA and VENCLEXTA, which combined nearly $5.5 billion in combined revenue with strong double-digit growth expected once again in 2020. IMBRUVICA remains the clear market share leader across all lines of therapy in CLL with a largest body of clinical evidence, a robust survival benefit and the highest category rating in treatment guidelines today, we remain confident that IMBRUVICA will be a significant growth contributor for many years to come. VENCLEXTA will also contribute substantially to our growth in 2020 with continued share expansion expected in both the broad relapsed/refractory and front-line CLL segments as well as continued penetration in front-line AML.

In our immunology business, the launches of SKYRIZI and RINVOQ are going exceptionally well. Both SKYRIZI and RINVOQ have demonstrated strong differentiated efficacy in their initial indications and we are making considerable progress to expand their uses in several additional immune-mediated diseases. SKYRIZI is already having an impact on AbbVie’s growth with sales of approximately $215 (Phonetic) million in the fourth quarter, which already equates to an annualized run rate approaching $900 million, and we expect robust growth in 2020. The launch execution has been nothing short of exceptional.

In a very short time frame, SKYRIZI has established the leading in-play psoriasis patient share, which includes both new and switch-in patients at roughly 25%. SKYRIZI is redefining the standard for efficacy and safety in the psoriasis market, where it’s not only demonstrated superiority to HUMIRA, the gold standard of care, but also outperformed other novel agents, including Cosentyx. SKYRIZI’s commercial access is now at parity to HUMIRA and above 95%.

While it’s still early in the launch, we’re also seeing robust demand trends for RINVOQ, which is performing well ahead of comparable analogs in the RA segment. In the first full quarter RINVOQ was on the market, we estimate more than 7,600 prescriptions were filled, including both paid prescriptions and those who received RINVOQ through our bridge access program. Based on this level of prescription volume, RINVOQ is currently capturing approximately 9% of in-play RA patients and has surpassed the in-play’s share for several other established brands. The cannibalization of HUMIRA market share in this segment remains very low thus far. Feedback from prescribing physicians has been very positive. And the strong benefit risk profile RINVOQ has demonstrated across our registrational trials has supported very rapid and broad formulary coverage for RINVOQ. Commercial access for RINVOQ is now at more than 95% and we expect paid prescription volume to increase significantly throughout 2020 as a result.

HUMIRA in the US continues to generate strong revenue, driving more than $1 billion of growth in 2019, and will remain a significant contributor to growth again in 2020. The international HUMIRA dynamics remain consistent with our expectations with 2019 revenues down roughly 28% on an operational basis.

Overall, I’m extremely pleased with the performance and the outlook for our immunology franchise. We had previously commented that SKYRIZI and RINVOQ would deliver more than $1 billion of revenue combined in 2020. Our 2020 guidance now contemplates that these two products will contribute approximately $1.7 billion in revenue together this year.

Since our inception, we have focused on building a robust pipeline and adding growth platforms that will allow AbbVie to absorb the eventual impact of biosimilar competition in US and maintain a strong and growing business. We continue to make excellent progress against that objective. As I just highlighted, the better-than-expected launch trajectories of SKYRIZI and RINVOQ, and the continued strong performance of our hematological oncology franchise has further increased our level of confidence that these platforms will drive significant growth over the long term.

Our R&D productivity over the past seven years has resulted in numerous new products, which collectively contributed approximately $9 billion in revenue in 2019. And our R&D pipeline continues to develop nicely with multiple programs well underway to expand the breadth of indications for SKYRIZI and RINVOQ, as well as the advancement of a significant number of early- and mid-stage programs, six of which will have proof of concept data readouts in 2020.

AbbVie’s R&D pipeline has been phase gated from the time we launched as an independent company back in 2013. Our initial priority was to develop next-generation assets that would be superior to HUMIRA and other competitive alternatives within our key immunology disease areas. And as you have seen, SKYRIZI and RINVOQ have demonstrated that type of performance across multiple clinical trials. Their successful launch trajectories demonstrate the value of these assets in two very large segments of immunology, which combined represent approximately 40% of US HUMIRA revenues today. We continue to rapidly progress the development of these assets in the remaining key HUMIRA disease areas as well as new indications, such as atopic dermatitis.

Our second priority was to build our hematological oncology franchise into a major growth engine for the Company. IMBRUVICA and VENCLEXTA have become roughly a $5.5 billion franchise, and growing rapidly. And we continue to expand these medicines into important new disease areas, such as multiple myeloma with VENCLEXTA in t(11;14) biomarker-defined patient population, and combination therapy with IMBRUVICA and VENCLEXTA, which have the potential to provide even deeper and more durable responses.

The third priority was the development of a robust early- and mid-stage pipeline, which now has nearly 40 clinical programs ongoing, including novel new mechanisms developed by AbbVie scientists as well as assets we are advancing across our many collaborations, such as Calico. The most advanced programs in our mid- to late-stage pipeline, which we expect to be approved by 2022, include navitoclax for myelofibrosis, ABBV-951 for the treatment of advanced Parkinson’s disease, and veliparib for the treatment of ovarian cancer and BRCA breast cancer. These approvals are on top of the numerous new opportunities expected for RINVOQ, SKYRIZI and VENCLEXTA. Over the same period of time, we anticipate approximately 30 proof of concept readouts from novel programs in our early-stage pipeline, which Mike will discuss momentarily. It is truly an exciting time for AbbVie science.

Another exciting aspect of our business is the planned acquisition of Allergan, which has significant strategic and financial merit. Allergan will provide AbbVie with highly valuable on-market assets with leadership positions across additional attractive growth segments, including new growth platforms in aesthetics and CNS neuroscience. The acquisition will further diversify AbbVie’s revenue and payer mix, and immediately accelerates the standalone scale of our non-HUMIRA business, the AbbVie growth platform, which is expected to drive high-single-digit annual growth revenue over the next decade and beyond.

The proposed acquisition is proceeding well. We recently received conditional approval from the European Commission. The FTC review continues to advance following the divestiture announcements for both Zenpep and Allergan’s IL-23. And we have completed the integration planning process, including confirmation of our synergy objectives. We remain on track for closing the Allergan transaction as expected in the first quarter of 2020.

We’ve entered 2020 with very strong momentum and we’re committed to delivering strong results, which is reflected in our guidance. We expect full year 2020 adjusted earnings per share of $9.61 to $9.71, representing growth of 8.1% at the midpoint. As I mentioned earlier, this guidance reflects AbbVie on a standalone basis. We will provide pro forma guidance for 2020, following the close of the Allergan transaction.

So in summary, as you can see from our 2019 results and our 2020 guidance, the performance of AbbVie’s business remains very strong. That performance combined with the late-stage pipeline, which includes more than 20 new medicines and major new disease indications as well as a robust early-stage pipeline gives us significant confidence in the future outlook of our Company. The AbbVie business will be even stronger and more diverse with the Allergan transaction. We look forward to another successful year and to welcoming our Allergan colleagues to the new AbbVie in the near future.

With that, I’ll turn the call over to Mike for additional comments on our R&D programs. Mike?

Michael E. SeverinoVice Chairman and President

Thank you, Rick. When we set out as an independent company, we knew that building a productive R&D engine was an essential part of our success and we’re proud of the progress we’ve made over the past seven years. We’ve built one of the strongest late-stage pipelines in our industry and brought to market six new assets, RINVOQ, SKYRIZI, IMBRUVICA, VENCLEXTA, MAVIRET and ORILISSA, which collectively delivered approximately $9 billion in sales in 2019. These assets are performing very well in their lead indications, and will drive significant growth for AbbVie over the long term, as we continue to build the body of evidence supporting their differentiated clinical profiles.

In immunology, both RINVOQ and SKYRIZI are off to a very strong start in rheumatoid arthritis and psoriasis, respectively. And we continue to generate clinical data sets that set them apart from competitive offerings. For example, we recently announced positive top line results from a Phase 3 head-to-head trial comparing SKYRIZI to Cosentyx in psoriasis. In this study, SKYRIZI demonstrated superiority to Cosentyx at week 52, with 87% of SKYRIZI patients achieving PASI 90 compared to 57% for Cosentyx.

SKYRIZI also demonstrated superiority to Cosentyx on all ranked secondary endpoints, including PASI 100, PASI 75 and sPGA clear or almost clear at week 52. These results underscore two critical components of SKYRIZI’s profile, the ability to drive high levels of response and the durability of that response at long-term endpoints.

In oncology, we will also continue to support our hem/onc franchise with important regulatory milestones and additional Phase 3 data readouts for our approved indications in 2020. We recently received a positive CHMP opinion for VENCLEXTA in previously untreated CLL. And we expect to receive an important label update for IMBRUVICA in the first half of this year based on results from the ECOG study, which demonstrated the superiority of IMBRUVICA to FCR in front-line fit patients with CLL.

When we think about sources of growth beyond the current indications for our recently approved assets, it’s important to consider two components of our late-stage pipeline. The first is a large number of programs that will allow us to drive our core assets into important new disease areas that represent large and attractive markets. And the second is a set of new assets that will help support additional growth in the future.

If we look first at our opportunity to move into new disease areas with our existing therapies, we see a number of commercially attractive programs that have been derisked based on strong data. For example, we recently announced top line results from the second Phase 3 study for RINVOQ in psoriatic arthritis which compared RINVOQ to both placebo and HUMIRA in patients who had an inadequate response to at least one non-biologic DMARD. In this study, both doses of RINVOQ met all primary and key secondary endpoints, demonstrating a significant impact on both joint and skin endpoints, as well as radiographic inhibition of damage to joint structure.

RINVOQ also demonstrated superiority to HUMIRA on ACR20 response at week 12 with the high dose and non-inferiority with the low dose. These data follow the positive results from our first registrational trial reported late last year. Detailed data from both pivotal studies will be presented at an upcoming medical meeting and we expect to submit our regulatory applications for RINVOQ in psoriatic arthritis in the second quarter with commercialization expected in 2021.

Following discussions with global regulators, our approval submissions in ankylosing spondylitis are planned for the second half of 2020 based on positive data already presented at ACR last November. In this study, RINVOQ demonstrated significantly greater improvements in signs and symptoms, as well as physical function and imaging endpoints compared to placebo. Together, psoriatic arthritis and ankylosing spondylitis make up an important segment of the rheumatology market with global market sales of approximately $14 billion.

The dermatology segment will also be an important area of growth for RINVOQ. Moderate to severe atopic dermatitis is a large market that we do not participate in today. And in the middle of this year, we expect to see Phase 3 data for RINVOQ in this indication. In our Phase 2b study, RINVOQ demonstrated a very strong effect on the easy composite endpoint and had a prominent impact on itch, which is one of the most troublesome symptoms of this disease.

Following the pivotal data readouts, we plan to submit global regulatory submissions later this year. We are also nearing completion of the registrational programs for SKYRIZI in several new disease areas. In the second half of this year, we expect to see data from Phase 3 studies in both psoriatic arthritis and Crohn’s disease with regulatory submissions for both indications expected in 2021.

The IBD segment, including both Crohn’s disease and ulcerative colitis, represents a significant opportunity with global market sales of approximately $18 billion. IBD is a growing segment, where there continues to be significant unmet need. And based on the efficacy demonstrated in our mid-stage studies, we believe both SKYRIZI and RINVOQ have the potential to drive higher levels of performance than other therapeutic alternatives. Together, we expect SKYRIZI and RINVOQ to have full coverage across the major disease areas for which HUMIRA is currently approved, plus new areas such as atopic dermatitis. With these two new medicines, AbbVie is well positioned to maintain its strong leadership in the $70 billion global immunology market.

Another growth asset that we expect to expand into important new areas is VENCLEXTA. CANOVA, our Phase 3 study in relapsed-refractory multiple myeloma patients with t(11;14) genetic mutation, is now well underway. And towards the end of this year, we plan to initiate a second Phase 3 study in the relapse/refractory t(11;14) population.

VENCLEXTA has the potential to become an important biomarker-driven treatment option in multiple myeloma. The transformed cells in t(11;14) patients have a B-cell-like phenotype and express high levels of BCL-2. We’ve seen very promising results in this population in early- and mid-stage trials with VENCLEXTA showing high overall response rates and prolonged progression-free survival. The level of efficacy that we’ve seen suggests that t(11;14) patients may be particularly responsive to VENCLEXTA. This biomarker-defined population makes up approximately 20% of the $18 billion multiple myeloma market, representing an important new opportunity for VENCLEXTA.

In addition to multiple myeloma, we will begin Phase 3 studies in two additional BCL-2 driven diseases in 2020. The first is AML. Building on our experience in the transplant and eligible population, we are initiating a study in fit patients with AML who have received stem cell transplant, but remain at high risk for recurrence.

The second is higher risk myelodysplastic syndrome or MDS. MDS is a malignant disease of bone marrow stem cells that is associated with significant morbidity and mortality due to the risk of bleeding, infection and transformation to acute leukemia. Some patients with MDS undergo stem cell transplant but many cannot, and these patients have very few treatment options. Pre-clinical and early clinical studies support a role for BCL-2 inhibition in these patients, and our Phase 3 studies with VENCLEXTA will begin later this year.

The second component of value in our late-stage pipeline includes important new therapies that we expect to launch in 2021 and 2022, including navitoclax, veliparib and ABBV-951. Navitoclax will be entering Phase 3 studies in the first half of this year in front-line and second-line myelofibrosis. Myelofibrosis is a malignant disease in which the bone marrow is replaced with fibrotic tissue leading to bone marrow failure. Currently, JAK-2 inhibition is the only approved therapeutic option. But despite treatment, many patients progress, and experience significant morbidity and mortality. Navitoclax is a first-in-class BCL-XL inhibitor with the potential to transform the treatment of myelofibrosis by deleting the clone that causes the disease.

At ASH last year, we presented encouraging data from a Phase 2 study, which demonstrated that up to 43% of patients who had failed JAK-2 inhibition responded to navitoclax based on a 35% reduction in spleen volume. In addition, responses deepened over time and we continue to follow these patients. Navitoclax treated patients also showed reductions in the number of malignant cells and decreases in bone marrow fibrosis, supporting the potential for disease modification.

In the area of solid tumors, we previously presented positive Phase 3 data from two veliparib studies in front-line ovarian cancer and BRCA breast cancer. Data from these two studies demonstrated significant prolongation of progression-free survival and support the use of PARP inhibition in combination with chemotherapy earlier in the course of treatment.

In ovarian cancer, veliparib will be the only PARP inhibitor to combine with front-line chemotherapy and treat a broader population that is not restricted to biomarker status or chemo responsiveness. In BRCA positive breast cancer, veliparib will also be the only PARP inhibitor to combined with platinum-based chemotherapy, giving these patients a valuable new treatment option.

Based on feedback from global regulatory authorities, we plan to submit our applications for veliparib in the first half of this year. Veliparib will be an important new treatment option for women with ovarian cancer and BRCA breast cancer, offering the potential to provide better outcomes. And in our late-stage neuroscience pipeline, we are making good progress with the Phase 3 program for ABBV-951, our innovative approach to delivering Duopa-like efficacy to our subcutaneous delivery system for advanced Parkinson’s disease. This approach is enabled by novel levodopa and carbidopa pro drugs, and would be a transformative improvement to current treatment options.

With a less invasive non-surgical delivery system, 951 has the potential to significantly expand the patient population currently addressed by Duopa or other more invasive therapies for advanced Parkinson’s, such as deep brain stimulation. We’ll see data from the pivotal program in 2021 with commercialization anticipated in 2022.

In addition to advancing our late-stage programs, we’ve also made tremendous progress building our early-stage pipeline. Following several years of investment, we’re beginning to see these efforts pay off. And over the next three years, we’re planning for prudent concept data readouts in approximately 30 programs. Our early pipeline is designed to include a mix of highly novel targets supported by strong underlying science and clinically-validated targets, where we think an opportunity exists to improve on current agents.

In the area of the immunology, I’ll highlight our TNF-steroid conjugate, ABBV-3373, which is novel technology that delivers a proprietary high potency steroid directly to activated immune cells by TNF-mediated uptake. We’ve shown in model systems that this approach has the potential to drive transformational efficacy. And our early clinical work has demonstrated that we can deliver 3373 at its anticipated therapeutic dose without systemic steroid effects. We will see efficacy data from this study later this year. If our clinical data reproduce what we have seen pre-clinically, our steroid conjugate technology has the potential to serve as a platform across a wide range of diseases, including RA, IBD and lupus.

We will also see proof of concept data this year from several other early-stage assets in our immunology portfolio, including data for ABBV-599, our JAK/BTK program, and ABBV-323, our CD40 antagonist program, which are both targeting multiple pathogenic nodes that are thought to play important roles in diseases such as RA, IBD, lupus and scleroderma, allowing us to restate standard of care in our core disease areas and move into new ones where no effective therapy exists today.

In oncology, we are building on what we have learned with venetoclax and navitoclax to advance a number of promising apoptosis programs. The most advanced of these are ABBV-155, which uses a B7-H3 targeting antibody to deliver a novel high potency BCL-XL warhead to solid tumors, and ABBV-621, which is designed to induce apoptosis by clustering trail and apoptosis-inducing ligand on the surface of cancer cells. We will see monotherapy data for ABBV-155 in 2020 and combination data in 2021. We expect to see proof-of-concept data for ABBV-621 in 2021 as well.

In immuno-oncology, we have a number of very promising T cell redirecting bi-specifics in the clinic and several more in pre-clinical development. The most advanced of these are BCMA bi-specifics in multiple myeloma, TNB-338B (Phonetic) and HPN217. These programs allow us to explore different epitope specificities and binding affinities to optimize the benefit risk of our candidates in this very promising area.

We are also pursuing several novel approaches designed to modify the tumor immunosuppressive environment. Here, I would highlight ABBV-151, our monoclonal antibody targeting GARP. Through its effect on GARP, ABBV-151 reduces TGF-beta-mediated signaling within tumors. TGF-beta is thought to be an important driver of tumor immune evasion and TGF-beta signaling is correlated with a lack of tumor immune infiltrate and PD-1 unresponsiveness.

In addition, I would highlight our CD39 inhibitor, TTX-030. Recently emerging data suggests that CD39 plays an important role in tumor immune evasion by converting pro-inflammatory ATP to anti-inflammatory ADP and adenosine in the extra cellular environment. TTX-030 is designed to restore this important pro-inflammatory signal and reduce tumor immunosuppression.

Lastly, in our early neuroscience pipeline, we have several promising disease-modifying candidates in the clinic for Alzheimer’s and Parkinson’s disease. In addition to our tau-directed programs, we have programs aimed at important regulators of the neuroinflammatory response, TREM2 and CD33, as well as a core driver of pathology in Parkinson’s disease, alpha-synuclein.

So, in summary, we’ve continued to see significant evolution of our early- and late-stage development programs. We have a late-stage pipeline that includes more than 20 programs in registrational studies and have nearly 40 programs in early- to mid-stage development that will mature over the next few years.

With that, I’ll turn the call over to Rob for additional comments on our 2019 performance and our 2020 guidance. Rob?

Robert A. MichaelExecutive Vice President and Chief Financial Officer

Thank you, Mike. Today, I’ll review our performance for the fourth quarter and full year 2019, and then walk through our 2020 outlook. We had another year of strong execution. We reported adjusted earnings per share of $8.94, reflecting growth of 13% compared to prior year and beating our initial guidance midpoint by $0.24.

For the full year, net revenues were $33.3 billion, up 2.7% on an operational basis, excluding a 1.1% unfavorable impact from foreign exchange. Strong growth from several key products and newly launched assets more than offset the impact of international biosimilar competition. For the fourth quarter, net revenues were $8.7 billion, up 5.3% on an operational basis, excluding a 0.5% unfavorable impact from foreign exchange.

US HUMIRA sales were $4 billion, up 9.8% compared to prior year, reflecting high-single-digit volume growth plus price. Wholesaler inventory levels remained below half a month in the quarter. Full year sales of HUMIRA in US were $14.9 billion, up 8.6% versus prior year. International HUMIRA sales were approximately $950 million in the quarter, down 25.4% operationally, reflecting biosimilar competition across Europe and other international markets, and in line with our expectations.

SKYRIZI continues to perform extremely well with global sales of $216 million in the quarter. RINVOQ is also demonstrating strong uptake with sales of $33 million in the first full quarter following the US launch in late August. For the full year, the combined revenues of SKYRIZI and RINVOQ were $402 million and above our initial expectations.

Hematologic oncology global sales were more than $1.5 billion in the quarter, up 37.2% on an operational basis, driven by the continued strong performance of both IMBRUVICA and VENCLEXTA. IMBRUVICA global net revenues were approximately $1.3 billion in the quarter, up 28.9%, driven by strong share in all lines of therapy and CLL. VENCLEXTA revenues were $251 million in the quarter, driven by continued share gains across all approved indications.

For the full year, our hem/onc global revenues were $5.5 billion, up 39.3% on an operational basis. Global HCV sales were $632 million in the quarter. For the full year, HCV sales were $2.9 billion, down 17.7% on an operational basis, driven by lower treated patient volumes in select international markets and increased competition within the US managed Medicaid segment. We also saw continued strong operational sales growth for Creon and Duodopa.

Turning now to the P&L profile for the fourth quarter. Adjusted gross margin was 81.6% of sales, up 180 basis points compared to the prior year, including the year-over-year benefit related to the expiration of HUMIRA royalties. Adjusted R&D investment was 15.3% of sales, supporting our pipeline programs on oncology, immunology and other areas.

Adjusted SG&A expense was 21.6% of sales, reflecting continued investment in our on-market products and newly launched assets. The adjusted operating margin ratio was 44.6% of sales, an improvement of 290 basis points versus the prior year. Adjusted net interest expense was $282 million and the adjusted tax rate was 8.8%. Fourth quarter adjusted earnings per share, excluding specified items, was $2.21, up 16.3% versus prior year.

As we look ahead to 2020, our full year adjusted earnings per share guidance is between $9.61 to $9.71, reflecting growth of 8.1% at the midpoint. Excluded from this guidance is $1.95 of known intangible amortization and specified items. On the top line in 2020, we expect revenue growth approaching 8% on an operational basis.

At current rates, we expect foreign exchange to have a minimal impact on reported sales growth. This forecast comprehends the following assumptions for our key products. In 2020, we expect US HUMIRA to deliver revenue growth of approximately 9%. We expect international HUMIRA to approach $3.4 billion at current exchange rates. As Rick noted, we expect global sales of our newly launched immunology products to reach approximately $1.7 billion in 2020. This includes SKYRIZI global revenues of approximately $1.2 billion and RINVOQ global revenues of approximately $500 million.

We expect our hem/onc franchise to grow 24% on an operational basis with IMBRUVICA global revenues of approximately $5.5 billion and VENCLEXTA global sales of approximately $1.3 billion. We expect HCV global sales of approximately $2.5 billion. For Creon, we expect revenue growth of approximately 10%. For Duodopa, we expect sales of approximately $500 million. For Lupron, Synthroid and Synagis, we expect sales to be roughly flat year-over-year. And we expect approximately $200 million in combined revenue from ORILISSA in endometriosis and elagolix in uterine fibroids.

Looking at the P&L for 2020. We are forecasting adjusted gross margin of approximately 81.5% of sales. We are forecasting adjusted R&D expense just above 14% of sales, reflecting continued investment across all stages of our pipeline. We are forecasting adjusted SG&A expense to be just above 19% of sales, including funding to maximize the sales potential of new products. We are forecasting an adjusted operating margin ratio of approximately 48% of sales, an improvement of roughly 70 basis points versus 2019. We expect adjusted net interest expense of approximately $1.2 billion and we model a non-GAAP tax rate of approximately 10%. Finally, our share count for 2020 will be roughly flat.

Regarding our first quarter outlook. We expect adjusted earnings per share between $2.28 and $2.30, excluding approximately $0.53 of known intangible amortization and specified items. We anticipate first quarter operational sales growth of approximately 7%. At current rates, we expect a modest unfavorable foreign exchange impact. For US HUMIRA, we expect sales of approximately $3.5 billion. We expect international HUMIRA sales of approximately $900 million, assuming current exchange rates. For SKYRIZI, we expect global sales of approximately $250 million. And for IMBRUVICA, we expect global sales approaching $1.2 billion.

Moving now to the P&L for the first quarter. We are forecasting an adjusted operating margin ratio of approximately 48.5% of sales. As a reminder, the 2020 guidance provided today reflects AbbVie on a standalone basis. We will provide combined AbbVie and Allergan guidance after the close of the transaction.

In closing, AbbVie has once again delivered outstanding results. And with our strong track record, combined with the momentum of our business, we are well positioned for strong growth in 2020.

With that, I’ll turn the call back over to Liz.

Liz SheaVice President of Investor Relations

Thanks, Rob. We will now open the call for questions. Operator, first question please.

Questions and Answers:

Operator

(Operator Instructions) Our first question today is from Geoffrey Porges from SVB Leerink.

Geoffrey PorgesSVB Leerink — Analyst

Thank you very much for the question and congratulations on the quarter. Rick, I just wanted to ask you, it’s been a while since you gave the kind of initial overview of the basis for the Allergan transaction. Could you talk about how the business performance of AbbVie and, frankly, also Allergan has been trending compared to the assumptions that you had going into the transaction? And then as you get close to closing, how confident are you about the $2 billion in synergies and how soon might they be realized? Thanks.

Richard A. GonzalezChairman of the Board and Chief Executive Officer

Hey, Jeff. I think you obviously seen the standalone AbbVie performance and we’re coming off of another very good year. And our projection, our guidance, obviously, is projecting from a standalone basis, another strong year for the Company. And I think, in particular, we’re very impressed with what we’re seeing out of our immunology franchise and what we’re seeing out of our hem/onc franchise and so we feel good.

We’ve been watching the Allergan performance. They reported two quarters that we’ve seen. They will be reporting another quarter here soon, probably sometime early next week. And I would say, at least for the two that have been reported, overall, the business is tracking, I’d say, slightly ahead of what our deal model had projected. As I mentioned, I think, a number of times, our deal model that we put together was a fairly conservative deal model, so that’s not too surprising. But I think as you look at the key products that are critical products for their business, they’re all performing in line or ahead of what our projections were.

As it relates to the synergies, as I mentioned in my formal comments, we have gone through all of the integration planning process with Allergan. Part of that process is to validate the synergies and so, we’re comfortable that the synergy target that we had communicated, which was $2 billion or greater than $2 billion, is an achievable number. Obviously, any time you do a transaction like this, you’re trying to maximize the synergies and obviously, maintain the business to perform at the level that you would expect it to perform. So, I feel good about the synergy projections.

We will provide final gating for those projections when we do the combined pro forma guidance and — but I feel great about the overall target over the first three years meeting or exceeding what we had projected. The timing close, everything is progressing as we had planned. And we still anticipate that we will see closure by the end of the first quarter.

The other thing I’d say is, as we step back and we look at what we’re trying to accomplish with the Allergan transaction, it was basically to try to build the business that ultimately would be even stronger than the AbbVie business over the long term. And I think one of the things as investors start to think about the business, it’s important to sort of put that in perspective. We want a business that’s more diversified, both from a revenue standpoint as well as a payer mix standpoint. We want a business that has durable positions. This business, the combined business, will have durable growth positions in eight different franchises and be able to drive strong growth. There’ll be four franchises for the new company that will be the major growth franchises for us. Obviously, immunology, hematological oncology, medical aesthetics and CNS neuro will be the four franchises.

This is a business that will have excellent payer diversity and payer mix. If you look at it as a percent of the global revenues, Medicare Part B will be about 2%, Medicare Part D will be about 16%, Medicaid will be about 3% and cash pay will be about 10%. So a nice balance and security along the payer base. It will be a business that’s driven by volume, not by price, and so that’s important. It will be a company that has a strong growing dividend. It’s underpinned by tremendous cash flow, which provide security to deliver a growing dividend over the long term and through the loss of exclusivity in 2023 in the US.

It will also have a number of recently launched products and growth products, in fact, there will be six of them if you think about it. You look at SKYRIZI, RINVOQ, VENCLEXTA, IMBRUVICA, those all have significant growth opportunities ahead of them on the AbbVie side. And then you look at the Allergan side, you have Vraylar, this is a product that has — it’s about $850 million product. I think the last numbers I saw showed it was growing about 70% and you have their recently launched oral CGRP that we haven’t seen any data on yet as far as their revenue performance because they just launched it, but I think that will be an important product over the long term.

So — and then that’s underpinned by our late-stage pipeline that has 20 new drugs and new major indications, and an early-stage pipeline that Mike outlined in his remarks, that’s a pretty impressive profile of a company in our industry. And that’s the kind of company we’re trying to build by combining these two companies together. So I think that’s how we think about it.

Geoffrey PorgesSVB Leerink — Analyst

Great, thanks very much, Rick.

Liz SheaVice President of Investor Relations

Thanks, Geoffrey. Operator, next question please?

Operator

Thank you. Our next question is from Steve Scala from Cowen.

Steve ScalaCowen — Analyst

Thank you and let me add my congratulations on another well executed quarter. I have two questions. First, SKYRIZI and RINVOQ are obviously off to great starts and the raised guidance for them in 2020 is impressive. Previously AbbVie had provided 2025 the guidance of $10 billion for these two products. And I’m just wondering how you are thinking about that number now?

And then secondly, the Company had given 2020 revenue guidance in 2015 of $37 billion. And then in 2017, said that that would be exceeded. I realize that in complicated businesses, there are always pushes and pulls. But it appears today’s 2020 revenue guidance implies a $36 billion revenue number in 2020. So I’m just curious for the reason for the delta. Thank you very much.

Richard A. GonzalezChairman of the Board and Chief Executive Officer

Well, I mean if you look at SKYRIZI and RINVOQ, obviously, they’re off to a very strong start. When you look at the $10 billion guidance that we had, that still had some level of risk adjustment for the follow-on indications associated with it. And obviously, as we move along, then those risk adjustments will come down probability of success will go up. So by definition, by the way, we look at things, you would expect SKYRIZI and RINVOQ to be able to exceed that level of performance, assuming all those follow-on indications perform at the level that we would expect and everything that we know would clearly indicate that that is the case. We’re not in a position where we’re going to up the guidance.

Now, in any complicated business like ours, on the $37 billion, obviously, there are things like SKYRIZI and RINVOQ that are ultimately performing better. Certainly, when you look at our hematological oncology business, that’s performing at a level that we would expect to deliver at least what we had expected back in that point in time, probably a little bit higher.

Now, you also have puts and takes. International biosimilars were more aggressive than we had anticipated. But net-net, I think we’re comfortable with that level of performance and more importantly, we’re comfortable with being able to deliver the kind of earnings that we would expect. And so I think we feel very good about how the Company is performing, and our ability to deliver on those long-term expectations.

The other thing I’d say is, as you look at the biosimilar — obviously biosimilars are important aspect of our particular business. And we’re now at a point where we’re basically lapping the first year of biosimilar experience in the international markets. And it gives us the ability to be able to look back and say, did our strategy work that we had put in place? And I think, we’ve obviously been able to learn from what that strategy has been able to do.

In general, I would tell you that I’m feeling pretty good about how the strategy played out. On the aggressive side, obviously, the biosimilar competitors before they entered the market, priced more aggressively than we had seen with the analogs, and so the shape of the curve was different, which we’ve talked about a number of different times.

Having said that, our strategy was to make sure that we could maintain as much share as possible of HUMIRA and maintain it as profitable as possible. And we can now step back and look at what does that look like. Well, what it basically looks like is, we have maintained about two-thirds of the volume. If you look specifically at the countries that went biosimilar and you look at what the erosion level is in those countries, it’s about 44%, 45% within those countries. So what that means is, we’ve obviously maintained a tail of about 55% of the HUMIRA volume, which is a pretty — the HUMIRA revenue, which is a pretty significant tail when you think about a product of the size of HUMIRA.

So I think overall, we feel good about how our strategy played out. Despite the fact that the biosimilar players were more aggressive. I think as we look at the US, there are some things that we can translate out of that experience and it gives us some feel for how the US will evolve as we enter that biosimilar phase in 2023.

Obviously, we have products like RINVOQ and SKYRIZI that are growing rapidly. We have a number of years to be able to drive that and we’re making very good progress on the follow-on indications and therefore, we should have a broad set of indications, approved indications, for those assets, which should drive very significant growth leading into that LOE event. The strategy that we’ll put in place is the exact same strategy that we did in the international markets. Our goal is to maintain as much share as we can and as profitable above (Phonetic) as we can.

There is no market exactly like the US market outside the US. But what I would say is, we would expect it to be competitive, like the international markets, we’ll have as — we’ll have more competitors entering the US market. So I think the shape of the curve will be similar to what we saw in the international markets. But I’d say, as far as our ability to maintain share, we certainly in the US have at least the same competitive position that we have in the international markets. And in all likelihood, we have a stronger competitive position in the US market.

So I would say, we would expect to fare at least as well or better from a standpoint of maintaining that tail over time. And so we’re feeling better about where we stand both the progress that we’re making against the assets that will allow us to be able to drive growth over the long term and the experience we’re getting with dealing with biosimilar competition in these markets.

Steve ScalaCowen — Analyst

Thank you.

Liz SheaVice President of Investor Relations

Thank you, Steve. Operator, next question please?

Operator

Thank you. Our next question is from Navin Jacob from UBS.

Navin JacobUBS — Analyst

Hello. Thanks for taking my question. A couple on RINVOQ and SKYRIZI. Number one, on SKYRIZI, wondering what the feedback from physicians and patients are regarding — I realize, it’s very early, but regarding average duration of therapy? How should we be thinking about that relative to your experience with HUMIRA?

And then on RINVOQ, wondering about the Q4 sales number, which came in a little bit lighter relative to how we were thinking about it based on the scripts. Wondering what the dynamic is from a $1 per prescription standpoint, how the couponing and sampling is affecting that? There was some commentary from Pfizer on Zelgen’s pricing that’s brought up some questions about pricing in this space. Obviously very early on, but would love any color there?

And as a corollary to that, with regards to the differences in the channel mix for RINVOQ versus SKYRIZI, any kind of color there would be appreciated, particularly as you said that, you have very good access in the commercial setting for RINVOQ, wondering about the access in the other parts of the channel as well? Thank you so much.

Richard A. GonzalezChairman of the Board and Chief Executive Officer

Okay. So on the first question, this is Rick. Average duration of therapy, obviously, SKYRIZI is a quarterly dosed product as a loading dose that occurs in the first phase. So we don’t have a tremendous amount of experience yet, but I’d say the experience that we have thus far is consistent with what our original launch assumptions would be, and that is the duration of therapy would be very high at HUMIRA levels or above. Obviously, it’s more convenient to have quarterly dosing. And so we’re not seeing anything there that is different than what we would have anticipated, albeit it’s early on.

As far as RINVOQ in the fourth quarter, I’d say RINVOQ is tracking well. It’s continuing to gain in-play share. Now, it didn’t get its significant uptick in market access until January. There was a fairly significant jump from December to January. So there was still a fair amount of prescriptions that were being driven through the — our access program, where we provide patients — if they don’t have access, we provide them with free product through our bridge program.

But now, as I mentioned, we’re over 95%. And our policy is, once we’ve achieved access in an account, we no longer allow bridge access for those products, in other words, from a compliance standpoint. And so, you should start to see those paid prescriptions ramping in line with what we would expect the access to be. SKYRIZI has very similar kinds of access.

As far as the channel mix is concerned, (Indecipherable) Rob to cover that.

Robert A. MichaelExecutive Vice President and Chief Financial Officer

Hi, Navin, it’s Rob. So if you think about the difference in the patient profile with RA versus psoriasis, obviously, we have older patient population, so you’d expect RINVOQ to be higher in terms of Medicare Part D. To give it just a range, it’s around 20% of the RINVOQ channel mix as Part D, whereas with SKYRIZI, it’s closer to 10%.

Richard A. GonzalezChairman of the Board and Chief Executive Officer

And the only other thing I’d mention is, the one thing that is very encouraging to us is, if you take SKYRIZI, about half, 49%, of the patients are naive patients and the other 51% are, obviously, second line and beyond. If we look at RINVOQ, it’s about 40% — 38%, 39% are naive patients, which, at this phase of the launch, is higher than what we had originally modeled. And the remaining are second line and beyond.

The other thing I’d say is, we obviously track how we’re doing against various competitors. It’s now — RINVOQ now has an in-play share that’s the equivalent of about 70% of of Xeljanz and, obviously, growing at a pretty rapid pace. And so I think, that’s an encouraging sign as well.

Liz SheaVice President of Investor Relations

Thank you, Navin. Operator, next question please.

Operator

Thank you. Our next question is from Terence Flynn from Goldman Sachs.

Terence FlynnGoldman Sachs — Analyst

Hi, thanks for taking the questions. Congrats on the quarter from me as well. One more on the guidance front, when you do give the pro forma guidance post deal close, I was just wondering if we should expect new longer-term guidance on that front as well? And then again, appreciate all the detail on the pipeline. In the slides you listed six proof of concept readouts this year. Just wondering, of those assets, what did you view as most transformational? Thank you.

Richard A. GonzalezChairman of the Board and Chief Executive Officer

Okay. On the pro forma guidance, we haven’t made a final decision. Obviously, we’ll be providing for calendar year ’20. We haven’t made a decision whether we’ll go out any further than that. So I’d say that’s a decision that we’ll make as we get closer to the close and, ultimately, announcing what the combined guidance is.

Mike, do you want to cover number two?

Michael E. SeverinoVice Chairman and President

Sure. So as you mentioned, we have six proof of concept readouts this year in our early- to mid-stage pipeline. And if I wanted to pick some examples of the most transformational, I think I would point to ABBV-3373, our TNF-steroid conjugate. If you look at the basic biology, the ability to drive to deliver this very, very high potency steroid directly to the activated immune cells that are dealing the damage in these diseases, really has tremendous potential.

In our pre-clinical work and our model systems, we see results that are really unlike anything we’ve ever seen with other sorts of agents. And we can deliver that kind of impact in those systems without systemic steroid effects. So if that plays out in the clinic, in the same way, it has in those model systems, that would really be transformational across a wide range of diseases, across a range of TNF-mediated diseases like RA, other rheumatologic conditions, inflammatory bowel diseases and many others. And you could also use that same technology with different targeting warheads to get into areas where there really aren’t effective therapies today, like lupus for example. So that really has transformational potential.

Maybe I would point to one other program on the onc side. If you look at our work in apoptosis, there really is a tremendous opportunity, I believe, in the future to get into solid tumors with our apoptosis programs. And one program that will have a readout, at least from the monotherapy component this year, is ABBV-155, our B7-H3 targeted XL delivery.

Liz SheaVice President of Investor Relations

Thank you, Terence. Operator, next question please.

Operator

Thank you. Our next question is from Vamil Divan from Mizuho.

Vamil DivanMizuho — Analyst

Hi, great, thanks for taking my questions. I just wanted to actually follow up on the comments Rick made regarding HUMIRA US erosion and Phase 1 biosimilars arrive. And I think you said, the overall shape of the curve, you think, will be similar to what we’ve seen outside the US. And I think you also previously mentioned that, part of the reason for the Allergan deal was to kind of give you the ability to address the various scenarios of HUMIRA erosion. So I’m just trying to get a sense as you think about the scenarios and how this might evolve in 2023, 2024. Do you expect that you will be continuing to grow sales and earnings right through those years, or do you think that if it is a somewhat rapid erosion, so there might still be a little bit of a decline during that time period?

And then my second question is just around pricing. And it sounds like you got maybe 1 percentage point or 2 percentage points of pricing growth for HUMIRA this year. Just wondering if that’s sort of a reasonable expectation for 2020 for HUMIRA? And also maybe just for the next couple of years, do you think you’ll still be able to get sort of a low-single-digit amount of price? Thanks.

Richard A. GonzalezChairman of the Board and Chief Executive Officer

Okay. Vamil, this is Rick. So I’ll take the first question and then Rob will cover the second question for you. We’re obviously not in a position where we’re going to give 2023 guidance at this point. What I was referring to is, if you look at consensus, today what it shows for HUMIRA is that it basically is a stair step down over the course of three or four years.

I would say our experience in international markets, by the way, multiple biosimilar competitors coming into the market simultaneously, created a sharper decline, a deeper decline in year one, and then it’s pretty much stabilized at that level. It might be some slight erosion after that, but relatively minor or moderate after that.

When I described the shape of the curve, I think that’s a more reasonable shape of a curve that we would expect in the US market based on the fact there will be probably seven competitors that enter the marketplace in 2023. As far as growth, it is our obvious objective to make sure that we’re in a position that we can grow over the long term, that’s an important objective for us and, certainly, an objective that we have been able to deliver on throughout our history as a company and it’s an important objective for us.

Now that doesn’t mean that in 2023 there couldn’t be some step down in 2023 and then return quickly to growth thereafter, but ultimately, as we get closer, I think we can provide more accurate guidance. But I have a high level of confidence that we are building an engine that will allow us to be able to grow through it over a long period of time, over the longer period of time. Allergan plays an important part of making sure that we can maintain the investment profile that we want to maintain in R&D and SG&A, to make sure we have the levels of cash flow to continue to support the dividend and grow the dividend. It plays a very important role in a number of aspects of how we manage the business over the long term.

Mike or — I’m sorry, Rob?

Robert A. MichaelExecutive Vice President and Chief Financial Officer

So Vamil, it’s Rob. So I’ll take your question on US HUMIRA. So of the approximate 9% growth we’ve guided, volume is going to be mid-single digits and price will be low-single digits. I think for modeling purposes, it’s fair to model low-single digits going forward. We’ll obviously provide that guidance at the appropriate time. But that’s the best way to think about it.

Vamil DivanMizuho — Analyst

Thank you.

Liz SheaVice President of Investor Relations

Thank you, Vamil. Operator, next question please.

Operator

Thank you. Our next question is from Randall Stanicky from RBC Capital Markets.

Randall StanickyRBC Capital Markets — Analyst

Great. Thanks, Rick. There has been a trend in large biopharma towards divesting legacy products. AbbVie has legacy products, you’re getting more from Allergan. How are you thinking about potential divestitures from the combined entity?

And then just secondly on ORILISSA, you’ve talked about the need to build awareness for activation. Is that still a $2 billion opportunity? And how are you thinking about the potential to inflect that back up? Thanks.

Richard A. GonzalezChairman of the Board and Chief Executive Officer

I mean, every company in our industry for the most part has some level of the legacy products. We do as well as others. I think many people want to divest those products typically not because those products aren’t profitable and provide significant earnings, but because they depress their overall growth if they are too large as it relates to their overall base of business.

I would say, as we look at our profile and our ability to be able to grow, we don’t believe that that’s a significant issue for us. It doesn’t mean that at some point in the future we might not reevaluate it, if we thought that was in the best interest of the Company overall. But I’d say, that’s not something that we have any plans for at this point in time.

ORILISSA, the point you raised is an accurate point, the challenge that we’ve had with ORILISSA in endometriosis has been activation of those patients at the rate that we would have expected. We have made some changes in the fourth quarter to our go-to-market strategy. We’ll have to see how those play out. And also we’ll have the launch of the uterine fibroid indication in 2020, that’s a different patient population. And so, I think it will have a different activation profile.

And — but I think we have to see how endometriosis whether or not we get an inflection point here that’s different than what we’ve seen thus far before we make any predictions about how we will change the long-term projections. We fundamentally believe this is a good drug. Everything we know about it says, it’s a good drug and it ultimately fits an important need. But we’re obviously going to have to change that activation curve to get to the level of expectation that we have had for that — for the drug.

Liz SheaVice President of Investor Relations

Thanks, Randall. Operator, next question please?

Operator

Thank you. Our next question is from Tim Anderson from Wolfe Research.

Tim AndersonWolfe Research — Analyst

Thank you. A couple of questions please. Just to round out the discussion on prior 2025 guidance for certain products, and asked about three of them so far. VENCLEXTA and IMBRUVICA, maybe you can just talk about how those are trending today relative to those projections? IMBRUVICA seems like it’s doing great, but you set really high 2025 guidance, I think it was $11.5 billion. And then VENCLEXTA, I think you guided for $6 billion and I think it finished out the year here at $800 million. So any comments on those two products?

And then a second question, just on, in the context of FTC being more unpredictable, with the brazikumab divestiture, a person could argue for different reasons FTC might raise an eyebrow about Astra taking back an asset that they got rid of originally. I think back then, it wasn’t core to their business. And frankly, when you look at Astra and what they’re concentrated now, it’s hard to see where it fits. So FTC could potentially question whether Astra is really a committed competitive developer of that asset. Just wondering if you can share thoughts on that. Thank you.

Richard A. GonzalezChairman of the Board and Chief Executive Officer

Sure. As far as VENCLEXTA and IMBRUVICA are concerned in the long-term guidance, we feel very comfortable with our long-term guidance for those two assets. If you look at this year for VENCLEXTA, it will be an important inflection year for VENCLEXTA and we would expect it to continue to grow quite nicely over time. Obviously, the multiple myeloma in t(11;14) is a significant opportunity for VENCLEXTA. I think that represents roughly 20% of the myeloma patients, and myeloma is, obviously, a very big market. So we feel good about that.

As far as the FTC is concerned, the way this process normally works is, you bring in the players that you’re considering to acquire a product, which we and Allergan did. And so, the FTC has had an opportunity to interact with both of the players and give us feedback around those players. So I think you can conclude from that that we will move forward with a player that the FTC told us they were uncomfortable with.

Tim AndersonWolfe Research — Analyst

Thank you.

Liz SheaVice President of Investor Relations

Thank you, Tim. Operator, next question please.

Operator

Thank you. Our next question is from Andrew Baum from Citi.

Andrew BaumCiti — Analyst

Thank you. Just in the psoriasis segment, you run a very impressive trial versus the leading IL-17 seemingly (Phonetic) taking away all that key selling points, both in terms of tax (Phonetic) as well as speed of onset and (Phonetic) response. To what extent do you think you’re going to accelerate eating into the IL-17 segment by leveraging that trial in the psoriasis setting?

And then secondly, back on CLL, could you just talk to how you see the near-term competitive risk from the introduction of Calquence among the patients who are struggling with IMBRUVICA tolerant? I realize it’s only a minority of those patients as they tolerate the first year therapy but whether we are going to see any patient shift across as it comes to market. And then second, longer term, now that you have the covalent — the non-covalent inhibitors coming on to the scene with ArQule, Lilly and others? Thank you.

Richard A. GonzalezChairman of the Board and Chief Executive Officer

So Mike, why don’t you cover one and three, and I’ll come back and cover the Calquence question.

Michael E. SeverinoVice Chairman and President

Sure, this is Mike. With respect to the head-to-head data we just released in the last several weeks against Cosentyx, really was a very strong result. And what I would say is, it highlights a number of the things that we said. One, we drive very, very high levels of response. That response is very durable over time. Although all the data haven’t been presented, they will be at an upcoming medical meeting. We said that we had across all of the ranked secondary endpoints, so it was very sort of broad-based result. And we had very good data at 16 weeks, as you said. So we think that that’s going to continue to drive the momentum of SKYRIZI into this space. Now having said that, SKYRIZI is already performing extremely well and we would expect that to continue.

So with the — for your third question on the competitive space for BTK inhibitors, we feel very, very good about the package of data that we have delivered around IMBRUVICA, it’s very broad. We have five large scale randomized readouts, we have a robust survival benefit. And that’s a data advantage that’s very hard to overcome.

If you look at the launch of some of the follow-on covalent BTK inhibitors, our data package still is the broadest and we believe this is the strongest in terms of showing the overall benefits. And the points of differentiation that folks had talked about in the past haven’t really materialized. So we feel good about our competitive position there. They’ll take some share as you’ve seen in MCL, but it’s nothing that that would change our ability to grow IMBRUVICA.

With respect to the non-covalent inhibitors, I think that the place for those is less clear. As I’ve said, we have many large scale Phase 3 data readouts, including survival benefits. So until those molecules really have an equivalent data set, it’s going to be very, very difficult for them to compete in this space where IMBRUVICA plays.

Now, there are a small number of patients who have (Indecipherable) mutations that lose response to covalent BTK inhibitors because of that. One might expect a non-covalent inhibitor to work there, but that’s really a much smaller opportunity and that follows the use of the covalent inhibitors. And we would say, in that space, that VENCLEXTA-based regimens are probably the best option and, certainly, have the most data today.

Richard A. GonzalezChairman of the Board and Chief Executive Officer

And then to your second question, as it relates to whether or not we’ll see patients being moved off of IMBRUVICA and on to Calquence based on side effect profiles, we don’t believe that will be the case. I mean, I think, as Mike pointed out, when you look at the body of data around IMBRUVICA and particularly the survival benefit that we see with IMBRUVICA, physicians are reluctant to move a patient off of a drug that gives them the opportunity to be able to have that level of survival benefit to something that has less data to be able to support that. The guidelines reflect that as well.

And most physicians know that when they have a side effect profile that they are having difficulty managing through that they routinely — prior to Calquence being on the market, what they would typically do is, take the patient off of therapy for a short period of time until it resolved and then put them back on therapy and many patients will ultimately be fine when they are put back on therapy. So moving to another non-differentiated product, we don’t think will have a fundamental impact.

We’re obviously watching the share data. It’s early on because the latest share data that we have is still November. And as you know, they were approved in November. Now they run guidelines for most of 2019 in CLL, but the share is very low. They have about 1% share in first-line, 2% share in second-line, about 6% share in third-line, but most of those patients in third-line, about half of them, are BTK failures, IMBRUVICA failures. So thus far, we don’t see anything that would suggest that it’s having a significant negative impact on our performance.

Andrew BaumCiti — Analyst

Thank you.

Liz SheaVice President of Investor Relations

Thank you, Andrew. Operator, we have time for one final question.

Operator

Thank you. Our final question today is from David Risinger from Morgan Stanley.

David RisingerMorgan Stanley — Analyst

Thanks very much and I wanted to add my congrats as well. I have two questions for you, Rick and the team. So with respect to looking at analogs, branded ex-US REMICADE has stair step down 30% annually over the past five years since biosimilars first launched and the 2019 sales are less than 20% of the 2014 sales. So could you discuss the considerations for AbbVie when your team has evaluated it as a potential analog for HUMIRA decline prospects?

And then second, with respect to ORILISSA, could you discuss efforts to change the mindset of younger women who may be hesitant to take hormonal therapies? Thank you.

Richard A. GonzalezChairman of the Board and Chief Executive Officer

Yes. So, David, this is Rick. For your first question, I think the difference between REMICADE and Enbrel as well actually, and the experience that we had with HUMIRA was in most of those cases only one or two competitors came in at a time. And so, what you’re seeing is, essentially the way we had originally modeled HUMIRA was that at year three, we would get to the levels that we’re at now, because it would stair step down. But I think what we learned in that process is when four competitors entered the market at one time, that the competitive dynamics between them to try to get share created an environment where they became far more aggressive early on. So I don’t think the curve will look as — it won’t look as if the same as REMICADE. Now, that doesn’t mean that over time, we won’t see some moderate continued erosion, but it’s — for a business of our size and with the growth prospects of our business, that’s not something that would inhibit our ability to be able to grow. I think you can see, we grew through, we ultimately had positive revenue growth in 2019, despite the fact that we had a very significant portion of our international business (Indecipherable) biosimilar in 2019.

The second question is, part of the activity that we’re working on now to try to drive activation at a faster rate in women on ORILISSA, that is one component. I wouldn’t say it’s the most significant component, but it is one component to better educate women on what this therapy is all about, what the side effect profile of this therapy really looks like, the safety profile of it and make sure that we do that in a way that it’s easily accessible for women in that age group. Meaning, it has a social media aspect to it that allows them to be able to access accurate information about ORILISSA and the benefits of it and the appropriate use of it. And so, that is part of the changes that we made in the fourth quarter, and we’re just going to have to see how those changes — the impact those changes have over time.

Liz SheaVice President of Investor Relations

Thank you, David. That concludes today’s conference call. If you’d like to listen to a replay of the call, please visit our website, at investors.abbvie.com. Thanks again for joining us.

Operator

(Operator Closing Remarks)

Disclaimer

This transcript is produced by AlphaStreet, Inc. While we strive to produce the best transcripts, it may contain misspellings and other inaccuracies. This transcript is provided as is without express or implied warranties of any kind. As with all our articles, AlphaStreet, Inc. does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company’s SEC filings. Neither the information nor any opinion expressed in this transcript constitutes a solicitation of the purchase or sale of securities or commodities. Any opinion expressed in the transcript does not necessarily reflect the views of AlphaStreet, Inc.

© COPYRIGHT 2020, AlphaStreet, Inc. All rights reserved. Any reproduction, redistribution or retransmission is expressly prohibited.

Psorilax:Semplice |crema per psoriasi fai da te

0

Psorilax: prezzo, funziona, recensioni, opinioni, quanto costa

L'indagine Rx Dermatology Topical Drug Delivery fornisce informazioni chiave sul settore, compresi fatti e cifre molto utili e importanti, opinioni di esperti e gli ultimi sviluppi in tutto il mondo. Il rapporto sul mercato globale è un documento importante per ogni appassionato di mercato, decisore politico, investitore e giocatore. Il rapporto fornisce fluttuazioni del valore CAGR durante il periodo di previsione 2019-2026 per il mercato. I rapporti di mercato di Rx Dermatology Topical Drug Delivery forniscono dati su modelli e miglioramenti e indirizzano settori e materiali aziendali, limiti e avanzamenti. In questo rapporto, viene fornita un'analisi SWOT e un'analisi degli investimenti approfondite che prevedono opportunità imminenti per gli operatori del mercato di Rx Dermatology Topical Drug Delivery.

Il mercato globale della consegna di farmaci per dermatologia Rx globale dovrebbe raggiungere 40.646,26 milioni di USD entro il 2026 da 29.475,18 milioni di USD nel 2018, con un CAGR del 4,2% nel periodo di previsione dal 2019 al 2026.

Scarica la copia di esempio gratuita in PDF di (e-mail protetta) https://databridgemarketresearch.com/request-a-sample/?dbmr=global-rx-dermatology-topical-drug-delivery-market

Analisi competitiva:

Alcuni dei principali attori che operano in questo mercato sono Galderma Laboratories, LP, Hisamitsu Pharmaceutical Co., Inc., Pfizer Inc., LEO Pharma A / S, GlaxoSmithKline plc., ALLERGAN, Bayer AG, 3M, Bausch Health Companies Inc., The Lubrizol Corporation, Cipla Inc., Kaken Pharmaceutical Co., Ltd. tra gli altri.

I farmaci topici svolgono un ruolo importante nella terapia delle malattie dermatologiche. I farmaci per dermatologia topica incorniciano una grande percentuale di prodotti nel mercato dei farmaci. Questi prodotti sono fabbricati attraverso processi di produzione specializzati come riempimento di volume preciso, miscelazione su larga scala, riscaldamento e imballaggio.

La somministrazione topica di farmaci può essere effettuata nel corpo attraverso percorsi oftalmici, rettali, vaginali e cutanei come vie topiche. Nel settore della dermatologia, la pelle svolge un ruolo importante nella somministrazione di farmaci topici per il trattamento delle malattie della pelle nei pazienti. I preparati topici vengono applicati sulla pelle per effetti superficiali, locali o sistemici. Le formulazioni topiche includono ingredienti terapeuticamente attivi che aiutano a trattare le malattie della pelle nei pazienti.

Il rilascio topico di farmaci è uno dei modi più efficaci di rilascio di farmaci in quanto fornisce risultati terapeutici ottimali. A poco a poco, il sistema topico di consegna dei farmaci è diventato sempre più importante nell'industria farmaceutica. La risposta farmacologica, sia l'effetto terapeutico desiderato sia l'effetto indesiderato indesiderato di un farmaco dipendono dalla concentrazione del farmaco nel luogo di azione, che a sua volta dipende dalla forma di dosaggio e dall'entità dell'assorbimento del farmaco nel sito di azione. Nel settore della dermatologia, molecola di farmaco applicata sulla pelle che penetra principalmente attraverso il percorso intercellulare tortuoso e continuo. Questi prodotti sono disponibili in diverse forme come unguenti, creme, lozioni, gel e altri che hanno la capacità di essere assorbiti nel corpo e mostrano rispettivamente la risposta positiva nella guarigione della ferita.

Mercato globale di consegna di farmaci topici dermatologici per tipo di prodotto (semisolido, liquido, solido), applicazione (infezioni della pelle, dermatite, antiaging, acne, iperpigmentazione, rosacea, cancro della pelle, psoriasi, onicomicosi, altri), categoria (marchiato, generico ), Geografia (Nord America, Europa, Asia-Pacifico, Sud America, Medio Oriente e Africa) – Tendenze e previsioni del settore fino al 2026

Segmentazione: Mercato globale della consegna di farmaci per dermatologia Rx globale

Il mercato globale della consegna di farmaci topici dermatologici Rx è segmentato in base al tipo di prodotto, all'applicazione e alla categoria.

  • Sulla base del tipo di prodotto, il mercato è segmentato in solido, liquido e semisolido. Il solido è sottosegmentato in polvere e altri. Il liquido viene suddiviso in soluzione, emulsione, sospensione, lozione e altri. Semisolid è sottosegmentato in creme, gel, unguenti, pasta, altri.
    • Nel dicembre 2016, Pfizer Inc. ha ricevuto l'approvazione da parte della Food and Drug Administration (FDA) statunitense per il prodotto chiamato EUCRISATM (crisaborole) unguento al 2%. È un nuovo inibitore topico non steroideo della fosfodieterasi-4 (PDE-4). È usato per il trattamento della dermatite atopica da lieve a moderata (AD). Con questo lancio del prodotto l'azienda ha costruito un patrimonio nel settore dell'infiammazione e dell'immunologia.
  • Sulla base dell'applicazione, il mercato è segmentato in acne, dermatite, psoriasi, infezioni della pelle, antiaging, cancro della pelle, iperpigmentazione, onicomicosi, rosacea, altri.
    • Nel marzo 2017, Galderma Laboratories, L.P., produttori del marchio Cetaphil hanno lanciato sette nuovi prodotti per la cura della pelle del viso. Con questo lancio dei prodotti il ​​portafoglio Cetaphil dell'azienda è aumentato. La società ha ora un'ampia gamma di soluzioni specializzate per i pazienti con problemi di pelle, tra cui idratazione e altri.
  • Sulla base della categoria, il mercato è segmentato in generico e marchiato.
    • Nel febbraio 2016, Allergan plc ha ricevuto un'approvazione per il suo prodotto ACZONE (dapsone) Gel, 7,5% dalla Food and Drug Administration (FDA) degli Stati Uniti. Questo prodotto è un nuovo trattamento topico di prescrizione che è utile per il trattamento dell'acne nei pazienti di età pari o superiore a 12 anni. Il prodotto ha aiutato il paziente a trattare facilmente l'acne che alla fine ha contribuito ad aumentare le entrate.

Richiedi questo rapporto dal nostro esperto @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-rx-dermatology-topical-drug-delivery-market

Recenti sviluppi:

  • Nell'aprile 2016, Allergan plc ha acquisito Topokine Therapeutics, Inc. con un pagamento anticipato di 85,8 milioni di USD ed è stato idoneo a ricevere pietre miliari potenziali di sviluppo e commercializzazione fino a 260,0 milioni di USD.
  • Nel febbraio 2019, Kaken Pharmaceutical Co., Ltd. ha concluso un accordo di licenza e distribuzione esclusiva per la formulazione topica di onicomicosi nella Repubblica popolare cinese. Secondo l'accordo Kaken Pharmaceutical Co., Ltd., ha fornito il diritto esclusivo per lo sviluppo e la commercializzazione del Prodotto in RPC e questo ha portato a un'elevata generazione di entrate.
  • Nell'aprile 2019, The Lubrizol Corporation ha lanciato il suo nuovissimo modificatore di reologia 2 in 1 multifunzionale, polimero Carbopol Style 2.0. Il prodotto ha i benefici per la cura della pelle come l'aspetto liscio lucido, le texture uniche e altro. Con questo lancio è aumentato il portafoglio di prodotti dell'azienda che ha comportato una maggiore generazione di entrate.
  • Nell'agosto 2018, Cipla INC. Ha ricevuto l'approvazione finale per la nuova domanda abbreviata di farmaci (ANDA) per Diclofenac Sodium Topical Gel, 1% dalla Food and Drug Administration degli Stati Uniti (US FDA). Per questo motivo l'azienda ha aumentato il proprio portafoglio di prodotti e una forte posizione sul mercato, specialmente nel campo della dermatologia.
  • Nel novembre 2010, 3M ha rilanciato la linea Cavilon Professional Skin Care. Questo prodotto ha aiutato a prevenire danni alla pelle da umidità, attrito e traumi adesivi. Il portafoglio di prodotti dell'azienda è aumentato per quanto riguarda la dermatologia archiviata e quindi le entrate sanitarie.

Opportunità:

BASSA PENETRAZIONE BIOLOGICA:

I biologici sono i farmaci che sono fatti da proteine ​​animali o umane che hanno la capacità di trattare rispettivamente le malattie. Hanno la capacità di trattare il numero di malattie come la psoriasi, l'artrite psoriasica, altri tipi di artrite e malattie infiammatorie intestinali. A causa della bassa attività dei farmaci biologici nel trattamento di eventuali malattie del derma, i farmaci topici stanno superando il mercato a fini terapeutici e quindi la sua domanda è in aumento sul mercato.

AUMENTO DEL CONCORSO CHE GUIDA AD ALTI INVESTIMENTI IN R&S PER INNOVARE NUOVI PRODOTTI:

La malattia della pelle negli ultimi tempi è una delle principali malattie tra le persone per le quali sono disponibili trattamenti. Uno dei trattamenti avanzati è il sistema topico di rilascio del farmaco in cui la pelle svolge un ruolo importante poiché il farmaco viene applicato sulla pelle che ha la capacità di trattare le aree colpite. Numero di aziende ha preso l'iniziativa nel fornire alta qualità di prodotti o farmaci per il trattamento delle malattie della pelle. Ciò comporta il processo di innovazione nella ricerca farmaceutica. L'aumento del numero di malattie richiede un trattamento adeguato per il quale i farmaci topici svolgono attualmente un ruolo importante. Di conseguenza, molte aziende hanno aumentato le proprie strutture di ricerca e sviluppo al fine di fornire i farmaci che saranno ritenuti un fattore importante per guidare il mercato in futuro.

AUMENTO DI FUSIONI E ACQUISIZIONI:

Le industrie farmaceutiche probabilmente subiscono la maggior parte dell'attività di fusione e acquisizione (M&A) rispetto a qualsiasi altra industria che coinvolge il numero di operazioni e la spesa in denaro. Questa attività è necessaria a causa dell'aumento dello sviluppo di un nuovo farmaco nell'industria farmaceutica. Ad esempio, a luglio 2018, Leo Pharma ha acquisito un'unità globale di dermatologia su prescrizione di Bayer AG (Germania) a un prezzo non divulgato. Lo scopo di questa acquisizione era di espandere il loro prodotto nei farmaci per la pelle. Leo Pharma sviluppa ulteriormente l'attività di dermatologia su prescrizione con questa acquisizione. L'aumento delle acquisizioni e delle fusioni aiuta le aziende a rafforzare i propri ricavi insieme a strutture di ricerca e sviluppo e produzione e questo ultimo aiuto nella crescita di un particolare mercato.

MERCATO EMERGENTE:

L'elevata accessibilità per i pazienti sta portando a maggiori investimenti da parte del settore privato. Molte aziende si stanno concentrando sull'intraprendere sviluppi strategici per aumentare la loro presenza nelle economie emergenti. Insieme a questo, l'invecchiamento della popolazione e l'aumento del reddito disponibile contribuiranno alla crescita del mercato. Il mercato di consegna di farmaci topici ha una grande opportunità in quanto questa piattaforma ha nuovi elementi che sono stati incorporati per il trattamento di malattie della pelle e delle mucose. Le condizioni della pelle stanno aumentando in tutto il mondo, che alla fine richiede un trattamento. Aumentare la consapevolezza delle malattie della pelle è anche un fattore che sta aiutando il mercato a crescere in futuro.

sfide:

EFFETTI COLLATERALI:

L'effetto collaterale dei farmaci si verifica nell'uomo a causa dell'uso a lungo termine dei farmaci. Ci sono alcuni effetti collaterali che possono verificarsi nel corpo del paziente dopo aver consumato farmaci topici. Ad esempio, il consumo a lungo termine di corticosteroidi può causare difetti alla nascita nel feto. I farmaci topici possono fornire un trattamento migliore ma a parte questo anche il prodotto ha effetti collaterali. Ciò accade a causa dell'uso eccessivo di trattamenti topici che aumentano il rischio di effetti collaterali sia cutanei che sistemici e quindi ostacolano la crescita del mercato.

RICHIAMO DEL PRODOTTO:

Negli ultimi anni, il numero di richiami di prodotti nel mercato topico della consegna di droghe è aumentato enormemente. Questi richiami di prodotti possono verificarsi a causa di inadempienze come difetti di progettazione o di fabbricazione che possono essere negoziati con la sicurezza, l'efficacia e la purezza del farmaco o dei dispositivi di consegna del farmaco da parte di un'azienda produttrice di farmaci. Ad esempio, a luglio 2016, GlaxoSmithKline (Regno Unito) ha annunciato il richiamo dell'unguento Bactroban e della crema Bactroban a causa della presenza di contaminazione durante la produzione; queste formulazioni sono state usate localmente per le infezioni della pelle. Inoltre, a giugno 2016, il cerotto per emicrania di Teva Phamaceutical chiamato Zecuity è stato ricordato per aver riportato gravi ustioni e potenziali cicatrici permanenti. Il richiamo dei prodotti influisce sui ricavi dell'azienda e, in definitiva, sul mercato particolare.

Nota: se hai esigenze particolari, faccelo sapere e ti offriremo il rapporto come desideri.

Informazioni sulla ricerca di mercato di Data Bridge:

Data Bridge Market Research si è presentata come una società di ricerca e consulenza di mercato non convenzionale e neoterica con un livello di resilienza senza precedenti e approcci integrati. Siamo determinati a scoprire le migliori opportunità di mercato e promuovere informazioni efficienti per far prosperare il tuo business sul mercato. Data Bridge si impegna a fornire soluzioni adeguate alle complesse sfide aziendali e avvia un processo decisionale senza sforzo.

Contatto:

Ricerche di mercato di Data Bridge

Tel: + 1-888-387-2818

E-mail: (E-mail protetto)

Psorilax:Il modo migliore per |www.terme comano creme per psoriasi

0

Psorilax: prezzo, funziona, recensioni, opinioni, composizione

Johnson & Johnson (NYSE: JNJ) Conference Call sugli utili del 4 ° trimestre 2019
22 gennaio 2020

Partecipanti aziendali:

Christopher DelOreficeVicepresidente delle relazioni con gli investitori

Alex GorskyPresidente, Consiglio di amministrazione e Amministratore delegato

Joseph J. WolkVicepresidente esecutivo, direttore finanziario

Gli analisti:

Chris SchottJPMorgan – Analista

Larry BiegelsenWells Fargo – Analista

David LewisMorgan Stanley – Analista

Kristen StewartBarclays – Analista

Josh JenningsCowen & Company – Analista

Matt MiksicCredit Suisse – Analista

Danielle AntalffySVB Leerink – Analista

Terence FlynnGoldman Sachs – Analista

Louise ChenCantor Fitzgerald – Analista

Presentazione:

Operatore

Buongiorno. Benvenuti alla teleconferenza sugli utili del quarto trimestre 2019 di Johnson & Johnson. (Istruzioni per l'operatore) Questa chiamata è in fase di registrazione. Se qualcuno ha delle obiezioni, puoi disconnetterti in questo momento.

(Istruzioni per l'operatore) Vorrei ora passare la teleconferenza a Johnson & Johnson. Puoi iniziare

Christopher DelOreficeVicepresidente delle relazioni con gli investitori

Buongiorno. Sono Chris DelOrefice, vicepresidente delle relazioni con gli investitori di Johnson & Johnson. Benvenuti nella revisione dei risultati aziendali della nostra azienda per il quarto trimestre e l'intero anno 2019.

Alla riunione di oggi mi uniscono Alex Gorsky, presidente del consiglio di amministrazione e amministratore delegato e Joe Wolk, vicepresidente esecutivo, direttore finanziario.

Qualche logistica prima di entrare nei dettagli. Questa recensione è stata resa disponibile tramite webcast, accessibile tramite la sezione Investor Relations del sito Web Johnson & Johnson all'indirizzo investor.jnj.com, dove è possibile trovare anche materiali aggiuntivi, tra cui la presentazione odierna e i relativi programmi.

Tieni presente che la presentazione di oggi include dichiarazioni previsionali. Ti invitiamo a rivedere questa dichiarazione cautelativa relativa a tali dichiarazioni incluse nella presentazione odierna, nonché il Modulo 10-K della Società che identifica alcuni fattori che possono far sì che i risultati effettivi della Società differiscano materialmente da quelli previsti.

I nostri documenti SEC, incluso il nostro modulo 10-K del 2018 e il nostro più recente 10-Q, insieme alle riconciliazioni delle misure finanziarie non GAAP utilizzate per la discussione odierna con le misure GAAP più comparabili, sono disponibili anche su investor.jnj.com.

Molti dei prodotti e dei composti discussi oggi vengono sviluppati in collaborazione con partner strategici o concessi in licenza da altre società. Questa diapositiva riconosce quelle relazioni.

Passiamo all'agenda di oggi. Esaminerò i risultati delle vendite e dei profitti del quarto trimestre per la società e i tre settori di attività. Alex fornirà quindi alcune prospettive sui nostri risultati complessivi e sui punti salienti del business per l'anno. Joe concluderà fornendo approfondimenti sulla nostra posizione in contanti, sulla distribuzione dell'allocazione del capitale e sulla nostra guida per il 2020. Il tempo rimanente sarà disponibile per le vostre domande. Prevediamo che il webcast durerà fino a 90 minuti.

Le vendite mondiali sono state di $ 20,7 miliardi nel quarto trimestre del 2019, con un incremento dell'1,7% rispetto al quarto trimestre del 2018. La crescita delle vendite operative, che esclude l'effetto della valuta traslazionale, è aumentata del 2,6% poiché la valuta ha avuto un impatto negativo di 0,9 punti.

Negli Stati Uniti, le vendite sono aumentate dell'1,4%. Nelle regioni al di fuori degli Stati Uniti, la nostra crescita segnalata è stata del 2,1%. La crescita delle vendite operative al di fuori degli Stati Uniti è stata del 4% con una valuta che ha influito negativamente sui risultati OUS riportati di 1,9 punti.

Escludendo l'impatto netto di acquisizioni e cessioni, la crescita delle vendite operative adeguate è stata del 3,4% in tutto il mondo; 2,7% negli Stati Uniti e 4,1% al di fuori degli Stati Uniti

Per l'intero anno 2019, le vendite consolidate sono state di $ 82,1 miliardi, con un incremento dello 0,6% rispetto all'intero anno del 2018. A livello operativo, le vendite dell'intero anno sono cresciute del 2,8% con una valuta che ha avuto un impatto negativo di 2,2 punti.

La crescita delle vendite negli Stati Uniti è stata dello 0,5%. Nelle regioni al di fuori degli Stati Uniti, la nostra crescita riportata è stata dello 0,7%. La crescita delle vendite operative al di fuori degli Stati Uniti è aumentata del 5,3% con una valuta che ha avuto un impatto negativo sui risultati OUS segnalati di 4,6 punti. Escludendo l'impatto netto di acquisizioni e cessioni, la crescita delle vendite operative adeguate è stata del 4,5% in tutto il mondo, del 2,3% negli Stati Uniti e del 6,7% al di fuori degli Stati Uniti

Passando ora ai guadagni. Per il trimestre, l'utile netto è stato di $ 4 miliardi e l'utile diluito per azione è stato di $ 1,50 contro un utile diluito per azione di $ 1,12 un anno fa. Escludendo le spese di ammortamento delle attività immateriali al netto delle imposte e le voci speciali per entrambi i periodi, l'utile netto rettificato per il trimestre è stato di $ 5 miliardi e l'utile diluito rettificato per azione è stato di $ 1,88, con una riduzione rispettivamente del 6,4% e del 4,6% rispetto al quarto trimestre del 2018.

Su base operativa, l'utile diluito rettificato per azione è sceso del 3%. Per quanto riguarda l'intero anno; L'utile netto del 2019 è stato di $ 15,1 miliardi e l'utile diluito per azione è stato di $ 5,63. L'utile netto rettificato del 2019 è stato di $ 23,3 miliardi e l'utile diluito rettificato per azione è stato di $ 8,68, rispettivamente del 4,5% e del 6,1% rispetto all'intero anno 2018. Su base operativa, l'utile diluito rettificato per azione è cresciuto dell'8,8%.

A partire dal Consumatore, ora commenterò l'andamento delle vendite del settore per il quarto trimestre, evidenziando gli elementi che si basano sulla diapositiva che hai di fronte. Salvo diversa indicazione, le percentuali indicate rappresentano la variazione operativa delle vendite rispetto al quarto trimestre del 2018 e pertanto escludono l'impatto della conversione valutaria.

Pur non facendo parte delle osservazioni preparate per la chiamata di oggi, abbiamo fornito ulteriori commenti sul nostro sito Web per le vendite dell'intero anno 2019 per segmento, per aiutarti ad aggiornare i tuoi modelli.

Le vendite del segmento Consumer in tutto il mondo sono ammontate a $ 3,6 miliardi, in crescita del 2,1%. Escludendo l'impatto netto di acquisizioni e cessioni, la crescita delle vendite operative rettificate è stata dell'1,4% con una crescita negli Stati Uniti dell'1,6% dovuta principalmente alla forte performance del nostro franchising OTC. La crescita al di fuori degli Stati Uniti è stata dell'1,3%.

I farmaci da banco sono cresciuti globalmente di quasi il 5% a livello operativo e su base adeguata. Negli Stati Uniti, la crescita di OTC è stata di circa il 10% e sta aumentando la quota di numerosi prodotti come adulti TYLENOL guidati da gel a rilascio rapido, PEPCID e ZARBEE. Tuttavia, la crescita degli Stati Uniti è stata aiutata da circa 200 punti base di stoccaggio a causa di programmi di distribuzione e promozione commerciale incrementali.

Il franchising Beauty è cresciuto del 4,3% o poco meno dell'1% se adeguato per escludere l'impatto dell'acquisizione di DR. CI: Cessione LABO e ROC. NEUTROGENA ha fornito ottime prestazioni a livello globale con una crescita del 4% al di fuori degli Stati Uniti, guidata dall'innovazione anti-invecchiamento e di pulizia nell'EMEA e dalla forza della categoria di umidità delle mani e del corpo nella regione dell'Asia del Pacifico. Negli Stati Uniti, la crescita della quota e del mercato è stata ampiamente compensata dal lappolamento delle costruzioni di pipeline di nuovi prodotti dell'anno precedente e da maggiori investimenti commerciali nel 2019 in NEUTROGENA.

Concludendo il segmento Consumer, Baby Care è diminuito del 9,3% a livello globale o negativo del 7% se adeguato per escludere l'impatto della cessione del Baby Center. Questo calo è dovuto principalmente alle continue pressioni concorrenziali nonché al confronto con le attività di rilancio dell'anno precedente, in particolare negli Stati Uniti.

Passando al nostro segmento farmaceutico; in tutto il mondo le vendite farmaceutiche di $ 10,5 miliardi sono cresciute del 4,4%, grazie alla crescita a due cifre di nove prodotti chiave. Il segmento ha realizzato un settimo trimestre consecutivo superiore a $ 10 miliardi di ricavi. Le vendite sono cresciute negli Stati Uniti di circa il 4% e sono aumentate al di fuori degli Stati Uniti di quasi il 5%. La concorrenza generica per ZYTIGA ha avuto un impatto negativo sulla nostra crescita in tutto il mondo e negli Stati Uniti rispettivamente di circa 180 punti base e 310 punti base.

Il nostro solido portafoglio di prodotti e capacità commerciali ci ha permesso di realizzare una crescita globale a livelli di mercato superiori, nonostante i significativi venti contrari biosimilari e generici. Il nostro portafoglio di oncologia ha registrato un altro trimestre forte con una crescita mondiale di oltre il 10%. DARZALEX ha continuato le sue ottime prestazioni crescendo di circa (fonetico) del 45% a livello globale. Gli Stati Uniti sono cresciuti di quasi il 38% con una forte crescita in tutte le linee di terapia, spinti dalla nuova indicazione in prima linea per la popolazione non ammissibile del trapianto di mieloma multiplo.

La continua forte crescita al di fuori degli Stati Uniti è guidata da una maggiore penetrazione e guadagni di condivisione. IMBRUVICA è cresciuta oltre il 26% a livello globale, trainata in gran parte dai guadagni della quota di mercato e dalla forte crescita del mercato, principalmente nell'indicazione di leucemia linfatica cronica negli Stati Uniti, insieme a una forte captazione al di fuori degli Stati Uniti.

Negli Stati Uniti, sulla base dei dati del terzo trimestre, IMBRUVICA ha guadagnato oltre 7 punti di quota di mercato nella terapia CLL Line 1. La crescita mondiale di ZYTIGA è diminuita di circa il 13% con una flessione di quasi il 45% negli Stati Uniti a causa della concorrenza generica, che è stata parzialmente compensata dalla continua forte crescita di quasi il 13% al di fuori degli Stati Uniti.

Continuiamo a essere soddisfatti del progresso di lancio di ERLEADA, che ha generato vendite globali di $ 116 milioni nel quarto trimestre e $ 332 milioni per l'intero anno, principalmente negli Stati Uniti. Continuiamo a crescere la quota di mercato nel carcinoma prostatico non metastatico resistente alla castrazione, guadagnando oltre due punti negli Stati Uniti in questo trimestre.

Le vendite negli Stati Uniti riflettono il primo trimestre completo per l'indicazione approvata per i pazienti con carcinoma prostatico sensibile alla castrazione metastatica. Siamo inoltre lieti dei progressi nel lancio in EMEA, dove ERLEADA è ora disponibile in 12 paesi. La nostra area terapeutica di immunologia ha registrato una crescita delle vendite globali di poco superiore al 6%, trainata dalle forti prestazioni a due cifre di STELARA e TREMFYA.

La crescita delle vendite è stata parzialmente compensata dalla continua erosione di REMICADE di circa il 16% a causa di maggiori sconti e modesta perdita di azioni negli Stati Uniti a meccanismi di azione alternativi e biosimilari. La crescita di STELARA di quasi il 19% è stata trainata principalmente dall'indicazione della malattia di Crohn in cui la quota di mercato è aumentata di 6 punti negli Stati Uniti rispetto al quarto trimestre del 2018. In ottobre, abbiamo ricevuto l'approvazione da parte della FDA degli Stati Uniti di STELARA per il trattamento degli adulti con colite ulcerosa gravemente attiva.

SIMPONI – SIMPONI ARIA ha registrato una crescita delle vendite del 7,6%, trainata da una forte crescita del mercato e guadagni di quote SIMPONI ARIA negli Stati Uniti TREMFYA sono cresciuti di oltre il 55% e hanno raggiunto una quota dell'8,3% del mercato della psoriasi negli Stati Uniti, che è aumentato di circa 2 punti da il quarto trimestre del 2018.

Nel settore delle neuroscienze, il nostro portafoglio a lunga durata di Paliperidone ha registrato una crescita del 15%, con una quota di mercato più elevata, trainata da nuovi inizi di pazienti e forte persistenza. Inoltre, continuiamo a progredire il lancio di SPRAVATO. La domanda dei pazienti continua a crescere e il bisogno insoddisfatto rimane molto elevato. I nuovi inizi di pazienti continuano ad aumentare costantemente ogni mese, con oltre 3.500 pazienti trattati fino ad oggi.

Inoltre, siamo lieti di segnalare che a dicembre SPRAVATO è stato approvato in Europa per gli adulti con disturbo depressivo maggiore resistente al trattamento.

Nelle malattie infettive, il nostro portafoglio è cresciuto del 9,6%, guidato da una forte crescita di SYMTUZA e JULUCA per l'HIV, parzialmente compensata dalla cannibalizzazione e dall'aumento della concorrenza generica in altri prodotti. Nel nostro metabolismo cardiovascolare e nel portafoglio di altri prodotti, abbiamo registrato vendite in calo del 9,5%, principalmente a causa del calo di INVOKANA e della concorrenza biosimilare per PROCRIT.

XARELTO è stato piatto con aumenti di volume compensati dagli sconti, principalmente a causa di un aumento del tasso legislativo per il foro della ciambella dal 50% al 70% insieme a un maggiore utilizzo di Medicare e foro ciambella. Nel nostro portafoglio totale di ipertensione polmonare, le vendite sono diminuite del 6,2% a seguito di una modifica del modello di distributore negli Stati Uniti per realizzare efficienze sfruttando le nostre capacità di distribuzione. Questo cambiamento ha avuto un impatto negativo sulla crescita delle vendite di circa 800 punti base con una crescita delle vendite del 2%, quando si è adattato a questo impatto una tantum.

Continuiamo a vedere una forte crescita delle quote per OPSUMIT e UPTRAVI e, quando ci si adegua all'impatto del modello di distributore una tantum, le loro vendite in tutto il mondo sono state rispettivamente di circa il 10% e il 30%. La crescita del portafoglio è stata inoltre influenzata dal calo delle vendite di TRACLEER a seguito della continua concorrenza generica.

Ora rivolgerò la tua attenzione al segmento dei dispositivi medici. Le vendite mondiali di dispositivi medici sono state di $ 6,6 miliardi in crescita dello 0,2%. Escludendo l'impatto netto di acquisizioni e cessioni, principalmente la cessione di ASP, la crescita delle vendite operative adeguate è stata del 2,7% in tutto il mondo.

Gli articoli una tantum hanno avuto un impatto negativo sulla crescita nel trimestre di circa 70 punti base, in gran parte legati a un sanguinamento degli acquisti a termine nel terzo trimestre, in Giappone, in vista della variazione dell'imposta sui consumi, che ha avuto un impatto principale sulla nostra attività di Vision. La maggior parte di questo è stata venduta nel quarto trimestre, mentre il resto dovrebbe avvenire nel primo trimestre 2020.

Inoltre, su base annua, siamo lieti di segnalare che Medical Devices ha accelerato la crescita delle vendite sottostanti in tutto il mondo di 130 punti base con la seconda metà del 2019 che ha registrato una crescita del 4%. Le soluzioni interventistiche sono cresciute oltre il 13% a livello globale, guidate da una continua forza nel nostro settore dell'elettrofisiologia che ha raggiunto circa il 14% di crescita in tutto il mondo e quasi il 16% per l'anno, continuando il suo trend di crescita a doppia cifra per l'11 ° anno consecutivo.

La crescita è stata forte in tutte le regioni guidate dalle nostre più recenti offerte di prodotti in ablazione e cateteri avanzati che hanno contribuito alla crescita del mercato procedurale della fibrillazione atriale. Inoltre, la nostra attività di Cerenovus ha realizzato il suo sesto trimestre consecutivo di crescita a doppia cifra, guidato dalla forte crescita del mercato e dall'innovazione di nuovi prodotti, tra cui EMBOTRAP per il trattamento dell'ictus ischemico.

La visione è cresciuta dello 0,9% o del 3% quando si è adattato per l'impatto negativo dell'acquisto a termine dell'imposta sui consumi in Giappone che ho menzionato in precedenza. La crescita è stata trainata principalmente dalle lenti a contatto che sono cresciute del 2,6% a livello globale o del 5% adeguate per l'emorragia dell'acquisto a termine dell'imposta sui consumi in Giappone, guidata da una crescita a due cifre dei prodotti usa e getta giornalieri nella famiglia OASYS.

Per l'anno, le lenti a contatto sono cresciute di quasi il 5%, che prevediamo essere in linea con il mercato globale, rappresentando il quarto anno consecutivo in cui le lenti a contatto sono cresciute sul mercato o al di sopra di esse. Nella visione chirurgica, abbiamo assistito a una forte crescita della OUS nel settore della cataratta a causa delle prestazioni di mercato superiori nelle IOL, principalmente nell'Asia del Pacifico.

Ciò è stato compensato dalla debole performance degli Stati Uniti dovuta alle pressioni della concorrenza e alla minore crescita del mercato nella chirurgia refrattiva. Continuiamo a vedere uno slancio positivo in ortopedia, garantendo una crescita per il trimestre dell'1,2%. Su base annuale, ogni piattaforma principale ha accelerato rispetto all'anno precedente e la crescita corretta per questo franchising è migliorata di 180 punti base.

Questo progresso riflette la continua esecuzione della nostra innovazione e strategie commerciali volte a migliorare le prestazioni. I fianchi sono cresciuti del 4,2%, guidati dalla nostra posizione di leadership nell'approccio anteriore, dalla forte domanda del nostro stelo primario ACTIS e da tecnologie abilitanti come il sistema di automazione chirurgica KINCISE e il sistema di navigazione JointPoint.

La crescita delle ginocchia è stata dell'1,4% nel trimestre, trainata dalle ottime prestazioni di nuove innovazioni come ATTUNE Revision, ATTUNE S plus intendo la piattaforma rotante Cementless ATTUNE lanciata alla fine del terzo trimestre. Una crescita degli OUS del 3,2% è stata guidata dall'Asia del Pacifico. Inoltre, gli Stati Uniti sono tornati alla crescita in questo trimestre.

La crescita del trauma del 2,5% a livello globale è stata trainata dalla crescita del mercato supportata dalla forte adozione di nuove innovazioni, come il nostro sistema di collo femorale. La spina dorsale è diminuita del 5,8% con gli Stati Uniti come motore principale, in parte a causa della mancata ripetizione del rialzo dei prezzi favorevoli del quarto trimestre 2018, che ha avuto un impatto negativo sulla crescita globale di 250 punti base.

Escludendo questo impatto, la performance del trimestre è stata in linea con l'intero anno. Mentre abbiamo perso quote nel trimestre, continuiamo a vedere un assorbimento positivo di nuovi prodotti e siamo soddisfatti del forte avvio del nostro sistema chirurgico SYMPHONY recentemente lanciato per l'uso nelle procedure posteriori della colonna cervicale.

La pressione sui prezzi continua a incidere su tutte le categorie in ortopedia. Il prezzo puro negli Stati Uniti nella colonna vertebrale è diminuito di circa il 3% dopo essersi aggiustato per il vero aumento dei prezzi dell'anno scorso. Il prezzo del trauma è stato coerente con il calo del 3% nel terzo trimestre. Il prezzo nei fianchi e nelle ginocchia è migliorato sia rispetto al 3 ° trimestre rispettivamente con l'1% negativo e piatto.

Passare ai risultati per l'attività chirurgica; la chirurgia avanzata ha prodotto una crescita globale di oltre il 3%, guidata da una crescita della bio-chirurgia di circa il 4%, con una crescita in tutte le regioni guidata dai guadagni della quota nell'area Asia Pacifico e dalla crescita del mercato. Tuttavia, la crescita nel trimestre è stata moderata poiché SURGIFLO ha continuato a risalire negli Stati Uniti.

L'energia e gli endocutters sono cresciuti rispettivamente di circa il 3% e il 2%, con una crescita degli OUS trainata dai guadagni azionari e dai nuovi prodotti nella regione Asia-Pacifico, parzialmente compensata dalla pressione competitiva negli Stati Uniti.

La chiusura della ferita è cresciuta di oltre il 2%, trainata dalla continua forte crescita del mercato in Cina e dai guadagni delle quote nelle suture convenzionali e spinate. Come previsto, i giorni di vendita hanno avuto un impatto irrilevante sui nostri tassi di crescita globali nel quarto trimestre. Nel 2020, i giorni di vendita avranno un impatto negativo sulla crescita dei dispositivi medici del primo trimestre di oltre 50 punti base, con la maggior parte compensata nel secondo trimestre.

Ora fornirò alcuni commenti sui nostri guadagni per l'anno. Si prega di rivolgere la propria attenzione alla sezione del riquadro in fondo al programma. Vedrai che abbiamo fornito le nostre entrate adeguate per escludere le spese di ammortamento immateriali e le voci speciali.

Come riportato stamattina, il nostro EPS rettificato di $ 8,68 riflette una crescita segnalata del 6,1% e una crescita operativa dell'8,8%, superando la fascia alta di entrambe le segnalazioni di un intervallo di guida EPS rettificato operativo da ottobre, guidato dalle nostre ottime prestazioni.

Coerentemente con la nostra guida, abbiamo assistito a una leggera flessione dei margini operativi ante imposte rettificati di 30 punti base, trainati dagli investimenti in chirurgia digitale e dispositivi medici.

Passare alla diapositiva successiva; il nostro reddito prima delle imposte rettificato per l'intero anno 2019 per l'impresa è migliorato di 170 punti base rispetto al 2018. Considerando il reddito ante imposte rettificato per segmento, i dispositivi medici al 35,4% sono più alti rispetto all'anno precedente, principalmente a causa delle maggiori plusvalenze nel 2019, parzialmente compensato da un aumento degli investimenti in chirurgia digitale.

I margini farmaceutici sono diminuiti di 200 punti base al 40%, spinti da una riduzione degli utili da cessione e da un aumento dei costi dei prodotti venduti a causa dell'impatto negativo della valuta. I margini dei consumatori sono migliorati di 90 punti base, portandosi al 21,4%, spinti dalla prioritizzazione pianificata e dalle riduzioni della spesa, parzialmente compensate da riduzioni delle plusvalenze nel 2018.

Ora, per quanto riguarda il nostro conto economico consolidato per il quarto trimestre del 2019, rivolgi la tua attenzione alla sezione in scatola del programma. Come indicato nella tabella delle misure non GAAP, gli utili netti del quarto trimestre 2019 sono adeguati per escludere le spese di ammortamento delle attività immateriali e le voci speciali di $ 1 miliardo al netto delle imposte, principalmente guidate da un ammortamento immateriale di $ 1 miliardo. Escludendo l'impatto di tali elementi, il nostro utile rettificato per azione è di $ 1,88, in calo del 4,6% rispetto al quarto trimestre 2018. L'EPS rettificato su base valutaria costante è stato di $ 1,91, in calo del 3% rispetto al quarto trimestre 2018.

Mi piace ora evidenziare alcune voci degne di nota che sono cambiate nel conto economico rispetto allo stesso trimestre dell'anno scorso. Il costo dei prodotti venduti ha subito una leggera riduzione della leva trainata principalmente da un aumento delle spese di ammortamento, parzialmente compensato dal favorevole mix di segmenti.

I margini di vendita, marketing e amministrativi per il trimestre sono migliorati a causa della prioritizzazione pianificata nel settore dei consumatori e del mix di segmenti favorevoli, parzialmente compensato da un aumento degli investimenti nel settore dei dispositivi medici. Gli investimenti in ricerca e sviluppo sono stati coerenti anno su anno con pagamenti leggermente inferiori nel settore farmaceutico, compensati da maggiori investimenti in soluzioni digitali nel settore dei dispositivi medici.

Gli interessi passivi netti sono stati inferiori di $ 50 milioni, principalmente a causa dell'effetto positivo degli accordi di copertura di investimenti netti, parzialmente compensato da minori interessi attivi derivanti da tassi di interesse più bassi guadagnati sui saldi di cassa. La variazione dell'altra linea di entrate e uscite è stata trainata principalmente da minori spese per contenzioso, maggiori guadagni non realizzati su titoli, parzialmente compensati da minori utili da cessioni.

Per quanto riguarda le tasse nel trimestre, la nostra aliquota fiscale effettiva è stata del 4,9% rispetto al tax rate del 2,6% del quarto trimestre 2018. Il trimestre in corso comprende un onere fiscale stimato per le disposizioni transitorie della riforma fiscale svizzera, parzialmente compensato dalla riorganizzazione di alcune filiali estere e dagli impatti aggiuntivi delle normative recentemente emesse associate alla riforma fiscale degli Stati Uniti. Ti invitiamo a fare riferimento al nostro 10-K per ulteriori dettagli su questa e altre questioni fiscali specifiche. Escludendo le voci speciali, l'aliquota fiscale effettiva è stata del 10,7%, relativamente coerente con lo stesso periodo dell'anno scorso, che era dell'11,1%.

Ora guardando il reddito corretto prima delle imposte. Nel quarto trimestre del 2019, le nostre entrate prima delle imposte rettificate per l'impresa in percentuale delle vendite sono diminuite dal 29,6% al 27,1% nel quarto trimestre del 2019, principalmente a causa dell'impatto delle plusvalenze nel quarto trimestre dello scorso anno.

Di seguito sono riportati i principali driver di reddito rettificato al lordo delle imposte per segmento. I dispositivi medici sono diminuiti di 830 punti base, guidati dal guadagno di cessione di LifeScan riportato nel 4 ° trimestre 2018, nonché da un aumento degli investimenti in robotica e soluzioni digitali nel 2019. I margini dei consumatori sono diminuiti di 280 punti base, principalmente a causa della cessione di ROC nel 4 ° trimestre 2018. Il leggero aumento dei margini farmaceutici di 30 punti base è stato principalmente guidato dalla riduzione dei pagamenti milestone. Ciò conclude le vendite e i punti salienti del conto economico per il quarto trimestre 2019 di Johnson & Johnson.

Per riferimento, ecco una diapositiva che riassume gli sviluppi notevoli che si verificano nel quarto trimestre, alcuni dei quali sono stati menzionati nei miei commenti. Ora sono lieto di consegnare la chiamata ad Alex Gorsky.

Alex GorskyPresidente, Consiglio di amministrazione e Amministratore delegato

Grazie Chris. E grazie a tutti voi per esservi uniti a noi oggi. Siamo molto lieti di mettere in evidenza il nostro quarto trimestre e la performance dell'intero anno. Nel 2019 abbiamo conseguito una forte crescita delle entrate e degli utili, superando i parametri di performance finanziaria stabiliti all'inizio dell'anno. Ora abbiamo raggiunto questo obiettivo facendo anche investimenti strategici che fanno avanzare la pipeline di opportunità e innovazione in tutti e tre i nostri segmenti di business e mentre affrontiamo una varietà di sfide dai dibattiti sul sistema sanitario nel nostro paese all'incertezza con il commercio globale fino ad oggi ambiente litigioso per citarne alcuni. Ora sono molto orgoglioso del fatto che, nonostante le sfide, rimaniamo ancora concentrati e portati a termine gli impegni e le responsabilità del nostro credo nei confronti dei nostri pazienti, dipendenti, comunità e azionisti, guidando in ultima analisi il nostro obiettivo di promuovere la salute per l'umanità. E sono fiducioso che siamo ben posizionati per sfruttare questo slancio e solide fondamenta mentre ci spostiamo nel 2020 e oltre.

Rimaniamo concentrati sul lungo termine, una mentalità che manteniamo da oltre un secolo, una mentalità che è direttamente collegata alla nostra esecuzione mirata, alla nostra ricerca incessante di innovazione, alle nostre persone di talento e appassionate, alla nostra cultura della cura del attenzione costante e incondizionata alla creazione di valore per tutti i nostri stakeholder.

In effetti, sono orgoglioso di sottolineare che il 2019 ha segnato il nostro 36 ° anno consecutivo di crescita degli utili operativi rettificati per Johnson & Johnson. Ora questa performance è indicativa della forza del nostro ampio business e rimaniamo concentrati nel guidare la prossima generazione di innovazione in tutto il nostro portafoglio in nuovi mercati, in mercati in cui abbiamo maggiori opportunità di competere e nei mercati in cui guidiamo, che includono le nostre 26 piattaforme che ogni anno generano $ 1 miliardo o più di vendite.

Nel settore farmaceutico, il nostro solido track record di successo è continuato di nuovo nel 2019 quando il nostro segmento Pharma ha superato il mercato, crescendo a livello operativo del 5,8%, che ha più che compensato la perdita di esclusività dovuta alla concorrenza biosimilare e all'erosione generica, nonché a nuovi concorrenti competitivi e altri mercati pressioni.

Ora, è importante notare che la nostra solida crescita può essere attribuita al volume e non al prezzo. E la nostra crescita delle vendite è un riflesso del crescente numero di pazienti che stiamo raggiungendo con i nostri farmaci trasformativi per esigenze insoddisfatte. Questa forte crescita, non solo ci ha permesso di fornire medicinali salvavita e che cambiano la vita alle persone in tutto il mondo, ma ci ha anche permesso di diventare la terza più grande azienda farmaceutica al mondo, mantenendo la nostra posizione di leadership numero 1 negli Stati Uniti e essere riconosciuto come la società farmaceutica numero 1 nell'elenco annuale delle aziende più ammirate della rivista Fortune. I nostri investimenti nel settore farmaceutico in ricerca e sviluppo continuano a alimentare anche una crescita eccezionale. Abbiamo raggiunto una crescita a doppia cifra per 10 prodotti chiave e fornito prestazioni elevate in tutte le regioni, anche nei mercati sviluppati ed emergenti.

Siamo molto orgogliosi ed entusiasti di aver ottenuto l'approvazione e di aver lanciato due nuovi medicinali trasformazionali, SPRAVATO per la depressione resistente al trattamento e BALVERSA per il carcinoma uroteliale metastatico. Continuiamo inoltre a massimizzare il valore nei nostri marchi di mercato, presentando numerosi documenti e ricevendo approvazioni per estensioni di linea per marchi chiave, tra cui STELARA, DARZALEX ed ERLEADA, molti con un potenziale di vendita superiore a $ 500 milioni. E continuiamo ad espandere il nostro portafoglio di licenze strategiche e acquisizione di nuovi asset e piattaforme, tra cui cusatuzumab di Argenx, un anticorpo sperimentale per il trattamento della leucemia mieloide acuta e delle sindromi mielodisplastiche ad alto rischio, una piattaforma di regolazione genica di MeiraGTx e bermekimab di XBiotech Inc., un alfa anti-IL-1 in fase II di sviluppo per il trattamento della dermatite atopica e dell'idradenite suppurativa.

Con questa pipeline leader del settore, le nostre capacità commerciali e la solida produttività in R&S, sono fiducioso che siamo ben posizionati per continuare a offrire una crescita sostenuta a lungo termine sul mercato nel 2020 e oltre. Ora, il 2019 ha segnato un anno di significative trasformazioni per il business della salute dei consumatori. Abbiamo ristabilito il nostro marchio e le nostre finalità e preso decisioni strategiche che nel tempo accelereranno la crescita, ridurranno la complessità e miglioreranno i margini operativi. Alimentato da marchi basati sulla scienza e basati su conoscenze professionali e forti opinioni dei consumatori, nel 2019 abbiamo focalizzato l'attenzione sulla definizione di un piano e un percorso chiari per raggiungere la redditività di riferimento nel 2020. E questo segmento è già sulla buona strada, fornendo 90 punti base di miglioramento del margine pretax adeguato per l'anno.

Inoltre, abbiamo integrato con successo le acquisizioni di Zarbee's, Inc., leader nei rimedi da banco a base naturale e nella linea di prodotti per la cura della pelle dermocosmetica Dr.Ci:Labo, rafforzando la nostra posizione in queste categorie a crescita più elevata. La nostra attività di consumo negli Stati Uniti continua a crescere al di sopra del mercato e le nostre aree prioritarie di bellezza e OTC hanno prodotto una solida crescita operativa per l'anno.

Sono anche lieto di condividere che Medical Devices ha accelerato di nuovo la crescita nel 2019. A causa della nostra incessante attenzione per l'esecuzione, l'innovazione e la gestione del portafoglio, la nostra crescita di base è stata di poco inferiore al 4%. Ora il miglioramento delle prestazioni è stato guidato dall'elettrofisiologia, raggiungendo il suo undicesimo anno consecutivo di crescita a doppia cifra; lenti a contatto, che hanno prodotto una crescita sul mercato o al di sopra del quarto anno consecutivo, le aziende energetiche e degli endocutters hanno fatto crescere cifre a metà singola e migliorato le prestazioni in ortopedia con ciascuna delle principali piattaforme in accelerazione rispetto al 2018.

Durante l'anno, abbiamo anche rafforzato il nostro impegno e accelerato l'ingresso in una delle categorie di assistenza sanitaria in più rapida crescita e in eccitanti campi di trasformazione della medicina, la chirurgia digitale. Coerentemente con il nostro storico spirito pionieristico nei dispositivi medici, siamo focalizzati sulla prossima frontiera della chirurgia. L'acquisizione di Auris Health, Inc., uno sviluppatore di tecnologie robotiche attualmente nel carcinoma polmonare, ha accelerato il nostro ingresso nella robotica come parte di un ecosistema di chirurgia digitale progettato per rendere l'intervento medico più intelligente, meno invasivo e più personalizzato per elevare lo standard di cura.

Inoltre, proprio il mese scorso, abbiamo annunciato un accordo per acquisire la partecipazione rimanente in Verb Surgical per rafforzare ulteriormente il nostro ecosistema. E abbiamo anche lanciato con successo prodotti critici in ogni franchising nel corso del 2019, incluso; il sistema di ginocchio Cementless ATTUNE, la nostra lente a contatto ACUVUE OASYS, unica nel suo genere, con TECNOLOGIA INTELLIGENTE TRANSITIONS LIGHT. La prima cucitrice circolare elettrica alimentata ECHELON del settore e la guaina orientabile VIZIGO nella nostra azienda di elettrofisiologia leader di mercato.

Il nostro team continua a concentrarsi sul miglioramento della nostra cadenza di innovazione e sull'ottimizzazione del nostro portafoglio, che comprendeva il completamento della cessione di prodotti per la sterilizzazione avanzata e l'esecuzione di oltre 50 acquisizioni o partnership strategiche che prevediamo aumenteranno ulteriormente la nostra crescita futura.

Ci impegniamo a sfruttare questo slancio nel 2020 e sono lieto di condividere che ospiteremo la nostra Giornata di riesame delle attività relative ai dispositivi medici il 13 maggio per evidenziare le strategie che riteniamo possano favorire un'ulteriore crescita e fornire ulteriori approfondimenti sui piani del team in chirurgia digitale.

Guardando al futuro, in tutti e tre i segmenti di business, sappiamo di avere ancora molto lavoro da fare, ma ci impegniamo a continuare a offrire una crescita superiore al mercato nel nostro settore farmaceutico, ampliando la portata del nostro business dei consumatori e soddisfando il pieno potenziale di la nostra attività sui dispositivi medici.

E uno dei fattori più critici per raggiungere gli obiettivi di tutte le nostre strategie aziendali è sostenere i nostri investimenti nell'innovazione. Ancora una volta nel 2019, abbiamo raggiunto livelli record di investimenti, investendo oltre $ 11 miliardi in ricerca e sviluppo. E in tutti i settori, rimaniamo tra le prime 10 aziende globali che investono ai massimi livelli in ricerca e sviluppo e innovazione.

Attraverso Johnson & Johnson, riconosciamo il forte impatto che la tecnologia, l'innovazione e le scoperte sulla salute hanno nel creare cambiamenti significativi nella vita delle persone e nel stabilire una differenziazione competitiva nel settore.

Ora, sarei remissivo se non riconoscessi che tutti questi molti risultati non sarebbero stati possibili senza gli sforzi, la passione e l'impegno dei nostri circa 132.000 colleghi globali Johnson & Johnson che continuano a dimostrare un impegno nel fornire soluzioni sanitarie che a beneficio di pazienti, consumatori e comunità in tutto il mondo.

La nostra cultura basata sul proposito e basata sul Credo pone i pazienti e le persone al primo posto, e questo è certamente vero nel modo in cui pensiamo ai nostri dipendenti e lavoriamo per coltivare costantemente la forza lavoro migliore, più sana e più coinvolta al mondo. The fact that our Johnson & Johnson colleagues are truly the driving force behind our successful performance and in fulfilling our purpose is something that we never, never take for granted and always celebrate.

We share the common objective of always making the health and well-being of the patients and consumers who use our products every day our number one priority and it has been this way for the last 134 years. We are on the front lines of developing medicines and revolutionary products that are literally saving people’s lives, and we’re working to prevent cancer, offer less-invasive surgeries and to end Ebola and HIV. This is what the world expects of us and this is what our global workforce is united around, committed to and prepared to do. Now, putting the needs of those we serve first also means protecting our shared environment in natural resources. We know that human health is directly linked to the health of the planet. Healthy people and communities go hand in hand with a healthy environment. This is why we are committed to reducing the environmental footprint of our operations, products and supply chain with 2020 targets to reduce carbon emissions by 20% and procure 35% of electricity from renewable resources.

Looking over the long term, we are optimizing our operations to improve water and energy efficiency while focusing on sustainable design and reduction in product packaging as well, all with the goal of delivering better health for people everywhere.

So now I’d like to close where I began. In spite of the numerous industry challenges we faced throughout 2019, I’m very pleased that we remain focused on meeting the needs of patients and consumers globally, delivering value to all of our stakeholders, innovating, driving growth, and achieving solid performance. Our sustainable business model is built for the long term and provides us with increased confidence about our business, our strategic direction and the healthcare industry in what may sometimes feel like uncertain times. You have our unwavering commitment that we will hold ourselves accountable to fulfill all of Our Credo responsibilities, where we always keep the patient at the center of everything we do and also ensure the continued long-term success of Johnson & Johnson.

We have an incredible opportunity to play a leading role in defining and driving the future of health care and putting it within the reach of everyone everywhere. This is why we are so very excited and confident about 2020 and beyond. I look forward to addressing your questions during the upcoming Q&A, but I’ll now turn it over to Joe, who will provide additional details about our results and guidance for 2020.

Thank you, Joe?

Joseph J. WolkExecutive Vice President, Chief Financial Officer

Thank you, Alex. Hello, everyone. We appreciate you joining today’s call. I will be providing additional context around our 2019 performance, including our year-end cash position and the capital allocation actions that we executed throughout the year, and then conclude with our guidance for 2020. As Alex and Chris mentioned, we delivered solid fourth quarter results, which capped a strong year of performance for Johnson & Johnson. Our full-year results reflect a continued commitment to our long-term strategic objectives. Throughout the quarter and the year, we maintained our focus on delivering life-saving and life-changing products to patients and consumers across the globe. Heading into 2020, we are confident in our overall strategy and ability to drive results across the enterprise that will yield strong shareholder returns. Our solid results during the year generated strong cash flow, our highest level ever of free cash flow of nearly $20 billion.

With respect to our cash position; at the end of 2019, we had approximately $8.4 billion of net debt, consisting of approximately $19.3 billion of cash and marketable securities and approximately $27.7 billion of debt. Although we don’t provide cash flow guidance, for transparency as we come off a record year of free cash flow generation, we do expect a decline in 2020 of approximately 10% as we are planning for a payment related to the agreement in principle to settle opioid litigation, as previously disclosed.

In 2019, we executed on all four elements of our capital allocation strategy. Our first objective within that framework is to invest in growth opportunities to solidify and advance our current business. Delivering transformative healthcare solutions and creating access is the top priority for Johnson & Johnson. And, as Alex mentioned, we invested more than $11 billion in R&D during 2019.

As investors in Johnson & Johnson know, delivering a competitive and increasing dividend is a capital allocation priority for us. In 2019, we returned almost $10 billion to investors, which is approximately 50% of our free cash flow, increasing the quarterly dividend by 5.6%. Once we’ve satisfied our dividend objectives, we seek M&A opportunities where our capabilities can create compelling value.

During the year, we completed a number of strategic acquisitions totaling almost $6 billion to further strengthen our portfolio which Alex outlined earlier in the call. Finally, after executing on these three important capital allocation priorities, we consider other prudent ways to return value to shareholders, such as the $5 billion share repurchase program we began in December of 2018 and concluded in the third quarter of 2019.

Let’s move the discussion to guidance and information to assist your financial modeling for the year ahead. I’ll begin with some qualitative comments that we considered in our outlook. First, our projected sales growth includes the benefit of an additional two to three shipping days associated with a 53rd week in our 2020 fiscal calendar. This will be partially offset by a SKU rationalization program in our Consumer segment/

As part of our efforts to further improve profitability in 2020, the consumer segment will continue to invest in platforms where we have differentiated brands with the greatest potential. Therefore, we plan to rationalize approximately 10% of the SKUs across the global portfolio, translating to a negative impact on 2020 topline growth of slightly over 100 basis points for the segment. This program will be primarily focused outside the U.S. with a larger impact coming in the second half of the year in the baby and beauty franchises, considering both the additional shipping days associated with a 53rd fiscal week and the consumer SKU rationalization program. The net impact is approximately 50 basis points to 100 basis points of benefit to the company’s sales growth outlook. Specific to each segment, our adjusted sales guidance also assumes continued above-market performance in our Pharmaceutical segment, driven by continued strong growth from key products such as DARZALEX, IMBRUVICA, TREMFYA, STELARA and ERLEADA due to increased penetration and new indications.

Continued acceleration of sales growth in Medical Devices generated by recent launches and improved execution. And in the Consumer Health business, we will continue to grow above the market in the U.S. while executing the SKU rationalization program to position the segment for benchmark profitability. Given these factors, we expect adjusted operational sales growth for the full-year of between 5.0% and 6.0% or 5.5% at the midpoint. The adjusted operational sales growth of 5% to 6% is on a constant currency basis, reflecting how we manage our business performance. Considering a negative impact from net acquisitions and divestitures, which we estimate at 50 basis points, we are comfortable with your models reflecting operational sales growth in the range of 4.5% to 5.5% or $85.8 billion to $86.6 billion.

As you know, we do not predict the impact of currency movements, but utilizing the euro spot rate relative to the U.S. dollar as of last week at 1.11, there is an estimated negative impact of foreign currency translation of approximately 50 basis points, resulting in an estimated reported sales growth between 4% and 5% compared to 2019 or $85.4 billion to $86.2 billion.

Let’s now discuss earnings per share. As you can see on your screen, here’s a slide depicting the components and assumptions included in our 2020 EPS guidance. Using the sales growth guidance I just referenced provides approximately $0.40 growth to EPS. The next column is based on expected operating margin improvement of approximately 100 basis points, which translates to an incremental $0.25 of contribution net of continued investments across our segments. Operating margin improvement will be primarily driven by continued efforts to improve manufacturing capabilities, optimize sales marketing and administrative expenses, and the consumer SKU rationalization just discussed.

This results in strong adjusted operational EPS growth for the core business of $0.65 or 7.5% versus the prior year. Offsetting those two operating components is the anticipated reduced level of other income of approximately $0.30 compared to 2019. You may recall that we benefited from a large divestiture gain from the sale of our Advanced Sterilization Products business in the second quarter of 2019.

The final element to this EPS waterfall chart is the 2020 benefit we will have from the share repurchase program completed in 2019 which adds $0.05 to EPS compared to 2019, resulting in an adjusted operational EPS of $9.08 at the midpoint or a growth rate of 4.6%. While not predicting the impact of currency movements using recent exchange rates, our reported adjusted EPS would be negatively impacted by approximately $0.05 per share, resulting in adjusted reported earnings per share of $9.03 at the midpoint, reflecting growth of approximately 4%.

Continuing with EPS guidance, this slide provides a summary of additional P&L items to better provide insight into our full-year 2020 guidance. As referenced earlier, for 2020 we are expecting our adjusted pre-tax operating margin to improve by approximately 100 basis points, while still prioritizing investment in our business that accelerates and further strengthens our pipeline of new products for the long term.

Although we are continuously evaluating external value creating opportunities for purposes of your models, we currently assume no major acquisitions or other major uses of cash and are therefore comfortable with your modeling net interest expense between zero and $100 million.

As a reminder, other income and expense is the line on the P&L where we record royalty income as well as gains and losses related to the items such as litigation, investments by our Johnson & Johnson development corporation, divestitures, asset sales, and write-offs.

We would be comfortable with your models for 2020 reflecting net other income and expense, excluding special items, as net income ranging from $1.5 billion to $1.7 billion. This is lower than 2019 as we had elevated levels of divestiture gains and we do not expect an event of that magnitude in 2020.

Moving on to taxes. Our effective tax rate guidance for 2020, excluding special items, is approximately 17.5% to 18.5% were higher than where we ended 2019, driven by expected changes in the mix of global earnings and miscellaneous one-time benefits not expected to reoccur in 2020.

Considering all these factors, we are comfortable with adjusted EPS guidance in a range of $9.00 to $9.15 per share on a constant currency basis, reflecting operational or constant currency growth of approximately 3.7% to 5.4%.

Again, while not predicting the impact of currency movements, but to provide some insight on the potential impact on EPS using exchange rates from last week, our reported adjusted EPS would be negatively impacted by approximately $0.05 per share. Therefore, our estimate for 2020 reported adjusted EPS is between a range of $8.95 to $9.10 per share or $9.03 per share at the midpoint.

As a final comment, our guidance assumes no formal share repurchase program at this time, I wanted to provide this reminder since the last time I looked, Street estimates utilized an average share count which is significantly lower than what we are assuming for our 2020 guidance.

We estimate the average diluted shares outstanding to be largely in line with the fourth quarter 2019 share count or 2.67 billion shares. Although we do not provide quarterly guidance, there are a few factors for you to consider in your models beyond the selling day fluctuations Chris mentioned in his remarks for Medical Device.

For sales, you can expect the fourth quarter of 2020 to have the benefit of the additional shipping days, partially offset by the Consumer SKU rationalization program that we are projecting throughout the year but more pronounced in the back half. With respect to earnings, the first quarter of 2019 included an equity gain related to the consumer acquisition of DR. CI:LABO, and the second quarter of 2019 included the gain associated with the ASP divestiture in medical devices.

We don’t anticipate similar events for other income and expense in the first half of 2020, but would expect elevated levels of other income aligned to today’s guidance in the second half of 2020. Lastly, based on today’s spot rates, currency will have a more negative impact in the first half of 2020.

That concludes prepared remarks of our financial summary of 2019 results and 2020 guidance. Our 2019 results reinforce our confidence in our broad-based business as we head into 2020 and we look forward to delivering continued value on behalf of all stakeholders.

As Alex mentioned, we will be hosting our Medical Device Business Review Day on May 13th and I look forward to seeing all of you in person at this exciting event, which will be held in New York City this year.

For your planning purposes and based on investment community feedback, please note that we will be highlighting our Consumer segment at consumer-focused events such as notable CPG conferences this year. A special thank you to our Johnson & Johnson associates around the world for their tireless efforts and commitment who make the results we have attained possible and the outlook so bright.

I will now turn the call back to Chris to begin the Q&A

Christopher DelOreficeVice President of Investor Relations

Thank you, Joe. We will now move to the Q&A portion of the webcast. Operator, can you please provide instructions for those on the line wishing to ask a question?

Questions and Answers:

Operator

Yes, thank you. (Operator Instructions) Your first question comes from Chris Schott with JPMorgan.

Chris SchottJPMorgan — Analyst

Great, thanks very much for the questions. The first was just on Pharma, can you just elaborate a little bit more on your expectations for growth in 2020. I guess specifically, what are you expecting in terms of patent expirations headwinds for this year? And can you also elaborate on the competitive dynamics you’re expecting for both TREMFYA and STELARA in psoriasis with the launch of Skyrizi. Thanks so much.

Christopher DelOreficeVice President of Investor Relations

Hey, good morning, Chris, and thanks for the question. Thanks for joining us today. So with Pharmaceuticals, as I mentioned in some of my prepared remarks, we do expect continued growth above the market. I think as we would have sat here last year, we expected a bigger impact in 2019 from the loss of exclusivity and generic and biosimilar competition to our products and to our teams credit, based on the data, the safety, the efficacy, the familiarity of the products and comfortability for physicians and patients, those products were able to retain that business a little bit longer.

We would expect that to bleed into 2020 and — but we still do even with that, I’ll call a neutralized headwinds. It’s not a tailwind per se, but I’ll call it a neutralized headwind compared to 2019. I think we do certainly expect that the portfolio of products will continue to outperform the general market of pharmaceuticals in general.

Alex GorskyChairman, Board of Directors and Chief Executive Officer

Hey Chris, this is Alex. Just to add one comment on to that, look, we’re extremely proud overall of the performance of our Pharmaceutical Group, but particularly our immunology group within Pharma. If you — if you just step back a moment and look over the past several years at — first of all, the way that they were able to manage the biosimilar impact with REMICADE, while simultaneously launching multiple new indications for compounds like STELARA launching TREMFYA.

To note that TREMFYA 55% growth in the quarter, STELARA had 19% growth. And frankly also, it’s the clinical development and the competitive differentiation with TREMFYA, for example, having comparative trials not only versus our own compounds but also against Humira and Cosentyx.

And I think what’s really important is that in areas that these products are used, it’s not only the short-term results, but it’s particularly important for the long-term results.

So many patients on psoriasis will shift from product to product and are suffering from this condition for a long time. And having in excess of 48 months’ worth of duration and treatment effect by a compound like TREMFYA, I think really helps explain its uptake and continued confidence and use by physicians and patients in the marketplace.

So and we combine that with the penetration rate of probably somewhere in the 30% to 40% rate in this overall category, we think that there is still a lot of unmet need.

We think that there is still a lot of opportunity with these compounds and that doesn’t even include some of the additional clinical development programs that we’re having in areas such as GI as well for these, where particularly for a compound like STELARA, we’re seeing great impact. We think that there is a lot of opportunity ahead.

Chris SchottJPMorgan — Analyst

Great, thanks for that. Maybe one other really quick one here. Other income, $1.5 billion to $1.7 billion. I think that’s still a bit above your historic levels of other income. I know this number can be a bit lumpy, but should we think about this type of level as a new norm or can we think about that number of declining further, as we look beyond 2020? Grazie.

Joseph J. WolkExecutive Vice President, Chief Financial Officer

Yeah, Chris, thanks for the question. I would say it’s certainly down from what we experienced in 2019. And I would expect not to provide any insight into 2021 just yet, but I would expect that number to come further down as we look out. So as you see this year, we’re improving our operating margins by nearly a 100 basis points to offset some of the effect that we had the benefit of in 2019. And I think we’ll continue to do that.

But to be truthful, we continually look and manage our portfolio in a very rigorous fashion, making sure that we’re the best owners of the assets that we have and that works both ways. So we look to complement our portfolio, but we’ll also look to take underperforming businesses and create value for shareholders in other ways.

Chris SchottJPMorgan — Analyst

Grazie.

Christopher DelOreficeVice President of Investor Relations

Chris, thanks for your questions. Next question please.

Operator

Your next question comes from Larry Biegelsen with Wells Fargo.

Larry BiegelsenWells Fargo — Analyst

Good morning, thanks for taking the question. Just one on the extra week and one of the litigation. Joe, can you talk about the impact of the extra week in 2020? In 2015, it was about 4% in Q4, 1% for the full year and neutral to EPS. Does it impact U.S. more than international? Does it impact some businesses more than other? I heard your comments on Consumer but I’m thinking more about Pharma and Med Tech? And I had one follow-up.

Joseph J. WolkExecutive Vice President, Chief Financial Officer

Sì. So Larry, with respect to the fiscal 53rd week that translates to about two to three shipping days, I would say that’s pretty much the norm for the Medical Device and Pharmaceutical units that you’ve asked about. It’s a little bit less in Consumer in terms of impact, because it doesn’t impact stocking during the holiday season. So — and you’re absolutely correct, we had the same assumptions around EPS. It’s pretty much neutral because you still have a full week of expenses without really the benefit of a full week of sales.

Larry BiegelsenWells Fargo — Analyst

Thanks for that. And Alex, just one on litigation. Just, what’s the latest on the opioid litigation, the latest on the $4 billion settlement you had previously announced? Any important dates and milestones we should think about. And just lastly on talc, when do you expect the decision from the Daubert hearing? Thanks for taking the questions.

Joseph J. WolkExecutive Vice President, Chief Financial Officer

Hey Larry, this is Joe. I’ll take that. Thanks for the questions. With respect to the opioid settlement, an agreement in principle that was announced shortly after our Q3 earnings where we set aside $4 billion, we continue to work with the Negotiating Committee of the State Attorney Generals to finalize the agreement in principle. We remain, I would say, cautiously optimistic that that’s progressing very well.

We’re highly engaged to the extent we can be to finalize that agreement in principle, and we hope to hear more over the coming months from the lead negotiators representing not just the states, but as you know the counties and municipalities.

With respect to talc and the Daubert litigation, we are awaiting Judge Wolfson’s verdict in that. Again, as you know, that’s an evidentiary standards hearing. So we’ll be able to make sure that there is great clarity and certainty as to the type of scientific evidence that needs to be presented.

As you know and you probably saw in the Journal of American Medical Association article published just a few weeks ago, probably one of the most comprehensive reports evaluating all studies from independent sources found no link between talc and cancer. So we think that’s, again, another independent source and we think those facts, those — that data, that scientific research will bear out in the end. Grazie.

Larry BiegelsenWells Fargo — Analyst

Great, thanks.

Christopher DelOreficeVice President of Investor Relations

Thanks, Larry. Rob. Next question please.

Operator

Your next question is from David Lewis with Morgan Stanley.

David LewisMorgan Stanley — Analyst

Grande. Just a couple of questions this morning, Joe, just one clarification and one qualitative on revenue. So the 5% to 6% operational guidance for 2020, the way to think about that is that includes about 50 basis points to 100 basis points of the net effect of selling days adjusted for the consumers SKUs.

Joseph J. WolkExecutive Vice President, Chief Financial Officer

That’s exactly right, David.

David LewisMorgan Stanley — Analyst

Va bene. And just a follow-up on revenue, and one more quick one after that. Just qualitatively Joe, can you sort of help us understand 2020, how you see it framing up from a Pharmaceutical, Consumer and Medical Device business, and historically, you’ve given us a sense of sort of which businesses are likely to accelerate and which businesses are sort of more stable. So across Pharma, MD and Consumer, how do you see sort of the qualitative parameters driving the 2020 guide?

Joseph J. WolkExecutive Vice President, Chief Financial Officer

Yeah, thanks for the question, David. So we have — I think right now, it is across all three of our businesses. If you look at Pharmaceuticals, we will continue to accelerate growth, I would say we’ll be above market. It’s probably not as robust as we would have thought this time last year, again because we were able to retain some of the business that was subject to generic and biosimilar competition.

But again, very healthy growth above market and we’ll be looking to complement the portfolio certainly with advancing our pipeline. We’ve got a couple of things that are — hopefully will be filed this year around Ponesimod for multiple sclerosis.

We hope to gain approval on the DARZALEX subcutaneous formulation, which is a tremendous benefit for patients and we’ll see the continued uptake of BALVERSA and SPRAVATO.

In medical Devices, we’re very pleased and just to put it into some context for the analyst community here. In 2017, we grew 1.6%. In 2017 — 2018, I’m sorry, we grew 2.7% and now we’re up to 3.9% and we’re not done. So we’re going to continue to accelerate growth, be towards that in the middle of the market range that we believe is on the horizon for 2020 and that’s before we have the opportunity to launch what we think will be a very differentiated offering around digital robotic surgery.

In Consumer; again, as Alex mentioned in some of his remarks, we have focused on profitability there. We focused putting investment behind our stronghold categories of skin-health and self-care, so that would be TYLENOL and MOTRIN for self-care; AVEENO and NEUTROGENA for skin health. Those brands continue to do extremely well. I would suspect we grow more in line with the market for that category, except for the SKU rationalization where we’ll be looking to de-prioritize some less productive brands. Okay?

David LewisMorgan Stanley — Analyst

And Joe — and then just, Joe, just one quick question, follow-up on margins. In some of the years you’ve had sort of other income headwinds, you’ve been able to offset it with more significant SG&A gains driving margins. You’re talking about a 100 basis points of margin expansion into 2020. Medical Devices with the JV (Phonetic) agreement continues to track well. Are there just spending dynamics or more visibility on sort of 100 basis points of underlying margin expansion in 2020 headwinds and tailwinds we should be thinking about? Thanks so much.

Joseph J. WolkExecutive Vice President, Chief Financial Officer

Yeah, I don’t know Chris, if you want to add something.

Christopher DelOreficeVice President of Investor Relations

I just wanted to amplify in Consumer just examples of that TYLENOL and NEUTROGENA for the full year this past year, NEUTROGENA at 6% growth TYLENOL 9% growth, just to build on what you were sharing on consumer.

Joseph J. WolkExecutive Vice President, Chief Financial Officer

Right, okay. Thanks, Chris. With respect to margin expansion, David, I think we would look to certainly manufacturing capabilities and improving our productivity there. I would point to the consumer SKU rationalization, the design behind that is specifically to improve profitability and then we’ll continue to look at other opportunities for enabling functions across finance, HR, information technology and procurement to get savings. So we think we’re in pretty good shape to deliver that for 2020.

Christopher DelOreficeVice President of Investor Relations

Grande. Thanks, David. Appreciate the questions. Rob. Next question please.

Operator

Your next question comes from Kristen Stewart with Barclays.

Kristen StewartBarclays — Analyst

Hi, thanks for taking my question. Just one clarification. The extra week with the SKU rationalization, it’s a net impact overall, it’s 50 to a 100 to the top line, is that correct?

Joseph J. WolkExecutive Vice President, Chief Financial Officer

That’s correct, Kristen.

Kristen StewartBarclays — Analyst

Okay, perfect. Just want to clarify that. And then just a big picture, I guess, question. Just on portfolio and capital allocation, I know you had mentioned just in terms of models need to take into consideration with the share count, no further share repurchase activity, you guys are in a pretty good position. Obviously from a share — I’m sorry, cash flow perspective, generating $20 billion this year, it sounds like your expectation is to pay out the opioid settlement, but I guess, why not get more aggressive from a share repurchase perspective? Just how should we think about capital allocation going forward?

Alex GorskyChairman, Board of Directors and Chief Executive Officer

Hey Kristen, this is Alex. Thank you very much for the question. And look, we’re really proud of our strong performance across our businesses, and frankly, as it relates to our capital allocation model this year and we’re very confident in it going forward. As we mentioned in the results earlier, if you think about the free cash flow spin-off that we had in 2019, I think it’s indicative of not only great discipline across our various lines and you see the P&L in front of you.

So overall, it was quite healthy. But it’s also important to note that we did that in the context of also continuing to invest in more than 11 acquisitions, about six licensing agreements where we invested almost $7.5 billion just in the course of the year. So, as we talked about in the past, we’ll continue to invest in our brands and in research and development at an appropriate rate.

If you go back over the last four years, I think if you add the numbers up in R&D, we’ve invested more than $45 billion during that timeframe, and we think that based upon the number of new product launches in our Pharma Medical Device business and our Consumer business that we’ve gotten a good return on that. We’ve continued to keep a healthy dividend at the same time. We realize how important that is.

During that same timeframe, four years, it’s a pretty similar number to our R&D. It’s about $40 billion to $45 billion. And of course, after that, we always take a look at value creating acquisitions. And again, during that same timeframe, I think the number comes to about $50 billion that we’ve invested.

Over the past year of note was, you might say, the additional investment that we made in Auris and we think combining that with the later buyout that we did with the Verb, with Verb and Verily is the right thing. If you think ahead in Medical Devices, there are probably few things that are going to represent a more secular shift in that domain than the shift into digital and robotic surgery. And bringing those together we think creates a very exciting opportunity for us.

But we also continue to do value creating tuck-in opportunities as well in our Pharmaceutical businesses. We just talked about the end of the year, we brought in two really exciting compounds bermekimab in particular in both AS as well as other conditions. We think it represents a great opportunity and it’s certainly in an area where we’ve got a lot of capability and a lot of expertise.

And finally, we talk about share repurchases. And I think we’ve demonstrated over the last four or five years that we’ll certainly employee share repurchases when we think that we’re undervalued particularly in a significant way. And again, I think an outcome of the way that we manage our overall P&L, it means that we can do these things simultaneously. It’s not necessarily in order and we continue to — we expect to continue that strategy going forward.

Kristen StewartBarclays — Analyst

Okay, great (Phonetic).

Joseph J. WolkExecutive Vice President, Chief Financial Officer

Yeah, Kristen. Just a quick comment and thanks for noticing the comments around share count. I have to tip my hat and complement the investment community because when we go through the consensus P&L, the income in terms of absolute dollars was almost spot on. It was the yearly close in fact, and then really the disconnect came in the form of share count where the average share count used in consensus was about 14 million shares less, which translates to about $0.05 or $0.06.

So we thought we were very much in line with what consensus expectations were, and while we don’t provide guidance assuming any share repurchase that’s not currently authorized. It seems that a few analysts may have made that assumption.

Kristen StewartBarclays — Analyst

Okay, perfect. Thank so much.

Christopher DelOreficeVice President of Investor Relations

Great, thank you Kristen. Rob, next question please.

Operator

Next question is from the line of Josh Jennings with Cowen.

Josh JenningsCowen & Company — Analyst

Hi, good morning. Thanks for taking the questions. First is on robotics, and you clearly have put a stake in the ground and with investments pursuing leadership in digital surgery ecosystem. I just wanted to see if — and I understand we’re going to get a big update at the Med Device day in May, but if you could whet our appetite at all today just give any updates on progress in the Auris launch, the timelines for Orthotaxy, and then any indications that you see where robotics is not in play today that could come into play over the next three to five years within your portfolio.

And then, second question is just for Joe and Alex. I guess it’s just on, you know the other income line has been a focus. I think the concerns are where that could fall off next year or in the out-years and you talk about your process for portfolio review and then pruning I mean the underperforming assets or assets don’t fit under your roof.

If you could just talk about that process and how regiment it is. Is there a formula? Is there 1% of the portfolio that gets pruned every year or is it just strategic and opportunistic annually? Thanks for taking the questions and I apologize for the background noise.

Alex GorskyChairman, Board of Directors and Chief Executive Officer

Hey Josh, thank you very much for the question. And look, I am really glad that you mentioned robotics and digital in terms of an entire platform for us because of course that’s exactly what it is. And let’s start first with our acquisition of Auris Health. And overall what we would say, it’s off to a great start where we couldn’t be more thrilled to have the robotics pioneer and former CEO Fred Moll and his team at J&J.

The Monarch Platform is off to a very good start. It’s going to play a critical role in our lung cancer initiative. And when you just look at the science and the technology and what it can do with the distal parts of the lung and what it brings in terms of potentially ablation leveraging it with our NeuWave technology.

And even longer term, having the potential to dispense oncolytic viruses in treating cancer in very new and unique ways is exciting. Physicians can perform more than 2000 bronchoscopy procedures with the Monarch Platform and we’re really pleased with what we’re seeing with it.

Second, you saw our announcement on Verb and we think combining Auris and Verb really helps ensure that we have a very strong role in the next generation of the digital surgery platform and ongoing development. Our teams are working now together in a really comprehensive way. We do look — sorry for that feedback. But we do look at this as a platform that is something that will be in place for the next several decades. Therefore, it’s really important that we step through this in the right way.

And what I would say is, the early results from the collaboration and the partnership that we’re seeing between these teams is very encouraging and that’s why we’re excited to give you this preview that Joe mentioned on May 13th in New York because we think it will provide very clear, transparent kind of tangible evidence of not only the machines, but also the digital platform component of this as well.

Next, we’re really excited about the progress that’s being made with VELYS in our orthopedics robotics platform as well. It’s an exciting technology. We think that it’s going to offer a portable low cost system that’s easy to use, will improve accuracy. It also is a nice combination to ensure if the surgeon remains intimately involved. And if we look at the training and technical support, it’s something that will be easily coordinated between ORs and surgeon.

So we’re progressing towards a mid-year 2020 regulatory submission for this. So really if you just step back and you think about what we have going with Auris and Monarch, if you think about the plans now that we have in place with VELYS in orthopaedics; and then longer term, as we bring out that next generation of digital and robotics platform more broadly across surgery, we’re very excited about it.

Joseph J. WolkExecutive Vice President, Chief Financial Officer

And, Josh, to address your question regarding the management of our portfolio, so I would say it’s rigorous, it’s not formulaic though. So we meet as a management team and executive committee monthly on what additions or deletions from our portfolio makes sense. And that — and makes sense probably should be defined in terms of we have aspirations in all the markets we play in to be either number one or number two in that space with the promise of bringing better solutions in that space to patients and consumers across the globe.

We have plans in place for all of our businesses to do that. But after a period of time when those plans don’t come to fruition, we’ll assess other alternatives. I would say under Alex’s leadership, we’ve gotten very disciplined in this this rigor and that’s proved to be pretty productive, I think, in terms of how we’ve been able to take underperforming businesses, turn that into gains and reinvest back in businesses in areas that we think we’ve got a differentiated right to win.

Christopher DelOreficeVice President of Investor Relations

Thanks Josh. Appreciate the questions. Rob. Next question please.

Operator

Your next question is from Matt Miksic with Credit Suisse.

Matt MiksicCredit Suisse — Analyst

Hi, thanks for taking the question. So, I just had one follow-up on one of your business lines in Med-Devices. In orthopedics clearly, it looks like you were able to deliver a pretty solid improvement in knees in the U.S. and just was wondering if you’d be willing to offer any color on the spine growth within the sort spine and other category. I think which parts of that were — what are the drivers of the decline. And then I had one follow-up if I could for Alex on digital health.

Alex GorskyChairman, Board of Directors and Chief Executive Officer

So, thanks for the question, Matt. Good to speak with you. So, we are very proud of the Knees performance. If you look, that was declining business in 2018. We’ve had almost a two point improvement there. So the team has done a very nice job.

We have ATTUNE, both the primary as well as the Revision platform available for patients. We’ve also made an entry into the Cementless side of the business, which as you know, is the fastest growing piece of that business. And, as Alex mentioned, we look forward to what VELYS could do on the horizon.

With respect to spine, I think you have to take into account the impact of 2018 U.S. rebate adjustment which impacted comparative growth, about 250 basis points. If you look at the growth in the U.S., it was probably about half of the decline of what you saw based on that comparison. We continue to see pretty good growth outside the U.S., specifically in Asia Pacific. I don’t know Chris, if there is any other commentary in spine other…

Christopher DelOreficeVice President of Investor Relations

Yeah, Matt, I would just say, if you adjust for that, I would say the business has stabilized at low-single digit declines. Where we’re seeing success is where we have new innovation in particular in degenerative spine with our 3D Cage and our VIPER PRIME systems. I think the next level of improvements will come from SYMPHONY System in posterior cervical which was launched later this year. So we really didn’t get that benefit in this year at all and we’ll expect to see that continued improvement through next year and beyond.

Matt MiksicCredit Suisse — Analyst

That’s great. And then just a follow-up. Appreciate the update and overview on the robotic surgery strategy, Alex. But I guess one of the things that we’ve noticed is just how quickly — and I realize it’s sort of a buzzwordy term and we see it in a lot of magazines, but artificial intelligence in digital health, for whatever reason implementation and you know innovation, but it seems to be moving perhaps the fastest of the categories of digital surgery and digital health.

Just wondering — one of your competitors has partnered with a smaller innovator in that space around stroke, I’m sure you’re watching it, I’m sure you’re making investments and looking at it. Just curious if you could give us an update or a preview, perhaps of which you’ll talk about in the spring.

Alex GorskyChairman, Board of Directors and Chief Executive Officer

Sure. Thanks again for the question, Matt. Look I — there are a few areas across our different innovation or technology platforms that are not being touched by some of this new technology, whether it’s AI whether it’s ML, whether it’s digital, whether it’s the cloud. I mean if you think about just our Pharmaceutical portfolio, for example, and you talk to Paul Stoffels or Mathai Mammen or Bill Hait, I think what they would tell you is one of the most important areas supporting that is our data sciences capabilities and the insights that we can gain from reviewing these large datasets and coming and developing much better insights frankly is helping — lead us to a much faster and more productive identification of new targets.

And it certainly is helping us when we apply those same skills and capabilities of the clinical development programs as you work with hospitals and large medical systems and you can review medical health records, for example, in a much more detailed way in terms of patient selection and tracking through development. So we’re certainly excited about there.

As it relates to Medical Devices, we’ve been, I think, very consistent in sharing our thinking that again this next generation is certainly about the robotics component that helps facilitate perhaps having more consistency in an exact procedure, perhaps getting into a tighter space, having better access. But we think longer term, the digital AI component of that in terms of helping preoperatively in developing a very detailed plan even being applied intraoperatively in terms of additional guidance systems.

And by the way, then that can be — not only to help a surgeon get to a particular area but it could also be to help him or her stay away from areas that may and could cause a problem. And so — and then of course, how that information can be utilized by large healthcare systems to really ensure that they’ve got the most effective and efficient and value-added health care delivery program is in place, we think will be more important than ever.

So hence our reason for partnering with Verb and Verily and Alphabet in building those capabilities and again it’s something that more broadly across Johnson & Johnson we’re spending a lot of time thinking about how all those capabilities are going to become more and more a part of our — of our doing business of our doing research and development across each one of our sectors.

Christopher DelOreficeVice President of Investor Relations

Thanks, Matt. Appreciate the questions.

Matt MiksicCredit Suisse — Analyst

Grazie.

Christopher DelOreficeVice President of Investor Relations

Rob. Next question please.

Operator

Your next question is from Danielle Antalffy with SVB Leerink.

Danielle AntalffySVB Leerink — Analyst

Hey, good morning guys. Thanks so much for taking the question. Just wanted to talk a little bit more about Medical Devices, specifically you guys saw a pretty strong sales growth acceleration on an operational adjusted basis this year. How do we think about the next year? I know Ashley has said in the past, it’s not linear quarterly. But I suspect we should be looking for another uptick. Can you help talk about that and what specifically will be the drivers in 2020 of that?

Alex GorskyChairman, Board of Directors and Chief Executive Officer

Sure Danielle, thank you very much for the question. Look we’re, again, we’re really proud of the progress that Ashley and her team has made over the last several years. Joe took you through the improvement from 2017 to ’18 to 2019 and we certainly expect that trajectory to continue in the coming years. If I just kind of zero down for a moment though on 2019, we saw first half growth of about 3.8% and we saw growth in the second half at 4%. And while there is a bit of lumpiness in the quarters, consistent with Ashley’s comments and look we’re still taking a look at Q4. We think that the timing of the holidays and a few other things, I think you always have to be careful what you attribute.

But if you just look at the number of days, between some of those we think that that could potentially have had an impact, but it really doesn’t change the overall trend of accelerated growth in second half versus first half. Now if we look at our business, it’s really being driven by a number of factors. In our surgery business, what you’re seeing is strong performance in areas like electrophysiology, another 14% growth in this quarter with great new technology. We expect a continuous launch in the coming year as well with new products.

You also saw good performance in our Energy business, so just about 3% growth and biosurgery coming in at about 4% growth. We think one of the growth drivers, frankly is just overcoming our supply issue in 2020 that probably cut our biosurgery growth rate and half, especially in the latter part of the year. So we think once we work our way through that that’s going to be a growth driver for us.

Our circular stapler launch is also going well. We’re going to lap the recall as well that we had in the past year. So we think those are definitely drivers in our core surgery business. If we look at orthopaedics, here too we’ve seen the steady cadence of improvement. Our knee business ATTUNE; the launch of the Cementless, the Revision is going very well. And you think about it, we’ve turn that from being down almost 0.5% to 1% to growing at 1.4% in this quarter, which again shows physicians increasing confidence in that platform and we’re starting to see an uptick again in ATTUNE primaries. And so we’re really pleased to see that.

And then, of course our Hip performance coming in at over 4%. Strong trauma at about 2.5%. We think is pretty consistent with the market. Chris addressed some of the issues in spine and how we see that moving forward. And then of course there’s Vision Care and I think what we see in Vision Care is fundamentally strong performance in contact lens. You saw about 3% growth overall in our contact lens business. But what’s important to note there is we had 9% growth in the United States.

So the transition lens, the astig lens, daily disposables continue to go well. Frankly, we’ve been disappointed in some of our surgical performance, particularly in the U.S. We’ve got plans in place to address that. If you look at the ongoing rollout that we’re going to have with the TECNIS and the Symphony and the synergy, we’re very optimistic that it’s going to make us more competitive, not only in the astig area, but really across that entire platform.

So we’re confident that that’s going to lead to continued growth trends as we go through 2020 and certainly setting ourselves up for even continued growth beyond that as well.

Danielle AntalffySVB Leerink — Analyst

Thank you so much.

Christopher DelOreficeVice President of Investor Relations

Thanks Danielle. Appreciate it. Rob, next question please.

Operator

The next question is from Terence Flynn with Goldman Sachs.

Terence FlynnGoldman Sachs — Analyst

Hi, good morning. Thanks for taking the questions. Maybe just two from me. You guys presented additional data at ASH from your BCMA CAR-T program in myeloma and recently got breakthrough designation, are planning to file for approval later this year. I would love your initial thoughts on overcoming some of the hurdles faced by other CAR-T drugs. And longer-term where you see this drug playing a role in the treatment paradigm.

The second question relates to the FDA announcement of a meeting next month on testing methods for asbestos and talc. I was just wondering if the company is participating and then what you think the key issues are that are going to be discussed there. Grazie.

Alex GorskyChairman, Board of Directors and Chief Executive Officer

Sure Terence, thank you very much. Let me take the first one regarding the CAR-T data at ASH. As I’m sure you saw when we released the data we were very excited when we saw those results. And again here too, I think it’s maybe important to just step back and think about the steps that our team has taken over the last several years regarding CAR-T therapy.

And when you look at the different development programs that are out there, how we were able to support or source this from Legend. The way that we were able to accelerate the development timelines, the ongoing great work that our supply chain is doing as well to ensure that we’ve got the strong integrity of that supply chain, the dependability that’s put in place. We’re really proud of the progress they made.

I think the results that we shared at ASH demonstrate our increasing confidence. And by the way, we think this is great news for patients, particularly those who have failed multiple other treatment lines in a very difficult to treat condition like multiple myeloma. And as we think about it going forward, look we think that this is truly an opportunity to transform the way patients are treated in this space. We’ve got a lot of confidence in our reimbursement teams. I think we demonstrated in other areas that we can work with payers in a very collaborative way.

We’re also innovative, not only in the products that we’re bringing, but frankly in the reimbursement programs that we introduced as well. And we intend to work just that way with payers and providers, both in the United States, but also abroad ultimately to make sure that this therapy is available for patients, they can get access to it and that it’s not only as effective as the data that you — that we saw at ASH, but it’s also cost effective to the overall healthcare system. Joe, did you want to…

Joseph J. WolkExecutive Vice President, Chief Financial Officer

Sure. And Terence, with respect to the meeting. I believe it’s next month, February 4th, regarding testing methods around talc. We certainly welcome any discussion around the safety and efficacy of the product, specifically. We will not be active participants at that meeting. However, I can say that our current internal testing methods exceed that of current FDA standards for cosmetic talc.

Terence FlynnGoldman Sachs — Analyst

Great

Christopher DelOreficeVice President of Investor Relations

Thank you, Terence. Appreciate the questions. Rob, we have time for one last question.

Operator

Yes, that last question will be coming from Louise Chen with Cantor Fitzgerald.

Louise ChenCantor Fitzgerald — Analyst

Hi, thanks for taking my questions here. So my first question for you is, what your view on M&A is this year and what areas you’re most interested in? Is it Pharma, Consumer or Devices or all the above? And then my second question is, how optimistic are you regarding a universal settlement for opioids? Grazie.

Joseph J. WolkExecutive Vice President, Chief Financial Officer

Va bene. Let me take the first part of that, Louise. Thank a lot for the question. Look, I think we demonstrated in 2019, as I mentioned earlier, that we remained active really across all three areas. I think we did 11 acquisitions, six licensing agreements and putting more than $7 billion worth of capital to work. We have continued, I think, our pattern of tuck-in acquisitions where we get new technologies as you saw that we did with both XBiotech and other opportunities in our Pharmaceutical business.

We would expect to continue that. We also did a — had a fair amount of activity in our Medical Device Group led by Auris that we did earlier in the year. And then, in our consumer group of course that was led by DR. CI:LABO which also gave us a great toehold, you might say, into the premium beauty segment, particularly in Asia, but with plans to expand that into the United States.

So we’ll be looking across all three of our segments. But we would expect there to be an ongoing cadence of M&A activity in those different areas.

Alex GorskyChairman, Board of Directors and Chief Executive Officer

And Louise, with respect to the opioid settlement. So we continue to work with the Negotiating Committee of the State Attorney General’s to finalize the agreement in principle. I would say, we remain optimistic and confident that the agreement is moving forward, but certainly can’t predict when that agreement in principle will be finalized. So we’ll continue to monitor that, engage as needed and hopefully come to a resolution.

Christopher DelOreficeVice President of Investor Relations

Thanks Louise, appreciate it. And thanks to everyone for your questions and continued interest in our Company. Apologies to those we couldn’t get to because of time but don’t hesitate to reach out to the Investor Relations team as needed.

I’ll now turn the call back to Alex just for some closing comments.

Alex GorskyChairman, Board of Directors and Chief Executive Officer

Well, thank you everybody for your ongoing support across 2019. As we mentioned earlier, we’re very proud of our strong performance, but we’re even more excited and more confident about what the prospects hold for 2020 and beyond.

I think we had a chance to review a lot of the opportunities that lie in front of us and we look forward to continuing to keep you updated throughout the year as we progress through our plan. So thank you very much everybody and have a great day.

Operator

(Operator Closing Remarks)

disconoscimento

This transcript is produced by AlphaStreet, Inc. While we strive to produce the best transcripts, it may contain misspellings and other inaccuracies. This transcript is provided as is without express or implied warranties of any kind. As with all our articles, AlphaStreet, Inc. does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company’s SEC filings. Neither the information nor any opinion expressed in this transcript constitutes a solicitation of the purchase or sale of securities or commodities. Any opinion expressed in the transcript does not necessarily reflect the views of AlphaStreet, Inc.

© COPYRIGHT 2020, AlphaStreet, Inc. All rights reserved. Any reproduction, redistribution or retransmission is expressly prohibited.

Psorilax:Buon prezzo |crema cerave psoriasi

0

Psorilax: prezzo, funziona, recensioni, opinioni, originale

Lunedì 31 marzo

  • Mentre migliaia di test continuano oggi nelle case degli anziani, lo apprendiamo numeri in lotta per la vita in terapia intensiva le unità in tutto il paese sono aumentate di altri 21 da ieri a 164.
  • 571 persone vengono ora trattati ospedali, circa 200 in più rispetto a quanto registrato prima del fine settimana.
  • I decessi sono fino a 140, con un incremento del 17,6% rispetto a ieri.
  • I casi sospetti sono aumentati del 16% a 44.206.
  • Il Segretario di Stato per la salute António Lacerda Sales ha dichiarato al briefing stampa di oggi: “Sono passate due settimane da quando abbiamo chiuso le scuole. Dobbiamo continuare questo lavoro (di isolamento forzato) perché questo virus non sta lasciando andare. Stare a casa significa salvare vite“.
  • Il briefing della stampa ha dettagliato la quantità di test e attrezzature dovrebbe arrivare questa settimana mentre il paese continua a combattere l'epidemia (66.000 ulteriori kit di test, 5,2 milioni di maschere chirurgiche, 1,2 milioni di respiratori e “altre attrezzature come abiti e stivali”)
  • Per ulteriori dettagli sui numeri clicca qui
  • Público sottolinea i dati riportati oggi mostrano l'aumento più basso nei nuovi casi dal momento del blocco.
  • 853 professionisti della salute sono stati infettati dal virus finora.
  • Donne incinte viene ora data la priorità per analisi.
  • diabetici sentito che ora fanno parte del gruppo che mostra “il peggiori complicazioni“Di infezione.

Domenica 30 marzo

Con l'ultimo briefing della stampa sui numeri in costante aumento, sono arrivate notizie su morte di un ragazzo di 14 anni di Ovar che secondo come riferito soffriva di una condizione autoimmune.

Dicono che il bambino è morto questa mattina presto.

È stato ricoverato all'Ospedale de São Sebastião di Santa Maria da Feira ieri (sabato).

Il sindaco di Ovar Salvador Malheiro ha detto ai giornalisti che il bambino “non è stato confermato di avere un'infezione (nuovo coronavirus) ma dopo essere stato portato in ospedale e testato, il test è tornato positivo. Aveva già problemi di salute”.

Noticiasaominuto descrive questi problemi come la psoriasi, una condizione della pelle autoimmune.

Rispondendo alle domande oggi, sia il ministro della salute Marta Temido che il direttore sanitario della DGS Graça Freitas hanno affermato che era troppo presto per dire che il bambino era morto specificamente per il virus, come il suo la situazione clinica era “complessa”.

Ulteriori indagini sul caso proseguiranno e per ora la morte del ragazzo non è stata inclusa nell'aggiornamento quotidiano, mostrando un totale di 119 morti e altre 792 persone che si sono dimostrate positive.

I dati DGS sono già stati caricati sul loro sito e possono essere visualizzati qui.

Il “Zone più colpite” rimanere il nord e quelli intorno a Lisbona, ma i numeri si stanno insinuando ovunque, con il L'Algarve ora registra 108 casi positivi (così come le due morti che hanno avuto luogo) e il Alentejo mostra 41.

Oltre 5.500 persone sono attualmente in attesa dei risultati dei test, mentre il numero di pazienti in cura (che indicano che i pazienti sono troppo gravemente malati per riprendersi dal virus “a casa”) è fino a 486 – 138 dei quali sono in terapia intensiva.

Il cosidetto “Percentuale di letalità” del virus complessivo è attualmente ancorato a 2%, ma ora sale a 8,1% negli anni '70.

Ieri la “percentuale di letalità” per gli over 70 è stata data al 7,9%.

In altre parole, il rischio per gli anziani sta diventando più acuto, quindi gli avvertimenti delle autorità al pubblico di rispettare le misure di “isolamento di emergenza” che sono così importanti.

Gran parte del briefing stampa di oggi è stato consegnato a consigli a tutti coloro che si prendono cura degli anziani all'interno della comunità per introdurre regole rigorose per garantire la loro sicurezza.

Nel frattempo il sindaco di Ovar – l'area ancora coperta da uno “Stato di calamità” a causa dell'elevato numero di casi all'interno del distretto – ha ricordato ai giornalisti che il blocco degli effetti imposto 11 giorni fa non si vedrà ancora da tempo in mente i casi positivi impiegano da due a tre settimane per “emergere”. Ha sottolineato che pensa che i casi positivi “aumenteranno molto” man mano che i test continuano e ha ripetuto richieste di aiuto da parte del ministero della salute.

Sabato 28 marzo:

  • Presentando l'aggiornamento di oggi, il ministro della salute Marta Temido ha sottolineato che la percentuale di mortalità negli over 70 (le persone più colpite dal nuovo coronavirus) in Portogallo ha raggiunto il 7,9%.
  • 24 ulteriori morti sono state registrate nelle ultime 24 ore, portando il numero totale finora a 100.
  • Il briefing stampa di oggi ha ascoltato la relativamente buona notizia che il La politica “resta a casa” funziona: la curva (di nuovi casi che necessitano di cure ospedaliere) si sta appiattendo delicatamente, inviando proiezioni per il “picco” del paese sempre più a maggio.
  • Non c'è comunque spazio per il compiacimento: il numero di casi infettivi è a 5.170 – 902 più di quanto sono stati registrati ieri.
  • Di questi nuovi casi, ci saranno “molte più persone che sono state infettate” in attesa dei risultati dei test.
  • Il numero delle persone in attesa i risultati di test è stato messo a 4.938.
  • 89% di casi lo sono trattati nelle proprie case.
  • 89 persone comunque lo sono ora in terapia intensiva.
  • I dati relativi alle varie regioni sono stati caricati sul sito dell'autorità sanitaria della DGS (fare clic qui).
  • Il nord è l'area più colpita, ma ciò che sembra non essere stato raccolto durante il briefing è stato il fatto la seconda morte in Algarve (vedi sotto) non fa ancora parte delle statistiche nazionali, sebbene sia stata inclusa nell'aggiornamento odierno di ARS Algarve (clicca qui)
  • Sia Marta Temido che il direttore della DG Graça Freitas hanno sottolineato la necessità, questo fine settimana, che i cittadini restino “a casa”. “Il numero di pazienti che avremo dipenderà da tutti noi”, ha detto il ministro. “Questo deve essere un diverso tipo di Pasqua per tutti noi così che possiamo tornare a stare di nuovo insieme ”.

Venerdì 27 marzo: l'insegnante di Portimão muore per infezione da Covid-19

  • Un insegnante di matematica maschile alla Escola Secundária di Portimão, Manuel Teixeira Gomes, è diventato la seconda fatalità dell'Algarve a seguito di Covid-19. Chiamato come Manuel Magalhães, è stato descritto da alcune fonti dei media come un collega dell'insegnante che è tornato dalle vacanze in Italia dopo la pausa di Carnevale diventando una delle prime infezioni registrate nella regione. (Vedi storia separata per maggiori dettagli.) Magalhães è descritto come nei suoi anni '60 e residente a Lagoa. Alcune fonti suggeriscono che avesse “precedenti problemi cardiaci”.
  • Nuovi dati oggi mostrano che il numero di decessi è aumentato a 76, con un altro picco del 20% nelle infezioni che ha portato il numero di quelli che si sono dimostrati positivi fino a 4.268.
  • Le infezioni in Algarve e in Alentejo continuano a salire. Il primo ora registra 99 persone che si dimostrano positive con il virus, il secondo 30. Un'ulteriore suddivisione delle aree mostra che in Algarve monchique e Olhão hanno aderito ora ai comuni interessati di Faro, Loulé, Albufeira, Tavira, Vila Real de Santo António, Portimão, Silves e Lagoa. Stranamente, le statistiche DGS hanno mostrato ieri che ci sono stati quattro casi di virus Lagos. Oggi Lagos non compare nell'elenco dei distretti con casi confermati.
  • 71 persone stanno combattendo per la propria vita in terapia intensiva, mentre 354 sono internati in vari ospedali.
  • La conferenza stampa di oggi ha visto concentrarsi molto sul modo in cui questo virus sta tagliando le case degli anziani. La direttrice del DGS Graça Freitas ha affermato che spetta a tutte le aree della casa degli anziani elaborare misure che proteggano gli occupanti. La prevenzione è assolutamente fondamentale.
  • Le case degli anziani nel nord hanno mostrato tassi allarmanti di infezione. In uno, a Vila Real, 99 persone (tra cui molti membri del personale sanitario) si sono dimostrate positive per il virus. Di conseguenza, il sindaco di Porto Rui Moreira ha annunciato che tutti coloro che vivono e lavorano in case di cura in tutta la città inizieranno a essere obbligatoriamente testati.
  • Poiché le misure preventive rallentano la diffusione del virus, le proiezioni su quando il Portogallo raggiungerà il suo apice vengono costantemente riviste. Freitas ha dichiarato oggi che le autorità non si aspettano il picco prima di maggio. Ha detto ai giornalisti: “I nostri matematici ci hanno consigliato che il picco non sarà un momento istantaneo. Ci sarà un altopiano di alcune settimane come sappiamo ora che questa malattia dura molto a lungo. Non raggiungeremo il “giorno x” e inizieremo immediatamente a (vedere i numeri) scendere “.
    • Secondo i numeri di oggi, il 'tasso di mortalità' tra i casi in Portogallo si trova a 1,7%.
  • Nel frattempo sono coinvolti i comuni su e giù per il paese mass-disinfezione operazioni, attraenti per i cittadini “Stai fuori dai piedi” mentre questi vanno avanti.

Giovedì 26 marzo:

  • Preparati per una marcata accelerazione nei casi in cui il paese entra nella “fase più complicata della pandemia (quella della” mitigazione “dovuta al virus ora in chiara trasmissione in tutta la comunità), ai medici è stato dato il via libera per curare i pazienti peggiori -affettato con antivirali per malaria, HIV ed Ebola. L'efficacia di questi farmaci è ancora sotto inchiesta, ma con l'aumentare del numero di infezioni man mano che i test diventano più efficaci, le autorità sanitarie della DGS hanno deciso che i benefici superano i rischi. I farmaci ora approvati per gli “scenari peggiori” lo sono Lopinavir / ritonavir (normalmente utilizzato per i casi di HIV), Remdesivir (Ebola) e clorochina e idrossiclorochina (malaria)
  • Le morti sono di nuovo in aumento, ma ancora niente come gli altri paesi europei. Il conteggio di ieri è aumentato di 17, da 43 a 60.
  • Anche le infezioni (quasi certamente a causa del marcato aumento dei test) sono fino a 3.544 (rispetto ai 2.995 di ieri), con un incremento del 18,3% -4
  • Anche i recuperi sono fino a 43, ovvero 21 in più rispetto a quanto dichiarato ieri guarito.
  • I test continuano con oltre 2.000 in attesa di risultati.
  • Le aree più colpite continuano ad essere il nord e Lisbona, rispettivamente con 1.858 e 1.082 casi. I decessi in entrambi sono di nuovo i più alti: 28 a nord, 18 nella zona di Lisbona. Il centro del paese segue con 435 casi e 13 morti – mentre l'Algarve e l'Alentejo suonano il numero più basso. Un decesso in Algarve (89 casi positivi), 20 casi in Alentejo, 24 casi nelle Azzorre e 15 in Madera. Per quanto riguarda l'Alentejo, i casi si stanno facendo strada verso il confine con l'Algarve a ovest, con la raccolta di frutta a Odemira tra le ultime statistiche.
  • Tutti gli ospedali sono ora coinvolti in questa lotta, compresi gli ospedali privati.
  • UN secondo bambino è nato da una madre Covid-19 positiva e risulta negativo.
  • Il presidente Marcelo ha annullato Festa del Portogallo commemorazioni previste per il 10 giugno.
  • Sta diventando sempre più “chiaro” le scuole non torneranno per il “terzo periodo” (periodo estivo). Vedi la storia a venire.
  • Dei casi confermati, sono stati registrati i numeri più alti, ancora una volta nella fascia di età 40-49 anni. Anche i bambini di età inferiore ai 10 anni sono positivi per Covid-19 (14 ragazzi e 29 ragazze), ma sono ancora gli over 70 che “ispirano la maggior parte delle preoccupazioni”.
  • Delle morti, queste hanno coinvolto tre uomini e una donna di età compresa tra 50 e 59 anni, otto uomini di età compresa tra 60 e 69 anni, 14 uomini e una donna nella fascia di età 70-79 anni e 16 uomini e 17 donne di età superiore agli 80 anni.
  • A causa di questa intensa fase di propagazione del virus, l'autorità di protezione civile ha messo le aree di Lisbona, Porto e Aveiro sotto “allerta arancione”. Ciò che ciò significa, tuttavia, è un po 'poco chiaro: il messaggio trasmesso ieri in una conferenza stampa era che le persone in quelle aree “restano a casa”. È il messaggio trasmesso a tutto il paese, ma forse suggerisce che i trasgressori a Lisbona, Porto e Aveiro saranno trattati in modo più duro.

Mercoledì 25 marzo:

Prima del briefing stampa di oggi, l'umore della stampa è cambiato radicalmente nelle ultime 24 ore con Expresso che raccontava come le associazioni di medici, infermieri e farmacisti abbiano effettivamente accusato il governo di “mentire”, in particolare quando si tratta di rifornimenti vitali di materiale medico che passa (vedi storia separata).

L'inferenza secondo cui la situazione del Portogallo potrebbe non essere così come è stata presentata è stata anche evidenziata dal sindaco di Ovar, che ieri sera ha pubblicato su Facebook che il numero di casi positivi nel suo distretto è “quasi il doppio” rispetto alla cifra annunciata dalle autorità sanitarie della DGS ieri.

“La situazione in Ovar continua ad essere molto complicata e stanno iniziando a comparire pazienti infetti in condizioni gravi o molto gravi”, ha scritto ieri sera. “Abbiamo davvero bisogno dell'aiuto del nostro ministero della salute. Nel frattempo, il numero aggiornato di infetti confermati in questo momento dal comune è 101, che è un po 'diverso dai 55 annunciati oggi ”.

Anche le case di cura hanno riportato situazioni gravi, con dozzine di detenuti anziani che mostrano segni di infezione e vengono spediti negli ospedali in attesa.

Oggi a mezzogiorno il Primo Ministro António Costa ha visitato l'ospedale Curry Cabral di Lisbona, che ora è dedicato esclusivamente al trattamento di pazienti affetti dal virus. Si è trattato di un chiaro esercizio di “limitazione dei danni” sostenuto dalla gerarchia dell'ospedale, il quale ha insistito sul fatto che non mancavano attrezzature o necessità mediche.

I dati pubblicati mentre Costa stava dando una breve conferenza stampa mostrano che i casi positivi ora sono poco meno di 3.000, il che rappresenta un aumento del 27% rispetto a quelli registrati ieri.

Anche i decessi aumentano, dal 33 al 43. I casi sospetti ora ammontano a 21.155.

A breve seguirà un rapporto del briefing stampa di oggi, ma dai diagrammi pubblicati sulla televisione nazionale emerge che il numero di infetti ora nell'Alentejo è balzato a 12 (dai 6 di ieri) e quelli in Algarve sono aumentati a 62 da quelli di ieri 46. ​​L'unica “grazia salvifica” qui è che tutti i casi si trovano nei distretti già colpiti: Portimão (11 casi), Lagoa (4), Silves (3), Albufeira (17), Loulé (7), Faro (17) , Tavira (1) e Vila Real de Sto António (3).

Le aree più colpite rimangono il nord e Lisbona.

L'80% dei decessi è avvenuto negli anni '70, motivo per cui le autorità si stanno sforzando così tanto di rammentare il messaggio per questa fascia d'età di “restare al chiuso”.

Parlando fuori dall'ospedale Curry Cabral di Lisbona, poco prima dell'inizio del briefing stampa, il primo ministro ha sottolineato che più di ogni altra cosa in questo momento, “più che numeri e tutte le domande poste, è la necessità di un'enorme disciplina”. I cittadini devono rimanere sotto il “massimo isolamento possibile” quando il paese entra nella fase più critica di questo focolaio: quella della “mitigazione” in cui è in corso la trasmissione della comunità. Non in modo esplosivo, sottolinea Graça Freitas dell'autorità sanitaria della DGS, ma comunque pericoloso.

I prossimi giorni saranno fondamentali nel vedere dove sta andando questa pandemia, in termini nazionali.

Martedì 24 marzo:

La conferenza stampa di “Covid-19” di martedì, che presenta i dati delle ultime 24 ore, è riuscita a mettersi in un pasticcio.

Innanzitutto è stato riferito che ci sono stati sei morti fino a mezzanotte della scorsa notte. Quel numero è cambiato improvvisamente in sette, e ora è alle 10.

La confusione derivava da dati utilizzati che non erano stati completamente aggiornati.

In totale, tuttavia, le infezioni sono state stabilite in 2.362 persone – che rappresenta un aumento di 302 sui totali di ieri.

I test continuano – forse non così ampiamente come potrebbe piacere al pubblico, quindi le cifre cambieranno costantemente.

Il briefing stampa di oggi è stato “più aggressivo” del solito in quanto i giornalisti hanno continuato a insistere per ulteriori dettagli. Chi erano gli ultimi morti, per esempio? (Beh, è ​​stato complicato mentre continuavano ad aumentare). Erano anziani nelle case di cura?

Nessuna delle risposte è davvero soddisfatta.

Abbiamo sentito che ci sono attualmente 203 persone internate in vari ospedali, 48 di loro in terapia intensiva.

Il il nord del paese continua ad essere il più colpito, con 1.130 casi di virus e nove morti.

Lisbona e Vale do Tejo verranno dopo con 852 casi registrati e otto morti.

Il centro del paese ha 293 casi e ha subito 11 morti.

Il L'Algarve ora ha 46 casi (solo un decesso finora, la scorsa settimana), mentre i casi nelle Azzorre e Madeira sono purtroppo in aumento di giorno in giorno: 12 nelle Azzorre finora, 11 a Madeira.

Il Alentejo, fino a qui l'area con il minor numero di casi, ha ora registrato sei persone con il virus, tutti hanno capito di averlo contratto tramite qualcuno che era recentemente tornato da “all'estero”.

Per la prima volta, la direzione sanitaria della DGS ha elencato i comuni colpiti dalla pandemia: Lisbona è la città con il maggior numero di casi (175), seguita da Porto (126), Maia (104), Vila Nova de Gaia (68) e Valongo (65).

Il pannello di oggi era senza il volto familiare (in qualche modo confortante) di Graça Freitas. Invece la direzione sanitaria della DGS era rappresentata da Diogo Cruz, il vicedirettore che lavorava a fianco della sig.ra Freitas, mentre il ministero della salute era rappresentato dal segretario di Stato António Lacerda Sales.

La “buona notizia” è stata questa le forniture di ventilatori sono in costante aumento – con 500 acquistati dal governo cinese attesi nel corso delle prossime settimane fino al 14 aprile.

La “non è una buona notizia” è che il paese è decisamente ora nella “fase di mitigazione” in questo la trasmissione della comunità è in chiara evidenza.

Tuttavia, ieri sera il primo ministro della televisione nazionale António Costa ha insistito sul fatto che il sistema sanitario non è in pericolo di collasso, né siamo vicini al punto di esaurire le scorte e i materiali necessari.

“Non perderemo il controllo della situazione”, ha detto ai suoi intervistatori, sottolineando tuttavia che “non possiamo creare l'illusione di superare questo senza dolore”.

Nel frattempo, il modo in cui gli ospedali portoghesi trattano pazienti positivi sta cambiando per garantire che solo quelli con i sintomi più gravi vengano internati.

Un altro nuovo sviluppo è quello chiunque ora mostri segni di persistente tosse secca e febbre si qualificherà per il test.

La pressione per testare le persone che non mostrano sintomi è stata finora respinta per essere suscettibile di creare un “falso senso di sicurezza”.

Nella sfera più ampia, quattro aerei partiranno Lisbona oggi per Germania, Brasile e Regno Unito evacuazione dei passeggeri della linea di crociera incagliata dal colosso multideck “MSC Fantasia”.

Lunedì 23 marzo:

Aggiornamenti dello “stato di emergenza” Covid-19: i casi in Portogallo superano il 2000 con l'aumento delle morti a 23

  • Gli ultimi dati pubblicati dalle autorità mostrano il numero di casi positivi in ​​Portogallo ha raggiunto i 2.060. Questo è un aumento del 29%. Il direttore della direzione della DGS per la salute Graça Freitas insiste che è ancora troppo presto per interpretare i risultati in relazione allo stato di blocco virtuale del paese.
  • Anche le morti sono aumentate, dal conteggio di ieri di 14 a 23. Ciò rappresenta un aumento del 64%, quindi è difficile fare qualsiasi tipo di giro positivo su di esso.
  • 201 persone vengono internate in ospedale: 47 in terapia intensiva.
  • Oltre 1.000 persone attendono i risultati di test.
  • 14 si dice che i pazienti lo siano stati guarito.
  • 82 medici e 37 infermieri sono stato infetto dal virus.
  • 11.482 persone sono sotto “rigorosi termini di vigilanza” (questo non include i 55.000 in blocco in Ovar).
  • Infezioni in Algarve sono aumentati a 42 (città da specificare a breve).
  • Infezioni in Alentejo sono aumentati a 5, principalmente nel Évora area e tutto “importato dall'estero”.
  • I nuovi decessi avvennero nell'area di Lisbona (quattro) e nel nord (quattro), nonché una nel centro del paese.
  • Il direttore dell'autorità sanitaria della DGS Graça Freitas sottolinea che i casi che emergono sottolineano il fatto che la “trasmissione della comunità” è attuale.
  • I passeggeri portoghesi con test negativi sulla nave da crociera Fantasia (vedi sotto) sono stati ammessi a bordo della barca. Un test positivo e nuovi test sono in corso. Tutti gli altri passeggeri sono in attesa di voli di rimpatrio verso i loro paesi di origine, cosa che il Portogallo ha affermato di non pagare. In effetti, il ministro dell'amministrazione interna Eduardo Cabrita ha suggerito che alcuni stranieri potrebbero non offrire voli di rimpatrio, a seconda di quali paesi stanno cercando di tornare a casa.
  • Il briefing con la stampa è proseguito poco prima di pranzo, con il messaggio che il Portogallo sta rafforzando le sue scorte di materiale richiesto dagli operatori sanitari in prima linea “tutto il tempo”. I test stanno andando avanti, con la capacità nazionale ora a 2.500 test al giorno.
  • Il segretario di Stato per la salute António Lacerda Sales, ha rivelato che dalla Cina arriveranno 4 milioni di maschere – nell'aereo inviato da Beja nel fine settimana – (vedi sotto) insieme a migliaia di altri articoli medici specifici richiesti.

Psorilax:Ottieni online |psoriasi e crema nivea

0

Psorilax: prezzo, funziona, recensioni, opinioni, dove si compra

Ho sviluppato la psoriasi alla fine della mia carriera in equipaggio di cabina, quando avevo 22 anni. Avevo appena lasciato il lavoro ed ero stressato perché mia madre Consy non stava bene.

Volevo solo tornare a casa, mi mancava molto. Ero sempre lontano da lei a causa del mio lavoro e mi sentivo come se non avessi alcun controllo nella mia vita.

Poi ho iniziato a sentire questo fastidioso prurito alle orecchie, ma principalmente al cuoio capelluto. È stato imbarazzante, perché quando lo hai sul cuoio capelluto sembra forfora.

Non vuoi che le persone ti guardino in modo divertente e può diventare davvero denso e scomodo.



Malin Andersson ha iniziato la sua lotta con la psoriasi
Malin Andersson ha iniziato la sua lotta con la psoriasi

L'unica volta che è mai stato avvampato è stato quando mia mamma si è ammalata, quando mia mamma è morta – sono salito anche sulle mie gambe, è stato davvero male.

Poi è andato via prima di tornare quando il mio bambino Consy era in ospedale, è rimasto per circa quattro o cinque mesi prima di ripetere nuovamente l'atto di scomparsa.

Ora è tornato con tutto lo stress coronavirus e l'auto-isolamento ha causato. In realtà è piuttosto male in questo momento e queste condizioni non aiutano neanche.



Malin ha detto che si accende sul suo cuoio capelluto, che può apparire denso e goffo
Malin ha detto che si accende sul suo cuoio capelluto, che può apparire denso e goffo

Il punto a riguardo che vorrei sottolineare è che la mia psoriasi si è manifestata in ogni momento significativo della mia vita. Fondamentalmente è il modo in cui il mio corpo dice “woah, woah, woah, rallenta, stai stressando adesso”.

In realtà è anche molto importante, perché le persone pensano solo che sia qualcosa con cui devono convivere e sopportare. Ma non lo è, tutto deriva dalla mente – ci credo moltissimo.

Mentre altre persone vedono che è solo una parte della loro vita, lo vedo come il mio corpo che mi dà un segnale di avvertimento per praticare la cura di sé.



Vede la condizione come un segnale di avvertimento, dicendole di prendersi cura di se stessa meglio
Vede la condizione come un segnale di avvertimento, dicendole di prendersi cura di se stessa meglio

Inizialmente sono andato al GP e mi hanno dato la crema steroidea, ma preferisco i rimedi naturali come l'olio di cocco mescolato con un po 'di olio essenziale di lavanda, che funziona meglio per me.

Ma tutto ciò che stai cercando di fare è togliere il sintomo, fermarlo dal prurito. Penso che tutte queste creme prescritte siano davvero dure sulla tua pelle. Il tuo corpo non ne ha bisogno.

Mi è stato detto che hai qualcosa che è un disturbo autoimmune, che non è reversibile, può essere scoraggiante. Volevo solo scoprire perché era successo e sapevo che era legato alla mia salute mentale e ai livelli di stress.

Leggi di più

Malin Andersson

Mi sono reso conto che c'erano alcuni fattori scatenanti che lo scatenavano come il fumo, l'alcol, una cattiva alimentazione, non l'esercizio … Tutto sommato.

Negli ultimi anni ho smesso di fumare, sono diventato un pescatore, quindi l'unica carne che mangio è il pesce, e faccio esercizio fisico regolarmente e non esagerare con il bere.

È stato difficile, perché attraversando traumi e dolore, volevo fumare e stavo bevendo molto quando il mio bambino è morto.

Solo quando ho iniziato a gestire correttamente il dolore ho cambiato il mio stile di vita, il che a sua volta ha chiarito la psoriasi.

Psorilax:a che serve |farmacia vaticana crema contro la psoriasi

0

Psorilax: prezzo, funziona, recensioni, opinioni, originale

INDIANAPOLIS, 30 marzo 2020 / PRNewswire / – Eli Lilly and Company (NYSE: LLY) ha annunciato oggi che la Food and Drug Administration (FDA) degli Stati Uniti ha approvato una domanda di licenza biologica supplementare (sBLA) per Taltz® (ixekizumab), 80 mg / mL per il trattamento di pazienti pediatrici (da 6 a 18 anni di età) con psoriasi a placche da moderata a grave che sono candidati per terapia sistemica o fototerapia. La psoriasi colpisce quasi 8 milioni di persone negli Stati Uniti1 Molte persone che vivono con la psoriasi sviluppano sintomi durante l'infanzia.2“data-reactionid =” 13 “>INDIANAPOLIS, 30 marzo 2020 / PRNewswire / – Eli Lilly and Company (NYSE: LLY) ha annunciato oggi che la Food and Drug Administration (FDA) degli Stati Uniti ha approvato una domanda di licenza biologica supplementare (sBLA) per Taltz® (ixekizumab), 80 mg / mL per il trattamento di pazienti pediatrici (da 6 a 18 anni di età) con psoriasi a placche da moderata a grave che sono candidati per terapia sistemica o fototerapia. La psoriasi colpisce quasi 8 milioni di persone negli Stati Uniti1 Molte persone che vivono con la psoriasi sviluppano sintomi durante l'infanzia.2

Jennifer Cather, M.D., Modern Research Associates, Dallas, Texas. “Nello studio pediatrico di Fase 3, la metà dei pazienti trattati con Taltz ha raggiunto una pelle completamente chiara dopo solo 12 settimane di trattamento. Questi risultati e la successiva approvazione della FDA rappresentano un valido esempio di Taltz come un'opzione terapeutica efficace che i medici devono considerare per i pazienti pediatrici con psoriasi a placche da moderata a grave. “” data-reazioni “=” 14 “>” Come ho visto spesso nella mia clinica, la psoriasi è particolarmente stimolante per bambini e adolescenti, con conseguente prurito e sintomi dolorosi che possono essere particolarmente imbarazzanti per i pazienti pediatrici durante un periodo cruciale di sviluppo nelle loro giovani vite “, ha detto Jennifer Cather, M.D., Modern Research Associates, Dallas, Texas. “Nello studio pediatrico di Fase 3, la metà dei pazienti trattati con Taltz ha raggiunto una pelle completamente chiara dopo solo 12 settimane di trattamento. Questi risultati e la successiva approvazione della FDA rappresentano un valido esempio di Taltz come un'opzione terapeutica efficace che i medici devono considerare per i pazienti pediatrici con psoriasi a placche da moderata a grave. “

Taltz non deve essere usato in pazienti con precedente grave ipersensibilità, come anafilassi, a ixekizumab o ad uno qualsiasi degli eccipienti. Taltz può aumentare il rischio di infezione. Altre avvertenze e precauzioni per Taltz comprendono la valutazione pre-trattamento di tubercolosi, ipersensibilità, malattia infiammatoria intestinale e immunizzazioni. Vedi importanti informazioni sulla sicurezza di seguito.

Patrik Jonsson, vicepresidente senior e presidente di Lilly Bio-Medicines. “Abbiamo oltre cinque anni di dati che dimostrano che Taltz è un'opzione di trattamento sicura ed efficace per la psoriasi negli adulti e con questa approvazione, siamo lieti di essere ora in grado di offrire Taltz a più persone che vivono con questa difficile condizione.” ” data-reactionid = “16”> “Alla Lilly stiamo lavorando per unire la nostra compassione per le persone con il nostro entusiasmo per la scoperta scientifica, nel tentativo di fornire medicinali che aiutino a migliorare la vita delle persone”, ha detto Patrik Jonsson, vicepresidente senior e presidente di Lilly Bio-Medicines. “Abbiamo oltre cinque anni di dati che dimostrano che Taltz è un'opzione di trattamento sicura ed efficace per la psoriasi negli adulti e con questa approvazione, siamo lieti di essere ora in grado di offrire Taltz a più persone che vivono con questa condizione difficile”.

La sicurezza, la tollerabilità e l'efficacia di Taltz in pazienti di età compresa tra 6 e 18 anni sono state dimostrate in uno studio di fase 3 randomizzato, in doppio cieco, controllato con placebo, che ha incluso 171 pazienti con psoriasi a placche da moderata a grave. Gli endpoint co-primari dello studio erano la percentuale di pazienti che raggiungevano un miglioramento del 75 percento rispetto al basale del loro punteggio di Indice di area e gravità della psoriasi (PASI 75) e una valutazione globale del medico statico di pelle chiara o quasi chiara (sPGA 0,1) alla settimana 12.

I pazienti sono stati randomizzati a ricevere Taltz (20 mg per <25 kg, 40 mg for 25-50 kg or 80 mg for >50 kg fino alla settimana 12, con dosi iniziali di 40 mg, 80 mg o 160 mg, rispettivamente) o placebo. A 12 settimane, la percentuale di pazienti che hanno raggiunto gli endpoint co-primari era superiore al placebo con differenza statisticamente significativa (P <0,001):

  • L'89 percento dei pazienti trattati con Taltz ha raggiunto la PASI 75 rispetto al 25 percento dei pazienti trattati con placebo.
  • L'81 percento dei pazienti trattati con Taltz ha raggiunto lo sPGA 0,1 rispetto all'11 percento dei pazienti trattati con placebo.

Taltz ha anche incontrato tutti i principali endpoint secondari nello studio (P <0,001), che includeva la proporzione di pazienti che raggiungevano PASI 90, sPGA (0) e PASI 100 alla settimana 12 e almeno un miglioramento di quattro punti nella scala di valutazione numerica Itch (Prurito NRS ≥4) tra i pazienti con prurito NRS ≥4 ≥4 alla settimana 12, nonché PASI 75 e sPGA 0,1 alla settimana 4.

Complessivamente, il profilo di sicurezza osservato nei pazienti pediatrici con psoriasi a placche trattati con Taltz ogni quattro settimane è coerente con il profilo di sicurezza nei pazienti adulti con psoriasi a placche, ad eccezione delle frequenze di congiuntivite (3%), influenza (2%) e orticaria (2%). In questo studio clinico, la malattia di Crohn si è verificata con una frequenza maggiore nel gruppo Taltz (0,9%) rispetto al gruppo placebo (0%) durante il periodo di 12 settimane, controllato con placebo. La malattia di Crohn si è verificata in un totale di quattro soggetti trattati con Taltz (2,0%) nella sperimentazione clinica. Il profilo di sicurezza di Taltz è stato studiato in 13 studi clinici su soggetti adulti con psoriasi a placche, con oltre 5.000 pazienti che hanno ricevuto Taltz, con un'esposizione totale di oltre 17000 pazienti-anno.

Stacie Bell, responsabile scientifico e medico della National Psoriasis Foundation. “Avere più opzioni di trattamento della psoriasi pediatrica approvate dalla FDA è un passo positivo nel contribuire ad alleviare il peso della psoriasi per i pazienti pediatrici, le loro famiglie e gli operatori sanitari che trattano questi giovani pazienti.” “Data-reagente =” 24 “>” A causa delle limitate opzioni di trattamento della psoriasi pediatrica disponibili, il trattamento di bambini e adolescenti con psoriasi a placche da moderata a grave può essere difficile “, ha detto Stacie Bell, responsabile scientifico e medico della National Psoriasis Foundation. “Avere più opzioni di trattamento della psoriasi pediatrica approvate dalla FDA è un passo positivo nel contribuire ad alleviare il peso della psoriasi per i pazienti pediatrici, le loro famiglie e gli operatori sanitari che trattano questi giovani pazienti.”

Marzo 2016 per il trattamento della psoriasi a placche da moderata a grave in pazienti adulti candidati a terapia sistemica o fototerapia. La FDA ha anche approvato Taltz per il trattamento degli adulti con artrite psoriasica attiva in Dicembre 2017 e per il trattamento di adulti con spondilite anchilosante attiva & nbsp; in Agosto 2019“data -eagid =” 29 “> Taltz è stato approvato per la prima volta dalla FDA in Marzo 2016 per il trattamento della psoriasi a placche da moderata a grave in pazienti adulti candidati a terapia sistemica o fototerapia. La FDA ha anche approvato Taltz per il trattamento degli adulti con artrite psoriasica attiva in Dicembre 2017 e per il trattamento di adulti con spondilite anchilosante attiva in Agosto 2019.

www.lilly.com“data -eagid =” 30 “> Lilly lavorerà con assicuratori, sistemi sanitari e fornitori per garantire che i pazienti possano accedere a questo trattamento. Pazienti, medici, farmacisti o altri professionisti sanitari con domande su Taltz devono contattare il Lilly Answers Center all'indirizzo 1-800-LillyRx (1-800-545-5979) o visitare www.lilly.com.

Prescrizione di informazioni e Guida ai farmaci per Taltz. Vedere Istruzioni per l'uso incluso con il dispositivo.“data -eagido =” 40 “>Si prega di consultare la guida completa per la prescrizione di informazioni e farmaci per Taltz. Vedere le istruzioni per l'uso incluse con il dispositivo.

lilly.com e & nbsp;lilly.com/news P-LLY “data-reazioni” = “45”>Informazioni su Eli Lilly and Company
Lilly è un leader mondiale dell'assistenza sanitaria che unisce la cura alla scoperta per creare medicinali che migliorano la vita delle persone di tutto il mondo. Siamo stati fondati più di un secolo fa da un uomo impegnato nella creazione di medicinali di alta qualità che soddisfano bisogni reali e oggi rimaniamo fedeli a quella missione in tutto il nostro lavoro. In tutto il mondo, i dipendenti Lilly lavorano per scoprire e portare medicine che cambiano la vita a coloro che ne hanno bisogno, migliorare la comprensione e la gestione delle malattie e restituire alle comunità attraverso la filantropia e il volontariato. Per ulteriori informazioni su Lilly, visitare il sito Web lilly.com e lilly.com/news P-LLY

Il presente comunicato stampa contiene dichiarazioni previsionali (come definito nella Legge sulla riforma del contenzioso in materia di valori mobiliari del 1995) su Taltz (ixekizumab) come trattamento per pazienti pediatrici con psoriasi a placche da moderata a grave e riflette l'attuale convinzione di Lilly. Tuttavia, come con qualsiasi prodotto farmaceutico, vi sono sostanziali rischi e incertezze nel processo di sviluppo e commercializzazione. Tra le altre cose, non vi è alcuna garanzia che Taltz riceverà ulteriori approvazioni normative o avrà successo commerciale. Per ulteriori discussioni su questi e altri rischi e incertezze, consultare i più recenti documenti di deposito 10-K e 10-Q di Lilly presso la Securities and Exchange Commission degli Stati Uniti. Salvo quanto previsto dalla legge, Lilly non si assume alcun obbligo di aggiornare le dichiarazioni previsionali per riflettere gli eventi successivi alla data di questa versione.

Stati Uniti d'America, LLC 2020. Tutti i diritti riservati. “Data -eagid =” 47 “> PP-IX-US-3694 03/2020 © Lilly Stati Uniti d'America, LLC 2020. Tutti i diritti riservati.

https://www.psoriasis.org/content/statistics. Accesso effettuato a marzo 2020.
2& nbsp; Mentore A, Cordoro K, Davis D et al. Linee guida della Joint National Academy of Dermatology National Psoriasis Foundation per la cura e la gestione della psoriasi nei pazienti pediatrici. J Am Acad Dermatol. 2020; 82: 161-201.
3& nbsp; Taltz Prescribing Information, 2020. “data -eagid =” 48 “>1 Statistiche. Sito web della National Psoriasis Foundation. https://www.psoriasis.org/content/statistics. Accesso effettuato a marzo 2020.
2 Mentore A, Cordoro K, Davis D et al. Linee guida della Joint National Academy of Dermatology National Psoriasis Foundation per la cura e la gestione della psoriasi nei pazienti pediatrici. J Am Acad Dermatol. 2020; 82: 161-201.
3 Taltz Prescribing Information, 2020.

Carla Cox; cox_carla@lilly.com; 317-431-9999 (media) & nbsp;
Kevin Hern; hern_kevin_r@lilly.com; 317-277-1838 (investitori) “data-reazioni” = “49”>Fare riferimento a:
Carla Cox; cox_carla@lilly.com; 317-431-9999 (media)
Kevin Hern; hern_kevin_r@lilly.com; 317-277-1838 (investitori)

Logo di Eli Lilly and Company. (PRNewsfoto / Eli Lilly and Company)

http://www.prnewswire.com/news-releases/lillys-taltz-ixekizumab-receives-us-fda-approval-for-the-treatment-of-pediatric-patients-with-moderate-to-severe-plaque- psoriasi-301031305.html“data -eagid =” 76 “> Visualizza contenuti originali per scaricare contenuti multimediali: http: //www.prnewswire.com/news-releases/lillys-taltz-ixekizumab-receives-us-fda-approval-for-the-treatment- di-pediatrica-pazienti-con-moderata-grave-placche-psoriasi-301031305.html

FONTE Eli Lilly and Company

Psorilax:Prezzo elevato |crema forte psoriasi cbd idroponica

0

Psorilax: prezzo, funziona, recensioni, opinioni, ingredienti

INDIANAPOLIS, 30 marzo 2020 / PRNewswire / – Eli Lilly and Company (NYSE: LLY) ha annunciato oggi che la Food and Drug Administration (FDA) degli Stati Uniti ha approvato una domanda di licenza biologica supplementare (sBLA) per Taltz® (ixekizumab), 80 mg / mL per il trattamento di pazienti pediatrici (da 6 a 18 anni di età) con psoriasi a placche da moderata a grave che sono candidati per terapia sistemica o fototerapia. La psoriasi colpisce quasi 8 milioni di persone negli Stati Uniti1 Molte persone che vivono con la psoriasi sviluppano sintomi durante l'infanzia.2

“Come ho visto spesso nella mia clinica, la psoriasi è particolarmente stimolante per bambini e adolescenti, con sintomi pruriginosi e dolorosi che possono essere particolarmente imbarazzanti per i pazienti pediatrici durante un periodo di sviluppo cruciale nella loro giovane vita”, ha detto Jennifer Cather, M.D., Modern Research Associates, Dallas, Texas. “Nello studio pediatrico di Fase 3, la metà dei pazienti trattati con Taltz ha raggiunto una pelle completamente chiara dopo solo 12 settimane di trattamento. Questi risultati e la successiva approvazione della FDA rappresentano un valido esempio di Taltz come un'opzione terapeutica efficace che i medici devono considerare per i pazienti pediatrici con psoriasi a placche da moderata a grave. “

Taltz non deve essere usato in pazienti con precedente grave ipersensibilità, come anafilassi, a ixekizumab o ad uno qualsiasi degli eccipienti. Taltz può aumentare il rischio di infezione. Altre avvertenze e precauzioni per Taltz comprendono la valutazione pre-trattamento di tubercolosi, ipersensibilità, malattia infiammatoria intestinale e immunizzazioni. Vedi importanti informazioni sulla sicurezza di seguito.

“Alla Lilly stiamo lavorando per unire la nostra compassione per le persone con il nostro entusiasmo per la scoperta scientifica, nel tentativo di fornire medicinali che aiutino a migliorare la vita delle persone”, ha affermato Patrik Jonsson, vicepresidente senior e presidente di Lilly Bio-Medicines. “Abbiamo oltre cinque anni di dati che dimostrano che Taltz è un'opzione di trattamento sicura ed efficace per la psoriasi negli adulti e con questa approvazione, siamo lieti di essere ora in grado di offrire Taltz a più persone che vivono con questa condizione difficile”.

La sicurezza, la tollerabilità e l'efficacia di Taltz in pazienti di età compresa tra 6 e 18 anni sono state dimostrate in uno studio di fase 3 randomizzato, in doppio cieco, controllato con placebo, che ha incluso 171 pazienti con psoriasi a placche da moderata a grave. Gli endpoint co-primari dello studio erano la percentuale di pazienti che raggiungevano un miglioramento del 75 percento rispetto al basale del loro punteggio di Indice di area e gravità della psoriasi (PASI 75) e una valutazione globale del medico statico di pelle chiara o quasi chiara (sPGA 0,1) alla settimana 12.

I pazienti sono stati randomizzati a ricevere Taltz (20 mg per <25 kg, 40 mg for 25-50 kg or 80 mg for >50 kg fino alla settimana 12, con dosi iniziali di 40 mg, 80 mg o 160 mg, rispettivamente) o placebo. A 12 settimane, la percentuale di pazienti che hanno raggiunto gli endpoint co-primari era superiore al placebo con differenza statisticamente significativa (P <0,001):

  • L'89 percento dei pazienti trattati con Taltz ha raggiunto la PASI 75 rispetto al 25 percento dei pazienti trattati con placebo.
  • L'81 percento dei pazienti trattati con Taltz ha raggiunto lo sPGA 0,1 rispetto all'11 percento dei pazienti trattati con placebo.

Taltz ha anche incontrato tutti i principali endpoint secondari nello studio (P <0,001), che includeva la proporzione di pazienti che raggiungevano PASI 90, sPGA (0) e PASI 100 alla settimana 12 e almeno un miglioramento di quattro punti nella scala di valutazione numerica Itch (Prurito NRS ≥4) tra i pazienti con prurito NRS ≥4 ≥4 alla settimana 12, nonché PASI 75 e sPGA 0,1 alla settimana 4.

Complessivamente, il profilo di sicurezza osservato nei pazienti pediatrici con psoriasi a placche trattati con Taltz ogni quattro settimane è coerente con il profilo di sicurezza nei pazienti adulti con psoriasi a placche, ad eccezione delle frequenze di congiuntivite (3%), influenza (2%) e orticaria (2%). In questo studio clinico, la malattia di Crohn si è verificata con una frequenza maggiore nel gruppo Taltz (0,9%) rispetto al gruppo placebo (0%) durante il periodo di 12 settimane, controllato con placebo. La malattia di Crohn si è verificata in un totale di quattro soggetti trattati con Taltz (2,0%) nella sperimentazione clinica. Il profilo di sicurezza di Taltz è stato studiato in 13 studi clinici su soggetti adulti con psoriasi a placche, con oltre 5.000 pazienti che hanno ricevuto Taltz, con un'esposizione totale di oltre 17000 pazienti-anno.

“A causa delle limitate opzioni di trattamento della psoriasi pediatrica disponibili, il trattamento di bambini e adolescenti con psoriasi a placche da moderata a grave può essere difficile”, ha detto Stacie Bell, responsabile scientifico e medico della National Psoriasis Foundation. “Avere a disposizione più opzioni di trattamento della psoriasi pediatrica approvate dalla FDA è un passo positivo nel contribuire ad alleviare il peso della psoriasi per i pazienti pediatrici, le loro famiglie e gli operatori sanitari che trattano questi giovani pazienti.”

Taltz è stato approvato per la prima volta dalla FDA a Marzo 2016 per il trattamento della psoriasi a placche da moderata a grave in pazienti adulti candidati a terapia sistemica o fototerapia. La FDA ha anche approvato Taltz per il trattamento degli adulti con artrite psoriasica attiva in Dicembre 2017 e per il trattamento di adulti con spondilite anchilosante attiva in Agosto 2019.

Lilly lavorerà con assicuratori, sistemi sanitari e fornitori per garantire che i pazienti siano in grado di accedere a questo trattamento. Pazienti, medici, farmacisti o altri professionisti sanitari con domande su Taltz devono contattare il Lilly Answers Center all'indirizzo 1-800-LillyRx (1-800-545-5979) o visitare www.lilly.com.

INDICAZIONI E UTILIZZO PER TALTZ
Taltz è approvato per il trattamento di pazienti pediatrici di età compresa tra 6 e 18 anni con psoriasi a placche da moderata a grave che sono candidati per terapia sistemica o fototerapia. Inoltre, Taltz è approvato per il trattamento di adulti con psoriasi a placche da moderata a grave che sono candidati per terapia sistemica o fototerapia. Taltz è anche approvato per il trattamento di adulti con artrite psoriasica attiva e spondilite anchilosante attiva.

IMPORTANTI INFORMAZIONI SULLA SICUREZZA PER TALTZ

CONTROINDICAZIONI
Taltz è controindicato in pazienti con una precedente reazione di ipersensibilità grave, come anafilassi, a ixekizumab o ad uno qualsiasi degli eccipienti.

AVVERTENZE E PRECAUZIONI
infezioni
Taltz può aumentare il rischio di infezione. Negli studi clinici su pazienti adulti con psoriasi a placche, il gruppo Taltz ha avuto un tasso di infezione più elevato rispetto al gruppo placebo (27% vs 23%). Un simile aumento del rischio di infezione è stato osservato negli studi controllati con placebo su pazienti adulti con artrite psoriasica e spondilite anchilosante e pazienti pediatrici con psoriasi a placche. Si sono verificate gravi infezioni. Chiedere ai pazienti di consultare un medico in caso di segni o sintomi di infezione cronica o acuta clinicamente importante. Se si sviluppa un'infezione grave, interrompere Taltz fino a quando l'infezione non si risolve.

Valutazione pre-trattamento per la tubercolosi
Valutare i pazienti per infezione da tubercolosi (TB) prima di iniziare il trattamento con Taltz. Non somministrare a pazienti con infezione da TB attiva. Iniziare il trattamento della tubercolosi latente prima di somministrare Taltz. Monitorare attentamente i pazienti che ricevono Taltz per segni e sintomi di tubercolosi attiva durante e dopo il trattamento.

ipersensibilità
Reazioni di ipersensibilità gravi, inclusi angioedema e orticaria (ciascuno ≤ 0,1%), si sono verificate nel gruppo Taltz negli studi clinici. L'anafilassi, compresi i casi che portano al ricovero, è stata riportata nell'uso post-marketing con Taltz. Se si verifica una grave reazione di ipersensibilità, interrompere immediatamente Taltz e iniziare la terapia appropriata.

Malattia infiammatoria intestinale
I pazienti trattati con Taltz possono essere ad aumentato rischio di malattia infiammatoria intestinale. Negli studi clinici, la malattia di Crohn e la colite ulcerosa, comprese le esacerbazioni, si sono verificate con una frequenza maggiore nel gruppo Taltz rispetto al gruppo placebo. Durante il trattamento con Taltz, monitorare i pazienti per insorgenza o esacerbazioni della malattia infiammatoria intestinale e, in caso di IBD, interrompere Taltz e avviare un'adeguata gestione medica.

vaccinazioni
Prima di iniziare la terapia con Taltz, prendere in considerazione il completamento di tutte le immunizzazioni appropriate all'età secondo le attuali linee guida per l'immunizzazione. Evitare l'uso di vaccini vivi nei pazienti trattati con Taltz.

REAZIONI AVVERSE
Le reazioni avverse più comuni (≥1%) associate al trattamento con Taltz sono reazioni nel sito di iniezione, infezioni del tratto respiratorio superiore, nausea e infezioni da tinea. Complessivamente, i profili di sicurezza osservati nei pazienti adulti con artrite psoriasica e spondilite anchilosante e nei pazienti pediatrici con psoriasi a placche erano coerenti con il profilo di sicurezza nei pazienti adulti con psoriasi a placche, ad eccezione dell'influenza e della congiuntivite nell'artrite psoriasica e congiuntivite, influenza e orticaria nella psoriasi pediatrica.

Si prega di consultare la guida completa per la prescrizione di informazioni e farmaci per Taltz. Vedere le istruzioni per l'uso incluse con il dispositivo.

IX HCP ISI 26MAR2020

Informazioni su Taltz®
Taltz® (ixekizumab) è un anticorpo monoclonale che si lega selettivamente con la citochina dell'interleuchina 17A (IL-17A) e ne inibisce l'interazione con il recettore dell'IL-17.3 L'IL-17A è una citochina presente in natura che è coinvolta nelle normali risposte infiammatorie e immunitarie. Taltz inibisce il rilascio di citochine e chemochine pro-infiammatorie.3

Informazioni sullo studio pediatrico di fase 3
L'approvazione della FDA di Taltz in pazienti pediatrici con psoriasi a placche da moderata a grave si basava su uno studio di fase 3, multicentrico, randomizzato, in doppio cieco, controllato con placebo per valutare la sicurezza, la tollerabilità e l'efficacia di Taltz in pazienti di età compresa tra 6 e 18 anni di età. Gli endpoint co-primari dello studio erano la percentuale di pazienti che raggiungevano un miglioramento del 75 percento rispetto al basale del loro punteggio di Indice di area e gravità della psoriasi (PASI 75) e una valutazione globale del medico statico di pelle chiara o quasi chiara (sPGA 0,1) alla settimana 12. Gli endpoint secondari chiave includevano la percentuale di pazienti che raggiungevano PASI 90, sPGA 0 e PASI 100 alla settimana 12 e almeno un miglioramento di quattro punti nella scala di valutazione numerica Itch (Itch NRS ≥4) tra i pazienti con prurito NRS al basale ≥4 alla settimana 12, nonché PASI 75 e sPGA 0,1 alla settimana 4.

Informazioni su Lilly in Dermatologia
Seguendo la scienza attraverso un territorio inesplorato, continuiamo l'eredità di Lilly di fornire medicinali innovativi che rispondono a bisogni insoddisfatti e hanno un impatto significativo sulla vita delle persone in tutto il mondo. Le malattie della pelle sono più che profonde. Comprendiamo l'impatto devastante che questo può avere sulla vita delle persone. In Lilly, stiamo incessantemente perseguendo una solida pipeline dermatologica per fornire soluzioni innovative e incentrate sul paziente in modo che i pazienti con malattie legate alla pelle possano aspirare a vivere la vita senza limiti.

Informazioni su Eli Lilly and Company
Lilly è un leader mondiale dell'assistenza sanitaria che unisce la cura alla scoperta per creare medicinali che migliorano la vita delle persone di tutto il mondo. Siamo stati fondati più di un secolo fa da un uomo impegnato nella creazione di medicinali di alta qualità che soddisfano bisogni reali e oggi rimaniamo fedeli a quella missione in tutto il nostro lavoro. In tutto il mondo, i dipendenti Lilly lavorano per scoprire e portare medicine che cambiano la vita a coloro che ne hanno bisogno, migliorare la comprensione e la gestione delle malattie e restituire alle comunità attraverso la filantropia e il volontariato. Per ulteriori informazioni su Lilly, visitare il sito Web lilly.com e lilly.com/news P-LLY

Il presente comunicato stampa contiene dichiarazioni previsionali (come definito nella Legge sulla riforma del contenzioso in materia di valori mobiliari del 1995) su Taltz (ixekizumab) come trattamento per pazienti pediatrici con psoriasi a placche da moderata a grave e riflette l'attuale convinzione di Lilly. Tuttavia, come con qualsiasi prodotto farmaceutico, vi sono sostanziali rischi e incertezze nel processo di sviluppo e commercializzazione. Tra le altre cose, non vi è alcuna garanzia che Taltz riceverà ulteriori approvazioni normative o avrà successo commerciale. Per ulteriori discussioni su questi e altri rischi e incertezze, consultare i più recenti documenti di deposito 10-K e 10-Q di Lilly presso la Securities and Exchange Commission degli Stati Uniti. Salvo quanto previsto dalla legge, Lilly non si assume alcun obbligo di aggiornare le dichiarazioni previsionali per riflettere gli eventi successivi alla data di questa versione.

PP-IX-US-3694 03/2020 © Lilly Stati Uniti d'America, LLC 2020. Tutti i diritti riservati.

1 Statistiche. Sito web della National Psoriasis Foundation. https://www.psoriasis.org/content/statistics. Accesso effettuato a marzo 2020.
2 Mentore A, Cordoro K, Davis D et al. Linee guida della Joint National Academy of Dermatology National Psoriasis Foundation per la cura e la gestione della psoriasi nei pazienti pediatrici. J Am Acad Dermatol. 2020; 82: 161-201.
3 Taltz Prescribing Information, 2020.

Fare riferimento a:
Carla Cox; cox_carla@lilly.com; 317-431-9999 (media)
Kevin Hern; hern_kevin_r@lilly.com; 317-277-1838 (investitori)

Psorilax:Sano |crema corpo idratante per psoriasi

0

Psorilax: prezzo, funziona, recensioni, opinioni, dove si compra

La disoccupazione post Covid-19 deve essere affrontata, dicono gli economisti

11 maggio

La pandemia di Covid-19 può portare a sfide economiche sconosciute mentre i paesi di tutto il mondo affrontano tassi di disoccupazione e inflazione in aumento.

I governi stanno cercando di ridurre al minimo l'impatto della pandemia attraverso pacchetti di aiuti economici, ma ciò può portare a enormi debiti.

Jonathan Portes, professore di economia al King's College di Londra, ha twittato le cose di base che devono essere fatte per affrontare il problema della disoccupazione nel Regno Unito.

Ha osservato che il reddito delle persone dovrebbe essere sostenuto, che i lavori fattibili dovrebbero essere resi disponibili per i lavoratori dopo la crisi e che i lavoratori dovrebbero trovare aiuto per trovare un nuovo tipo di lavoro se i loro vecchi lavori non sono più fattibili

Portes ha aggiunto che l'assistenza dovrebbe essere fornita ai giovani che stanno entrando nel mercato del lavoro durante la recessione economica.

Leggi di più

10:35

Previsioni economiche: le piccole imprese sotto pressione – Hamada mette in guardia contro l'allentamento monetario – le previsioni sugli investimenti “populisti” aumenteranno

11 maggio

L'indagine sulle PMI delle banche centrali europee ha mostrato che le PMI stanno segnalando un rapido deterioramento dell'ambiente economico nel contesto di Covid-19.

L'indagine mostra che le aspettative sulla disponibilità di prestiti bancari stavano diminuendo in modo significativo nell'area dell'euro (-11%, in calo rispetto al 4% nel 2014 in cui è stata effettuata l'ultima indagine), con un livello di deterioramento che varia da paese a paese.

Riflettendo sulla gravità della pandemia di coronavirus in diversi paesi, le PMI italiane hanno riportato il peggioramento in termini netti (-13%, dal 9%), seguite dalle PMI francesi e spagnole (-9% e -12%, dall'8% e – 1%, rispettivamente).

Il professore di economia dell'Università di Yale, Koichi Hamada, ha messo in guardia dai pericoli di allentamento monetario guidati dagli Stati Uniti.

Hamada ha scritto nel suo blog pubblicato dal World Economic Forum: “Oggi, i governi sono generalmente concentrati sull'appiattimento della curva della loro prima ondata di infezioni da Covid-19 o, sempre più, sull'evitare una seconda ondata di infezioni mentre allentano i social protocolli distanziati e consentire di riprendere l'attività economica.

“Ma, con gli Stati Uniti apparentemente intenzionati a inondare i mercati globali di dollari, anche le economie che finora hanno gestito la crisi in modo efficace potrebbero avere altra scelta se non quella di perseguire il proprio allentamento monetario”.

Commentando l'impennata della disoccupazione nella banca d'investimenti statunitense Citi ha affermato di aspettarsi che posizioni più populiste guadagnino forza nelle economie occidentali.

Da un punto di vista del mercato azionario, la banca ha dichiarato: “il rifocalizzarsi su settori focalizzati sul mercato interno rispetto a quelli orientati a livello globale potrebbe rivelarsi un'opportunità per titoli di valore in quanto la spinta anti-globalizzazione influisce negativamente sui settori globali e promuove campioni nazionali” nazionali “.

“La pressione sui riacquisti di azioni potrebbe significare la fine di una mentalità” acquista solo il mercato “e inaugura un nuovo periodo sottolineando l'importanza della selezione dei titoli e dei dividendi nella ricerca di rendimenti positivi.”

L'analisi della banca ha anche aggiunto che: “Attualmente, i mercati azionari statunitensi stanno valutando un rimbalzo degli utili, ma con preoccupazioni sulla caduta dei margini di profitto a causa della flessione, le aspettative di crescita degli utili a medio termine potrebbero essere ottimistiche”.

10:07

Rapporto giornaliero Covid-19: i decessi mostrano una tendenza al ribasso: gli Stati Uniti continuano a registrare il maggior numero

11 maggio

Il numero di decessi Covid-19 ha continuato a diminuire, con tutti i paesi con il maggior numero di morti che vedono una traiettoria generale verso il basso quando si osserva una media mobile di decessi.

Le cifre oggi sono probabilmente inclinate verso il basso dall'effetto del fine settimana, quindi i progressi giornalieri potrebbero sembrare migliori di quanto non siano.

Gli Stati Uniti continuano a registrare il maggior numero di morti nel mondo, registrando 731 ieri – più del doppio del Regno Unito che ha visto 268.

Tuttavia, entrambi i paesi sembrano seguire una traiettoria lenta verso il basso.

Rapporto giornaliero Covid-19

9:33

I casi Covid-19 potrebbero aver raggiunto il picco nel Regno Unito, ma il declino dovrebbe richiedere molto tempo

Covid-19, la malattia causata dal nuovo coronavirus, ha avuto un enorme effetto sul Regno Unito. GlobalData ha aggiornato il suo modello di previsione del rischio di trasmissione in tre scenari utilizzando dati storici Covid-19 aggiornati del database Johns Hopkins Covid-19, nonché i rapporti sulla situazione Covid-19 dell'Organizzazione mondiale della sanità (OMS).

Il modello esamina la sequenza temporale prevista per i prossimi due mesi, inclusi i calcoli di picco e di recupero. Sulla base dei dati storici relativi ai nuovi casi Covid-19, il Regno Unito sembra aver subito un plateau esteso nelle ultime settimane. Leggi di più qui.

9:21

Riassunto delle notizie dell'azienda Coronavirus – Prova di lancio di NIAID che combina remdesivir con il baricitinib di Lily – L'Università di Hong Kong trova presto una promessa nella terapia a tripla combinazione

11 maggio 2020

Una sperimentazione clinica sponsorizzata dal Istituto nazionale di allergie e malattie infettive (NIAID) negli Stati Uniti ha lanciato per valutare Gilead Sciences'Remdesivir plus Eli LillyIl farmaco antinfiammatorio baricitinib per il trattamento di Covid-19. L'obiettivo principale della sperimentazione è di confrontare i tempi di recupero tra remdesivir da solo e remdesivir più le braccia di baricitinib.

Primi dati da un piccolo studio clinico condotto dal Università di Hong Kong ha dimostrato di essere promettente per il trattamento di Covid-19 con una combinazione di lopinavir-ritonavir, farmaco per l'epatite ribavirina e interferone beta per la terapia della sclerosi multipla. I pazienti trattati con la tripla combinazione di farmaci sono risultati negativi per il virus cinque giorni prima rispetto a quelli che assumevano il solo farmaco HIV.

Il Ricerca medica del Consiglio indiano (ICMR) ha stretto una partnership con il produttore nazionale di vaccini Bharat Biotech International nel tentativo nazionale di sviluppare un vaccino contro Covid-19. L'ICMR ha dichiarato in una dichiarazione che il ceppo virale isolato presso l'Istituto nazionale indiano di virologia sarà utilizzato per sviluppare il vaccino.

Sorrento Therapeutics e Sistema sanitario del Monte Sinai hanno collaborato allo sviluppo di un cocktail di anticorpi, chiamato COVI-SHIELD, per il potenziale trattamento di Covid-19. Lo scopo è quello di creare anticorpi che sarebbero uno “scudo protettivo” contro Covid-19 inibendo e neutralizzando l'attività del virus SARS-CoV-2. Ogni dose di COVI-SHIELD dovrebbe comprendere un cocktail di tre anticorpi.

Il Dipartimento della salute e dei servizi umani degli Stati Uniti (HHS) ha finalizzato il piano di assegnazione per remdesivir donato da Gilead Sciences e ha iniziato a spedire il farmaco ai pazienti ricoverati in ospedale a Covid-19. HHS ha dichiarato che le dosi donate verranno utilizzate per trattare i pazienti nelle aree statunitensi più colpiti dalla pandemia. La società ha accettato di fornire circa 607.000 fiale del farmaco nelle prossime sei settimane per curare quasi 78.000 pazienti Covid-19 ricoverati in ospedale.

9:14

Aggiornamento internazionale: decessi Covid-19 cadono a New York – nuovo scoppio in Cina – gli scienziati trovano prove di mutazioni del coronavirus

11 maggio

NOI: New York ha riportato il minor numero di nuovi decessi Covid-19 – 207 – dalla fine di marzo e altri indicatori hanno iniziato a mostrare lo scoppio vicino al livello del punto di partenza per quello che il Governatore Andrew Cuomo ha definito “questo viaggio infernale”.

UK: Nel Regno Unito, il Primo Ministro Boris Johnson ha annunciato piani per allentare le restrizioni, ma sono stati etichettati come divisori, confusi e vaghi, dopo che ha detto che alcuni posti potrebbero riaprire e che il governo stava “incoraggiando attivamente” le persone a tornare al lavoro, senza fornendo dettagli su come.

Nuova Zelanda: La Nuova Zelanda passa al blocco di livello 2, allentando alcune restrizioni. Jacinda Ardern ha detto che feste, matrimoni, addii al celibato e funerali saranno chiusi alle dieci, sia all'interno che all'esterno, dal momento che il direttore generale della salute ha ritenuto questi eventi “ad alto rischio”.

Corea del Sud: La Corea del Sud ha segnalato 35 nuovi casi Covid-19 lunedì, 29 dei quali collegati a club e bar di Seoul, a cui hanno partecipato un uomo di 20 anni.

Giappone: Il Giappone potrebbe sollevare lo stato di emergenza in molte regioni questa settimana se i nuovi casi di coronavirus sono sotto controllo, ha detto lunedì il ministro dell'economia.

Cina: Un focolaio di coronavirus non rintracciato in una città cinese vicino al confine russo e una serie di nuovi casi a Wuhan ha suscitato il timore di una nuova ondata di infezioni in Cina. Wuhan ha registrato il più alto numero di nuove infezioni dall'11 marzo, riportando cinque nuovi casi per il 10 maggio, tra 17 nuovi casi a livello nazionale, il più alto in quasi due settimane.

Gli scienziati hanno trovato prove di mutazioni in alcuni ceppi del coronavirus che suggeriscono che l'agente patogeno potrebbe adattarsi all'uomo dopo la fuoriuscita dai pipistrelli.

Pakistan: Il Pakistan consentirà l'apertura di mercati e negozi per diversi giorni alla settimana a partire da lunedì, allentando il blocco del coronavirus.

Arabia Saudita: Lunedì il re Salman dell'Arabia Saudita ha ordinato la distribuzione di “aiuti del Ramadan” per un valore di 1,85 miliardi di riyal (492,6 milioni di dollari) per i beneficiari della sicurezza sociale.

9:35

Rapporto epidemiologo GlobalData: i casi globali di Covid-19 superano i 3,8 milioni – picchi di numeri in Germania – basso tasso di recupero nel Regno Unito

9 maggio

A livello globale, i casi confermati totali di Covid-19 hanno raggiunto oltre 3.834.000, con oltre 269.000 morti e 1.278.000 recuperi.

Mentre i casi confermati giornalieri e il decesso stanno diminuendo nella maggior parte dei paesi europei, il Regno Unito ha registrato un notevole aumento dei nuovi casi quotidiani il 6 maggio.

Mentre il numero di decessi confermati quotidianamente sta ancora diminuendo nel Regno Unito, il numero totale di casi recuperati nel Regno Unito è molto basso con circa 960 casi.

Rispetto al tasso di recupero globale del 32%, il tasso del Regno Unito dello 1,46% è preoccupante e dimostra che il Regno Unito deve ancora fare molto per arrivare al pieno recupero.

La Germania, un paese spesso usato come modello per la risposta di Covid-19 in Europa, ha anche registrato picchi in nuovi casi di oltre 1.000 mercoledì e giovedì.

Altri paesi come Russia, Brasile, India, Egitto e Messico stanno ancora registrando un aumento dei casi confermati.

Vi sono indicazioni di un lento spostamento della pandemia verso i paesi africani.

Anche se confrontati con gli Stati Uniti e l'Europa, i numeri dei casi confermati non sono significativamente elevati.

Bahram Hassanpourfard, MPH, epidemiologo, GlobalData

12:58 pm

Stato dei trasporti Covid-19: Berlino, Milano, Madrid, la mobilità di Roma in su – Londra in aumento

8 maggio
Il traffico stradale e l'uso dei trasporti pubblici a Berlino, Roma, Milano e Madrid sono aumentati mentre i governi dell'Europa continentale hanno ridotto le restrizioni al blocco questa settimana.

Tutte e quattro le città hanno mostrato un netto aumento della mobilità, sebbene il movimento a Milano e Roma rimanga all'incirca il 10% dei livelli visti prima dell'arrivo di Covid-19.

Ciò potrebbe riflettere una certa confusione e compromessi nelle nuove regole introdotte in Italia, il che significa che la maggior parte dei negozi rimarrà chiusa per altre due settimane e alle persone è consentito visitare la famiglia e coloro con i quali hanno un legame “stabile e duraturo”.

Questa settimana la congestione stradale e l'uso dei trasporti pubblici a Berlino hanno superato il 20% dei livelli di pre-blocco; Madrid ha visto il doppio del trasporto pubblico.

Tra i paesi in cui restano in atto rigidi blocchi, Londra ha visto l'uso del trasporto pubblico superare il 10% dei livelli di pre-blocco – un risultato, forse, di messaggi un po 'confusi su come e quando il governo di Westminster prevede di allentare le attuali restrizioni, nonché aneddoticamente “stanchezza da blocco”, segnalata dal clima mite primaverile che mette alla prova la determinazione delle persone.

Il blocco di Covid-19: tracciare se, quando e dove il mondo ricomincia a muoversi

Questo grafico è alimentato da tre fonti chiave.

Utilizziamo l'indice di mobilità di Citymapper per monitorare l'utilizzo dei trasporti pubblici, l'indice di traffico in tempo reale di TomTom per misurare l'uso della strada e i dati di riepilogo di FlightRadar24 per contare il numero totale di voli commerciali ogni giorno.

Grafico dell'indice di trasporto urbano

11:10

La FDA autorizza Moderna a condurre uno studio di fase II sul vaccino Covid-19

L'U Food and Drug Administration (FDA) ha completato la revisione della domanda di indagine sui nuovi farmaci (IND) di Moderna per il candidato al vaccino Covid-19, mRNA-1273, autorizzando la società a condurre uno studio di Fase II.

È stato inoltre finalizzato il protocollo per lo studio di fase III dell'mRNA-1273. Mentre la sperimentazione clinica di Fase II inizierà presto, lo studio di Fase III sarà condotto entro la fine dell'anno.

9:02

I pacchetti di salvataggio Covid-19 rischiano anni di debito pubblico, dicono gli economisti

Le preoccupazioni sul debito pubblico sono espresse dai principali influenzatori macroeconomici.

I governi di tutto il mondo stanno fornendo pacchetti di stimolo per proteggere le persone dall'impatto della pandemia di Covid-19.

Sebbene questi pacchetti siano essenziali, poiché milioni di persone hanno perso il lavoro a causa di misure di blocco, ciò potrebbe comportare livelli enormi di debito pubblico. Le conseguenze del debito dovrebbero avere un impatto a lungo sulle economie.

David W Versailles, un economista, ha condiviso un articolo su come il debito pubblico nelle economie anticipate raggiungerà livelli elevati nella pandemia di Covid-19.

L'articolo rileva che i governi dovrebbero trovare un equilibrio tra stimolo e moderazione poiché un debito pubblico eccessivo può gravare sulle società per gli anni a venire.

Leggi di più

8:26

Rapporto epidemiologo GlobalData: quasi 88.000 nuovi casi Covid-19 – Allentamento dei blocchi – aumento di nuovi casi

8 maggio

Con 87.941 nuovi casi confermati segnalati, il numero totale di casi confermati ha superato 3.775.000 a livello globale.

Circa il 75% del totale dei casi confermati appartiene agli Stati Uniti e all'Europa.

Il conteggio globale dei decessi totali è 264.437 e il totale recuperato è 1.254.744 (circa il 33% del totale dei casi confermati).

A seguito della consistente riduzione dei casi confermati quotidianamente in Europa, i governi hanno aumentato ulteriormente le restrizioni.

Tuttavia, permangono preoccupazioni circa la visualizzazione di ulteriori picchi dovuti alla rimozione della restrizione troppo presto.

Anche altre parti del mondo stanno revocando le restrizioni, ma hanno già osservato impennate.

Ad esempio, dopo un mese di riduzione dei casi confermati quotidianamente, i funzionari iraniani hanno consentito incontri in molte regioni.

Solo pochi giorni dopo, a partire dal 1 ° maggio, i nuovi casi confermati giornalieri sono aumentati in modo significativo e il paese ha superato 101.000 casi confermati.

I casi confermati quotidianamente in paesi come Russia, Messico e Brasile sono ancora in aumento.

Il Brasile, in particolare, ha riferito ieri 10.503 nuovi casi confermati (quasi il doppio di quello riportato il giorno prima).

Le aree urbane alte e popolose, come San Paolo, sono aree da monitorare.

Bahram Hassanpourfard, MPH, epidemiologo, GlobalData

8:16

Il regolatore giapponese approva il remdesivir di Gilead per il trattamento di Covid-19

Gilead Sciences ha ricevuto l'approvazione dal Ministero giapponese per la salute, il lavoro e il benessere (MHLW) per il suo farmaco antivirale remdesivir, con il marchio Veklury, per il trattamento dell'infezione da Covid-19.

L'approvazione giapponese è supportata dai risultati dello studio globale di Fase III del National Institute of Allergy and Diseases (NIAID) degli Stati Uniti e dallo studio SEMPLICE di Fase III di Gilead in pazienti con gravi manifestazioni di Covid-19.

Leggi di più qui

11:29

AbbVie, gli inibitori della proteasi di Ascletis scatenano prospettive scettiche per l'attività riproposta in Covid-19

Inibitori di proteasi come Kaletra (lopinavir / ritonavir), farmaco anti-HIV di AbbVie e Ganovo (danoprevir) di Ascletis Pharma, terapia con HCV di Ascletis Pharma suscitano sospetti per il loro potenziale in Covid-19, poiché esiste una bassa probabilità che un inibitore sia efficace contro due virus separati con strutture distinte .

A marzo, AbbVie ha affermato che ci sono stati resoconti dei media non confermati secondo cui le informazioni provenienti dalla Cina hanno mostrato l'efficacia di Kaletra in Covid-19, ma che non aveva accesso a tali dati. Leggi di più qui.

10:44

Covid-19 Daily Report: decessi negli Stati Uniti più alti da due settimane – la tendenza globale è in calo

7 maggio

Gli Stati Uniti hanno registrato il più alto livello di decessi Covid-19 per più di due settimane.

Ieri sono stati registrati in America circa 2.367 nuovi decessi, il più in un solo periodo di 24 ore dal 21 aprile.

A livello globale ci sono stati 6.592 decessi ieri, portando il totale settimanale a 36.166 – in calo rispetto a 40.724 della settimana precedente.

Rapporto giornaliero Covid-19

10:14

Previsioni economiche: Bank of England prevede che il PIL del Regno Unito scenderà di quasi il 30% nel secondo trimestre – Deloitte afferma che la disoccupazione di massa potrebbe ridurre i salari

7 maggio

La Banca d'Inghilterra ha affermato oggi che Covid-19 ha ridotto drasticamente posti di lavoro e redditi nel Regno Unito, con una spesa per consumi aggregata in calo molto significativa. Nel 2020 Q2, si prevede che sarà quasi il 30% inferiore rispetto al Q4 2019.

Inoltre, la Banca d'Inghilterra prevede che il PIL del Regno Unito dovrebbe essere inferiore del 30% circa nel 2020 Q2 rispetto alla fine del 2019.

Si prevede che il PIL del Regno Unito sia diminuito di circa il 3% nel 2020 Q1 e quindi di un ulteriore 25% nel secondo trimestre.

S&P ha affermato di prevedere una riduzione del PIL di circa il 7,3% nella zona euro e del 6,5% nel Regno Unito quest'anno, con un graduale rimbalzo del 5,6% e del 6% nel 2021.

L'agenzia di rating ha anche affermato di riscontrare maggiori rischi economici, poiché gli scoppi potrebbero ripresentarsi quando i blocchi vengono allentati in tutto il mondo.

Il riepilogo economico globale di Deloitte di questa settimana parla del rischio di deflazione.

Gli economisti di Deloitte hanno dichiarato: “Abbiamo già assistito a un drammatico calo dei prezzi del petrolio e di altre materie prime.

“La disoccupazione di massa significherà probabilmente una pressione al ribasso sui salari.

“Anche se recentemente ci sono state carenze di alcuni punti di consumo (carta igienica, ad esempio), i primi dati indicano che l'inflazione è rallentata.

“Anche quando arriverà la ripresa, la tendenza deflazionistica sarà probabilmente invertita solo gradualmente.”

9:55

L'inflazione moderata può aiutare a far fronte all'enorme debito creato da Covid-19, affermano gli economisti

7 maggio

La pandemia di Covid-19 ha portato a livelli di disoccupazione senza precedenti, enormi livelli di debito e una minaccia imminente di inflazione o persino deflazione.

Gli economisti ritengono che livelli moderati di inflazione possano aiutare le economie di tutto il mondo a far fronte al debito e a riprendersi dalla crisi.

Atif Mian, un economista, ha twittato che il mondo sta assistendo per la prima volta ai più alti livelli di debito da molti anni. Ha aggiunto che il modo migliore per ridurre questo debito sarà l'inflazione moderata, in particolare nelle economie avanzate.

Mian ha osservato che l'attuazione di un'inflazione mirata moderata potrebbe rappresentare una sfida a breve termine.

Leggi di più

9:14

Aggiornamento internazionale: 3,75 milioni di casi confermati di Covid-19 a livello globale – L'OMS avverte dei rischi di emergere da restrizioni di pandemia

Globale: Ci sono 3,75 milioni di casi confermati di coronavirus in tutto il mondo, secondo i dati della Johns Hopkins University. Il numero di casi confermati si è attestato a 3.755.341 giovedì, con 263.831 morti.

Il direttore generale dell'Organizzazione mondiale della sanità avverte dei rischi di tornare al blocco se i paesi che emergono da restrizioni pandemiche non gestiscono le transizioni “in modo estremamente accurato e con un approccio graduale”.

Si ritiene che almeno 90.000 operatori sanitari in tutto il mondo siano stati infettati, afferma l'International Council of Nurses (ICN), sottolineando che la cifra reale potrebbe essere addirittura doppia.

Le Nazioni Unite stanno lanciando un nuovo appello per 4,7 miliardi di dollari in finanziamenti per “proteggere milioni di vite e arginare la diffusione del coronavirus nei paesi fragili”.

I controlli alle frontiere, i blocchi e le carenze di volo legate al coronavirus stanno rendendo le droghe illegali più costose e difficili da ottenere in tutto il mondo, secondo l'Ufficio delle Nazioni Unite contro la droga e il crimine.

Il Fondo monetario internazionale ha approvato 739 milioni di dollari in finanziamenti di emergenza per il Kenya, in quanto la pandemia di Covid-19 prende un grave tributo sull'economia della nazione dell'Africa orientale e crea esigenze di finanziamento esterno.

UK: Il governo britannico esporrà i dettagli del suo piano per facilitare il blocco domenica, afferma il primo ministro Boris Johnson, aggiungendo la speranza che alcune misure possano entrare in vigore il giorno seguente.

Svezia: La Svezia si avvicina a 3000 morti. L'agenzia di sanità pubblica del paese riferisce che sono stati confermati un totale di 23.918 casi e registrati 2.941 decessi; un aumento di 87 morti rispetto al giorno prima.

India: Il ministero della salute indiano afferma che il numero di infezioni da coronavirus è salito a 52.952 nel paese, in aumento di 3.561 rispetto al giorno precedente, nonostante un rigoroso blocco di settimane. Il bilancio delle vittime è aumentato dall'89 al 1783.

L'India sta cercando di attirare le imprese statunitensi, incluso il colosso dei dispositivi medici Abbott Laboratories, per trasferirsi dalla Cina.

Cina: Le esportazioni cinesi registrano una sorpresa del 3,5% in aprile, mentre le importazioni calano. Le esportazioni cinesi hanno visto uno shock aumentare del 3,5% in aprile nonostante un colpo alla domanda esterna dalla pandemia di coronavirus, i dati ufficiali hanno mostrato giovedì.

Giappone: Il Giappone dovrebbe approvare giovedì il farmaco antivirale remdesivir per l'uso contro il nuovo coronavirus, ha affermato il Primo Ministro Shinzo Abe.

Brasile: Il Congresso brasiliano ha approvato due progetti di incentivo che forniranno un aiuto finanziario a stati e comuni e accantona 700 miliardi di reais ($ 122 miliardi) per la ripresa economica dalla pandemia, consentendo al contempo alla banca centrale di acquistare obbligazioni societarie.

8:46

Riassunto delle notizie dell'azienda Coronavirus – Gilead cerca di aumentare la produzione di remdesivir – L'India produce linee guida sull'uso off-label di farmaci per l'HIV per Covid-19

7 maggio 2020

Il Consiglio di ricerca scientifica e industriale (CSIR) in India ha proposto il test del farmaco per il trattamento della sepsi come vaccino per Covid-19. CSIR sta attualmente riproponendo un farmaco micobatterio per la sepsi gram-negativa come parte di studi clinici randomizzati per il trattamento di pazienti con Covid-19 gravemente malati. Le prove sono attualmente condotte da CSIR in collaborazione con Cadila Pharmaceuticals.

Gilead Sciences sta discutendo con alcune delle principali aziende manifatturiere farmaceutiche per supportare la produzione del suo remdesivir farmaco antivirale brevettato. Questo farmaco ha recentemente ricevuto l'autorizzazione all'uso da parte della Food & Drug Administration degli Stati Uniti ai pazienti Covid-19.

LakePharma ha annunciato che la società fornirà le proteine ​​del picco SARS-CoV-2 ricombinanti del Mount Sinai Health System al Mount Sinai Laboratory per completare parte del suo esame del sangue per la risposta anticorpale contro SARS-CoV-2, il virus che causa Covid- 19.

Corpo dell'apice dell'India Consiglio indiano per la ricerca medica ha fornito linee guida dettagliate sull'uso di Lopinavir / ritonavir, una combinazione di farmaci a dose fissa per l'HIV, che viene riproposta per Covid-19. Secondo le linee guida, questo farmaco può essere utilizzato su pazienti in ospedali con moderato grado di gravità.

7:41

Rapporto epidemiologo GlobalData: il Regno Unito ha il più alto tasso di mortalità per caso Covid-19 tra i dieci paesi più colpiti – più del doppio del tasso globale

7 maggio

I casi confermati totali di Covid-19 sono 3.682.968 nel mondo, mentre il tasso di mortalità * rimane al 7% con un totale di decessi di 257.906.

L'andamento positivo dei casi di recupero giornaliero si è interrotto dal 1 ° maggio.

Tuttavia, questa riduzione non ha modificato in modo significativo il tasso totale recuperato. La caduta dei casi confermati ogni giorno continua negli Stati Uniti e in Europa.

Tra i primi dieci paesi più colpiti, il tasso di mortalità per caso del Covid-19 varia notevolmente.

Il Regno Unito ha il tasso più alto al 15%. La Russia ha il tasso più basso intorno all'1%.

Il tasso di mortalità per caso in Russia potrebbe aumentare presto dopo il recente aumento dei casi confermati.

La Russia – simile alla Germania – ha uno dei più alti letti ospedalieri e infermieri al mondo, il che indica la capacità del paese di controllare la pandemia.

Tuttavia, la denuncia dei decessi non è uniforme in tutti i paesi e anche l'accuratezza delle segnalazioni varia, pertanto i dati sui decessi potrebbero non riflettere accuratamente il vero onere dell'epidemia.

Bahram Hassanpourfard, MPH, epidemiologo, GlobalData

* il tasso di mortalità per caso è definito come la percentuale di casi confermati di Covid-19 che hanno provocato decessi.

14:42

In sole sei settimane Twist ha identificato gli anticorpi monoclonali per formare la base delle terapie Covid-19

Twist Bioscience ha scoperto anticorpi monoclonali competitivi contro SARS-CoV-2, il virus che causa Covid-19, che potrebbe essere utilizzato per sviluppare candidati terapeutici e strumenti diagnostici.

Gli anticorpi monoclonali scoperti si legano con un'alta affinità con il dominio di legame del recettore sulla proteina spike di SARS-CoV-2, che ha dimostrato di essere centrale nel virus che infetta le cellule umane. Altri si legano al recettore cellulare ACE2 umano, che è il sito di legame del virus nel corpo umano.

Emily Leproust, CEO e co-fondatrice di Twist, ha osservato: “La rapida insorgenza di una pandemia globale richiede contromisure agili che riuniscono le migliori scienze per sconfiggere COVID-19 e abbiamo implementato le nostre attività biofarmaceutiche per affrontare questa sfida.

“Sfruttando la nostra capacità unica di scrivere con precisione il DNA insieme alle nostre librerie di anticorpi completamente umani derivati ​​da anticorpi umani naturali, abbiamo trovato contatti con antigeni coinvolti nell'infezione SARS-CoV-2.

“Abbiamo generato anticorpi monoclonali altamente potenti e funzionali contro COVID-19 nel giro di sole sei settimane.”

14:24

PrecisionLife identifica 59 farmaci per migliorare la sopravvivenza nei pazienti Covid-19 che sviluppano sepsi

La medicina di precisione AI con sede nel Regno Unito, PrecisionLife, ha identificato 59 farmaci che potrebbero essere riproposti per migliorare il tasso di sopravvivenza dei pazienti gravi di Covid-19 che sviluppano sepsi potenzialmente letale.

Questi farmaci sono stati trovati estraendo la biobanca britannica per trovare geni a rischio di sepsi e stabilire quanti sono presenti nei pazienti gravi di Covid-19; PrecisionLife ha trovato 70 geni di sepsi, di cui il 61% si presentava in pazienti Covid-19 e 13 di quelli con target drogabili.

Il Dr. Steve Gardner, CEO della società, ha spiegato: “I nostri strumenti di analisi genomica ad alta risoluzione ci hanno permesso di sviluppare nuove conoscenze su due malattie gravi e complesse per le quali sono urgentemente necessarie nuove opzioni terapeutiche.

“Speriamo che questi possano portare a una migliore comprensione di ciò che guida la sepsi nei pazienti COVID-19 e portare a nuovi modi per curare i pazienti gravemente malati”.

14:02

Rapporto giornaliero Covid-19: decessi in costante declino nella maggior parte degli hotspot globali: gli Stati Uniti hanno ancora molta strada da fare

Gli Stati Uniti continuano a distinguersi come l'unico grande hotspot Covid-19 che non può affermare definitivamente di essere sulla buona strada per vincere la lotta contro la prima ondata del virus.

Il nostro grafico traccia i decessi confermati da Covid-19 come media mobile di tre giorni per aiutare a smussare le stranezze nei totali giornalieri.

I totali statunitensi sono diminuiti su base settimanale, ma rimangono ostinatamente alti.

Al contrario, Italia, Spagna e Francia stanno registrando decessi ben al di sotto di un terzo dei tassi di “picco”, con l'Italia in particolare che mostra consistenti cali percentuali.

Il grafico globale rimane in gran parte un prodotto dei grafici di Stati Uniti, Regno Unito, Francia, Italia e Spagna, che insieme sono stati responsabili di quasi tre quarti delle morti in tutto il mondo.

Grafico dei decessi giornalieri medi Covid-19

11:44

CSL Behring Australia si unisce alla gara per lo sviluppo della terapia Covid-19

La consociata australiana di CSL Behring è destinata a sviluppare un terapeutico derivato dal plasma per il trattamento di gravi complicanze nei pazienti Covid-19.

La società intende concentrarsi sui pazienti la cui infezione sta progredendo verso il requisito della ventilazione.

Nominata immunoglobulina Covid-19, la terapia sarà sviluppata da CSL Behring Australia nel suo stabilimento di produzione a Broadmeadows, Victoria.

Leggi l'articolo completo qui

10:31

Aggiornamento internazionale: blocco dei rischi di aumento della tubercolosi – i casi Covid-19 superano 3,65 milioni – i decessi negli Stati Uniti superano i 70.000

Globale: I casi confermati globali superano 3,65 milioni. I ricercatori della Johns Hopkins University affermano che almeno 3.656.644 persone sono state infettate dall'inizio dell'epidemia, mentre almeno 256.736 sono morte.

La chiusura globale causata da Covid-19 rischia un impennata “devastante” nei casi di tubercolosi, con circa 1,4 milioni di morti in più per il più grande killer infettivo del mondo entro il 2025, secondo una nuova ricerca mercoledì.

Le maschere per il viso dovrebbero essere indossate sui voli in futuro. L'International Air Transport Association, che rappresenta le compagnie aeree globali, afferma che raccomanda di indossare maschere sui voli, sebbene sia possibile mantenere la normale assegnazione dei posti.

Regeneron Pharmaceuticals Inc. ha affermato che un trattamento anticorpale sperimentale per Covid-19 potrebbe essere disponibile entro la fine dell'anno, una sequenza temporale accelerata per un farmaco che dovrebbe essere studiato sugli esseri umani per la prima volta a giugno.

Gilead Sciences Inc. è in trattativa per espandere la produzione di remdesivir, il suo trattamento Covid-19 che è stato autorizzato dalle autorità sanitarie statunitensi per l'uso di emergenza.

NOI: Il bilancio delle vittime negli Stati Uniti supera 70.000. Almeno 70.847 persone sono ora note per essere morte negli Stati Uniti, secondo i dati raccolti dalla Johns Hopkins University.

La pandemia è costata 1,4 miliardi di dollari a Walt Disney negli ultimi tre mesi quando ha chiuso i suoi parchi a tema in tutto il mondo e fermato le produzioni cinematografiche e televisive, ha annunciato la compagnia.

La Casa Bianca sta discutendo di sciogliere la task force del coronavirus del presidente, probabilmente non appena il Memorial Day (25 maggio), ha detto ai giornalisti il ​​vicepresidente Mike Pence.

Francia: Il produttore farmaceutico francese Sanofi afferma che prevede di arruolare migliaia di persone in tutto il mondo nelle prove di un vaccino sperimentale contro il coronavirus che si sta sviluppando con la britannica GlaxoSmithKline (GSK).

UK: Il bilancio delle vittime della Gran Bretagna da parte del coronavirus è passato dall'Italia a diventare il secondo più alto al mondo dopo gli Stati Uniti, e ha avuto il maggiore impatto in Europa.

Cina: Suifenhe, la città cinese al confine nord-orientale del paese, sta allentando le restrizioni al coronavirus che sono state introdotte dopo un'ondata di casi tra i viaggiatori di ritorno dalla Russia, secondo il Global Times.

L'ambasciatore cinese nel Regno Unito, Liu Xiaoming, ha dichiarato che i politici britannici che hanno chiesto un ripristino dei legami tra le due nazioni rischiano di avvelenare la relazione. La retorica anti-cinese rischia di minare la solidarietà internazionale nella lotta contro la pandemia di coronavirus, ha detto martedì in un webinar.

10:20

Rapporto giornaliero Covid-19: il peggior Regno Unito in Europa quando i decessi si avvicinano a 30.000 – la cifra globale supera i 257.000

Il Regno Unito ha ora superato l'Italia secondo il conteggio giornaliero del governo di morti Covid-19 per diventare il luogo più colpito in Europa, con 29.501 morti.

Ieri è stato riferito che il Regno Unito ha avuto il maggior numero di decessi in Europa osservando le sue registrazioni sui certificati di morte – un metodo di conteggio più lento che è diverso dalle cifre giornaliere rilasciate dal governo.

Tuttavia, il Regno Unito ha ora superato l'Italia usando la metrica giornaliera – che esamina solo i decessi in cui le persone sono risultate positive alla malattia ed è quindi più comparabile ai dati giornalieri italiani (che includono anche i decessi nella comunità).

Nel mondo sono morte almeno 257.239 persone.

Tuttavia, quella cifra cupa sottostima ancora il vero costo umano del virus – che è meglio misurato usando un numero eccessivo di morti – confrontando il numero di morti con il solito numero in questo periodo dell'anno.

Rapporto giornaliero Covid-19

9:46

Gli impegni di mercato necessari per sviluppare il vaccino Covid-19 affermano che gli influenzatori macroeconomici

6 maggio

Poiché l'economia degli Stati Uniti continua a contrarsi a causa delle misure di blocco, è in corso un dibattito sull'opportunità di aprire l'economia per salvare posti di lavoro o rischiare una seconda ondata di infezioni.

Il modo migliore per affrontare questo enigma è identificare i settori che possono essere riaperti in modo sicuro, accelerando allo stesso tempo lo sviluppo di un vaccino contro la malattia di Covid-19.

Erik Brynjolfsson, professor at Massachusetts Institute of Technology, shared an article by four prominent economist on the development of a vaccine against Covid-19 disease.

The article notes that the government should invest billions of dollars into a vaccine development programme, while providing advance market commitment to manufacturers.

Leggi di più

9:24 am

Coronavirus company news summary – Novartis and Incyte to launch second Phase III trial of Jakafi – Gilead to ramp up manufacturing capacity for remdesivir

6 maggio 2020

Scientists at Lazzaro Spallanzani National Institute for Infectious Diseases in Italy have claimed that a vaccine candidate could neutralise coronavirus within human cells. According to findings from the tests conducted at Spallanzani Hospital in Rome, the vaccine had generated antibodies in mice that also work on human cells.

Gilead Sciences is in discussions with chemical and pharmaceutical manufacturing companies for the production of its experiment antiviral drug remdesivir, which is being tested as a potential Covid-19 treatment, for global supply through at least 2022. The company aims to form a consortium of manufacturing partners in an effort to maximise supply worldwide.

Novartis’s partner Incyte is set to launch a second Phase III clinical trial in the US to assess Jakafi (ruxolitinib) to treat Covid-19 patients on mechanical ventilation with acute respiratory distress syndrome (ARDS). The first Phase III trial of the drug, which is investigating if the drug can treat Covid-19-related cytokine storm, is sponsored by Incyte in the US and by Novartis outside of the US.

Regeneron Pharmaceuticals has said that its investigational antibody therapy for Covid-19 could be available for dosing by the end of August this year. The company advanced its lead neutralising antibodies into pre-clinical and clinical-scale cell production lines last month. The company is also working to rapidly scale-up manufacturing.

6:58 am

GlobalData Epidemiologist Report: Reduction of Covid cases in Europe continues – sharp rise in India amid concerns of management response

6 May

Currently, there are over 3,600,106 confirmed cases of Covid-19 reported in 189 countries.

About 60% of the total confirmed cases globally were reported by the US, the UK, Germany, Spain, France and Italy.

A total of 1,173,147 cases had recovered and 251,898 cases had died of Covid-19.

The reduction of Covid-19 cases in European countries continues.

For the UK, after the last week’s rise, there has been a significant reduction in the number of daily confirmed cases and deaths.

Brazil, Russia and Mexico appears to not have reached their transmission peak.

Yesterday, India reported 3,932 new confirmed cases and 175 new deaths, which indicates a sharp rise in Covid-19 cases. At the same time, India reached a new peak of 1,072 recovered.

India has a large population living in dense urban areas, which make it difficult to control the pandemic.

There are concerns about how the India government is managing the pandemic response.

Bahram Hassanpourfard, MPH, Epidemiologist, GlobalData

6:05 pm

The UK now has the highest coronavirus death toll in Europe

The UK now has the highest number of confirmed coronavirus deaths in Europe.

The latest death toll for the UK has reached 29,427, according to the Office for National Statistics, higher than Italy at 29,315 and Spain at 25,613.

The number of confirmed coronavirus cases in the UK has reached 194,990, with the government due to set out a strategy on how to “unlock” the economy.

According to Johns Hopkins University, the number of coronavirus deaths worldwide has now exceeded 250,000.

3:44 pm

GlobalData sees mild reversal in fortune for global innovative pharma companies by market capitalisation in Q1 2020

Over 50% of the top 20 global innovative pharma companies saw a decrease in their market cap (MCap) in the first quarter (Q1) of 2020, while nearly all of these pharma companies saw an increase in their MCap over 2019 (Q1 to Q4 2019), witnessing an overall 7.9% decrease in MCap over Q1 2020 equivalent to $2.2 trillion.

The reversal of fortune of the companies on this list due to Covid-19 may seem dramatic due to their long-term growth. Leggi di più qui.

3:35 pm

Economic Forecast: Western nations revised downwards again – UK drop off ‘particularly steep’

The economic forecasts for the biggest Western nations affected by Covid-19 have been revised downwards once again — with the UK seeing a particularly steep drop-off.

Italy’s GDP is expected to drop by more than 9.3% in 2020, according to the latest forecasts from GlobalData.

France’s GDP is set to drop by 7.3% during the year, the UK’s by 7.0% and Germany’s by 6.3%.

The UK saw the biggest downwards revision from last week, when it’s economy was expected to shrink by just 5.4% in 2020.

The news came on the day the UK registered the highest known Covid-19 death toll in Europe.

The US economy is now expected to shrink by 5.2%. Japan’s is expected to shrink by 4.3%, slightly less than the 4.4% forecast last week.

Stock markets have generally remained stable across all markets in our tracker.

Covid-19 macroeconomic dashboard

2:19 pm

International Update: Covid-19 global death toll passes 250,000 – US outbreak projected to accelerate – 135,000 deaths predicted

5 May

Global: Confirmed global death toll exceeds 250,000. According to research by both the Reuters news agency and Johns Hopkins University, at least a quarter of a million people are now known to have died as a result of the pandemic.

US: An internal US government projection shows the nation’s coronavirus outbreak vastly accelerating by June to more than 200,000 new cases and 2,500 deaths per day — far more than the country is currently experiencing.

Anthony Fauci, the US government’s top infectious disease expert, said there are regions and counties in the US where “you can pull back” restrictions put in place to contain the pandemic.

A newly-revised coronavirus mortality model predicts nearly 135,000 Americans will die from Covid-19 by early August, almost double previous projections, as social-distancing measures are relaxed.

Europe: The European Commission registered $8 billion in pledges from donors worldwide at the starting day of a Coronavirus Global Response fundraiser on Monday. The goal is to finance the collaborative development and universal deployment of diagnostics, treatments and vaccines to fight the coronavirus.

Italy: Italy’s death toll is far higher than reported. Statistics bureau ISTAT said its analysis showed an extra 11,600 deaths were unaccounted for, and it was reasonable to assume these people either died of COVID-19 without being tested or that the extra stress on the health system due to the epidemic meant they died of other causes they were not treated for.

Germany: Germany’s Robert Koch Institute says the number of coronavirus cases in the country has risen by 685, bringing the total to 163,860. A further 139 deaths were reported, bringing the total to 6,831.

China: China’s National Health Commission says the country found just one case of coronavirus on Monday, in someone who had returned from overseas. It also reported 15 asymptomatic cases of the disease and no new deaths.

Hong Kong will soon ease social distancing measures after largely containing the spread of COVID-19, Chief Executive Carrie Lam told a briefing Tuesday ahead of a meeting of her advisory Executive Council.

India: More than a quarter of India’s labour force are without a job after businesses were forced to shut during a nationwide lockdown that began in the last week of March, according to a survey by the Center for Monitoring Indian Economy Pvt.

Antipodes: Australia and New Zealand committed to introducing a shared travel zone as soon as it is safe to do so, Prime Ministers Scott Morrison and Jacinda Ardern said in a joint statement on Tuesday.

1:42 pm

Pfizer and BioNTech dose first patients in US Covid-19 vaccine trial

Pfizer and BioNTech have announced the dosing of the first participants of its US Phase I/II Covid-19 vaccine study. The pair has four vaccine candidates against the novel coronavirus in the BNT162 development programme; a study of these products are already underway in Germany.

Pfizer chairman and CEO Albert Bourla said: “With our unique and robust clinical study program underway, starting in Europe and now the US we look forward to advancing quickly and collaboratively with our partners at BioNTech and regulatory authorities to bring a safe and efficacious vaccine to the patients who need it most.

“The short, less than four-month timeframe in which we’ve been able to move from pre-clinical studies to human testing is extraordinary and further demonstrates our commitment to dedicating our best-in-class resources, from the lab to manufacturing and beyond, in the battle against Covid-19.”

12:08 pm

Nearly 40,000 more deaths than normal since the start of Covid-19 outbreak in England and Wales says ONS

By Nicu Calcea

England and Wales have recorded 38,554 more deaths than usual between the start of the Covid-19 outbreak in March and 24 April, new figures from the Office for National Statistics (ONS) show.

Of those, only 71% were officially attributed to Covid-19 – leaving some 11,260 deaths unaccounted for.

Some of these “unexplained” deaths may be a direct result of the coronavirus while others may be due to limited access to healthcare during the pandemic.

The figures are based on weekly monitoring of deaths from all causes. We can compare this with the average number of deaths seen during comparable weeks over the last five years.

11:16 am

Covid-19 Daily Report: Global deaths down week on week – confirmed cases rise by more than 76,000

The number of people dying from Covid-19 rose again yesterday, following a dip in reporting over the weekend.

Some 4,067 people died, with Italy and France seeing their numbers rise compared to Sunday.

However, the number of new deaths continued to remain below the figures seen this time last week, with both the US and UK seeing numbers decline compared to Sunday.

At least 251,537 people have now died across the world from the virus.

Confirmed cases rose by 76,326.

Covid-19 daily report

10:43 am

Economics round up: Frankel warns against W shaped recession – JP Morgan predict U shaped – McKinsey call for business ‘urgency’

5 May

Harvard University professor Jeffrey Frankel has warned against a so called W recession that could happen if global leaders lift restrictions too soon and declare victory over the virus.

He said that historical data from the 1918 epidemic suggests that ending lockdowns too quickly could bring about a deadlier second wave.

He also warned that political leaders might also abandon economic stimulus too soon – the second mistake that could lead to a W-shaped recession.

He said: “US policymakers made a similar blunder after the 2008 global financial crisis. President Barack Obama’s fiscal stimulus program, enacted in February 2009, together with the Fed’s monetary expansion, halted the economy’s free fall.

“The recovery began in June of that year. But in 2011, after Republicans took control of the US Congress, the fiscal stimulus was prematurely ended, impeding the recovery considerably.”

However, J.P.Morgan Asset Management still predicts a U shaped recession for the US and says the decline in real GDP growth in Q1 is consistent with their forecast of a U-shaped recession, or a fall, a stall and a surge.

Meanwhile, McKinsey described five qualities that will be critical for business leaders to find their way to the post Covid-19 new normal : resolve, resilience, return, reimagination, and reform. With some of these likely to overlap and differ based on sector and country.

The consulting firm also said there are four strategic areas to focus on: recovering revenue, rebuilding operations, rethinking the organisation, and accelerating the adoption of digital solutions.

McKinsey also called on companies to act with urgency: During the current crisis, businesses have worked faster and better than they dreamed possible just a few months ago.

Maintaining that sense of possibility will be an enduring source of competitive advantage.

9:47 am

Federal job guarantee can avoid mass unemployment amid Covid-19 – macroeconomic influencers

5 May

Over the last two months the US has witnessed more than 30 million workers filing for unemployment benefits.

Although unemployment benefits are being provided to some of the people, these benefits are not reaching everyone due to wide disparity in processing claims and eligibility criteria.

Timothy McBride, Bernard Becker Professor at Washington University in St. Louis’ Brown School, tweeted an article detailing how mass unemployment can be avoided if a federal job guarantee is provided.

The current unemployment benefits programme is inefficient and uses disparate policies to process claims, leaving many unemployed workers at risk of food insecurity, depression, and losing their homes.

A federal job guarantee programme can help unemployed people by providing minimum wages enabling them to meet basic needs and maintaining their health.

Leggi di più

9:25 am

Coronavirus company news summary – World leaders pledge $8bn to Covid-19 efforts – Catalent signs another coronavirus manufacturing agreement

5 maggio 2020

At a Coronavirus Global Response pledging event led by the European Commission (EC), world leaders committed €7.4bn ($8bn) to support the development and universal access to Covid-19 vaccines, treatments and diagnostics. Notably absent from the EC’s event was the US. The event also encouraged further collaboration in the fight against Covid-19 to be led by organisations such as the OMS, CEPI, il Wellcome Trust e il Gates Foundation.

Researchers at Utrecht University e Erasmus Medical Centre in the Netherlands, in alliance with China-based firm Harbour BioMed, have identified a fully human monoclonal antibody with activity against the novel coronavirus, SARS-CoV-2. According to the team, the antibody could prevent SARS-CoV-2 virus from infecting cultured cells.

Eli Lilly has partnered with Junshi Biosciences to co-develop therapeutic antibodies to potentially treat and prevent Covid-19 infection. Junshi Biosciences has already engineered several neutralising antibodies and the lead candidate is set to begin clinical testing in the second quarter of this year.

Researchers at the Israel Institute for Biological Research (IIBR) have isolated a coronavirus antibody, reported Reuters citing Defence Minister Naftali Bennett. The monoclonal antibody is said to be capable of neutralising the coronavirus inside carriers’ bodies.

Arcturus Therapeutics has partnered with Catalent to manufacture its Covid-19 mRNA vaccine candidate, LUNAR-COV19. Catalent will produce the vaccine at its drug substance bio-manufacturing facility in Madison, Wisconsin, to support human clinical studies and potential commercialisation. Manufacture of the first batches are scheduled to be completed by June 2020. Catalent previously signed a similar manufacturing agreement with J&J for its Covid-19 vaccines.

7:43 am

GlobalData Epidemiologist Report: Global Covid-19 cases pass 3.5 million – fatalities approach 250,000 – sharp rise of cases in Russia

5 May

T​he total confirmed cases of Covid-19 passed 3,529,408 globally and the daily confirmed recoveries reached a new peak of 65,151 on 1 May.

The global mortality rate of Covid-19 is now over 7%, with the total deaths count at 248,025.

Since the start of the outbreak, over a third of confirmed Covid-19 cases have recovered.

Spain, Italy, France, and Germany along with many other European countries eased up their lockdown restriction further.

However, the UK experienced an increase in their daily confirmed cases on 30 April and 1 May, which might be a sign that the country is not ready to reduce the restrictions.

​The US appears to have passed the transmission peak, though more time is needed to monitor the situation, especially with phased opening up of the country.

For Russia, the daily confirmed cases have been increasing sharply over the past week.

Iran’s confirmed cases show a slight increase which might be as a result of the government’s decision to open up public places in certain regions of the country.

Bahram Hassanpourfard, MPH, Epidemiologist, GlobalData

5:08 pm

Vir and Alnylam partner on developing RNAi Covid-19 drug

Vir Biotechnology and Alnylam Pharmaceuticals are going to collaborate on a RNAi therapeutics targeting to SARS-CoV-2 genome. Alnylam screened over 350 small interfering RNAs (siRNAs) to decide on one candidate – VIR-2703 – to progress into pre-clinical development.

The partners are hoping to meet with the FDA to discuss an accelerated path for filing an investigational new drug application at around the end of 2020.

Vir CEO George Scangos said: “Vir is committed to applying industry-leading technologies in our fight against Covid-19.

“Our fruitful and expansive collaboration with Alnylam has rapidly led to identification of a development candidate targeting SARS-CoV-2.

“With this candidate now in hand, we will further accelerate our efforts and plan to begin studies in humans at or around year-end.

“Our ultimate goal would be to provide rapid worldwide access, if approved, to an effective therapeutic to combat Covid-19.”

3:19 pm

The value of real-world evidence during the Covid-19 outbreak

As the Covid-19 outbreak continues to take its toll on global markets, real-world evidence (RWE) is set to become the most influential emerging technology to help in the fight against the Covid-19 outbreak, according to the latest poll on GlobalData’s Pharmaceutical Technology website. In this poll, which was completed by 935 of its readers during 6-20 April, more than one-third of the respondents indicated that real-world evidence will have the greatest impact in the management of Covid-19. A smaller percentage of the readers identified telemedicine (28%) and artificial intelligence (AI) (20%) as the most important emerging trends.

The utilisation of RWE in infectious disease control is not a new concept. During the Ebola outbreak in 2014, forecasters successfully used Global Epidemic and Mobility (GLEaM) simulations that combined real-world data on populations and their mobility with rigorous stochastic models of disease transmission to predict the global spread of the disease. By understanding where and how quickly the outbreak is likely to spread, the same tracking models could be adapted to fight any upcoming Covid-19 outbreaks. Even though most countries have announced decreasing death rates from Covid-19, a vaccine against Covid-19 is expected to take more than one year to reach the market, and scientists predict that there will be more than one wave of the outbreak. As such, real-world evidence may become an essential tool in trying to suppress Covid-19.

To read more, please click here.

2:12 pm

Covid-19 Cities and Regions: Cases falling in major cities around the world – US still behind the curve

4 May

The number of confirmed Covid-19 cases is falling in major cities across the world, with countries in Europe registering the biggest changes in daily new cases.

Our tracker – which shows new daily cases by region in the countries with the most Covid-19 deaths – shows generally stable decreases over the past week.

In the UK, the number of new cases has dropped by more than half compared to the previous week, except in Scotland, where things haven’t changed significantly.

Italy and Spain have been registering a generally stable fall in the number of cases for nearly a month.

The US is still behind the “curve” compared to Europe, but the number of new cases has been dropping over the past week, especially in New York.

Monitoring the cities at the heart of the Covid-19 outbreak

Cities – with their high population density, young and mobile demographics, and developed public transport systems – are particularly susceptible to rapidly-spreading viral outbreak.

Here we drill down into subnational Covid-19 figures to show which areas are seeing disproportionate numbers of Covid-19 cases.

While different countries count at different administrative levels, the pattern is clear: London and Madrid are “regions” in their own right, while New York State includes New York City and Lombardy covers Milan.

This chart is currently being updated weekly with the latest figures – although some countries have a slight delay in publishing the very latest case numbers by region or state.

Covid-19 regional comparison chart

11:10 am

Economics round-up: US unemployment claims pass 30 million – global GDP in decline – earnings estimates down 20%

4 May

Macroeconomic data is starting to reveal the devastating impact of the Covid-19 crisis, according to a Fitch Ratings‘ Report.

Outright GDP contractions in 1Q 2020, rising unemployment and collapsing consumer spending and confidence are among the themes highlighted.

According to the ratings agency: Quarter-on-quarter GDP declined in China, Korea, the US, eurozone, France, Italy, Spain and Mexico in 1Q20 due to the coronavirus outbreak and the measures necessary to contain its spread.

In response, central banks have launched a campaign of interest rate cuts and balance-sheet expansion, with the latter reflected in strong money supply growth (M2) in the US, eurozone, China, Japan, the UK, Australia, Canada, Brazil, Russia, India, Korea, Indonesia, Mexico, Poland, Turkey and South Africa.

In addition, equity markets moved sharply lower in 1Q20 across virtually all Fitch20 economies.

An additional 3.8 million Americans filed for unemployment insurance last week, bringing total initial claims over the past six weeks to over 30 million.

Wells Fargo Securities update and commentary for last week said that with so many jobs lost and more at risk, consumers have cut back sharply on spending.

Consumers are shaken, as confidence in current conditions slid 90 points in April, the largest drop in data going back to 1967.

However, expectations remain lofty and supportive of an eventual rebound in spending, according to the bank.

An analysis by JP Morgan said that by Friday 1 May nearly half of S&P 500 companies have reported 1Q20 earnings, and that the bank’s current estimate is for a -20% decline relative to a year prior.

According to the bank’s analysis, this earnings season has been about the good, the bad and the ugly:

The good: the health care sector has seen solid demand for over-the-counter pharmaceuticals and branded drugs. In consumer staples, strength has been concentrated in food products and household items. Technology and communications are seeing strength in hardware, software and content that can be consumed at home.

The bad: financial service company earnings have been weak, as rising loan loss provisions have offset solid capital markets activity.

The ugly: industrials and energy are in bad shape. Lower oil prices are impacting energy revenues, and forcing companies to take impairment charges on oil field assets.

9:50 am

Covid-19 Daily Report: Global deaths dropping slowly – US still recording daily deaths in four figures

4 May

Global deaths from Covid-19 continue to drop slowly as mainland Europe begins edging out of lockdown.

There have been 37,570 deaths recorded over the past week – down from 38,769 in the week before.

Italy, Spain and France all recorded fewer than 200 new deaths yesterday. Those figures must be treated with some caution as weekend reporting has typically been lower than weekday reporting.

The general downward trend remains apparent, however, in all three countries. Italy and Spain in particular appear well past peak levels of cases and deaths, and governments in both have begun loosening their strict lockdowns.

Spain allowed outdoor exercise from Saturday while Italy is doing the same from today.

The US remains the only country consistent recording four-figure daily death totals.

Covid-19 daily report

9:31 am

Vaccination against Covid -19 estimated to cost more than $20bn say leading macroeconomic influencers

4 May

The trillions of dollars in lost GDP due to the Covid-19 pandemic has highlighted the importance of vaccinating the population and realignment of business models in order to reopen the economy.

Investment in vaccination is essential even if the cost is high to ensure that the pandemic does not resurface and cause greater damage in the long run.

George Magnus, an economist, shared an article on the cost of vaccinating billions of people against the Covid-19 disease, which is estimated at $20bn.

He noted that the pandemic is estimated to cost the world more than $2tn in lost GDP.

Magnus added that even if the cost of vaccination is $100bn, it will still be worth the investment to protect both the population and the economy.

9:14 am

Coronavirus company news summary – remedesivir receives EUA from the FDA – Canadian Government to spend $175.6m on AbCellara’s antibody drugs

4 maggio 2020

Gilead Sciences has secured emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for remdesivir to treat Covid-19. The authorisation is set to allow broader access to the drug for treating hospitalised patients with severe Covid-19 across the US. Gilead will work with the government to allocate the currently limited supply of the drug. Leggi la storia completa qui.

Il Canadian Government has agreed to provide up to $175.6m funding to support Vancouver-based AbCellera in the identification of antibody-based therapies against Covid-19. The funds will also be used to develop technology and manufacturing infrastructure for antibody treatments for future pandemics.

Researchers at University Hospital Southampton in the UK are conducting a clinical trial to assess a new Covid-19 drug candidate developed by biotech firm Synairgen, according to the BBC. The drug candidate is made of interferon beta that is directly delivered to the airways. Initial data from the trial is set to be available by the end of next month.

Athersys e University Hospitals Cleveland Medical Center (UH Cleveland) have activated the first clinical site for the MACOVIA clinical trial of MultiStem Cell Therapy to treat acute respiratory distress syndrome (ARDS) caused by Covid-19. The primary objective of the study is the number of ventilator-free days through day 28 versus placebo.

8:22 am

Covid-19 Healthcare Daily Update: Vaccine still elusive – Japan to ride out Covid-19 upsurge – surveys need more study before easing lockdowns

4 May

Japan on track to stamp out the recent Covid-19 surge but more likely in the future
Japan’s Covid-19 case count and infection rate have been relatively mild since its first reported case on 16 January. The rate for total infections in Japan was as low as one case per million population one month later in February, and seven cases per million population two months later in March. For comparison, the first suspected domestic transmission in the US occurred on 26 February. The rate for total infections one month later in the US was already at 255 cases per million population, and a staggering 2,946 cases per million population two months later.

Covid-19 treatment on the horizon but vaccine remains elusive
According to GlobalData’s Pharma Intelligence Center Pipeline Database and the Coronavirus Disease 2019 (Covid-19) dashboard, there are, as of 23 April, 80 therapeutic drugs in Phases I, II, and III that may be able to treat Covid-19, but only nine prophylactic vaccine drugs in Phases I and II, indicating that while a possible cure for Covid-19 may be imminent, a prophylactic vaccine to combat the pandemic may need more time to come to fruition.

Preliminary antibody survey results require further investigation to ease social restrictions
Large-scale studies of the general population are needed in order to determine how wide the disease has spread, how deadly the virus really is, and whether enough of the population has become immune for social distancing restrictions to ease. Several survey results from Germany, the Netherlands, the US, and Switzerland find that anywhere from 2% to 30% of certain populations have already been infected with Covid-19. Yet these results have been heavily criticized as too preliminary, with larger-scale studies required to draw any sort of conclusions.

Covid-19: Some biopharma companies have seen market cap growth due to the pandemic
Covid-19 has had a financial impact on the world’s capital markets, but for some biopharma companies, this has meant an opportunity for unprecedented growth in value. Financial data from GlobalData’s Pharma Intelligence Center Companies Database reveals that small cap ($0.3–2.0B) public companies developing a Covid-19 drug, either therapeutic or prophylactic, are seeing significant growth in market cap while other industries are plunging.

Incyte and Eli Lilly may have JAK inhibitor edge over Pfizer for Covid-19
Incyte and Eli Lilly’s Janus kinase (JAK) 1/2 inhibitors—Jakafi (ruxolitinib) and Olumiant (baricitinib), respectively—may have a mechanism edge over Pfizer’s JAK 1/3 inhibitor Xeljanz (tofacitinib) in Covid-19. However, Theravance Biopharma’s pan-JAK inhibitor TD-0903 stands out for its nebulised mode of administration but there is still uncertainty about its value.

4:29 pm

GlobalData Epidemiologist Report: – Comoros, East Africa, latest country to register Covid-19 – global recoveries pass 1 million

3 May

Comoros in East Africa is the most recent country to report a case of Covid-19 making Lesotho the only African country to report no cases.

To date 3,276,373 confirmed cases of Covid-19 have been reported across 189 countries. The number of total recovered cases has surpassed 1 million, and 38,487 newly recovered cases have been reported.

Global active cases have declined by 12,843 cases to 2,017,846 cases.

The US, UK and Italy are the top three countries with the most active cases reported (853,066 cases, 144,778 cases, and 101,551 cases, respectively).

Comoros, Mauritania, Suriname and Western Sahara are the countries that have reported the least number of active cases, only one in each nation.

In the last two weeks global total confirmed cases have increased from 2,120,824 on 4/16 to 3,276,373 as of 1 May.

Ana Fernandez-Menjivar, MSc, Senior Epidemiologist, GlobalData

6:46 pm

Japan is on track to quickly stamp out the recent Covid-19 surge but more are likely in the future

GlobalData has created three-scenario peak-week models for all countries enduring more than 100 cases of Covid-19. While the peak-week models fit the epidemiology curves in markets such as the US and Western Europe, some Asian countries do not fit the assumed exponential curves of a conventional epidemiology outbreak in an immune-naïve population.

GlobalData’s epidemiology team used its expertise in modelling the global Covid-19 outbreak to investigate the factors causing Asian countries to have distinct outbreak trajectories and produced an alternative forecast model for Japan.

Read more here

4:46 pm

Preliminary antibody survey results require further investigation to ease social restrictions

Large-scale studies of the general population are needed in order to determine how wide the disease has spread, how deadly the virus really is, and whether enough of the population has become immune for social distancing restrictions to ease.

Several survey results from Germany, the Netherlands, the US, and Switzerland find that anywhere from 2% to 30% of certain populations have already been infected with COVID-19. Yet these results have been heavily criticized as too preliminary, with larger-scale studies required to draw any sort of conclusions.

Clicca qui per leggere l'articolo completo.

4:00 pm

WHO and EIB expand commitment to reduce impact of Covid-19 and future emergencies

The World Health Organization (WHO) and the European Investment Bank (EIB) have strengthened their collaboration to address the health impact of Covid-19, particularly in low and middle-income countries.

In addition, the partners want to work together to improve resilience and reduce the impact of future public health emergencies, particularly in Africa, as well as commit to overcoming the market failure in tackling global health in the long-term.

WHO director-general Dr Tedros Adhanom Ghebreyesus said: “Combining the public health experience of the World Health Organization and the financial expertise of the European Investment Bank will contribute to a more effective response to COVID-19 and other pressing health challenges.”

EIB president Werner Hoyer added: “The world is facing unprecedented health, social and economic shocks from COVID-19.

“The EU Bank’s new partnership with the WHO will help communities most at risk by scaling up local medical and public health efforts and better protect people around the world from future pandemics.”

3:45 pm

One of the companies with the biggest increase in market cap was the small cap company CanSino Biologics Inc

The coronavirus pandemic has had a major financial impact on the world’s capital markets. However, some biopharma companies have seen this as an opportunity for unprecedented growth in value.

Financial data from GlobalData’s Pharma Intelligence Center Companies Database reveals that small cap ($0.3–2.0B) public companies working on the development of a Covid-19 drug are witnessing growth in market cap among the plunge of other industries.

Read more here

3:32 pm

Covid-19 treatment on the horizon but vaccine remains elusive

The Covid-19 pandemic that has swept the globe has led to a massive search for a drug with which to combat this deadly virus, yet despite many pharmaceutical companies continuing to pour their resources into a cure for this virus, the development of prophylactic vaccines for Covid-19 appears to be lagging.

According to GlobalData’s Pharma Intelligence Center Pipeline Database and the Coronavirus Disease 2019 (Covid-19) dashboard, there are, as of 23 April, 80 therapeutic drugs in Phases I, II, and III that may be able to treat Covid-19, but only nine prophylactic vaccine drugs in Phases I and II, indicating that while a possible cure for Covid-19 may be imminent, a prophylactic vaccine to combat the pandemic may need more time to come to fruition.

Clicca qui per leggere l'articolo completo.

3:32 pm

Amgen to study anti-inflammatory drug Otezla against Covid-19

In its first quarter (Q1) 2020 results, Amgen announced it will study Otezla (apremilast) and its immunomodulatory impact against Covid-19 in upcoming platform trials.

Otezla was bought for $13.4bn in November last year from Celgene, before it was acquired by Bristol-Myers Squibb; in the Q1 2020, it generated $470m of sales for Amgen.

The drug is a PDE4 inhibitor approved to treat inflammatory conditions, such as psoriasis and psoriatic arthritis. Plaque psoriasis is caused by overactive inflammation, an overactive immune system, and related hyper inflammation, is believed to be central to why so many late-stage, severe Covid-19 patients require ventilation in the ICU, and sadly, often die.

Amgen is also partnering with Adaptive Biotechnologies to discover neutralising antibodies against SARS-CoV-2, the virus that causes Covid-19, to find potential ways to prevent or treat the disease.

2:46 pm

Moderna signs manufacturing agreement to scale Covid-19 vaccine production

US biotech Moderna has signed a ten-year manufacturing collaboration with Lonza for its Covid-19 vaccine, mRNA-1273, as well as future Moderna products.

The biotech will leverage Lonza’s manufacturing in the United States and Switzerland beginning in June this year.

Moderna’s mRNA Covid-19 vaccine is one of the furthest along in clinical trials; it applied for FDA approval to progress to Phase II studies if . To date, the programme has received funding and support from the US Govt through BARDA, as well as through CEPI.

Moderna CEO Stéphane Bancel noted: “We are very pleased to partner with Lonza, which shares our commitment to rapidly addressing this pandemic which has created a global health crisis.

“This long-term strategic collaboration agreement will enable Moderna to accelerate, by ten-times, our manufacturing capacity for mRNA-1273 and additional products in Moderna’s large clinical portfolio.

Lonza’s global presence and expertise are critical as we scale at unprecedented speed. Our common goal is to potentially enable manufacturing of up to one billion doses of mRNA-1273.”

Lonza chairman and interim CEO Albert M. Baehny added: “Moderna’s technology represents a significant opportunity to change the way we protect people against disease.

“The current pandemic illustrates the need to combine the best science with resilient supply chains that can scale.

“We are fully committed to leveraging our global network and experience in manufacturing technologies to support Moderna’s manufacture of mRNA-1273 as well as collaborating on future Moderna products.”

2:23 pm

Incyte and Eli Lilly may have JAK inhibitor edge over Pfizer for Covid-19

Incyte’s and Eli Lilly’s Janus kinase (JAK) 1/2 inhibitors, Jakafi (ruxolitinib) and Olumiant (baricitinib) could have a mechanism edge over Pfizer’s JAK 1/3 inhibitor Xeljanz (tofacitinib) in Covid-19. Theravance Biopharma’s pan-JAK inhibitor TD-0903 is distinct for its nebulised method of administration, but there is still scepticism of its benefit.

Jakafi and Olumiant could provide a more precise link to downregulating interleukin (IL)-6 to mitigate cytokine storm syndrome (CSS) seen in Covid-19 associated with Xeljanz. Leggi di più qui.

2:17 pm

Mobility Update: Traffic on the move ahead of lockdowns being lifted – Berlin shows biggest increase

1 May

Our weekly mobility chart shows a clear trend: some world cities are seeing increased movement even before lockdown restrictions are eased.

Berlin has seen the biggest increase in both public transport activity and in traffic congestion over the last fortnight.

Schools, museums, galleries, zoos, playgrounds and churches are expected to reopen in Germany on Monday for the first time since the lockdown started. Some shops have already re-opened ahead of the lockdown lift.

Chancellor Angela Merkel – who is riding a wave of popularity on the back of her country’s relative success in controlling the outbreak – has stressed that social distancing must continue, and that the restrictions would return in the event of a second wave.

Madrid, London and Moscow are also seeing small bumps in activity – although the change is slight and could be due to changes in local circumstances rather than a sign people are flouting rules.

However, international travel is still stagnant.

Ryanair and British Airways have both recently announced they are cutting jobs due to low sales, with Ryanair expecting passenger numbers to stay under pre-coronavirus crisis levels at least until summer 2022.

The Covid-19 lockdown: tracking if, when and where the world starts moving again

Restrictions on international and national travel to slow the spread of the virus caused a dramatic fall in global traffic by road, sky and sea. But the picture is not uniform across the world. Some cities in the Far East have avoided a total lockdown and as such have been seeing patterns which are a little closer to the norm.

In order to track the latest situation, this graphic is fed by three key sources. We use Citymapper’s mobility index to monitor public transport use, TomTom’s live traffic index to measure road use, and summary data from FlightRadar24 to count the total number of commercial flights each day.

City transport index chart

1:07 pm

Economic Outlook: EU sees sharpest GDP decline as 7.4% unemployment rate recorded – EM capital flows ‘bad news but not catastrophic’

1 May

Seasonally adjusted GDP decreased by 3.8% in the euro area and by 3.5% in the EU during the first quarter of 2020, compared with the previous quarter, according to a preliminary flash estimate published by Eurostat, the statistical office of the European Union. These were the sharpest declines observed since 1995.

Eurostat also estimates that 14.1m men and women in the EU, of whom 12.1m were in the euro area, were unemployed in March 2020.

Compared with February 2020, the number of persons unemployed increased by 241,000 in the EU and by 197,000 in the euro area.

In March 2020, the euro area seasonally-adjusted unemployment rate was 7.4%, up from 7.3% in February 2020. The EU unemployment rate was 6.6% in March 2020, up from 6.5% in February 2020.

Emerging markets (EM) are suffering two sudden stops – in economic activity and in capital flows – but only one of them is ‘unprecedented’, writes David Lubin, Head of Emerging Markets Economics at Citi.

“As far as capital flows are concerned, the news is bad but not catastrophic, and risk appetite towards EM seems higher today than it did at the same point of the Global Financial Crisis.

“The collapse in emerging market inflation will give central banks more scope for easing. We think emerging markets might see rate cuts in the coming months that, by normal standards, might seem shockingly low.

“A key question for emerging markets is whether investors, both domestic and foreign, have any confidence that these countries can grow out of their debt, and on this issue we are pessimistic. Low interest rates in developed markets might help push capital towards emerging markets, but that’s not a reason to be confident about the future of the asset class given the uncertainties that now afflict the global economy.”

HSBC’s head of equity strategy for Asia-Pacific, Herald van der Linde, has written in a blog that many countries are trying to look at suppliers outside of China in light of the Covid-19 pandemic, with some governments encouraging ‘re-shoring’ – bringing factories home.

“But highly complex production networks established over decades cannot be easily re-shored or relocated. Where products are highly specialised or where mainland China is dominant, as with 5G telephony or cosmetics, it is nearly impossible – or it will take considerable time – to move those supply chains.”

In addition, Van der Linde notes there are companies using the current situation to increase operations in China, with the Chinese government offering incentives to attract foreign investment.

Van der Linde also predicts that tensions between Beijing and Washington could accelerate plans for China to become self-sufficient in energy, power and technology.

12:31 pm

Covid-19 Daily Report: Coronavirus deaths on a downward trend in Europe – US has more than 2,000 deaths for third consecutive day

1 May

The number of new Covid-19 related deaths dropped below 300 in Spain, Italy and France yesterday.

The UK – which previously only counted deaths in hospital in its figures, but is now including care homes and other settings – saw 676.

The US saw more than 2,000 new deaths for the third day in a row.

Globally there have been 233,388 deaths, with 39,711 of those in the last week.

That compares with 42,892 deaths the week before.

Covid-19 daily report

9:50 am

Women accounted for majority of the 30 million workers who filed for unemployment benefits in the US in the last two months

Women accounted for majority of the 30 million workers who filed for unemployment benefits in the US in the last two months.

Women working as waitresses, hairdressers and cosmetologists, retail salespeople, bartenders, and childcare workers were some of the hardest hit by the lockdown measures implemented to curb the spread of Covid-19.

The unprecedented surge in claims has made it difficult for states to clear them.

While some experts recommend an increase in unemployment benefits, others warn that it may lead to more unemployment as workers may be reluctant to return to work.

Leggi di più

9:22 am

Company coronavirus news summary – Clinical trials of favipiravir to begin in India – UC San Diego to study hypertension drug for Covid-19 – Gilead and Pfizer to boost manufacturing

1o maggio 2020

Following positive results from a NIAID-led trial of remdesivir, Gilead Sciences is expanding the production of its investigational drug for Covid-19. The company aims to manufacture more than 140,000 treatment courses of remdesivir by the end of this month, which will rise to more than one million treatment courses by the end of the year.

Glenmark Pharmaceuticals has received approval from the Drug Controller General of India (DCGI) to evaluate antivirial drug favipiravir in clinical trials to treat patients with Covid-19. Favipiravir is a generic version of Fujifilm Toyama Chemical‘s influenza drug Avigan. Glenmark developed the drug’s API and formulations internally.

Inovio Pharmaceuticals has entered a manufacturing alliance with German contract manufacturer Richter-Helm BioLogics for large-scale production of its DNA vaccine candidate, INO-4800, against Covid-19. The deal is partly supported by an initial grant of $1.3m from the Coalition for Epidemic Preparedness Innovations (CEPI).

Researchers from University of California San Diego School of Medicine have initiated a clinical trial to study hypertension drug Ramipril as a potential Covid-19 treatment. Ramipril, an ACE inhibitor, will be evaluated in up to 560 patients with Covid-19 symptoms at emergency departments or hospitalised due to the infection.

Pfizer has plans to rapidly boost manufacturing of Covid-19 vaccine candidate to approximately ten to 20 million doses by the end of this year for emergency use, if it demonstrates safety and efficacy in the coming months, reported Reuters. Being developed in alliance with BioNtech, the vaccine candidate is currently in a clinical trial in Germany and a study in the US is expected to begin soon.

8:42 am

Could an innovative mRNA-based vaccine win the race for a Covid-19 vaccine?

mRNA-based vaccine technology is arising as one of the frontrunners among those being tested to produce a vaccine for Covid-19. A total of 18 mRNA-based vaccine candidates are in production across the world, according to GlobalData’s Pharma Intelligence Center Drugs Database.

Information related to these vaccines can now be extracted using the Molecule Type mRNA vaccine filter, available in a number of databases in the Pharma Intelligence Center. Leggi di più qui.

8:19 am

Covid-19 Healthcare Daily Update: Recruitment difficulties for Covid-19 drug treatment trials – Kevzara preliminary results announced

1 May

Gilead’s suspension of remdesivir Covid-19 trials in China should serve as a bellwether for studies in other countries
As the Covid-19 outbreak becomes controlled, developers will increasingly face difficulties in recruiting infected patients for trials. In fact, as Gilead experienced in China, companies may have plans in place to initiate a trial, but when it comes time to begin enrolment, there may be insufficient numbers of patients to power the study.

Results from Sanofi’s Kevzara trial allows a more targeted approach for its final stages
On 27 April, Regeneron and Sanofi announced the preliminary results from the Phase II portion of an ongoing Phase II/III clinical trial evaluating Kevzara (sarilumab), an antibody targeting the interleukin-6 (IL-6) receptor, in hospitalised patients with severe or critical respiratory illness caused by Covid-19.

Fujifilm’s Phase II US trial of Avigan recruits ten out of 50 hospitalised Covid-19 patient target
Fujifilm Toyama Chemical’s US-based Phase II trial investigating Avigan (favipiravir) in hospitalised Covid-19 patients has recruited ten out of its 50-patient target, a source familiar with the trial said. The aim is to close enrolment this month, he added. While recruitment is expected to complete on time, the source noted a potential logistical challenge is the trial’s (NCT04358549) follow-up period: patients are required to do on-site visits to allow for nasal swabs, but those who drop out due to this trial design element would affect outcomes.

NIH/FDA working on standardised language for Covid-19 severity and trial templates
The National Institutes of Health (NIH) along with the US Food and Drug Administration (FDA) and medical bioresearchers are in the process of developing standardised Covid-19 severity terminology, as well as clinical trial templates to address, among other issues, biomarkers used in current clinical trials, like IL-6 and oxygen levels, said the FDA’s Center for Drug Evaluation and Research (CDER) Director, Janet Woodcock.

7:25 am

GlobalData Epidemiologist Report: Covid-19 now in 188 countries – recovered cases approach 1 million

1 May

The number of countries reporting cases of Covid-19 has increased from 187 to 188.

To date there have been 228,229 reported deaths due to coronavirus. The number of total recovered cases is now 986,062, globally.

Spain has reported the highest number of recovered cases with a total of 132,929 cases. The US follows Spain with 124,023 recovered cases reported.

The top five countries with most recovered cases are Spain, the US, Germany, Mainland China, and Iran.

The number of active cases reported globally is nearly 2 million. The US has reported 855,466 active cases making up 43% of all reported active cases, globally.

In Europe, the UK has reported the highest number of active cases at 139,418 cases, approximately 7% of the global total.

Russia has the highest number of active cases in Asia (93,806 cases, approximately 5% of the global total).

In South America, Brazil leads the count of active cases with 40,040 cases reported representing 2% of the global total of active cases.

Ana Fernandez-Menjivar, Msc, Senior Epidemiologist, GlobalData

4:33 pm

Results from Sanofi’s Kevzara trial allows a more targeted approach for its final stages

On 27 April, Regeneron and Sanofi published provisional results from the Phase II section of an ongoing Phase II/III clinical trial assessing Kevzara (sarilumab), in hospitalised patients with severe or critical respiratory illness caused by Covid-19.

The randomised trial compared the drug, administered intravenously at two different doses of 200mg and 400mg, with placebo. Leggi di più qui.

4:25 pm

Fujifilm Biotech reserves manufacturing space for Gates Foundation’s Covid-19 accelerator

Fujifilm Diosynth Biotechnologies has agreed to reserve manufacturing capacity for a future Covid-19 therapy developed through the the COVID-19 Therapeutics Accelerator.

This programme was launched in March by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to remove barriers to drug development, and therefore speed up the therapeutic response to the novel coronavirus pandemic.

The manufacturing space reserved by Fujifilm Biotech in its facility in Hillerød, Denmark will be to support the supply of Covid-19 drugs to developing countries.

Fujifilm Biotech chief business officer Andy Fenny said: “Humanity is facing one of its most challenging times in recent history.

“Resolution calls for a global effort in collaboration between public, private and charitable entities.

“This partnership allows Fujifilm to deploy its leading technical expertise and significant production capacity to have a meaningful impact in the fight against this pandemic.”

2:06 pm

Economic Outlook: Covid-19 puts 1.6 billion jobs at risk – Q1 company earnings ‘most watched in history’ say Goldman Sachs

The Covid -19 pandemic has puts nearly half of the global workforce at risk of losing their livelihoods, according to the International Labour Organisation (ILO)

According to the IOL: The continued sharp decline in working hours globally due to the Covid-19 outbreak means that 1.6 billion workers in the informal economy – that is nearly half of the global workforce – stand in immediate danger of having their livelihoods destroyed.

At sector level the IOL says the hardest-hit include the 232m workforce in wholesale and retail, 111m in manufacturing, 51m in accommodation and food services, and 42m in real estate and other business activities.

According to the recent gender equality paper from the US National Bureau of Economic Research, women disproportionately occupy jobs in sectors most affected by physical distancing measures, and will likely be overwhelmingly impacted by school closures.

However, the paper notes a plausible positive long-term impact, as a shift towards flexible work arrangements or childcare norms, may result in positive long run impacts on gender equality.

With Q1 earnings season in full swing, Matt Gibson, co-head of Goldman Sachs Global Investment Banking Services, has said that preparing for the earnings calls has become much more a management and board undertaking on how to tell a particular company’s story through this crisis.

Many say this is the most watched earnings season in history, according to Gibson.

In an audio released by the investment bank, Gibson says that some of the key conversations happening around boardrooms concern capital allocation, dividends, share repurchases, management compensations, outlooks for the business as well as how best to deal with governments.

12:55 pm

Automotive jobs slump as world economy takes a Covid-19 hit

Jobs available in the automotive industry dropped sharply last week as the world economy continued to toil under the Covid-19 pandemic.

Our job tracker – powered by intelligence from GlobalData – looks at open positions across the world in a range of industries.

The number of “active” jobs each day are indexed against the situation on 1 March, shortly before the pandemic was declared by the WHO.

Only the food service, power and pharmaceutical industries have seen a rise in active jobs since then.

Jobs in the automotive industry were down from 65.2% of March 1 levels on April 17 to 51.9% of March 1 levels on April 24 – the biggest negative week-on-week change in any sector.

Travel and tourism remains the worst hit industry over the course of the pandemic, with active jobs at just 28.4% of the levels seen on March 1. The next worst-hit sectors – medical, insurance, mining and oil and gas – saw further week-on-week drops in job activity, too.

Tracking the economic sectors hit hardest by the Covid-19 outbreak

Covid-19 has had a major, ongoing economic impact across the globe; but that impact is not uniform across different industries. While some economic sectors have seen business rapidly decline, others have – to date – been more stable. Some have even seen an increase in demand.

This chart aims to give a broad overview of which sectors are suffering the most since the WHO declared Covid-19 a pandemic.

It uses exclusive dynamic intelligence provided by GlobalData to track the number of jobs open for applications, across the world, across 19 economic sectors.

The summary chart shows the six which have seen the biggest percentage drop in these “active” jobs.

Economic sector impact chart

11:47 am

GDP of majority of the economies to be below pre-Covid-19 levels for two to three years

The economic impact of the Covid-19 pandemic is expected to last more than three years for majority of the countries affected.

GDP levels are likely to fall to new record low levels and majority of the global workforce is expected to face unemployment.

More than 430 million businesses in sectors such as retail and manufacturing are expected to face serious disruption.

Leggi di più

11:25 am

UK Govt financially supports Gavi’s efforts for universal access to a Covid-19 vaccine

The UK Government has committed £330m annually over the next five years to Gavi, the Vaccine Alliance, to support its work of immunising 300 million across the developing world, as well as its commitments to ensure a Covid-19 vaccine, once developed, will be available to all.

Secretary of State for International Development Anne-Marie Trevelyan noted: “The coronavirus pandemic shows us now more than ever the vital role vaccines play in protecting us all.

“By supporting Gavi, the Vaccine Alliance, we are helping stop the spread of infectious diseases, saving millions of lives.

“As coronavirus vaccine trials begin, we need to make sure any successful vaccine will be available to everyone.”

Gavi CEO Dr Seth Berkley added: “This funding will not only protect hundreds of millions of children against disease, it will also help health systems to repair and rebuild after the enormous impact of Covid-19 has subsided. This is our best shield against future pandemics which, as we have seen all too clearly in recent months, do not respect borders.

“Finally, it means we can continue our work leading international efforts to ensure universal access to a Covid-19 vaccine, as well as to maintain the infrastructure needed to deploy it at scale around the world, which offers our best means of ending this crisis.”

11:16 am

AstraZeneca and Oxford University partner on Covid-19 vaccine

AstraZeneca has signed an agreement with the University of Oxford to develop and distribute the university’s Covid-19 vaccine candidate, ChAdOx1 nCoV-19.

As part of the collaboration, AstraZeneca will carry out the development and global manufacturing and distribution of the Covid-19 vaccine.

Read the full article here

10:52 am

International Update: Global Covid-19 deaths pass 225,000 – inflammatory syndrome in children linked to Coronavirus – US deaths pass 60,000

30 April

Global: The official global death toll passed 225,000, according to Johns Hopkins University data, with the official toll at 227,644. At least 3,193,961 people have been infected worldwide.

Doctors around the world have reported more cases of a rare but potentially lethal inflammatory syndrome in children that appears to be linked to coronavirus infections. Nearly 100 cases of the unusual illness have emerged in at least six countries, with doctors in Britain, the US, France, Italy, Spain and Switzerland now reported to be investigating the condition.

The International Monetary Fund is approving $650m in emergency assistance to the Dominican Republic to combat the impact of the coronavirus pandemic.

Doctors Without Borders is criticising the US government for threatening trade sanctions against countries it believes are not adequately protecting intellectual property policies in the pharmaceutical sector.

South Korea: South Korea reports no new domestic cases for first time since 29 February. South Korea reported on Thursday no new domestic coronavirus cases for the first time since its 29 February peak, the Korea Centers for Disease Control and Prevention said.

US: President Donald Trump has said the federal government will not be extending its coronavirus social distancing guidelines once they expire on Thursday. Meanwhile, the number of Americans who have died of coronavirus surpassed 60,000, a toll far higher than any other country.

China: China’s Forbidden City will reopen on Friday, three months after it closed due to the coronavirus crisis – the latest signal that the country has brought the disease under control. The sprawling imperial palace was shut down on January 25.

Japan: Japan expected to extend the state of emergency by a month. Japan’s government is expected to extend a nationwide state of emergency for another month, after prime minister, Shinzo Abe, described the coronavirus outbreak as “severe”.

South Africa: South Africa’s virus cases jump past 5,000 after its highest daily rise. The number of coronavirus cases in South Africa surged past the 5,000 mark on Thursday after it saw the largest single-day jump to date, health ministry figures showed. A total of 354 new cases were confirmed on Thursday, bringing the overall total to 5,350, and the number of fatalities spiked by 10 to 103.

Ireland: Ireland looks set to extend its lockdown, despite growing calls to ease restrictions and salvage the economy. The taoiseach, Leo Varadkar, said on Wednesday that new cases of Covid-19 infections, deaths and intensive care admissions appeared too high to start relaxing rules that are to expire on 5 May.

Switzerland: The Swiss government has extended its ban on public events exceeding 1,000 people until the end of August, even as it announced the easing of some other restrictions on sporting events, shops, restaurants and museums.

UK: The UK government is still aiming for 100,000 daily tests by tomorrow (1 May), according to the environment secretary, George Eustice. He said the search for an effective antibody test was still under way and denied that earlier introduction of testing at care homes would have saved lives.

Air passenger numbers are down 99% in the UK, the home secretary told MPs, as she defended the government’s decision not to test individuals entering the country. On Friday, a total of 9,906 people entered the country.

France: Societe Generale SA posted a first-quarter loss as the bank set aside 820 million euros ($890 million) for bad loans and its stock traders were wiped out by the market volatility in the wake of the coronavirus outbreak.

Thailand: Thailand will begin easing its emergency virus lockdown curbs on May 3 to allow some businesses to restart operations, according to Taweesilp Witsanuyotin, a spokesman for Thailand’s COVID-19 center.

Australia: The cost of Australia’s economic lockdown to the nation’s major banks has topped A$5 billion ($3.3 billion) as bad-debt provisions blow out to levels not seen since the global financial crisis.

9:21 am

Coronavirus company news summary – Gilead’s remdesivir meets endpoint in NIAID study – Pfizer-BioNTech commence dosing in vaccine study

30 aprile 2020

Preliminary data from a clinical trial led by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) showed that Gilead Sciences’ remdesivir led to faster recovery in Covid-19 patients. Results showed a 31% faster time to recovery in patients treated with Gilead’s drug versus placebo. The median time to recovery was 11 days versus 15 days, respectively.

Johnson & Johnson (J&J) subsidiary Janssen has partnered with Catalent for the manufacturing of its Covid-19 vaccine candidate. Catalent’s Biologics business unit will enable manufacturing as well as prepare for large-scale commercial production at its facility in Bloomington, US. J&J signed its first manufacturing deal with Emergent BioSolutions last week.

Il UK Government has launched a new clinical trial programme called ACCORD to fast-track the development of new drugs to treat hospitalised Covid-19 patients. Designed to cut the time taken to start trials from months to weeks, the initiative will initially involve six drug candidates. BerGenBio‘s AXL kinase inhibitor bemcentinib is the first candidate to enter the ACCORD programme.

BioNTech e Pfizer have completed dosing participants in the first cohort of a Phase I/II clinical trial being conducted to assess Covid-19 vaccine candidate BNT162 in Germany. Dosing was commenced on 23 April and 12 volunteers have received the vaccine so far. The companies also intend to launch trials of the vaccine candidate in the US.

Il Indian Institute of Technology (IIT), Guwahati has partnered with domestic pharmaceutical company Hester Biosciences to develop a potential Covid-19 vaccine candidate. The vaccine, which will build on recombinant avian paramyxovirus-based vector platform, is expected to be ready for animal studies by the end of this year.

7:36 am

GlobalData Epidemiologist Report – Covid-19 now affects 187 countries – over 1 million cases in US

30 April

To date, 187 countries have been affected by the spread of Covid-19 and the number of new countries have not changed in the last two weeks.

Globally, over 3 million confirmed cases have been reported. The US is leading in number of confirmed cases at over 1 million, contributing to approximately 32% of total cases reported globally.

Spain follows the US with approximately 232,128 cases (around 7% of total confirmed cases reported globally).

Italy comes third reporting 201,505 confirmed cases, approximately 6% of global cases.

The five countries with the most reported cases of Covid-19 are the US, Spain, Italy, France and the UK, and together make up approximately 57% of Covid-19 cases reported globally.

In the Middle-East, Turkey has reported the highest number of confirmed cases at 114,653 while Russia leads the count in Asia with 99,399 cases reported.

In South America, Brazil and Peru have reported the most cases at 73,235 cases and 31,190 cases, respectively.

Ana Fernandez-Menjivar, MSc, Senior Epidemiologist, GlobalData

7:39 pm

Up to one in 17 UK care home residents have died in five weeks since the start of the Covid-19 outbreak

29 April

Nicu Calcea, data journalist, New Statesman

As many as one in 17 UK care home residents may have died during just five week since the start of the Covid-19 outbreak.

New data released yesterday show that the number of care home deaths has gone beyond “alarming” and is proving to become a national scandal.

That was even before today’s figures from Public Health England, showing that 29.1% of all care homes in England had seen an outbreak of Covid-19 by the end of April.

We need to be clear on what we do – and don’t – know. While there are a number of different official and semi-official counts of how many people have lost their lives because of Covid-19, none is perfect – or perfectly up-to-date.

Counting Covid-19 is a difficult task. It’s even more difficult when it happens in care homes – where many people are already frail and vulnerable, and many have a number of serious existing medical conditions.

Read the full article on New Statesman

3:38 pm

US economy falls by 4.8%

The US economy has contracted at an annual rate of 4.8%, the steepest slump since the 2008 recession. This brings the longest ever period of economic expansion in the US to an end.

It is predicted that gross domestic product (GDP) could drop by 30% in the next quarter, as many “stay-at-home”  measures were only implemented at the end of this quarter, with a sharp rise in unemployment also anticipated.

35 US states currently have stay-at-home orders in place, with eight states relaxing restrictions. According to Johns Hopkins University, there have now been 1,012,000 confirmed coronavirus cases in the US.

2:51 pm

European Investment Bank collaborates with CEPI

The European Investment Bank (EIB) has signed an advisory agreement with Coalition for Epidemic Preparedness Innovations (CEPI) and its partners to support Covid-19 vaccine development across the world.

The agreement will also see the EIB and CEPI collaborate to improve how financial ecosystem’s pandemic preparedness, including looking at development of a new financing mechanism to mobilise capital.

EIB vice-president Ambroise Fayolle said: “Vaccine development is vital in the fight against global infections, including the current coronavirus pandemic.

“We are pleased to join forces with CEPI to jointly identify vaccine initiatives and suitable funding solutions to get these projects off the ground.

“The Bank offers numerous options for companies looking for funding to develop the next generation of vaccines in the search for solutions to global disease outbreaks.”

CEPI chief executive officer Dr Richard Hatchett added: “The Covid-19 pandemic presents the world with an unprecedented challenge.

“Developing a vaccine that is available to all is going to be the world’s best exit strategy from this crisis, protecting lives and allowing societies to return to normal.

“I am very pleased to be partnering with the EIB which will help us in our work to develop a vaccine against this deadly disease.”

2:32 pm

Economic Outlook: Businesses warned of recession worse than the Great Depression – oil prices to bounce back – rising debts to slow recovery

Bain & Company’s macro trends managing director Karen Harris has warned busineses to prepare for a two to three quarter recession.

“Based on our analysis, two months of heavy mitigation could result in the US permanently losing up to one-quarter of all business establishments, accounting for $4 trillion of revenue (about 10% of total national revenue).

“We expect other advanced economies to suffer disruption on that scale as well. Traditional, after-the-fact stimulus likely won’t be capable of containing and moderating that type of shock to a country’s economic structure.

“Barring a significant change in governments’ models for backstopping their respective economies, a global recession that is worse than the Great Recession is now the upper bound.”

Investment bank UBS has predicted a recovery to $43 per barrel in the price of Brent crude by the end of the year.

This is roughly double the current market price but still only two thirds the price it was trading at the start of the year.

The bank said in an update from its investment office: “While the oil market is heavily oversupplied this quarter, we expect it to move toward balance next quarter and become under-supplied in 4Q this year as lockdown restrictions are eased and oil demand picks up.

“We forecast Brent to recover to USD 43/bbl by year-end.”

Looking to the world beyond Covid-19, accountancy giant Delloitte’s chief economist Ian Stewart warned that rising debt levels will slow down economic activity: “The world had a growth problem before Covid-19. A great effort will be needed to ensure this crisis doesn’t make it worse.

“Government debt will need to be repaid, financed by higher taxes or whittled away through inflation. More indebted corporates and households have less headroom for investment, risk taking or discretionary purchases.

“A period of balance sheet repair is likely, with an intensified focus on cutting costs and paying down debts.”

1:10 pm

International Update: US Covid-19 cases pass 1 million – Russia to remain in lockdown as cases surpass China’s

Global: Known global death toll exceeds 217,168. According to the Johns Hopkins researchers, at least 3,116,680 people have been infected worldwide and at least 217,168 have died since the outbreak began.

Brazil: Brazil deaths reach record amid deepening Bolsonaro scandal.

Brazil’s Health Ministry reported a record 474 people died from Covid-19 in the last 24 hours, bringing the country’s death toll to 5,017.

China: China’s parliament will start its key annual session in Beijing on 22 May, more than two months later than originally planned.

Starbucks Corp. has opened almost all its locations in China, but still sees the lingering impact of the coronavirus pandemic trimming same-store sales.

US: President Donald Trump says the US is considering testing passengers on international flights for the coronavirus.

US Covid-19 cases rose 2.5% from the day before to pass 1 million, according to data compiled by Johns Hopkins University and Bloomberg News.

Trump indicated he wouldn’t allow federal aid for states facing budget deficits from the coronavirus outbreak unless they take action against “sanctuary cities”.

California, which has closed schools for the academic year, is considering bumping up the start of the new school year to late July or early August.

The US government’s top infectious disease specialist is “cautiously optimistic” scientists will develop a Covid-19 vaccine that can protect against future outbreaks of a virus he said is unlikely to disappear.

Russia: President Vladimir Putin ordered Russians to remain under lockdown through 11 May after the total number of coronavirus cases in the country surpassed China’s.

Europe: Several European countries are eyeing a gradual end to their coronavirus lockdowns as infection rates slow and death rates decline.

Spain aims to remove most restrictions on daily life and return to a “new normal” over the next eight weeks, Prime Minister Pedro Sanchez said.

12:34 pm

Daily Covid-19 Chart: Downward path from peak death rate is slow – Italy in stable decline – UK erratic

29 April

Two things are clear from our latest charts plotting the rise and fall of Covid-19 deaths across the world.

The first is that countries like Italy and Spain are in a different phase of virus control to the UK and, in particular, the US.

Italy has been showing a stable decline in daily deaths for more than a month; Spain, for nearly a month. Deaths in the UK are also in decline, even if the figures have been more erratic.

More data is needed before we can say the same about the US with absolutely certainty.

The second is that the path down from the peak is a long and slow one.

Our chart looks at a three-day rolling average of daily death counts to smooth out “noise” caused by unusually low or high reporting on individual days. At the peak of its Covid-19 outbreak, Italy recorded an average of 855 deaths in the three days to 30 March.

A month on and that three-day average still stands at 325. Or to put it in more stark terms: up to 30 March, 11,591 people had died from Covid-19.

Since then there have been 15,768 more deaths in Italy, and we are not yet two-thirds of the way down from the peak.

Many more deaths will, sadly, follow; other countries can expect to tread a similarly grim path.

Covid-19 daily death totals: plotting the path down

While every nation is giving regular updates on deaths linked to the virus, it can be difficult to interpret this data.

Daily death totals are volatile and can fluctuate rapidly from day to day; countries can change the time they report, or their methodology, leading to sudden and abrupt change.

In the charts below we smooth out the data by using a rolling three-day average of deaths. Each day is plotted against the average number of new deaths reported over the previous three days. The percentage increases (or decreases) are plotted separately.

The charts cover the countries with the highest number of deaths overall, excluding China – where daily confirm deaths have slowed to a trickle – and Iran, where the data may not be reliable.

The charts start at the point each country passed 1,000 Covid-19 deaths in total.

Covid-19 average daily deaths chart

10:18 am

UK Government launches platform to fast-track drugs into Covid-19 trials

The UK Government has launched the Accelerating COVID-19 Research & Development (ACCORD) platform to fast-track potential treatments for Covid-19 through the early stages of clinical trials. If they show promise, they will be fed into large-scale studies, such as the University of Oxford’s RECOVERY trial.

The platform itself is to be provided by IQVIA, and the project is being funded by the Department of Health and Social Care and the UK Research and Innovation (UKRI). It is also supported by expert advice from the National Institute for Health Research (NIHR), as well as academia and industry.

Secretary of State for Health and Social Care Matt Hancock commented: “Currently no drugs in the world have been clinically proven to treat COVID-19. But our Therapeutics Taskforce has identified a number of promising candidates.

“Currently, 6 different treatments have been entered into national clinical trials and the first is ready to enter the next stage: a new early phase clinical trial platform that we are launching today. This is a national effort made possible by government, academia and industry working together.”

The government’s Therapeutics Taskforce will continue to evaluate further therapies to also be included in the project, while industry are able to also suggest other treatments they think should be studied through the platform.

NIHR Covid-19 Research Operations director Dr Jonathan Sheffield said: “ACCORD will transform the way in which the UK’s research community finds treatments for global healthcare challenges such as COVID-19.

“ACCORD is an exemplary case of government, industry and research organisations working together with urgency, to the benefit of patients and the NHS.”

9:50 am

Covid-19 Daily Report: Daily deaths rise in US, Italy and UK but over all trend is downward

Daily deaths from Covid-19 rose in the US, Italy and the UK yesterday – but all three countries now appear to be on a downward trend over all.

The US recorded 2,096 new virus-related deaths – more than one in three of the 5,986 deaths seen worldwide and up from 1,378 the day before. Some of that may be due to slower reporting after the weekend and the US daily deaths figure was still lower than those being seen at the end of last week.

Hospital deaths in the UK were up from 363 on April 27 to 588 on April 28. Again that is most likely to represent a lag in reporting rather than a new wave of cases, since the numbers are still down on the same days last week.

Recorded deaths in Italy rose from 333 on April 27 to 382 on April 28.

The US and four countries in Europe – Italy, Spain, France and the UK – account for nearly three-quarters of the 217,153 reported Covid-19 deaths worldwide since the start of the outbreak.

Covid-19 daily report

9:26 am

Covid-19 pandemic: how modelling can support drug development

Better knowledge about SARS-CoV-2 and COVID-19 can support the identification of new drug targets or which existing drugs could help tackle this viral disease.

All viruses have different structures that impact how they infect and enter people’s cells and then reproduce. Coronaviruses use a so-called ‘spike protein’ as one method to invade patients’ cells, however, each virus in that class has a slightly different-shaped protein.

In mid-March, National Institutes of Health (NIH)-funded scientists at the University of Texas at Austin mapped the molecular structure of the SARS-CoV-2 spike protein.

ImmunityBio’s collaboration with Microsoft built on the work of the NIH’s digital blueprint of the spike protein, but applied molecular dynamics to create a 3D model of SARS-CoV-2’s spike protein. This model can support drug repurposing and development, as well as vaccine research.

Computational modelling has uses in the battle against Covid-19 beyond analysing the structure of the virus itself. French artificial intelligence start-up ExactCure is seeking to model and predict the efficacy and pharmacokinetics of already approved drugs being studied for Covid-19.

To date, ExactCure has begun simulating two drugs being studied against Covid-19: anti-malarial hydroxychloroquine and lopinavir/ritonavir, a protease inhibitor combination indicated for HIV. However, it is leveraging with Elsevier’s PharmaPendium database to create state-of-the-art models for 20 drugs.

Leggi la storia completa qui.

9:12 am

Coronavirus company news summary – Shionogi joins research efforts against Covid-19 – Roche’s Actemra performs well in severe patients

29 aprile 2020

Novartis is set to conduct a Phase III clinical trial to assess canakinumab in Covid-19 patients with pneumonia. Canakinumab is an interleukin (IL)-1β blocker and is expected to help address the severe immune overreaction, known as cytokine release syndrome, Covid-19 causes in patients.

Pfizer has begun to restart clinical trial enrolment across its development portfolio, including new studies, at all sites that are currently active. The company temporarily stopped the recruitment for some studies and delayed several new study starts amid Covid-19 pandemic last month. The company is also continuing its efforts to develop treatments and vaccine against Covid-19.

Early data from a clinical trial in France has demonstrated encouraging profile of Roche unità Genentech’s rheumatoid arthritis drug tocilizumab (Actemra) to treat seriously ill Covid-19 patients. The study, which was conducted by the Paris university hospital trust (AP-HP), showed that the drug was able to ‘significantly’ decrease the number of deaths or life support interventions when compared to a control group.

University of St Andrews spin-out Pneumagen has reported positive findings from three in-vitro studies of Neumifil and other multivalent carbohydrate binding modules (mCBMs) to prevent infection by coronaviruses. The mCBMs, based on the company’s GlycoTarge platform, led to decrease in the number of SARS-CoV-2 plaques when tested using plaque reduction assays.

Japanese company Shionogi is working to identify potential treatments and vaccines against Covid-19. In alliance with the Hokkaido University Research Center for Zoonosis Contro, the company discovered multiple lead compounds during in-house in-vitro studies. Meanwhile, Shionogi group company UMN Pharma is leveraging its Baculovirus Expression Vector System technology to potentially identify and develop a recombinant protein vaccine against the coronavirus infection.

8:33 am

Covid-19 Healthcare Daily Update: New Parkinson’s drug launch delayed – Covid pandemic could increase levels of PTSD

Neurocrine’s new Parkinson’s drug suffers launch delay due to Covid-19
On 27 April, Neurocrine Biosciences announced that it has received FDA approval for Ongentys (opicapone), an oral drug that is used as an add-on treatment to the standard-of-care drug, levodopa, in patients with Parkinson’s disease who experience end-of-dose motor fluctuations.

However, the company will not launch Ongentys until later in 2020, given the disruption caused by Covid-19.

Covid-19 pandemic could cause an increase in prevalence of PTSD
The Covid-19 pandemic has the potential to increase stress and anxiety, both because of the fear of infection and because of uncertainty about how the outbreak will affect people socially and economically.

After the severe acute respiratory syndrome (SARS) outbreak in 2003, front-line healthcare workers and people who were self-quarantined exhibited the symptoms of PTSD.

7:55 am

GlobalData Epidemiologist Report: Covid-19 cases in Brazil exceed 66,000 – US, Spain and Italy have most reported cases

29 April

Globally, there have been 3,061,521 cases of Covid-19 reported.

The US, Spain and Italy are the three countries with the most reported cases.

Brazil has the largest number of confirmed cases of Covid-19 (66,501 cases) in South America, and is among the top ten countries with the highest total confirmed deaths (4,603 deaths).

Local transmission in Brazil has been traced to travel to Italy.

While there has been no nationwide lock-down, local authorities in the states of Santa Catarina and Sao Paulo (now the epicenter of the outbreak in Brazil) have established social distancing measures to curb the spread of the disease.

Countries worldwide are in various stages of lock-down and opening up.

An important step in easing social distancing measures will be increasing testing to get an accurate idea of the gap between official figures and the actual spread of the virus.

Ana Fernandez-Menjivar, MPH, Senior Epidemiologist, GlobalData

5:39 pm

Covid-19’s impact on drug contract manufacture in Italy

As of 21 April, one of the worst Covid-19 outbreaks in Europe remains in Italy, with 184,000 individuals diagnosed, as well as 24,650 confirmed fatalities. At the beginning of March, the Italian government applied a lockdown of the predominantly affected Northern regions to stop the spread of infection to the rest of the country. However, this measure was then extended across the country just a few days later.

GlobalData’s Contract Service Provider database shows there are 148 CMOs with Italian facilities; this database has also been used to provide the information for contract service providers shown in this article.

5:15 pm

More than half of age-related macular degeneration cases go undiagnosed in major pharmaceutical markets

Age-related macular degeneration (AMD) is a progressive eye disease that affects the retina, the area of the eye responsible for central vision and sharpness. AMD is the most common cause of irreversible vision loss among the elderly, specifically those ages 50 years and older.

In the nine major pharmaceutical markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, Australia, and China), GlobalData epidemiologists found that less than half of AMD cases were diagnosed in 2019, with Japan and China experiencing the most undiagnosed cases due to the large number of AMD cases in these markets.

Clicca qui per leggere l'articolo completo.

3:24 pm

UQ vaccine demonstrates good immune response in pre-clinical models

The University of Queensland (UQ), Australia, has announced impressive pre-clinical results for its Covid-19 vaccine, one of the first candidates to receive funding from the  Coalition for Epidemic Preparedness Innovation (CEPI).

The results showed the vaccine was able to raise significant antibodies to neutralise the virus. The UQ team had decided to prioritise getting robust pre-clinical data before progressing the vaccine to human, clinical trials.

They were supported in this part of their development by the Peter Doherty Institute for Infection and Immunity.

UQ project co-leader professor Paul Young commented: “This is what we were hoping for, and it’s a great relief for the team given the tremendous faith placed in our technology by CEPI, Federal and Queensland Governments and our philanthropic partners.

“We were particularly pleased that the strength of the antibody response was even better than those observed in samples from COVID-19 recovered patients,” who have natural immunity to the virus.”

University of Melbourne and Doherty Institute professor Kanta Subbarao added that the high-level of neutralising antibodies “is a very important finding because similar immune responses with SARS vaccines in animal models were shown to lead to protection from infection.”

3:14 pm

Economic outlook: GDP growth forecasts for EU and India worsen – UNIRO says Covid-19 will leave a legacy for years to come

28 April

Morgan Stanley has revised down its GDP growth forecast for the European Union and is now predicting an 11.8% contraction in 2020.

The US investment bank said: “In particular, the lockdown has been longer and tougher in France, Italy and Spain than in Germany, and these are also economies with a high share of tourism and therefore more exposed.”

Fitch Ratings has revised down its economic growth forecast for India to 0.8% for the fiscal year to March 2021 (down from growth of 5.6% predicted pre Covid-19).

The ratings agency said: “Risks to the medium-term economic outlook will increase if India experiences another bout of stress in its financial system.

“The current slowdown will reverse at least some of the improvement of the past few years in banking-sector health.

“Prolonged financial-sector weakness could weigh on credit growth, economic output, investment and productivity.”

Adnan Seric, writing for the United Nationals Industrial Research Organisation, has warned that Covid-19’s impact on global production networks will leave a legacy for years to come.

He said: “Exports from China have declined to all regions across the world. This decline has been severe across the globe, with the exception of North America, where trade was already in decline for more than a year due to the ongoing trade disputes between the US and China.

“The picture of a steep decline in goods received from China is similar when looking at numerous individual European countries, including Austria, France, Germany, Italy and Spain.

“The collapse in production activity at the heart of many GVCs necessarily has implications for producers and consumers in countries further up and down the products’ value chains.”

2:20 pm

Neurocrine’s newly approved Parkinson’s drug suffers launch delay due to Covid-19

Neurocrine Biosciences has announced it has received FDA approval for Ongentys (opicapone), an oral drug used as an add-on treatment to the standard-of-care drug, levodopa, in patients with Parkinson’s disease experiencing end-of-dose motor fluctuations. However, the company will not launch the drug until later this year, due to Covid-19 disruption.

GlobalData predicts that if the drug launches later in 2020 it will have a slow uptake in its first year, reaching peak global sales of $303M in 2025.

2:00 pm

Daily Economic Forecast: GDP – Major Western nations all down – Italy to see drop of more than 8%

28 April

Global economic forecasts for major western nations hit by Covid-19 have been revised downwards again – with Italy now set to see its GDP drop by more than 8% during the year.

The latest figures from GlobalData suggest the UK’s economy will shrink by 5.4%, France’s by 6.0% and Germany’s by 5.2%. All three of those forecasts are worse than similar figures produced the previous week.

Japan has seen an even sharper dip in its economic prospects after a rise in Covid-19 cases saw prime minister Shinzo Abe declare a national state of emergency. GlobalData now predict negative GDP growth of 4.4% for Japan across 2020 – down from a predicted 3.2% the previous week.

Overall, the global economy is now expected to shrink by 2.2% in 2020 – a slight improvement on the 2.3% predicted the previous week. That is mainly down to relative success in containing major coronavirus outbreaks to Europe, North America and parts of Asia – so far.

Major stock markets indices in the UK, France, Germany and Italy were stable this week but remain at below 90% of pre-pandemic levels.

Covid-19 macroeconomic dashboard

We are using exclusive dynamic figures provided by GlobalData analysts to track key economic indicators in major world economies hit by Covid-19.

Deaths from the virus are plotted alongside the indexed performance of each country’s major stock exchange. Figures are tracked daily from 1 March, 2020.

Covid-19 macroeconomic dashboard

1:01 pm

Covid-19 pandemic could cause an increase in prevalence of PTSD

Post-traumatic stress disorder (PTSD) can occur in those who have witnessed or experienced a traumatic event such as a natural disaster, a serious accident, a terrorist act, war, rape or violent personal assault.

As the intensity of the psychological impact of the Covid-19 pandemic is rising globally, GlobalData epidemiologists expect a significant increase in the total prevalence of PTSD, with the risk for women being twice as high.

10:52 am

From Covid-19 to SARS: what becomes of the whistleblowers?

Following death of Chinese doctor Li Wenliang, the man who tried to warn officials about the threat of Covid-19, Chloe Kent finds out about the role of whistleblowers in healthcare and what happened to those who tried to warn us about the threat of serious health risks in the past.

Read more here

10:32 am

International update: WHO say ‘pandemic far from over’ – China’s top scientists ‘novel coronavirus will not be eradicated’

April 28

Global: The World Health Organization is concerned about the rising number of cases in Latin America, Africa, some Asian countries, as well as eastern Europe, Director-General Tedros Adhanom Ghebreyesus said, adding that the pandemic is far from over.

HSBC Holdings Plc took its biggest charge for bad debt in almost nine years as the coronavirus outbreak roiled the economies of its main markets. Banco Santander SA reported the highest provisions by a bank in continental Europe so far this quarter as it attempted to put a number on potential loan losses caused by the coronavirus outbreak.

Scheduled airline capacity rose for the first time in nearly 10 weeks as some countries begin to ease coronavirus lockdown restrictions, with a 2% increase in seats this week, according to OAG Aviation Worldwide.

China: China has reported six new coronavirus cases and no deaths.

China’s top scientists said the novel coronavirus will not be eradicated, joining a growing consensus around the world that the pathogen will likely return in waves like the flu.

Hong Kong’s chief executive Carrie Lam says civil servants will begin returning to work from 4 May but the government has still to decide on whether to ease travel and social distancing measures that are due to expire next week.

US: Donald Trump has said the US will conduct “serious investigations” into China’s handling of the coronavirus outbreak and could pursue the country for billions in damages because China “could have stopped” the coronavirus. Trump also said he “does not” take responsibility for reports that people have may ingested disinfectant after his recent comments on its effectiveness.

Austria: Austria’s lockdown to be lifted at end of April. General lockdown measures in Austria will expire at the end of April, said the country’s health minister, Rudolf Anschober.

Japan: The head of the Japan Medical Authority said it would be “difficult” to hold the Olympics, even after it was delayed until 2021, unless a vaccine is developed

New Zealand: New Zealand has partially relaxed restrictions and said that 75% of the economy is now operational as 1 million people return to work and restaurants open for takeaway.

Indonesia: More than 2,200 Indonesians may have died from Covid-19, without being recorded in official death totals, according to a Reuters analysis.

Australia: Australia’s iconic Bondi Beach has re-opened as the state of New South Wales said it would partially ease restrictions by Friday.

Malaysia: Human Rights Watch is calling on Malaysia to stop jailing people who flout the Movement Control Order that was imposed on March 18, with more than 15,000 people arrested for breaching the order so far.

10:22 am

Pharma FDI in the times of Covid-19: A challenging pill to swallow

Political and economic stability, and a coherent Covid-19 containment strategy are among the key factors in attracting biopharma FDI. With supply chains disrupted and the world veering all its attention towards halting Covid-19, FDI flows into the pharmaceutical sector will strongly depend on countries’ ability to respond to the epidemic, and their overall stability.

Read more here

9:58 am

Covid-19 Daily Report: Confirmed cases top 3 million – new cases in stable decline

28 April

There were 69,401 new Covid-19 cases confirmed yesterday, bringing the global total to 3,041,764.

Our daily coronavirus dashboard shows that the number of new cases is in stable decline across the world.

There was a slight uptick in the number of new deaths in all countries in our dashboard except the UK, most likely owing to the fact some hospitals do not report deaths that happened over the weekend until the following week.

Nevertheless, all major countries – including the US, which has taken longer to pass its peak – have seen their numbers decrease by considerable margins compared to last week.

Covid-19 daily report

9:08 am

Coronavirus company news summary – Gilead’s remdesivir likely to receive rapid approval in Japan – Moderna hopes to advance Covid-19 vaccine to Phase II – CEPI funds its ninth vaccine candidate

28 April 2020

Moderna is seeking approval from the US Food and Drug Administration (FDA) to conduct a Phase II clinical trial of its Covid-19 vaccine candidate, mRNA-1273, if positive safety is obtained in the Phase I study. The Phase II trial is set to begin in the second quarter of this year in around 600 healthy volunteers.

Japan will soon approve Gilead Sciences’ anti-viral drug remdesivir, which is currently in clinical trials, to treat Covid-19, according to Kyodo News citing Prime Minister Shinzo Abe at a parliamentary session. Gilead is yet to submit an application to the Japanese government, which is expected to fast-track the approval process and perform domestic studies later.

Merck has entered into a research collaboration with the Institute for Systems Biology (ISB) to study molecular mechanisms of Covid-19 infection and identify targets for drugs and vaccines. Merck also signed another agreement for funding support from the US Biomedical Advanced Research and Development Authority (BARDA).

Il Coalition for Epidemic Preparedness Innovations (CEPI) has agreed to provide $3.5m funding for Clover Biopharmaceuticals to support the preparation and launch of a Phase I trial of its protein-based Covid-19 S-Trimer vaccine in Australia. Clover is the ninth organisation to receive CEPI support and funding for Covid-19 vaccine candidates.

Humanised monoclonal antibody drug leronlimab has shown ‘impressive results’ in a small observational Covid-19 study, said the drug’s developer HIV pharma company CytoDyn CEO Dr Nader Pourhassan in a conference call. Diagnostic firm IncellDX CEO Dr Bruce Patterson also noted that the drug decreased plasma viral load and restored immune cells; IncellDX’s lab analysed blood samples of the first ten patients in the Covid-19 trial.

8:57 am

Covid-19: Healthcare daily update – established drugs join expanding trials list – serology tests needed to ease lockdowns

28 April

Roche’s Actemra sales jump amid testing in Covid-19 patients
While many drugs have not seen success in treating Covid-19 patients, testing of Roche’s Actemra (tocilizumab) raises hopes that targeting interleukin 6 (IL-6) can effectively treat severe Covid-19 patients experiencing respiratory failure.

ARDS treatments are important for severe Covid-19
Pharmaceutical companies continue their work on finding treatments to lessen the symptoms of the disease and improve the survival of the most severely affected patients. Several drugs are under investigation for their ability to reduce acute respiratory distress syndrome (ARDS), a cause of death in Covid-19 patients.

With the initiation of the olumiant clinical trial, Eli Lilly joins the Covid-19 fight
Eli Lilly is one of the latest pharma developers to join the fight in treating Covid-19. In April Lilly announced that it was entering into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to study Olumiant (baricitinib) as an arm in NIAID’s Adaptive Covid-19 Treatment Trial (NCT04280705). Olumiant is a JAK1/JAK2 inhibitor currently approved for rheumatoid arthritis patients. Once added to the trial, Lilly’s Olumiant will join Gilead’s remdesivir in treatment of Covid-19 patients.

Covid-19 serology tests will tell us when lockdown can end
Covid-19 serology tests are the next critical phase of Covid-19 testing as they will be a powerful tool in determining a country’s immunity to the disease, which will allow governments to determine when social isolation could lessen and businesses re-open. As the global Covid-19 pandemic has progressed, testing has been of the utmost importance to determine how widespread the disease is, and hence how severe social distancing should be and if lockdown is required in order to “flatten the curve.”

7:43 am

GlobalData Epidemiologist Report: Covid-19 globally confirmed cases approach 3 million – recovered patients testing positive for second time

28 April

Nearly 2,994,690 confirmed cases and 207,270 deaths of Covid-19 have now been reported globally.

In the US, New York State has the highest number of confirmed Covid-19 cases (288,076 confirmed cases).

New York City has seen a decline in daily confirmed cases. In light of the decline New York State is considering to ease on lockdown restrictions.

However, the World Health Organization (WHO) has expressed concerns because studies have not confirmed that one time infection with Covid-19 leads to immunity.

Data reported from South Korea has shown that approximately 2% of recovered patients tested positive a second time, and quarantine facilities in Wuhan in China also reported that 5%-10% of recovered patients tested positive a second time.

As many nations are also easing or planning to ease lock-down measures, close monitoring of the situation is important to prevent second waves.

Ana Fernandez Menjivar, MSc, Senior Epidemiologist, GlobalData

3:40 pm

ViiV commits £3m to research and mitigate impact of Covid-19 on HIV patients

HIV-speciality company ViiV Healthcare has created a £3m global fund, known as the Global HIV and Covid-19 Emergency Response Fund, to research medical impact of Covid-19 on people living with HIV. It will also support necessary local initiatives and organisations that are struggling to support the HIV community in the pandemic.

The company has pledged £1.5m to research projects studying the impact on people living with HIV. While the remaining £1.5m will be dedicated to a Community Emergency Response Fund.

ViiV chief medical officer Harmony Garges commented: “Because Covid-19 is caused by a novel virus, we don’t have scientific data to answer some of the important questions that are being raised by people living with HIV and their physicians.

Does HIV put a person at greater risk of getting COVID-19? Are people living with HIV more at risk of severe infection? Is the pandemic preventing people with HIV from seeing their healthcare providers and getting the treatment and care they need?

“The HIV community at large has asked us for help to immediately start studying these issues and the Global HIV and Covid-19 Emergency Response Fund has been created to support their efforts.”

21 Mar:

First death in Singapore, Israel

– Singapore’s health ministry confirmed the first two deaths in a 75 year-old female national and a 64 year-old man from Indonesia. The country has at least 385 confirmed cases.

– Israel’s first death from the coronavirus is an 88-year-old man with other illnesses. The country reported 705 cases so far.

Papua New Guinea confirms first case

– Papua New Guinea Prime Minister James Marape confirmed the country’s first COVID-19 case.

– The patient is a 45-year-old mine worker who arrived from Spain via Singapore.

– The country banned all international flights for one week starting on 22 March.

US vice president’s staff member tests positive

– The White House reported that a member of Vice President Mike Pence’s staff tested positive.

– Pence’s spokeswoman said that the staff member did not have ‘close contact’ to the vice president or President Donald Trump.

– According to the CDC, the US has 15,268 cases and 201 deaths.

New Zealand introduces new alert system

– New Zeland Prime Minister Jacinda Ardern placed the country at two on a four-level COVID-19 alert system.

– People have been asked to avoid non-essential travel within the country and those aged above 70 have been advised to stay at home.

– The nation confirmed 13 new cases to total 52. The health ministry said that community transmission could not be ruled out among the new cases.

South Korea records 147 new cases

– The Korea Centers for Disease Control and Prevention recorded 147 new cases, which take the total to 8,799.

Eighth Diamond Princess death

– Japan’s health ministry reported that a Canadian national who was on board the Diamond Princess cruise ship died of COVID-19.

– This marks the eighth coronavirus death among the cruise passengers.

New deaths, cases in Turkey

– The number of cases in Turkey increased to 670 from 359 a day earlier. Also, the total fatalities in the nation reached nine.

China’s Wuhan reports no new cases

– China’s Wuhan city and its Hubei province registered no new cases for the third day in a row as of 20 March. However, the province saw seven deaths, of which six are in Wuhan.

– The mainland China reported 41 new cases, all of which were imported.

– China has a total of 81,008 cases and 3,255 deaths. A total of 71,740 patients had been declared cured and released from hospital.

Death toll tops 11,300

– The number of deaths from the novel coronavirus exceeded 11,300 globally while the total infections increased to more than 275,400, as of end of 20 March.

– Meanwhile, the number of worldwide recoveries exceeded 88,200.

20 Mar:

UK closes pubs, cafes and bars, and announces other measures

– In his daily briefing, the UK Prime Minister Boris Johnson announced that cafes, pubs, and bars to close, as well as shops, theatres and leisure centres, are to close to protect public health.

– The government are deferring taxes to the end of the financial year, as well as waiving VAT for some businesses. It will also provide a job retention scheme to pay 80% of wages for those who cannot work due to the pandemic.

Syria bans visitors

– Syria banned entry of visitors from multiple countries affected by the coronavirus pandemic. The government said that the cases in the nation remain zero.

Cases in Mexico cross 200

– Mexico’s health ministry reported that the total number of cases in the country increased from 164 to 203.

UK reports 33 new deaths; total 177

– The death toll in the UK increased by 33 to 177.  The number of confirmed cases in the country reached 3,983.

Germany cases jump to 13,957

– Germany’s Robert Koch Institute (RKI) reported that the number of cases surged by 2,958 to 13,957.

– The number of deaths increased by 11 to 31.

Spain’s deaths cross 1,000

– The death toll in Spain increased to 1,002 from 767, said the country’s health emergencies chief Fernando Simon .

– The number of cases jumped to 19,980 from 17,147 on Thursday.

Cape Verde, Madagascar confirm first case

– Cape Verde reported its first coronavirus case in a 62-year-old British national who arrived on 09 March.

– Madagascar President Andry Rajoelina confirmed the country’s first three cases.

Cases in Ireland reach 557

– The total number of cases in Ireland increased to 557 from 366 the previous day.

– According to the health department, this is the highest daily jump so far.

Qatar confirms eight new cases; total 460

– Qatar has confirmed eight new cases, taking the overall tally to 460.

– The health ministry approved home quarantine as a second option for families arriving from overseas, after passing mandatory medical examination.

New deaths and cases in Iran

– Iran reported 149 new deaths, taking the total to 1,433 amid, while the  confirmed cases neared 20,000.

Cases rise in Taiwan, Indonesia, Hong Kong, Philippines

– The number of cases in Taiwan increased to 135, including two deaths.

– Indonesia cases jumped to 369, with 32 fatalities.

– Hong Kong’s cases surged to 256, while the Philippines recorded 230 cases and 18 deaths.

South Africa cases reach 202

– South Africa’s Health Minister Zweli Mkhize reported that the number of cases in the country increased to 202.

130 new cases in Malaysia

– Malaysia registered 130 new cases, bringing the total to 1,030.

– Of the new cases, 48 are traced to a religious gathering of around 16,000 participants near the capital, Kuala Lumpur.

– More than 670 cases in Southeast Asia have been linked to this gathering in Malaysia.

Singapore sees 40 new cases

– With 40 new confirmed cases, the tally in Singapore increased to 385. Majority of the new cases are said to be imported from the UK.

Belgium cases top 2,000

– The number of cases in exceed 2,000 to total to 2,257, while the number of deaths surged to a total of 37.

Fifth death, new cases in India

– India reported its fifth death while the total confirmed cases increased to 224, including one case from Punjab.

South Korea reports 87 new cases

– South Korea confirmed 87 new cases and three additional deaths, bringing its totals to 8,652 cases and 94 deaths.

No new cases in Wuhan for second day

– China’s epicentre, Wuhan city in Hubei province, recorded no new cases of infection for two consecutive days as of 19 March.

Death toll crosses 10,000 worldwide

– The COVID-19 death toll has crossed 10,000 across the world, as of the end of 19 March.

– The total number of infected people has increased to 244,000 while the recoveries stand at 86,000.

Italy’s death toll crosses China’s

– The death toll in Italy stands at 3,405, surpassing the number of deaths in China which stands at 3,252.

– The total confirmed cases in Italy stands at 41,035, more than half of that in China which stands at 81,193.

19 Mar:

Deaths in France reach 372

– French health reported an increase in death toll by 108 to total 372, representing a surge of around 40%.

– The number of cases jumped to 10,995, a 20% rise in 24 hours.

Israel orders stay at home

– Israeli Prime Minister Benjamin Netanyahu tightened a nation-wide stay-at home policy to control coronavirus spread.

– The country confirmed 573 cases to date.

Croatia registers first death

– Croatia reported its first death in a 70-year-old man. The country confirmed 102 cases to date.

Chad reports first case

– Chad government reported its first case in a Moroccan national who arrived from Cameroon.

Iran reports 1,284 deaths

– Iran reported that COVID-19 is claiming one life every ten minutes in the country, raising its toll to 1,284, said health ministry in a tweet.

– The number of infections in the nation increased to 18,407.

Brazil death toll reaches six

– Brazil reported deaths of two elderly patients in Rio de Janeiro, increasing the toll in the country to six. The country registered nearly 430 cases.

Cambodia confirms 47 cases

– Cambodia reported ten new cases, taking its total to 47. The country will ban entry for all international travellers from midnight on Monday.

Greece has 464 cases

– Greece confirmed 464 cases and recorded six deaths, according to a health ministry official.

Mexico reports first death

– Mexico reported its first death as a 41-year-old citizen who was suffering from diabetes. The number of cases in the country jumped by 27% in the last 24 hours to 118 from 93.

US CDC confirms nearly 10,500 cases

– US CDC reported 3,404 new cases to total 10,491 infections. The country reported its biggest daily jump in death toll from around 55 to 150.

– California governor ordered its 40 million residents to stay at home starting tonight.

Bank of England cuts interest rates to 0.1%

– In a second emergency cut since the outbreak began, the Bank of England has reduced interest rates to 0.1% in an attempt to limit the economic impact of the virus.

Spain records 200 new deaths

– With 209 additional deaths, Spain’s death toll increased to 767.

– A surge of approximately 25% increased the total cases in the country to 17,147.

First death in Russia

– Russia’s first casualty was a a 79-year-old woman in Moscow with underlying health issues.

– The country has reported 199 cases so far.

Fourth death, new cases in India

– India has confirmed its fourth Covid-19 death, while the number of infections increased to 184.

– The country’s Prime Minister Narendra Modi calls for  citizen curfew on 22 March.

Thailand reports 60 new cases

– Thailand confirmed 60 new cases in the biggest daily jump, taking its total to 272. The country registered one death to date.

Malaysia reports 110 new cases

– Malaysia reported 110 new cases to total 900. Majority of the new cases were linked to a religious gathering by 16,000 people at a mosque.

UK’s MHRA commits to prioritise and support Covid-19 clinical trial applications

– The UK’s healthcare regulator The Medicines and Healthcare products (MHRA) has declared it will prioritise assessments of Covid-19 clinical trials, as well as providing rapid advice to manufacturers and other regulators.

– This builds upon the MHRA’s response to previous outbreaks, such as Ebola.

Mauritius registers first three cases

– Mauritius reported its first three cases, including two who worked on cruise ships and one who returned from the UK.

South Korea has 152 new cases

– The Korea Centers for Disease Control and Prevention reported 152 new cases, taking the total to 8,565.

– South Korea had confirmed fewer than 100 new cases for four consecutive days until Wednesday.

World Bank increases response package to $14bn

– The World Bank has increased its support package for businesses and economies to $14bn.

Wuhan and Hubei report no new cases

– China’s epicentre of the outbreak, Wuhan, and its Hubei province have reported no new cases for the first time.

Death toll rises to 8,800

– The death toll due to COVID-19 coronavirus has increased to 8,809 as of the end of 18 March.

– The total confirmed cases has passed 218,000 worldwide while recoveries stand at 84,000.

UK deaths rise to 103

– The death toll in the UK increased from 71 to 103, including a total of more than 2,640 cases.

California governor says 60,000 homeless could contract COVID-19

– California, US governor said that according to models more than 60,000 homeless people in the state could contract the novel coronavirus over the next eight weeks.

– The US has more than 9,400 cases and 150 deaths so far.

18 Mar:

Portugal declares emergency

– Portugal declared 15-day state of emergency to combat coronavirus. The number of cases in the country neared 650.

Italy reports 475 more deaths

– The death toll in Italy increased by 475 to 2,978, a surge of 19%.

– The total number of cases jumped by 31,506 to to 35,713, up 13.35%, said the Civil Protection Agency.

Swiss cases cross 3,000

– The number of cases in Switzerland has jumped to 3,028, including 21 deaths.

France reports 89 new deaths; total 264

– France confirmed 89 new deaths in the past 24 hours, taking the death toll to 264. The number of cases in the nation reached 9,134.

Cases in Singapore reach 313

– Singapore’s health ministry reported 47 new infections to total 313.

– Starting Friday, the country will impose self-quarantine measures for 14 days on everyone entering, as well as citizens and residents.

Second death in Turkey

– Turkey confirmed its second death in a 61-year-old male. The first fatality occurred on Tuesday.

– With 93 new cases, the nation’s total increased to 191.

Cases in Spain reach 13,716

– Spain health emergency center head Fernando Simon said that the country’s total cases surged to 13,716, including 558 deaths.

Iran’s death toll rises to 1,135

– With 147 new fatalities, Iran’s death toll jumped to 1,135.

– The total infections in the nation had reached 17,361, with 1,192 new cases in the last 24 hours.

Austria announces 38bn aid package

– Austria Chancellor Sebastian Kurz announced up to 38bn aid to secure jobs and ensure coronavirus affected companies remain liquid.

– The country is also offering 9bn in guarantees and warranties, 15bn in emergency aid and 10bn in tax deferrals.

Study says initial infections on Diamond Princess came from food worker

– In a study published by the CDC, it was found that the initial cases of the COVID-19 on the cruise ship came from food workers.

– It stated that of the 20 confirmed cases of crew members, 15 were from food service members.

– Malta will stop all incoming passenger flights from Saturday to prevent spread. The country has 38 cases, of which 32 contracted the infection abroad.

– Malaysia closed its borders with Singapore, starting 14-day partial lockdown as the number of infections in the country reached 673.

Kyrgyzstan, Djibouti, Zambia register first cases

– Kyrgyzstan recorded its first cases in three citizens who returned from Saudi Arabia.

– Djibouti confirmed its first case as a Spanish national who was part of a 32-member Spanish special forces unit that came to the country on 14 March.

– Zambia’s health ministry confirmed its first two COVID-19 cases today.

Moldova confirms first death

– Moldova confirmed its first death today, while the cases in the country increased to 30.

– The nation declared a state of emergency on Tuesday.

Philippines, Indonesia, Malaysia report new cases

– The Philippines’ health ministry reported 15 additional cases to total 202.

– Indonesia recorded 55 new cases, taking the total to 227, including 19 deaths and 11 recoveries.

– With 117 new cases, Malaysia registered 17% rise in infections to total 790.

South Korea reports 93 new cases

The  Korea Centers for Disease Control and Prevention reported 93 new cases to total 8,413. This is the fourth consecutive report of fewer than 100 new cases.

Cases in India reach 149

– The number of cases in India reached 149, including one new case each in Pondicherry and Pune, Maharashtra.

First death, new cases in Pakistan

– With new cases reported on Monday and Tuesday, the number of cases in Pakistan reached 236.

– The country also confirmed the first death of a suspected coronavirus patient in Lahore, Punjab. The patient is reported to have recently arrived from Iran.

– Prime Minister Imran Khan said that Pakistan cannot currently afford the economic cost of closing down its cities.

WHO calls for ‘aggressive’ action in Southeast Asia

– The WHO has asked Southeast Asian countries to implement ‘aggressive’ action to control the spread of the virus.

WHO regional director Poonam Khetrapal Singh said: “More clusters of virus transmission are being confirmed. While this is an indication of an alert and effective surveillance, it also puts the spotlight on the need for more aggressive and whole of society efforts to prevent further spread of COVID-19.”

New Zealand reports new imported cases

Nuovo Zealand has confirmed eight new cases, all in people who had recent international trips, said the health ministry.

– The totale number of cases in the country reached 20.

Death toll increases to 7,900

– The death toll due to COVID-19 has increased to 7,900 as of the end of 17 March.

– The total cases cross 198,000 while the recoveries stand at 81,000.

17 Mar:

Australia declares human biosecurity emergency

– Australian Prime Minister Scott Morrison has declared a human biosecurity emergency, which enables closure of cities or regions, curfews and quarantine.

– Currently, the country’s travel advice is ‘Level 4: Do not travel’ to any country worldwide.

– The government also banned non-essential indoor gatherings of more than 100 people.

Italy registers 345 more deaths; total 2,503

– Italy’s death toll surged by 345 to 2,503, a jum of 16%, said the Civil Protection Agency.

– The total cases in the country increased by around 12% from 27,980 to 31,506.

Gambia, Barbados, Montenegro and Montserrat report first case

– Gambia confirmed its first case as a 20-year-old woman who had recently visited the UK.

– Barbados registered its first two cases in a 48-year-old visitor from the US and a 39-year-old female national who returned from the US.

– Montenegro reported its first cases in two females who returned from the US and Spain, said Prime Minister Dusko Markovic.

– Montserrat recorded its first case among the three samples sent abroad for testing, said health ministry.

– Brazil confirms first death

Brazilian President Jair Bolsonaro reported the nation’s first death, while Sao Paulo and Rio de Janeiro declared a state of emergency.

– The number of cases in the country stand at 321.

– Finland interior minister Maria Ohisalo said that the country will begin to heavily restrict traffic over its borders from Thursday. The country has 319 cases to date.

– Bosnia declared a nationwide state of emergency as the number of cases in the country grew to 26.

– Vietnam will impose mandatory quarantine for all arrivals from the US, Europe and ASEAN regions. The country, which confirmed 61 cases, will also suspend the issuance of new visas.

– Canada’s Ontario banned gatherings of more than 50 people, closed bars and restaurants to control coronavirus spread. The number of infections in Canada reached 407, including four deaths.

– Sri Lanka, which reported 28 cases, banned all incoming flights for two weeks.

– Planemaker Airbus will suspend production in France and Spain for the next four days.

– Hong Kong will quarantine all people entering the city for 14 days from midnight on Thursday.

– Swiss federal health agency’s head of infectious diseases Daniel Koch said that hospitals in the country could collapse if the novel coronavirus continues rapid spread.

– China’s Shanghai has extended quarentine to visitors from the UK, Switzerland, Sweden, Belgium, Norway, the Netherlands, Denmark and Austria. The city already imposed same measures for passengers from France, Spain, Germany, the US, South Korea, Italy and Iran.

– Carmaker Volkswagen is preparing to suspend production to contain coronavirus spread.

UK sees 26% surge in infections

– The number of coronavirus infections in the UK increased by 26% to 1,950 from 1,543 the previous day. The death toll in the nation stands at 56.

Greece cases rise to 387

– Greece’s COVID-19 cases jumped to 387, while the death toll increased to five.

EU to close external borders

– European Union agreed to close Europe’s borders for 30 days. The regions will, however, build fast-track lanes to keep goods moving.

– According to European Commission President Ursula von der Leyen, European countries would decide whether to close their borders to third countries.

Two WHO staff test positive

– Two WHO staff members have tested positive, announced an official from the agency. These are the first cases reported at the agency.

Cases in Spain top 10,000; announces 200bn package

– Spain’s COVID-19 cases exceeded 10,000 to total 11,178, including 491 deaths.

– The country announced a 200bn package to aid companies, as well as protect workers and other vulnerable groups affected by the outbreak

Iran’s death toll climbs to 988; temporarily releases prisoners

– Iran’s health official confirmed 135 new deaths, bringing the total death toll to 988. The nation reported 16,169 infections so far

– The country has temporarily released approximately 85,000 prisoners, including political prisoners, said a judiciary spokesman.

Malaysia confirms first deaths

– Malaysia confirmed its first death in a 60-year-old pastor. The Sarawak state had said that 193 close contacts of the deceased have been traced and are under home quarantine.

– The second casualty in the nation was a 34-year-old man who attended a mass religious gathering in February in Kuala Lumpur. The country has at least 550 cases.

New cases in Philippines, Thailand, Indonesia

– Philippines’ health ministry reported 45 new cases, taking the total to 187.

– Philippine Airlines suspended all domestic flights due to quarantine imposed across the Luzon island.

– Thailand reported 30 new coronavirus cases, which increase its total to 177, including one death.

– Indonesia reported 38 new cases in the last two days, rising the total to 172, with five casualties.

First Covid-19 vaccine trial begins in US

– The first US clinical trial of a Covid-19 vaccine candidate, which is Moderna’s mRNA-1273, has started.

Cambodia cases double; total 24

– The number of cases in Cambodia doubled from 12 to 24. Of the new cases, 11 had visited Malaysia for a religious event at a mosque.

Brazil’s Foreign Trade Secretary tests positive

– Brazil’s Foreign Trade Secretary Marcos Troyjo tested positive. The official was part of a delegation that recently visited Florida, US.

– The nation’s cases stand at 234.

South Korea reports 84 new cases

– South Korea has confirmed 84 new cases, marking the third day with less than 100 new infections.

– The total infections in the nation increased to 8,320, including 81 deaths and 1,401 recoveries.

India reports third death

– India reported third death, while the total cases has touched 132.

Pakistan cases rise to 189

– With new cases in Punjab, Sindh and Khyber Pakhtunkhwa provinces, the number of cases in Pakistan increased to 189.

Ireland estimates cases to rise to 15,000 by March-end

– Ireland Prime Minister Leo Varadkar said that the number of cases in the country may rise to approximately 15,000 by the end of March from current 223.

– The country advised against all non-essential overseas travel.

– All schools, universities, bars and childcare facilities have been closed until 29 March and mass gatherings have been limited.

Spain deploys troops to help in lockdown

– Spain has been under partial lockdown since 14 March. Citizens were allowed to leave home only for work, buy food, visit a pharmacy or hospital.

– More than 1,000 troops were deployed in 14 cities across Spain to help in the lockdown.

– The country reported nearly 9,900 cases and 340 deaths so far.

US boosts measures to combat coronavirus

– The White House urged citizens to avoid gatherings of more than ten people.

– The government also called for closure of bars, gyms, restaurants and other venues in states with local transmission of coronavirus.

– To date, the nation has at least 4,660 confirmed cases and 85 deaths.

WHO calls for increased testing

– The World Health Organization asked all countries to boost testing programmes in an effort to slow the pandemic.

Death toll crosses 7,100

– The death toll due to COVID-19 has increased to more than 7,100 globally in 155 countries.

– The total number of cases has surpassed 182,000 while recoveries stand at 79,000.

16 Mar:

First death in Portugal, Dominican Republic

– Portugal reported the first COVID-19 death in the country in an 80-year-old man with pre-existing health conditions. The country is mulling over declaring a state of emergency.

– The Dominican Republic’s first casualty is a 47-year-old woman who returned from Spain.

UK cases and deaths rise

– UK’s confirmed coronavirus cases increased to 1,543, while deaths rose to 53.

France confirms 21 new deaths; total 148

– France’s Public Health Authority confirmed 21 new deaths to total 148, indicating a 16% jump.

– The number of cases had risen by more than 20% to 6,633.

Poland’s environment minister tests positive

– Poland’s environment minister Michal Wos tested positive for coronavirus. The country confirmed 156 cases and three deaths to date.

Cases in Austria rise to 1,018

– The total number of cases in Austria have increased to 1,018.

– The government will provide €2bn of loan plus €4bn aid fund to support the economy.

Braemar cruise ship to dock in Cuba

– A Bristish cruise ship, Braemar, with five positive coronavirus cases is setting sail to Cuba after being turned away from several Caribbean ports over coronavirus fears, announced owner Fred Olsen Cruise Lines.

UK actor Idris Elba tests positive

– UK actor and musician Idris Elba has tested positive for coronavirus.

– Finland would close all its schools and universities from Wednesday as the number of cases in the nation rise to 272.

– The Switzerland government declared a state of emergency until 19 April. It banned all public and private events, and deployed 8,000 military members for aid.

– Bosnia’s autonomous Bosniak-Croat Federation declared a state of disaster as the cases in the country increased to 24. Banja Luka town along with some other towns closed bars, restaurants and shops, except food stores, for one week.

– Guatemala President Alejandro Giammattei said that the country will close its borders for the next two weeks to prevent spread of virus.

– Turkey ordered temporary closure of cafes, sports and entertainment venues, as well as suspension of mass prayers in mosques. The coronavirus cases in the country reached 47.

– Russia banned entry to foreign nationals from 18 March to 1 May. It closed state schools and limited public gatherings in Moscow as COVID-19 cases reached 93.

– Venezuela has decided to impose a nationwide quarantine after 16 new cases were confirmed today. The total cases in the country reached 33.

– Egypt will suspend all flights from its airports, from Thursday until 31 March to control coronavirus spread. The nation has 166 cases and four deaths.

– Canada imposed tougher screening measures for visitors as the number of cases in the country increase to approximately 320.

– Morocco will close all mosques, eateries, cinemas, theatres, sports, public clubs and entertainment  centres to prevent spread. Markets, shops with essential goods and restaurants with delivery service are given exemption.

– Chile President Sebastian Pinera said that the country will close its borders to foreigners from Wednesday. The nation confirmed 155 cases to date.

– Greece ordered 14-day quarantine for people from abroad. The government will also close shops from Wednesday, except supermarkets, pharmacy stores and food delivery services.

– The Philippines ordered home quarantine and suspension of work and transport across Luzon as the country’s cases reach 140.

– Armenia declared state of emergency for one month from March 16 until April 16. The country confirmed 30 cases and has closed all educational institutions.

– Ghana announced closure of all schools and universities, as well as suspended public events to control the spread of coronavirus.

– Germany government advised against all non-essential international trips. The number of cases in the country increased to 6,012, including 13 deaths.

– Hungary announced plans to close borders to international passengers, suspend cultural and sports events and establishments. The government advised people aged over 70 to stay at home.

– Georgia would deny entry to all foreigners over coronavirus concerns. The country has 33 cases.

– Auto company Fiat Chrysler announced suspension of production at majority of its European plants until 27 March.

– South Africa plans to revoke around 10,000 visas issued to people from China and Iran. Also, visas will be needed for other ‘high-risk countries’ that had been visa-free, including Italy.

– Ukraine’s capital Kyiv, along with Lviv and Odessa cities, will close bars, restaurants, cafes and shopping malls from 17 March.

– A Northern Irish mother whose daughter has underlying health conditions and is at greater risk will launch a legal challenge against UK’s decision to keep schools open, her lawyers said.

Cases in Netherlands jump to 1,413

– The number of coronavirus cases in the Netherlands have jumped by 278 to 1,413, reported the National Institute for Public Health (RIVM).

– The death toll in the country stands at 24.

Spain’s cases grow to 8,744

– Spain’s health officials reported that the number of coronavirus cases in the country grew to 8,744, including 297 deaths.

– The regional leader of Spain’s Catalonia, Quim Torra, tested positive and is under self-isolation. Catalan government deputy head Pere Aragones also tested positive earlier.

Iran reports 129 new deaths

– With 129 new deaths, the death toll in Iran reached 853, while the number of infections increased to 14,991.

Liberia, Tanzania, Somalia, Benin confirm first case

– Liberia reported its first coronavirus case, without providing further details.

– Tanzania health ministry also confirmed its first case of coronavirus infection.

– Somalia health ministry announced its first Covid-19 case.

– Benin reported its first case in a national who returned from Belgium on 11 March.

Singapore cases rise to 243

– Singapore confirmed 17 additional cases to total 243. Of the new cases, 11 are said to be imported.

Malaysia reports 125 new to total 553

– Malaysia confirmed 125 new cases to total 553. Majority of the new infections have been traced to a religious gathering attended by nearly 16,000 people.

Bahrain confirms first death

– In a tweet, Bahrain health ministry confirmed its first death in a 65-year-old national with underlying health conditions. The country recorded at least 210 cases.

Pakistan cases rise to 122

– Pakistan reported a surge in cases to total 122, including 76 infections among people released from 14-day quarantine at Taftan.

Thailand records 33 new cases; total 147

– Thailand confirmed 33 new cases to total 147, marking the largest daily increase in infections.

Sweden announces $30bn crisis package

– The Swedish government announced an approximately SEK300bn ($30.9bn) crisis package to support the economy during the outbreak.

– The package includes various measures, including the central government assuming the cost of sick leave from companies in April and May.

– The country has 1,032 cases, including three deaths, to date.

Taiwan announces eight new cases; total 67

– The number of cases in Taiwan surged to 67, including eight new infections.

– The nation imposed a 14-day quarantine for all people from Europe’s Schengen border-free travel zone, the UK and Ireland.

– Taiwan also advised against non-essential travel to 13 European countries, 15 Middle Eastern countries, five countries in Africa and nine in Central Asia.

South Korea expands screening to all arrivals from Europe

– South Korea expanded screening measures to arrivals from all European countries. Initially, the screening was applicable for only six European countries.

– The KCDC confirmed 74 new cases today, taking the total to 8,236.

Turkey reports 12 new coronavirus cases

– Turkey confirmed 12 new cases to total 18.

– Of the new patients, two were linked to the nation’s first case, seven arrived from Europe, and three travelled to the US.

– The government closed schools and universities, and suspended flights to multiple countries to control the spread.

New Zealand bars gatherings

– New Zealand has banned gatherings of 500 people or more. The number of cases in the country reached eight.

Cases in India increase to 114

– The total number of confirmed cases in India has reached 114, with one fresh case each reported in Maharashtra and Karnataka and two cases in Kerala.

US death toll stands at 69

– The death toll in the US has increased to 69 while the total number of cases stands at 3,774.

Japan traces 15 clusters; total at 1,528

– Japan’s health ministry announced the identification of 15 clusters, with the largest being in the Osaka region.

– The total infections in the country stand at  1,528, including 697 from the Diamond Princess cruise ship and 14 evacuees from China. Around 30 people died due to COVID-19.

Cases in Rwanda rise to five; Cambodia at 12

– The number of cases in Rwanda grew to five from one, reported the health ministry late on 15 March. The country reported its first case on 14 March.

– Cambodia’s total infections increased to 12, with four new cases including  a four-month-old French boy and two people arriving from Malaysia.

China boosts quarantine for international arrivals

– China tightened quarantine measures for international arrivals in capital Beijing as the number of imported cases in the country reach 123.

Death toll increases to more than 6,500

– The Covid-19 death toll has crossed 6,500, as of the end of 15 March.

– The total number of confirmed cases has increased to more than 169,000 while recoveries stand at around 77,000.

15 Mar:

– Ukraine’s railways company Ukrzaliznytsia will bar all international passenger trains from 17 March. The country already suspended international flights and banned entry to foreign nationals until 3 April.

– Kenya would deny entry to all except citizens and residents as the number of cases rose to three. The country will also close primary and secondary schools from Monday, while boarding schools and universities will shut by the end of the week.

– Serbia’s president declared a state of emergency to contain the spread of the coronavirus. The country, which has at least 45 cases, deployed soldiers to guard hospitals and closed several public spaces.

– Argentina ordered ban on entry for 30 days to non-residents who visited a highly affected country in the last 14 days. The country has 45 cases.

– From 17 March, Estonia will deny entry to foreign travellers. Estonians, people living in the country and foreigners with family members living in the country will be able to enter. The nation registered 115 cases so far.

– Morocco suspended all international flights to and from its airports. The nation reported 28 cases, including one death and one recovery.

UK to isolate elderly people

– The UK government plans to isolate people aged above 70 and those at higher risk for four months to fight the coronavirus pandemic.

– In addition, complete families will be asked to self-isolate even if one person falls sick.

– The total number of cases in the UK neared 1,400, while the death toll stands at 35.

– The government asked manufacturers to boost production of ventilators and private hospitals to prepare more beds as coronavirus spreads.

Qatar coronavirus cases rise to 401

– Qatar reported 64 new cases to total 401. Nearly 7,950 people have been tested to date.

– The government will ban entry to non-nations for two weeks as of Wednesday. It will also suspend entry to passenger flights.

– All health clubs such as spas and restaurants in hotels, said Qatar National Tourism Council.

Equatorial Guinea confirms first case

Equatorial Guinea confirmed its first case as a 42-year-old woman who arrived in the capital Malabo from Spain on 13 March.

Spain reports 2,000 new cases

– Spain confirmed nearly 2,000 new cases to total to 7,753 and more than 100 deaths to total 288.

Deaths in Iran rise to 724

– With 113 new deaths in the last 24 hours, Iran’s death toll increased to 724, said a health ministry official. The total number of infections in the country reached 13,938.

The Netherlands, Greece report new cases and deaths

– The Netherlands has confirmed eight new deaths, taking the death toll to 20 in the country. The total number of cases has increased to 1,135.

– Greece confirmed one more death, taking the total to four. The number of infections grew by 103 to total 331.

Italy reports 368 new deaths

– Italy has reported 368 new deaths in the country, bringing the death toll to 1,809. The total cases in the country stand at 24,747.

France reports 29 deaths

– The death toll in France has increased to 127, with 36 additional deaths reported. This marks the biggest jump in cases so far.

– The confirmed cases in the country stand at 5,423.

Malaysia confirms 190 new cases; total 428

– With 190 new cases reported today, Malaysia’s total increased to 428. Majority of the infections are linked to a mosque gathering.

Cases in Vietnam reach 57; Philippines has 140

– Vietnam reported four new cases today, which increase its total to 57. The country ordered mandatory quarantine and testing of passengers from or through China, South Korea, the UK and Schengen countries.

– The Philippines confirmed four additional deaths to total 12 and 29 new cases to total 140.

Slovenia, Hungary report first death

– Slovenia health ministry confirmed first death in an elderly man with a chronic disease. The number of cases in the country stand at 219.

– Hungary’s first death is a 75-year-old national hospitalised with severe pneumonia. The country has 32 cases.

First case in Delhi, India recovers

– The first case confirmed in Delhi, a 45-year-old man, has fully recovered from Covid-19 coronavirus. India currently has 102 confirmed cases and two deaths.

US President tests negative, travel ban extended to the UK

– US President Donald Trump has tested negative for Covid-19.

– The US has extended the travel ban to include the United Kingdom and Ireland.

– The US has confirmed more than 2,900 cases with 57 deaths so far.

NHS and private hospitals to partner to tackle the coronavirus pandemic

– The NHS has announced its plans to partner with the private hospitals to deal with the pandemic as the public hospitals in the countries are reportedly not equipped to handle the large influx of coronavirus patients.

– The UK has 1,143 confirmed cases with 21 deaths so far.

Wife of Spanish PM tests positive

– Begoña Gómez, the wife of the Spanish Prime Minister has tested positive for Covid-19. She, along with the PM, are reported to be doing well.

Philippines closes Manila for domestic travellers

– Philippines has closed its capital, Manila with the help of the police, for all domestic travellers. The city of around 12 million residents is reported to be closed for around a month.

Australia imposes self-quarantine for people arriving from abroad

– PM Scott Morrison has announced that any arriving passenger from abroad to Australia will have to undergo a mandatory 14-day self-quarantine.

– Cruise ships will also not be allowed to dock in the country for one month. People have also been advised to implement ‘social distancing’.

Mexico reports 41 cases, boosts measures

– Mexican health ministry reported increase of cases to 41 on Saturday.

– The government warned that the outbreak could last all year and bolstered measures to control the outbreak, including ban on large gatherings and extension of school holidays.

Death toll rises to more than 5,800

– The death toll due to Covid-19 has increased to more than 5,800 worldwide with around 156,000 confirmed cases and almost 74,000 recoveries, as of 14 March.

14 Mar:

– Egypt to close schools and universities for two weeks from Sunday, as the number of cases reach 110 with two deaths.

– Kuwait will close all shopping malls, excluding those related to food supplies. The country also called for closure of children’s entertainment centres and salons.

– Bolivia will ban the entry of visitors from China, South Korea, Italy and Spain. The country reported ten cases so far.

– Sudan ordered the closure of schools and universities for 30 days from Saturday. The coutry also banned public gatherings and social events.

– Denmark has reported its first death due to COVID-19 and has closed its borders for foreign travellers for one month.

– Cambodia would deny entry to visitors from Italy, Germany, Spain, France and the US for 30 days from 17 March. The nation’s confirmed seven cases.

– Colombia ordered closure of the border with Venezuela to contain spread of the coronavirus. As of Friday, the country reported nine cases.

– New Zealand Prime Minister Jacinda Ardern asked everyone entering the country from midnight Sunday to self-isolate for 14 days. All cruise ships will also be denied entry until 30 June.

– Rwanda, Seychelles, Congo Republic and Central African Republic report first cases.

Thailand reports seven new cases; total 82

– Thailand confirmed seven new coronavirus cases, taking the total to 82.

Uzbekistan confirms first case

– Uzbekistan health ministry confirmed first case in a national who returned from France.

– The country will close schools, colleges and universities for three weeks from Monday, and cancelled all public events.

– In addition, flights have been suspended to some cities in Western Europe, Asia and the Middle East until the end of April.

Sixth death in Philippines

– The Philippines confirmed its sixth fatality in a 54-year-old resident of Metro Manila. The country reported at least 64 cases.

Japan cases rise to 1,423

– NHK reported a total of 1,423 infections early today, including 697 from the Diamond Princess cruise ship and 14 evacuees from China.

– The country saw 28 deaths, including seven from the cruise ship,

107 new cases in South Korea; total 8,086

– For the second consecutive day, South Korea reported more recoveries than new infections.

– The Korea Centers for Disease Control and Prevention (KCDC) confirmed 107 new cases, rising the total to 8,086. Meanwhile, 204 people have recovered and discharged from hospitals.

Australia bans public events

– Prime Minister Scott Morrison suspended all non-essential gatherings of more than 500 people, including sporting and cultural events.

– The government also advised people against overseas trips.

– A total of 197 cases and three deaths have been reported.

US declares national emergency

– US President Donald Trump declared a national emergency over the coronavirus spread, enabling $50bn in federal aid.

– The country now has over 1,700 confirmed cases and 40 deaths.

Europe now epicentre of outbreak, says WHO

– WHO called Europe the pandemic’s current epicenter, with the continent now reporting more cases and deaths compared to the remaining global regions, except China.

Death toll nears 5,500

– Deaths due to COVID-19 have neared 5,500, as of 13 March. The total infections increased to 145,300 worldwide, with more than 71,600 recoveries.

13 Mar:

– Jamaican Prime Minister Andrew Holness declared disaster over coronavirus. The country, which reported eight cases, is also seeking 100 Cuban nurses to help.

– Chilean President Sebastian Pinera ordered a ban on public events of more than 500 people from Monday. The country registered 43 cases so far.

– Spain declared a state of emergency today over the coronavirus outbreak. This is the first of three state of emergency stages.

– From Monday, Singapore will ban entry to people who had been to Italy, France, Spain and Germany in the past 14 days.

– Romanian interim prime minister Ludovic Orban will be under self-quarantine after coming into contact with one of his party’s senators who  later tested positive.

– Moldova would suspend all flights to European regions from Sunday. The country has six cases to date.

– France will close all nurseries, schools and universities from Monday to fight the spread of the virus, said President Emmanuel Macron. The country also banned public gatherings of more than 100 people.

– Boeing official said that more than 50% of flights have been cancelled in Asia Pacific over coronavirus fears.

– Czech Republic announced that the country would deny entry to foreigners and banned its nationals from travelling abroad as of Monday.

– Bulgaria foreign ministry banned all travel to Iran, and asked people to avoid non-urgent travel to 11 countries. The country already suspended visits to China and advised against travel to Italy.

– North Macedonia suspended public gatherings and would ban entry to foreign nationals arriving from ‘high-risk countries’. A total of nine cases have been reported in the country.

– Iraq banned entry to visitors from Germany and Qatar, expanding its list to 13 countries.

– Australian Minister for Home Affairs Peter Dutton tested positive.

First cases in Guinea, Sudan, Mauritania

– Guinea’s first case is an employee of the European Union delegation.

– Sudan confirmed its first case in a man who died on Thursday and had arrived from the UAE earlier this month. The country suspended flights to eight countries.

– Mauritania’s health ministry also reported the first coronavirus case.

Italy death toll rises to 1,266

– The  number of deaths in Italy increased by 25% in the last 24 hours to total 1,266. Also, the number of infections surged by nearly 17% to 17,660.

Guatemala, Kosovo, Uruguay, Venezuela confirm first cases

– Guatemala confirmed its first case of coronavirus infection. The nation banned arrivals from some heavily affected countries, including the US and Canada.

– Kosovo’s first cases are a 20-year-old Italian woman and a 77-year-old Kosovar man.

– Uruguay confirmed its first four cases in people who arrived from Milan, Italy.

– Venezuela reported its first two cases and declared a state of alarm as the country is said to be unprepared to fight the pandemic.

Germany cases cross 3,000

– The number of cases in Germany grew by 671 to 3,062, including five deaths.

Second death in India

– India reported its second death in a 68-year-old woman with other health conditions in New Delhi.

– The nation confirmed 82 cases so far.

New cases in Mexico, Panama, Egypt, Saudi Arabia

– Cases in Mexico grew to 26 from 15 the previous day.

– Panama’s confirmed cases increased to 36, including three foreign nationals.

– With 13 new cases, the total cases in Egypt reached 93.

– Saudi Arabia confirmed 24 new cases to total 86.

Canada boosts measures

– Canada boosted measures to fight the outbreak, including emergency measures such as half-point interest rate cut.

– Ottawa asked citizens to avoid non-essential foreign travel.

– The total cases in the country neared 200, including one death.

Iran to empty city streets; cases reach 11,364

– IRNA reported that Iran’s security forces will empty city streets in the next 24 hours to combat the spread of the coronavirus.

– The country registered 11,364 cases and 514 deaths so far.

Infections in Netherlands rise to 804

– The number of coronavirus infections in the Netherlands increased from 614 a day earlier to 802 today.

– The number of deaths in the county doubled to ten.

Indonesia cases double to 69

– Indonesia confirmed 35 new coronavirus cases, which rise its total to 69. Three of the latest cases had died, said Reuters.

27 cases in Belarus

– Belarus registered six new cases on Friday, increasing the total to 27.

17 new cases in Saudi Arabia; total 62

– Saudi Arabia confirmed 17 new cases, including 11 Egyptians, reported state news agency (SPA). The total cases reached 62.

Thailand issues new coronavirus warning

– Thailand issued a new coronavirus warning to party-going people following a cluster of 13 cases traced to a group of friends who shared cigarettes and drinks.

– The number of cases in the country stand at 75.

Kenya, Kazakhstan, Ethiopia confirm first cases

– Kenya health minister reported the country’s first case in a person who arrived from the US via London.

– Kazakhstan healthcare minister Yelzhan Birtanov confirmed the first cases as nationals who returned separately from Germany on 9 March and 12 March. The ministry will quarantine people on the 9 March flight, while people on the 12 March flight are already under quarantine.

– Ethiopia’s first case is a Japanese national, reported the country’s public health institute.

Google employee in India tests positive

– Google has announced that an employee at its office in Bangalore, Karnataka, India tested positive.

– India reported nearly 80 COVID-19 cases so far, including the Google employee.

South Korea reports more recoveries for first time

– South Korea reported 110 new cases today, representing a decrease from 114 confirmed a day earlier. This takes the total to 7,979.

– 177 patients were released from hospitals today, marking the first time the country had more recoveries than infections since its outbreak.

Ghana, Gabon confirm first cases

– Ghana’s health ministry confirmed its first two cases in people who had recently visited Norway and Turkey.

– Gabon’s first case is a 27-year-old-man who had returned from France on 08 March.

Indonesia to ban face mask exports

– Indonesia is set to temporarily ban face masks export to ensure domestic supply amid the outbreak.

US implements more measures to contain spread

– US states are implementing more measures to contain the spread of coronavirus. Some states, such as Seattle and Ohio, have even closed schools.

– Hospitals across the country are setting up tents to cater to the increasing inflow of patients. In Hawaii, urgent care clinics are offering drive-through testing.

– The number of cases in the country increased to more than 1,300, with 39 deaths.

Death toll reaches 4,700

– Deaths from Covid-19 have crossed 4,700 globally, with a total of more than 128,330 infections and 68,300 recoveries, as of the end of 12 March.

12 Mar:

– US’ Council on Foreign Relations cancelled a conference called ‘Doing Business Under Coronavirus’ in New York amid coronavirus outbreak.

– Bulgaria intends to declare emergency, said Prime Minister Boyko Borissov. The country’s cases increased from seven on Wednesday to 23, with first death reported on Wednesday.

– Chinese medical adviser Zhong Nanshan says coronavirus outbreak could be over by June if countries take firm measures.

– Tecnologico de Monterrey university in Mexico would suspend all academic events and classes from 17 March to control spread.

– Portugal Prime Minister Antonio Costa said on TV that all schools will be closed from Monday to contain the outbreak.

– Belgium’s government also ordered closure of schools, cafes, restaurants and some shops from Friday midnight until 03 April.

– Costa Rica ordered suspension of all university classes and certain schools over coronavirus fears.

– Qatar government also announced a set of regulatory measures to prevent the spread, including closure of theatres, play areas and gyms.

– Turkey’s schools will be closed for one week and universities for three weeks from March 16, while all sports events will take place without spectators until the end of April.

Trinidad & Tobago confirms first case

– Trinidad & Tobago confirmed its first case as a 52-year-old male who arrived from Switzer­land on Mon­day.

Italy deaths cross 1,000

– Deaths from coronavirus in Italy have increased 23% to 1,016. The total number of cases rose 21.7% from 12,462 to 15,113.

– A total of 1,258 patients in the country had fully recovered.

Canadian Prime Minister’s wife tests positive

– Canadian Prime Minister Justin Trudeau’s wife tested positive for coronavirus after returning from London.

– Trudeau has no symptoms but will be in isolation for two weeks as a precaution. The number of cases in Canada reached 142, including one death.

UK cases at 590; peak 10 to 14 weeks away

– The cases in the UK grew 29% to 590 in the last 24 hours, with a total of ten deaths.

– The government’s chief scientific adviser Patrick Vallance said that coronavirus peak in the country may be 10 to 14 weeks away.

Spain’s King Felipe and Queen Letizia tested

– King Felipe VI, Queen Letizia and the entire cabinet were tested after the  equalities minister Irene Montero tested positive.

– Only one cabinet minister – Carolina Darias – tested positive so far.

– A total of 3,146 cases have been reported in Spain, including 86 deaths.

First death in India

– India reported its first death in a 76-year-old man from Karnataka. Authorities ordered schools, theatres and cinemas closed in New Delhi, as total cases reached 79.

Azerbaijan confirms first death; Hong Kong sees fourth casualty

– Azerbaijan confirmed its first death in a woman who was quarantined after returning from Iran. The number of cases in the country stand at 15.

– Hong Kong reported its fourth death in a 80-year old man, reported Reuters. The country’s has nearly 130 cases.

Cases in Ireland increase to 70

– Ireland Department of Health reported that the number of cases in the country increased to 70 from 43 a day earlier.

Egypt reports 13 new cases; total 80

– Egypt confirmed 13 new coronavirus cases, which rise the total to 80. The new cases also included one death.

Germany cases increase to 2,369

– Robert Koch Institute said that the number of cases in Germany increased to 2,369 from 1,567 the previous day.

– The country saw five deaths so far.

Morocco suspends travel to Spain and Algeria

– Morocco suspended all flights and passenger ships to and from Spain, reported Morocco’s state news agency.

– Algerian presidency statement said that all flights between Algeria and Morocco have been suspended.

Infections in Netherlands jump to 614

– The number of new cases in the Netherlands grew 22% to 614 on Thursday, according to health officials.

– The Dutch National Institute for Public Health (RIVM) noted that 273 of the infections are in the southern province of Noord-Brabant.

Deaths in Spain rise to 84 ; Iran’s reach 429

– The number of coronavirus deaths in Spain increased to 84 from 47 on Wednesday. A total of 2,968 cases have been reported so far.

– The Covid-19 death toll in Iran reached 429. Health Ministry spokesman Kianush Jahanpur reported a total of 10,075 infections.

– Iran asked the International Monetary Fund (IMF) for $5bn emergency funding to control the coronavirus outbreak.

Armenia to replace used banknotes

– The Armenian central bank announced plans to replace used banknotes in an effort to control the coronavirus spread.

– The bank asked people to prefer online payments instead cash.

Thailand reports 11 new cases; nine in Malaysia

– Thailand health officials confirmed 11 new cases, taking the total to 70.

– Malaysia reported nine new cases today to total 158.

First local transmission in South Africa

– South Africa’s first case of local transmission is a 32-year-old man who came into contact with a Chinese businessman, said health ministry.

– The number of confirmed cases in the country reached 17.

Spanish minister tests positive

– Spain’s Equality Minister Irene Montero tested positive for the new coronavirus, while the Deputy Prime Minister Pablo Iglesias was quarantined.

– The country’s prime minister will hold further meetings via video conference.

Singapore to close mosques

– Singapore will close all mosques for a minimum of five days for deep cleaning. The closures would take effect on Friday, said the Islamic Religious Council of Singapore.

– The country reported a total of 178 cases.

First death in Austria, Poland, Algeria, Norway

– Austria reported its first Covid-19 fatality as a 69-year-old man in Vienna. The country has 302 cases to date.

– Poland’s first coronavirus death occurred in Poznan, reported broadcaster TVN24. The country confirmed 47 cases to date.

– First death from Covid-19 in Algeria has occurred today. The number of cases in the country stand at 24.

– Norway reported its first death in an elderly patient. The total number of infections in the country passed 620. Restaurants, cafés, bars, schools, day care centres and companies have been closed to control the spread.

114 new cases in South Korea

– South Korea confirmed 114 new cases, which take the total to 7,869, including 66 deaths.

– Health authorities are working to trace and control multiple new clusters, including in capital Seoul.

Cases in India reach 73

– The Ministry of Health and Family Welfare said that the total number of cases in India reached 73.

– Of the total patients, 17 are foreign nationals.

New cases in Saudi Arabia; suspends travel

– The number of cases in Saudi Arabia increased to 45, with 24 new infections reported early today, said the state news agency.

– Of the 24 new cases, two people returned from Iraq, one had contact with infected person from Iran, and 21 had contact with an Egyptian visitor who previously tested positive.

– The country suspended travel and flights to several countries, including the European Union, India and the Philippines.

Guyana, French Polynesia, St Vincent confirm first case

– Guyana reported its first Covid-19 case in a 52-year-old woman who died after returning from the US last week. The patient had underlying illnesses and tested positive for coronavirus after death.

– French Polynesia’s first case is politician Maina Sage who returned from Paris on 7 March.

– St Vin­cent and the Grenadines confirmed its first case in a fe­male who had trav­elled to the UK.

Sweden, Greece announce first death

– Sweden reported its first death in an elderly patient with an underlying sickness. The government banned public gatherings of more than 500 people.

– Greece’s first fatality is said to be a 67-year-old man who had recently returned from Israel and Egypt.

Actor Tom Hanks and wife test positive

– Oscar-winning actor Tom Hanks and his wife Rita Wilson have tested positive in Australia.

– In a tweet, the actor said that he is working on a film in Australia and was tested along with his wife after experiencing slight fevers.

Asian Development Bank, Philippine Senate closed

– The Philippines Senate and the Manila headquarters of the Asian Development Bank have been closed after visitors to both buildings tested positive.

Death toll increases to 4,600

– Deaths from Covid-19 have reached to more than 4,600, including 3,169 in mainland China, as of the end of 11 March.

Global infections have increased to nearly 126,140, with a total of approximately 68,200 recoveries.

11 Mar:

WHO declares the outbreak to be a pandemic

– In response to the escalating Covid-19 outbreak, the WHO has declared the situation to be a pandemic. WHO director-general Dr Tedros Adhanom Ghebreyesus said in a statement: “We have never before seen a pandemic sparked by a #coronavirus. And we have never before seen a pandemic that can be controlled at the same time.”

Ireland confirms first death

– Ireland health ministry reported the country’s first coronavirus death. The number of cases in the country reached 43.

Cuba, Ivory Coast report first cases

– Cuba confirmed its first three cases in tourists who tested positive today.  The government asked citizens to make their own masks, in addition to its textile industry, amid declining supplies globally.

– Ivory Coast reported its first case in a 45-year-old national who recently travelled to Italy.

US restricts travel from Europe

– The US has restricted travel from Europe for 30 days in an effort to control the rapid spread of coronavirus.

– President Donald Trump said that the restriction, which will come into effect on midnight Friday, does not apply to Britain.

– The country has 1,322 confirmed cases and 38 deaths so far.

Qatar reports 238 new cases

– Qatar confirmed 238 new cases among people under quarantine in one residential compound. This increase the total cases to 262.

– These new patients reside in the same compound as three people who were diagnosed on Sunday.

New cases in Spain, Egypt and Costa Rica

– The number of cases in Spain increased to 2,277, including 55 deaths. In capital Madrid, the number of cases had risen to 1,024 from 782 on Tuesday, reported health authorities. State-run museums in Madrid will be closed to contain the spread.

– Egypt reported seven new cases taking the total to 67.

– The total cases in Costa Rica increased to 22 from previously confirmed 13.

Italy tightens lockdown

– Italy has tightened its nationwide lockdown to include shutting of bars, hairdressers and restaurants.

– The number of cases on the country have raised to 12,462 and death toll  increased to 827.

UK cases rise to 456

– With 74 new cases, the total number of infections in the UK reached 456, including six deaths.

– Prime Minister Boris Johnson will chair an emergency committee on 12 March. The meeting is to discuss moving to the ‘delay phase’ from ‘contain’.

Honduras reports first case

– Honduras confirms first two cases of Covid-19, two women with travel history to Spain and Switzerland.

New cases reported in Maldives, Pakistan, Denmark and Philippines

– Total cases in Maldives has increased to eight, including two newly reported cases.

– One more case has been detected in Gilgit Baltistan, taking Pakistan’s total to 20.

– Denmark has reported 78 additional cases, bringing the country’s total to 340.

– Philippines has confirmed 16 new cases of Covid-19 in the country. The total confirmed cases in the country stand at 49.

Cases rise in Malaysia, South Africa and Israel

– Malaysia has reported additional 20 cases of Covid-19, taking the total to 149.

– South Africa’s Minister of Health has announced six new cases, bringing the total to 13.

– Health Ministry of Israel has announced eight additional coronavirus cases. The country’s total stands at 76.

Bahrain records 77 new cases

– Bahrain registered 77 new cases among evacuees from Iran, taking the total to 189.

First death reported in Indonesia and Belgium

– Indonesia’s Health Ministry has announced the death of a 53-year-old foriegn woman due to Covid-19. She is reported to have been in serious condition when she was admitted.

– Belga news agency stated that the Belgium’s health ministry reported the first death in the country. The patient is reported to be 90-years-old.

Vietnam cases jump to 35

– The country reported nearly 20 new cases to total 35. 13 of the new patients were on a Vietnam Airlines flight from London to Hanoi on 2 March.

Australia cases rise to 122; announces $1.6bn health package

– The number of cases in Australia has increased to 122, including three new cases of women who visited Europe.

– The country announced a A$2.4bn ($1.56bn) health package to help fight the coronavirus outbreak.

Cases in India reach 62

– With new cases reported in the late night of 10 March from Kerala, Karnataka, Jammu & Kashmir, the total in India increased to 62.

– Of the 18 new cases reported on 10 March, eight are from Kerala, five from Maharashtra, four in Karnataka and one in Jammu & Kashmir.

– The country cancelled visas granted to Germany, France and Spain nationals on and before Thursday. Indian citizens have been asked to avoid travelling to these countries.

UK Health Minister tests positive;  sixth death reported

– UK Health Minister Nadine Dorries has tested positive for Covid-19 and is currently undergoing self isolation at home.

– The country has also reported its sixth death – a man in his 80s with other health issues. The total confirmed cases in the UK stand at 373.

KCDC reports 242 new cases

– The KCDC has stated that 242 additional cases were detected in the country, taking the count to 7,755.

– The total number of deaths has also increased to 60, with six new deaths reported today morning.

361 Taiwan evacuees return from Wuhan

– Two flights with a total of 361 Taiwanese have returned from Wuhan.

– One plane flew citizens back to the island in early February and disputes delayed the others.

Death toll rises to more than 4,200

– The Covid-19 death toll has risen to more than 4,200, with around 3,100 cases in Mainland China, as of the end of 11 March.

– The total confirmed cases has increased to more than 119,000 in 114 countries while recoveries has increased to around 65,000.

10 Mar:

Bolivia, Turkey, Jamaica report first cases

– Bolivia Health Minister Anibal Cruz confirmed the country’s first two Covid-19 cases.

Turkey reported its first case as a male citizen who returned from Europe.

– Jamaica’s first case is a female with a travel history to the UK.

Death toll in Italy increases by 36%

– The death toll in Italy has increased to 631, a jump in 168 cases which marks a 36% increase, according to Civil Protection Agency.

– The total number of confirmed cases increased from 9,172 to 10,149.

Democratic Republic of Congo confirms first case

– Democratic Republic of Congo reported its first positive case of coronavirus in a person who returned from France.

Panama confirms first death

– Panama reported the first Covid-19 death and confirmed seven new cases, only a day after the country reported its first case.

Couple on Grand Princess sues cruise line

– A couple from Florida, US quarantined on the Grand Princess filed a lawsuit against the company Princess Cruises.

– The lawsuit stated ‘lackadaisical approach to the safety of the plaintiffs, its passengers and crew about the Grand Princess, plaintiffs are at actual risk of immediate physical injury’.

Spain ramps up measures to prevent spread

– Spain has closed schools in some parts of the country and stopped all flights arriving from Italy to ‘avoid Italian scenario’.

– The total cases in Spain stand at 1,695 with 35 deaths so far.

Spanish lawmaker tests positive

– A Spanish lawmaker from the Vox political party has tested positive for Covid-19. Along with 51 of his other party lawmakers, he will work from home.

Japan declares $4bn package for Covid-19

– Japan has annoucned a $4bn package to support small and mid-sized firms affected by Covid-19. This is the second set of relief measures announced by the government.

– The country reported 59 new cases on 10 March, taking the total to 1,278 cases, including 696 from Diamond Princess and 14 evacuees from China.

– This increase on 10 March is said to be the biggest single-day rise since the start of the outbreak.

India evacuates citizens from Iran

– A transport aircraft belonging to the Indian Air Force has evacuated 58 Indian citizens from Iran.

UAE reports 15 additional cases

– The UAE has announced 15 additional cases in the country, taking the total to 74. The total recoveries stand at 12.

Italian couple in India given anti-HIV drugs for treatment

– An Italian couple that tested positive for Covid-19 in India has been given a combination of two drugs that are generally used to control HIV. This marks the first instance of using anti-HIV drugs against Covid-19 in India.

Philippines reports increase in cases

– The Department of Health in the country has announced 11 additional cases, bringing the total in Philippines to 35.

President Xi Jinping visits Wuhan

– Chinese President Xi Jinping has visited Wuhan for the first time, to meet health professionals who helped in treating the coronavirus.

– Hubei Province has planned to adopt a health code to permit people to return to work.

Cases rise in India

– The total cases in India has increased to more than 50, with new cases reported in Kerala and Karnataka.

– Kerala reported six new cases, taking the state wide cases to 15. Kerala Chief Minister has announced a total shutdown of the state.

– Karnakata has reprorted three more cases in the state. Karnataka now has four cases.

Death toll increases to 4,000

– The death toll increases to more than 4,000, with around 3,100 cases in Mainland China, as of end of 10 March.

– The total confirmed cases has increased to more than 113,000 around the world while recoveries has increased to around 59,000.

9 Mar:

First death reported in Canada

– British Columbia in Canada has reported its first death, a man in his 80s who is reported to have other health issues.

– Five more cases were also reported in British Columbia, taking the province’s cases to 32. Total cases in Canada stand at 77.

Italian PM imposes country wide lockdown

– In a press conference, Prime Minister Giuseppe Conte announced that the travel restrictions applicable to the north of Italy would extend to the entire country.

New cases reported in Cyprus, Brunei, Burkina Faso, Mongolia and Panama

– Cyprus has announced the first two cases in the country, a man with travel history to northern Italy and one to the UK.

– A man tested positive for coronavirus in Brunei, the first case in the country. The man returned from Malaysia on 3 March.

– Burkina Faso reported its first two cases of Covid-19, according to local media. The infected are a couple with a travel history to France.

– Mongolia has announced its first coronavirus case, a French national who arrived from Moscow. The country has barred travel from and to the cities for six days.

– A woman who arrived in Panama from Spain has tested positive for Covid-19, the first case in the country.

Italy Covid-19 death toll and cases rise

– Italian authorities announced that cases in Italy have increased to 9,172 with 463 deaths in the country. Recoveries have increased to 724.

US death toll increases to 26

– The total number of deaths in the US has increased to 26 with new deaths reported. The confirmed cases stand at more than 700.

Six die in Italy prison riot

– Six inmates had been killed in a prison riot in Italy, while guards were taken hostage at another jail, indicating the rising unrest in the country’s prisons over coronavirus.

Iran death toll jumps to 237; releases prisoners

– Coronavirus has claimed 237 lives and infected total 7,161 people in Iran, with 595 new infections and 43 deaths in the last 24 hours.

– The country has temporarily released nearly 70,000 prisoners due to the outbreak, said judiciary chief Ebrahim Raisi.

Indonesia confirms 13 new cases to total 19

– Indonesia confirmed 13 new cases – 11 nationals and two foreigners, which the country’s total to 19.

UAE cases stand at 59

– With 14 new cases, the UAE confirmed a total of 59 cases, according to state news agency WAM.

Vietnam to temporarily suspend visa-free travel to eight European countries

– Vietnam announced plans to temporarily suspend visa-free travel for citizens from Denmark, Norway, Finland, Sweden, the UK, Germany, France and Spain.

– The move comes after 11 of the country’s 14 new cases had a travel history to Europe. A total of 30 cases have been confirmed in the nation.

Costa Rica cases reach nine

– The total number of Covid-19 cases in Costa Rica increased to nine.

Canada to repatriate citizens onboard Grand Princess

– Canada has arranged a flight to repatriate its citizens onboard the Grand Princess cruise ship.

– The passengers will be taken from San Francisco to the Canadian forces Base Trenton in Ontario and put under quarantine.

Qatar imposes travel ban on 14 countries

– Qatar has temporarily suspended entry of travellers from 14 countries, after the number of cases in the nation increased to 15.

– The ban applies to India, Bangladesh, China, Egypt, Iran, Iraq, Lebanon, Nepal, Pakistan, the Philippines, South Korea, Sri Lanka, Syria and Thailand.

– The country previously suspended flights to and from Italy.

– Today, the country also announced plans to suspend schools and universities from 10 March.

Philippines declares health emergency

– The Philippines declared a health emergency over fears of community transmission.

– A total of ten cases have been confirmed in the country, including one death.

Cases in India rise to 43

– With new cases reported in Kerala, Jammu & Kashmir, Delhi and Uttar Pradesh, the number of cases in the country increased to 43.

Albania confirms first cases

– Albania confirmed its first Covid-19 cases in a father and son who had recently travelled to Italy.

South Korea reports 69 new cases

– South Korea reported 69 new cases to total 7,382 on Monday. The death toll in the country is 51.

– The rate of rise in new infections is said to have dropped to its lowest in ten days on Sunday.

Death toll jumps to 3,800

– The death toll due to Covid-19 rises to 3,800 including around 3,100 in Mainland China, as of end of 8 March.

– The total number of cases in the world has increased to more than 110,000 in 108 countries around the world. The recoveries currently stand at 61,000.

Wuhan closes 11 makeshift hospitals

– Wuhan has closed 11 of 14 makeshift hospitals as the number of new infections decline, reported state broadcaster CCTV.

UK reports 273 cases and three deaths

– The UK Department of Health and Social Care reported 64 new cases, which represent a 30% rise to total 273.

– Also, the country saw its third Covid-19-related death in a 60-year-old man who had ‘underlying health conditions’.

First death in Egypt

– Egypt Health Ministry confirmed the first fatality in the country as a 60-year-old German tourist who died on Sunday.

– The nation’s total number of cases stands at 55.

Saudi Arabia imposes lockdown, restricts travel

– Saudi Arabia, which confirmed a total of 15 cases, imposed a temporary lockdown on its Qatif province, where most of its cases were reported.

– The country also suspended schools and universities, and suspended travel with nine countries, including the UAE, Bahrain, Kuwait and Egypt.

8 Mar:

Costa Fortuna ship heads to Singapore

– Cruise ship Costa Fortuna is said to be heading to Singapore after it was denied entry at ports in Malaysia and Thailand over coronavirus fears.

US cases near 550; Grand Princess quarantine

– The number of cases in the US have neared 550, including 22 deaths.

– According to health officials, Grand Princess cruise will be allowed to dock at a terminal near Oakland, where passengers will disembark. The passengers will be sent for quarantine elsewhere in California.

– US Army restricted travel to and from Italy and South Korea.

New deaths in Netherlands, Switzerland

– Health officials reported two additional deaths in the Netherlands, bringing the total fatalities to three. The total number of cases in the country  increased to 265.

– A patient at Liestal in Switzerland had died, taking the total to two. The number of cases stand at 281.

Bulgaria, Moldova report first cases

– Bulgaria confirmed its first four cases – two men from Pleven and two women from Gabrovo tested positive.

– Moldovan health ministry reported the nation’s first case in a 48-year-old woman who returned from Italy.

Ten die in China quarantine hotel collapse

– A total of ten people have died and 23 remain trapped at the hotel collapse site in the Chinese city of Quanzhou.

South Korea cases rise to 7,134

– KCDC has reported 367 new cases, taking the total to 7,134. It also reported six new deaths taking the death toll to 50 in the country.

Deaths in Italy rise to 366

– The total number of deaths in Italy have increased to 366 while the total cases in the country stand at 7,375.

Bangladesh reports first case

– India’s neighbouring country Bangladesh has reported its first coronavirus cases on Sunday.

– Director of the Institute of Epidemiology, Disease Control, and Research Meerjady Sabrina Flora confirmed three new cases of coronavirus infection in the country, of which two are men and one is woman.

– Two of the three affected people had travel history from Italy and the third person is related to one of them.

Iran marks highest single-day toll with 49 new cases

Iran reported its highest single-day toll on Sunday with 49 new coronavirus deaths, taking the death toll to 194.

Cases in India rise to 39

– Five additional people in Kerala, India have tested positive, increasing the total to 39. All the five cases are from Pathnamthitta district.

– Three of the new patients had returned from Italy on 29 February, while two others are their relatives.

First death in Argentina

– Argentina reported its first death of a Covid-19 patient, marking the first fatality in Latin America.

21 new cases in Greece; total 66

– Greece registered 21 new coronavirus cases in one day, bringing its total to 66.

– Majority of these cases were part of a travelling group that had gone on a pilgrimage to Israel and Egypt

Third death in Australia

– Australia health authorities confirmed the third death in the country as a man in his 80s at a hospital in Sydney.

– The total number of cases in the nation reached 74.

Four people die in China hotel collapse

– Four people have died in the hotel collapse in the Chinese city of Quanzhou, reported local media.

– In addition, four have severe injuries and one is in critical condition.

Death toll nears 3,600

– Deaths from Covid-19 have neared 3,600, including 3,097 in mainland China, as of the end of 07 March.

– The number of global infections has increased to more than 106,150, with nearly 59,930 recoveries.

– On March 7, mainland China saw 44 new cases and 27 deaths.

Italy to lockdown northern parts

– Italy will put a virtual lockdown on its northern regions, including the capital Milan, Lombardy and 11 provinces in four other regions.

– The lockdown applies to nearly 16 million people. It involves shutting down of all museums, gyms, cultural centres, ski resorts and swimming pools in the target regions.

– The number of cases and deaths on the country stand at 5,883 and 233, respectively.

Bahrain calls for self-quarantine

– In a tweet, Bahrain asked people who traveled to Lebanon, Egypt, Italy or South Korea to self-quarantine for two weeks.

7 Mar:

Iran death toll jumps to 145

– Iran confirmed 21 additional deaths, bringing the total to 145. A health ministry official noted that the number of infections had risen to 5,823.

Cases in UK jump to 206

– With additional cases reported, the total in the UK reached 209. So far, two people have died in the country.

Germany cases reach 684

– The number of coronavirus cases in Germany stand at 684. This represents about ten times increase compared to previous week, when total 66 cases were reported on 29 February.

Quarantine hotel in China collapses

– Nearly 70 people were said to be trapped in the collapsed hotel used for quarantine of coronavirus patients in the city of Quanzhou.

– 42 individuals had been retrieved from the site of the collapse, while around 38 people remain trapped.

US deaths reach 19

– Two additional patients in Washington state have died, taking the total to 19.

– The number of cases in New York increased by 13 to 89. The state declared emergency.

Maldives, Paraguay, Malta report first cases

– The Maldives has confirmed its first two cases, who are believed to have been infected after coming in contact with an Italian tourist. The tourist had tested positive after returning to Italy.

– Two island resorts in the Maldives have been locked down to prevent coronavirus spread.

– Paraguay confirmed its first case in a tweet, which did not disclose any further details.

– Malta’s first case is a 12-year-old Italian girl who returned from Trentino via Rome.

India reports three new cases; total jumps to 34

– India reported three new covid-19 cases on Saturday (two from Ladakh and one from Tamil Nadu), taking the total confirmed cases in the country to 34.

– Ladakh cases had travel history from Iran, while Tamil Nadu patient had travel history from Oman.

– Union Health Ministry special secretary for health Sanjeeva Kumar said that all the three patients are in stable condition and are undergoing treatment in isolation.

Kuwait suspends flights; Saudi limits land crossings

– Kuwait civil aviation directorate said in a tweet that the country suspended  flights to and from Egypt, Lebanon, Syria, Bangladesh, Philippines, India and Sri Lanka for seven days.

– Saudi Arabia limited land crossings with the UAE, Kuwait and Bahrain to commercial trucks in an effort to contain the virus. Flights from the three countries are temporarily limited to three airports.

South Korea cases reach 6,767

– South Korea reported 174 new cases, taking the national total to 6,767. The number of deaths stand at 44.

Doctor in Australia tests positive

– Australian health authorities closed a clinic after a doctor who recently returned from the US tested positive.

– Health officials are contacting approximately 70 patients of the doctor and will also contact passengers who were on his flight.

– The total number of cases in Australia has neared 70.

Death toll crosses 3,450

– Deaths from Covid-19 have crossed 3,450, including 3,070 in mainland China, as of the end of 06 March.

– The number of global infections has increased to more than 101,731, with nearly 57,390 recoveries.

UK confirms second death

– England’s chief medical officer Chris Whitty confirmed the second death in the country at Milton Keynes University Hospital.

6 Mar:

– Vietnam reported its 17th case, which is said to be the first in three weeks.

– The UAE identified 15 new cases to total 45, said the health ministry.

– Iraq recorded eight new cases, which take the total to 46, and total three deaths. The country added France and Spain to its entry ban list.

– With two new cases, Indonesia’s total increased to four.

Colombia, Costa Rice, Peru, Togo report first case

– Colombia reported its first case in a 19-year-old female who had visited Italy.

– The first case in Costa Rica is a 49-year-old woman from the US.

– Peru President Martin Vizcarra confirmed the country’s first case in a 25-year-old man who had travelled to Europe.

– Togo’s first case is a 42-year-old woman with a recent travel history to France.

US cases surge to 329

– The US recorded a sharp rise of nearly 100 cases in 24 hours to total 329. Coronavirus-related deaths in the country stand at 17.

Italy deaths jump to 197

– Italy recorded an increase in the number of deaths to 197. The total cases in the country reached 4,636.

21 people on Grand Princess ship test positive

– 21 people aboard Grand Princess ship, which was denied entry at San Francisco Bay, have tested positive.

– Out of 46 people, 19 crew members and two passengers were found to have contracted the virus.

– The ship will be taken to a non-commercial port and all passengers will be tested.

– Cases in Belgium more than doubled to 109, said health ministry. Majority of the new patients had travelled to Italy.

– Romania confirmed its seventh case in a 16-year old girl in Timisoara.

– Estonia reported eight new cases to total ten. The country’s Health Board examined samples of 183 passengers on a flight from Bergamo, Italy to Riga and ten tested positive.

– Iran health ministry confirmed 1,234 new cases and 17 deaths from a day earlier to total 4,747 infections and 124 casualties.

– Egypt reported 12 new cases on a Nile cruise ship. The country previously confirmed three cases.

– Malaysia health ministry reported 28 new cases today, taking the total to 83.

Netherlands registers first death

– The Netherlands registered its first coronavirus fatality in a 86-year-old man at the Ikazia Hospital in Rotterdam.

– The source of infection of the man is said to be unclear.

First case in Slovakia

– Slovakia reported the first case in a 52-year-old man. The patient did not travel abroad but his son, who had no symptoms, visited Venice, Italy.

Vatican, Cameroon, Serbia confirm first cases

-Vatican City has confirmed its first Covid-19 case, said spokesman Matteo Bruni. Outpatient services in Vatican clinics had been suspended for sanitisation, while emergency services will continue.

– Cameroon has reported the country’s first case as a 58-year-old French national who arrived in February.

– Meanwhile, Serbia registered its first positive coronavirus case in a 43-year-old man who traveled to Budapest, Ungheria.

Germany reports 134 new cases; total 534

– Robert Koch Institute in Germany reported 134 new cases, which take the total to 534.

Cases in India reach 31

– Confirmed cases in India increased to 31, with a Delhi man who recently travelled to Thailand and Malaysia, testing positive.

Bhutan confirms first case

Bhutan, which shares border with India, confirmed its first case in a visiting American. The country has admitted eight Indian tourists with symptoms in a local hospital.

Hungary cases rise to three; Philippines has five

– Hungary confirmed a total of three cases. The latest is a Hungarian man who had returned from Milan, Italy. The first two cases were Iranian students.

– With two new cases, the number of cases in the Philippines increased to five.

Ireland reports seven new cases to total 13

– Seven new cases of coronavirus have been reported in Ireland, a surge from six the previous day. The total number of cases in the country stands at 13.

– Four of the new cases are males who returned from Italy, two are women who are believed to have had close contact with an infected person and one man is said to be a case of community transmission.

Infected man attended rock concert in NZ

– A man in New Zealand confirmed to have Covid-19 was revealed today to have attended the Tool concert at Spark Arena in Auckland on 28 February.

– According to health ministry, the man was in the general admission standing area in the front left-hand quadrant. The ministry is asking people who were in the same area to be aware of symptoms.

– The man has been isolated at home since 04 March.

First school closed in Australia after student tests positive

– Australia closed its first school – Epping Boys High School –  in Sydney after a 16-year-old student tested positive.

– The pupil is believed to be a case of local transmission.

– The total number of confirmed cases in the country stands at 60, including deaths of two elderly people.

Cases in South Korea reach 6,593

– The number of Covid-19 infections in South Korea have reached 6,593. The country reported 43 deaths so far.

Death toll rises to 3,380

– Covid-19 death toll has increased to around 3,383 worldwide, with more than 98,380 infection cases and 55,420 recoveries, as of the end of 05 March.

– China reported 143 new cases and 30 deaths to total 80,552 infections and 3,042 fatalities.

UK, Switzerland report first death

– England’s chief medical officer Chris Whitty confirmed the nation’s first coronavirus-related death in an elderly man with underlying health conditions.

– The total number of cases in the UK reached 116.

– Switzerland reported its first death in a 74-year-old woman from Vaud.

Bosnia confirms first cases

– Bosnia has confirmed its first two cases in a man who returned from Italy and his child.

Dominican Republic reports second case

– Dominican Republic reported its second case as a 70-year-old Canadian tourist who arrived on 25 February.

Province in China reports 11 new cases from Iran

– The Gansu province in China reported 11 new coronavirus cases in people who arrived on commercial flights from Iran, said state media.

– 311 passengers from Iran have been quarantined at the provincial capital of Lanzhou, reported state broadcaster CCTV.

Two-week quarantine for South Korea visitors in Japan

– Japanese Prime Minister Shinzo Abe imposed a two-week quarantine for people coming from South Korea and banned visitors from highly affected areas.

– South Korea protested Japan’s decision, calling it unreasonable and excessive. Seoul’s foreign ministry plans to meet the Japanese ambassador to discuss the concerns.

5 Mar:

– Luxembourg health ministry confirmed the second Covid-19 case.

– With three new cases, the total number of infection in Ecuador increased to 13.

– Eight additional positive cases in Iceland bring the country’s total to 34.

– Czech Republic health ministry confirmed 12 cases so far.

– Saudi Arabia reported three new cases to total five.

– Singapore minister Lawrence Wong said that the outbreak is “starting to look like a global pandemic”.

Spain records third death

– Spain recorded its third death in a 99-year old woman who lived at a nursing home in Madrid.

– At least nine other people at the nursing home have tested positive, according to Madrid’s health authority. Other residents will also be tested.

Japan says Diamond Princess cases 696

– The Ministry of Health, Labor and Welfare in Japan has corrected the number of Diamond Princess cases to total 696 , saying that some people were counted twice.

Estonia confirms third case; Pakistan six

– Estonia health authorities reported the country’s thrid Covid-19 case in person who was on the same flight from Italy as the second case.

– Pakistan has confirmed a total of six cases so far.

New cases in Austria, Switzerland , Norway and Netherlands

– With additional infections confirmed, the number of cases in Austria has reached 42.

– Switzerland also reported new confirmed coronavirus cases to total 119, while infections in Norway increased to 91.

– The number of cases in the Netherland grew to 82, with 44 new cases reported on 05 March.

Palestine confirms seven cases

– Palestine confirmed seven coronavirus cases in Bethlehem in the occupied West Bank. President Mahmoud Abbas declared a 30-day state of emergency.

– The government imposed a two-week ban on visitors to cities and sites, including Bethlehem’s Church of the Nativity.

Cases in Slovenia rise to six

– A total of six cases have been confirmed in Slovenia. The first case in the country was reported on 04 March.

Death toll in Italy surges to 148

– Italy confirmed 41 new coronavirus-related deaths, taking the total to 148. The number of infections in the country increased to 3,858.

Brazil cases increase to eight

– A total of eight cases have been reported in Brazil, including the first cases of local transmission from a Sao Paulo man.

Legislator in France hospitalised

– One of France’s National Assembly member has been hospitalised after being infected with coronavirus, reported Reuters.

– France had confirmed 423 Covid-19 cases, with a total of seven deaths, as of late 05 March.

Cases and deaths rise in US; Congress allots $8.3bn

– The number of cases in the US increased to total 233, including 12 deaths.

– The Congress passed an $8.3bn emergency spending bill to fight the outbreak, which has now spread to at least 14 states. President Trump is yet to sign the bill.

Poland, Gibraltar, Hungary report first cases

– Poland announces its first case of coronavirus. Almost 70 people were tested for the Covid-19.

– Gibraltar confirms its first case of coronavirus.

– Hungary confirmed its first two cases, both Iranian students.

– Three new deaths have been reported in South Korea, bringing the country’s death toll to 35. The number of infections also increased to 5,766.

– Iraq reports third death, of a 65-year-old individual living in Baghdad.

– Spain reports third death, of a 99-year-old woman.

– Leading scientist Professor Neil Ferguson, of Imperial College London told BBC Programme Today that the world tried hard to halt the virus but has failed and over 80 nations have confirmed cases.

– An expert with China’s top panel said that Wuhan is likely to see new infections drop to zero by the end of March.

– China gives approval to use Roche’s anti-inflammation drug Acetemra to fight against Covid-19.

– Princess Cruises’ Grand Princess is being held off the California coast due to fears that passengers and crew members developed coronavirus (Covid-19).

– India reports new case, taking its confirmed cases to 30.

– India to set up a lab in Tehran, the capital of Iran, for mandatory testing of passengers before board a plane to the country.

-The pet dog of a coronavirus-infected patient in Hong Kong was confirmed to be infected with Covid-19, making it a possible case of human-to-animal transmission.

– Tunisia, which confirmed its first case of Covid-19 on 2 March, has announced plans to suspend passenger ferry services to northern Italy.

-Portugal reports its sixth case, and the first of a woman. The patient was in Italy and is now hospitalised in Lisbon.

– Senegal confirms third and fourth case.

-Saudi Arabia confirms its second case. The patients has come from Iran through Bahrain. Saudi reported its first case on 2 March.

-Three more people test positive in Czech Republic, taking its total to eight.

-Iceland confirms ten more cases, taking its total to 26.

-Ecuador reports ten cases until 4 March, while Republic of San Marino reports 15 cases.

– Republic of Ireland reports four more cases, taking its total to six.

– Indian student in Dubai tests positive.

– Romania reports sixth confirmed case.

-Algeria reports nine new cases taking its total to 17.

– Greece’s total cases touch nine, while in Croatia, tenth case has been confirmed.

– Switzerland, which is one of the ten countries mostly affected by coronavirus Covid-19, has more than 100 positive cases.

-Bahrain confirms three new cases, while Lebanon confirms two new cases.

-16 new cases reported in Stockholm takes Sweden’s total to 57.

– Thailand reports four new cases, taking its total to 47, while Malaysia’s figures touch 55.

– France now reports 285 confirmed cases.

– Coronavirus could cost airline industry $113bn in lost revenue, says airline industry body IATA.

– Belgium reaches 50 confirmed cases, with the addition of 27 new cases.

Death toll increases to more than 3,200

– The death toll due to Covid-19 has increased to more than 3,200, as of the end of 4 March.

– The confirmed cases has increased to 95,000 with 80,000 cases in Mainland China, while the number of recoveries stands at more than 53,000.

4 Mar:

South Korea reports additional cases and deaths

– KCDC has announced additional 516 cases, taking the total to 5,328. The death toll in the country has also inceased to 32, with four new deaths reported.

Death toll in Iran increases to 92

– The Health Ministry of Iran has confirmed additional new deaths, which takes the total deaths to 92. The confirmed cases in the country stands at 2,922.

Abu Dhabi stops International Patient Care

– Abu Dhabi Department of Health (DoH) has announced that it has suspended the international patient care services temporarily due to the Covid-19 epidemic.

– Under IPC, UAE citizens are sent abroad for treatment if the necessary procedures are not available in the Emirates.

Additional cases confirmed in Malaysia, UK, Germany

– Malaysia has confirmed additional 14 cases, taking the total to 50. The recovered cases stand at 22.

– Cases in UK have increased to 85, with 34 new cases reported. Of the 34, 29 patients have a history of travelling abroad while it is not known where the other three got infected.

– Cases in Germany have also increased to 240, announced Robert Koch Institute.

India confirms new Covid-19 cases; total 28

– India has confirmed additional Covid-19 cases in two other states, taking to total to 28 in the country.

– Of the new cases, 16 are Italian nationals while one is Indian driver who tested positive in Jaipur, Rajasthan.

– Another six cases were confirmed in Agra, family members of the man who tested positive in Delhi.

– Previously, three cases were confirmed in Kerala, one in Hyderabad, one in Delhi. The patients from Kerala have recovered.

Death toll increases to 3,198; confirmed cases more than 93,000

– The Covid-19 death toll has increased to more than 3,198 as of end of 3 March.

– The number of confirmed cases have crossed 93,000 while recoveries stand at more than 50,000.

3 Mar:

Portugal, Canada and Qatar report rise in cases

– Two more people have tested positive for Covid-19, taking the total to four.

– Canada has confirmed three more cases in British Columbia, bringing the country’s total tally to 33.

– Qatar has announced that the total cases has increased to eight, including the one new case confirmed.

Spain confirms first death

– Spain has announced the first death in the country, a man who died on 13 February.

– In a press conference, regional health chief Ana Barcelo stated that the post-mortem tests showed that coronavirus was the cause of death.

Iran temporarily releases 54,000 prisoners

– Iran has temporarily released over 54,000 prisoners from its crowded jails to stop the spread of coronavirus.

– However, prisoners who have been sentenced for more than five years have not been released.

UAE reports six new cases

– The UAE has reported six new Covid-19 cases, two Italians, two Russians, one Colombian and one German. The total cases in the country stand at 27.

– The confirmed cases are a part of the cancelled UAE cycling tour, from which two other cases were confirmed.

US deaths increase to nine

– The death toll in the US has increased to nine, with additional deaths reported in the state of Washington.

– All the deaths so far have been reported from Washington; eight from King County and one in Snohomish County. The total cases in Washington stand at 27.

– Total cases in the US stand at 124.

Death toll in Italy rises to 79

– Death toll in Italy has increased to 79 from 52 reported yesterday.

– The total confirmed cases have also risen to 2,263 while 160 people are said to have recovered.

Germany reports increase in cases

– Germany has announced that the total cases in the country has increased to 196. North Rhine-Westphalia is the most affected with 103 cases.

– There are death cases in Germany so far.

WHO states Covid-19 mortality rate increased to 3.4%

– WHO has stated that the mortality rate of Covid-19 coronavirus stands at 3.4% globally, which is higher than the previous estimate of 2%.

– WHO director general stated that Covid-19 ‘spreads less efficiently than flu’ and is a results in a severe illness compared to flu. There are no vaccines or therapeutics for it and it is possible to contain it.

Malaysia reports seven new cases

– Malaysia has reported seven new cases in the country, taking the total to 36. All patients are reported to be stable.

First case reported in Ukraine, Argentina and Chile

– Ukraine has reported its first case, a man who arrived from Italy via Romania. The patient is said to be stable while his wife is under self-isolation.

– Argentina has announced that the country’s citizen who arrived from Italy on 1 March tested positive for Covid-19, the first case in the country.

– Chile has confirmed its first case in a 33-year-old Chilean who arrived from Singapore on 25 February.

Additional cases reported in Czech Republic

– Czech Republic has reported two additional cases of the coronavirus. Two women who had contact with the previous cases tested positive.

Cases rise in Germany

– Germany has reported that the total number of cases in the country has increased to 188.

Iran reports 11 more deaths

– Iran has announced 11 more deaths, taking the country’s death toll to 77. The total number of cases stand at 2,336.

South Korea reports 600 new cases, six deaths

– KCDC has reported an additional 600 cases in the country, taking the total to 4,812. It also reported six new deaths. The death toll in South Korea stands at 28.

Death toll increases to 3,100; China cases decrease

– The death toll due to Covid-19 has increased to approximately 3,100, as of the end of 2 March. The deaths in Mainland China stand at 2,943.

– The total number of cases has crossed 90,000, with around 80,000 of the cases in Mainland China.

– As per the NHC report on 3 March, 125 people tested positive while 31 people died, all in the Hubei Province. Additionally, 2,742 people recovered and were discharged.

Senegal reports first case

– Senegal has reported its first infection on Monday in a French man who arrived from France on 26 February.

2 Mar:

– UAE has evacuated its citizens from Iran, where 66 people have died due to coronavirus. The citizens are under quarantine and their health is being monitored.

France reports two new deaths; total four

– Two more patients had died in northern France, bringing the country’s death toll to four, said Le Parisien newspaper citing the mayor of Compiegne.

Cases in UK reach 40

– The total number of coronavirus cases in the UK increased to 40, including a pupil of Churston Ferrers Grammar School in Torbay, Devon.

– On 3 March, Prime Minister Boris Johnson will launch the government’s action plan to combat the spread of coronavirus.

Tunisia, Morocco confirms first case

– Tunisia confirmed its first case in a national who returned from Italy.

– In Morocco, the first Covid-19 patient is a Moroccan citizen who returned from Italy.

Qatar cases increase to seven

– Qatar’s health ministry reported four new coronavirus cases to total seven.

– Of the new patients, two are Qatari nationals and two are ‘domestic workers’ of undisclosed nationality who accompanied them to Iran.

US death toll rises to six

– The state of Washington in the US has reported four more death cases, taking the total to six in the country.

– The total cases in the country stand at 91, of which 45 are repatriated citizens from the Diamond Princess cruise ship and three from Wuhan.

Oman bans vistiors

– Oman banned visitors from countries where coronavirus has spread, the country’s foreign ministry tweeted, without specifying countries.

– The move is said to be a precautionary measure, which is applicable on all ports, including land, sea and air.

Pakistan reports additional case

– Pakistan has reported another case of Covid-19, taking the total to five. The patient is reported to have a previous travel history to Iran.

Iran death toll rises to 66; Iranian Expediency Council member dies

– Deputy Health Minister Alireza Raisi told state television that the country has reported 523 additional cases and 12 deaths, bringing the total to 1,501 cases with 66 deaths.

– Among the deceased is an Expediency Council member Mohammad Mirmohammadi.  Many other senior officials have also tested positive for coronavirus.

Italy cases and deaths rise

– As per 2 March reports, Italy’s Health Ministry has stated that 52 people have died, a sharp increase compared to yesterday’s 34.

– The number of cases has also increased from 1,577 to 1,835. Lombardy in the northern region continues to be the most affected region with 1,254 cases.

Cruise ship faces protests in Reunion Island

– The Sun Princess cruise ship, owned by Princess Cruises, faced violent protests when it docked at Reunion Island over Covid-19 fears.

First cases confirmed in Saudi Arabia and Jordan

– Saudi Arabia confirmed that a Saudi citizen returning from Iran via Bahrain tested positive for the coronavirus. This is the first case in the country.

– Jordan has confirmed its first case, a citizen who arrived from Italy 16 days ago. The patient has been quarantined for two weeks and is reported to be recovering.

Wuhan closes one Covid-19 hospital

– Wuhan, the epicentre of the outbreak, has shut down the one of the 16 hospitals that were built to treat people affected by the coronavirus epidemic.

– State broadcaster CCTV stated that the hospital closed its doors after discharging the final patents who recovered.

– China saw a decline in the daily reported cases in Hubei Province and Wuhan in the past few days while China is monitoring people who may return from other countries where the outbreak has spread.

Evacuees test negative in India

– The Indian Ministry of Health has stated that the evacuees from China and the Diamond Princess cruise ship have tested negative in the first round of testing in the isolation camps at Chhawla and Manesar

– An Italian man is reported to have tested positive for Covid-19 in the state of Rajasthan in India. The samples are sent for confirmation to National Institute of Virology in Pune.

WHO staff tests positive

– In a media briefing, WHO director-general stated that a staff member of the WHO has tested positive for Covid-19 and is said to have ‘mild disease’.

Japan reports 15 new cases

– Kyodo newswire has stated that Japan has confirmed atleast 15 new cases of coronavirus on 2 March.

Iceland reports first three cases

– Iceland’s Department of Civil Protection and Emergency Management announced the country’s first three cases, late on Sunday. All three confirmed cases had a previous travel history to Italy.

Cases in Germany rise to 150

– Robert Koch Institute for Disease Control in Germany has stated that the confirmed cases in the country has increased to 150 from yesterday’s 129.

EU raises risk level to high

– The European Centre for Disease Prevention and Control (ECDC) has risen the coronavirus risk level in the European Union from moderate to high, said European Commission president Ursula von der Leyen at a press conference.

– Health commissioner Stella Kyriakides noted that 2,100 Covid-19 cases were confirmed in 18 of the 27 EU states, and 38 EU citizens had died from the infection.

Cases and deaths rise in Iran

– In an announcement on state TV, Iran’s deputy health minister Alireza Raisi said that coronavirus caused 1,501 infections and 66 deaths so far.

Andorra, Portugal report first cases

– European country Andorra has reported its first case of Covid-19 – a 20 year-old man who recently visited Milan, Italy.

– Portugal also recorded its first two cases – one is said to be a man who recently visited Italy and another one in a man who returned from Spain.

Kuwait confirms ten additional cases

– A health ministry official announced ten new cases, which take the total to 56.

Australia confirms two cases of community transmission

– Australia has reported two cases of community transmission in a 41-year-old woman whose brother returned from Iran and a 31-year-old doctor.

– The total cases in Australia currently stand at 33.

India confirms two new cases

– India has confirmed two new cases of coronavirus infection, taking its total to five.

– One of the new cases, which was identified in capital New Delhi, has a travel history to Italy.

– The second case identified in Telangana state recently travelled to Dubai.

Indonesia reports first cases

– Two Indonesian nationals have tested positive for Covid-19, the first cases in the country.

South Korea reports 476 additional cases

– KCDC has announced 476 new confirmed cases, taking the total to 4,212 with 22 deaths, including four announced today.

Cases in Israel rise to ten

– Israeli health ministry confirmed additional coronavirus cases, bringing the total in the country to ten.

More cases reported in Algeria and Egypt

– Algeria has reported two more confirmed cases, which takes the country’s count to three.

– In a Facebook post, Egypt’s health ministry has announced the second confirmed cases of coronavirus. It was also reported that the first confirmed case has recovered from the virus.

Deaths cross 3,000 globally, confirmed cases cross 89,000

– The death toll due to Covid-19 has crossed 3,000, as of the end of 1 March. The number of deaths in Mainland China stands at 2,912.

– The total confirmed cases worldwide has increased to more than 89,000 while recoveries cross 45,000.

– Mainland China reported 42 deaths and 204 new cases, as per daily breifing reports by NHC on 2 March.

1 Mar:

France records total 130 cases

– French health officials said that the total cases in the country now reached 130, of which nine are in serious condition.

Cases in Norway reach 19; Finland cases at six

– With new cases reported, Norway’s total of positive Covid-19 cases reached 19, including five hospital workers.

– Finland confirmed four new cases, which bring the nation’s total to six.

Ecuador cases increase to six

– The total number of cases in Ecuador surged to six, with five new cases reported a day after the country reported its first case.

– All the five new patients are said to have had direct contact with the first case.

Bahrain says total cases grew to 47

– Bahrain health ministry confirmed six new coronavirus cases to total 47. The new patients are five Bahraini nationals and one Saudi citizen who arrived on indirect flights from Iran.

Mexico reports more cases; total five

– Mexican authorities reported additional positive cases of coronavirus, taking the total to five. All the five patients had a history of travelling to Italy.

Iran death toll rises by 11

– The death toll in Iran has increased to 54 with 11 new deaths reported. The total number of cases has also increased to 978.

Scotland records first case

– A man with previous travel history to Italy has tested positive in Scotland. This is the region’s first confirmed case of Covid-19.

– England has also reported 12 new confimed cases. The total cases in the UK stand at 36.

Qatar reports two additional cases

– Qatar Ministry of Public Health has reported two additional cases of Covid-19, taking the nation’s total to three.

– The confirmed cases are two citizens who were repatriated from Iran, and are under quarantine.

– Qatar imposed a temporary ban on entry of travellers coming from Egypt through intermediate points.

– In light of increasing cases of Covid-19, France has closed its Louvre Museum in Paris and South Korea has closed some churches.

Additional cases reported in Lebanon, Kuwait, Greece, Brazil and Pakistan

– Lebanon has confirmed additional cases of Covid-19, taking the total cases to ten.

– Kuwait announced one more case of coronavirus, bringing the total to 46.

– With three new cases, Greece has confirmed total seven cases. Two of the confirmed cases are related to the existing cases in the country while the other visited Italy in recent times.

– Brazil has confirmed the country’s second case of coronavirus – a patient who travelled to northern Italy.

– Pakistan has reported two more coronavirus cases in the country, bringing the total to four.

Dominican Republic, Armenia, Czech Republic and Ireland record first cases

– The Dominican Republic health officials have announced that a man who arrived from Italy has tested positive for the coronavirus.

– An Armenian national returning from Iran has tested positive, Prime Minister Nikol Pashinyan stated in a Facebook post.

– Czech Republic has confirmed its first three cases of the coronavirus – all three with travel history to northern Italy.

– Ireland has recorded its first Covid-19 case – a man who with a travel history to northern Italy.

Singapore records four additional cases

– Minstry of Health in Singapore has announced four additional cases of Covid-19, taking the total to 106. Additionally, the recoveries stand at 74, including the two recently discharged cases.

South Korea reports additional cases, one death

– The total cases in South Korea has increased by 210, taking the total to 3,736. The number of deaths in the country has also increased to 18, including one newly reported deaths, as per KCDC 1 March evening reports.

Italy cases and deaths continue to rise

– Italy’s Ministry of Health has announced that the total cases in the country has increased to 1,577.

– The deaths in the country has increased to 34 from the previous 29. Additionally, 83 people have recovered.

The US reports second death

– The US has reported a second death in King County, Washington. The deceased is a man in his 70s who is reported to have underlying health issues.

Death toll nears 3,000 worldwide, recoveries cross 42,000

– The number of deaths due to Covid-19 is more than 2,970, as of end of 29 February.

– The total number of cases increased to more than 86,500, with more 79,824 cases confirmed in Mainland China. The recoveries have also increased to more than 42,000 globally.

– Mainland China reported 573 new cases and 35 more deaths.

Iran reports nine new deaths

– Iran has reported nine new deaths and 205 confirmed cases, taking the death toll to 43 and confirmed cases to 593.

– One of the nine new fatalities is the death of the country’s member of parliament infected with coronavirus.

South Korea reports 376 cases

– KCDC reports additional 376 cases, taking the total to 3,526 while the death toll stands at 17.

Australia and Thailand report first deaths

– A 78-year-old repatriated man from the Diamond Princess cruise ship has died in Australia, the country’s first death case. The total cases in the country stand at 27, including two new confirmed cases.

– Thailand also reported its first death, reported the Ministry of Public health. The deceased was a 35-year-old man who also suffered from dengue fever before testing positive for coronavirus. The total cases in Thailand stand at 42.

29 Feb:

The US reports first death

– The US reported its first death; the deceased was in his 50s and was from Seattle, Washington. He was reported to have underlying health conditions.

– The US has also increased its travel restrictions South Korea, Iran and Italy due to the increasing number of cases in the countries.

New cases reported in Ecuador and Luxembourg

– Ecuador’s health minister stated that the country has recorded its first case of coronavirus.

– A man who arrived from Italy to Luxembourg has tested positive for Covid-19.

Total cases cross 1,000 in Italy

– Italy’s Civil Protection head Angelo Borrelli confirmed that the total confirmed cases increased to 1,128 with 29 deaths so far.

Qatar reports new case

– Qatar has confirmed its first case of Covid-19, a Qatari national who arrived from Iran recently. The patient is said to be stable.

First cases reported in Monaco, Mexico and Azerbaijan

– A man from Monaco has reported the first case of Covid-19. The man is admitted in a hospital in France.

– Mexico reported its first two cases in the country, one who tested positive and another who is awaiting test results. The second case is considered as confirmed.

– Azerbaijan has reported its first case of Covid-19. The patient was from Russia who arrived from Iran.

Romania, Denmark, Norway and Georgia report new cases

– Romania has reported two additional cases, bringing the total to three.

– Denmark confirmed its second coronavirus case, a man who returned from northern Italy.

– Three others have tested positive in Norway, taking the country’s total cases to four.

– Georgia has also recorded its second case of the virus. The woman a 31-years-old and travelled to Italy.

Singapore confirms four cases of coronavirus

– Singapore has reported four additional cases, taking the total to 102. Singapore’s Ministry of Health has added that it also discharged three cases.

– The total recovered cases in the country stands at 72.

South Korea reports additional cases; one death

– KCDC has announced 219 additional cases and one new death. The country’s death toll stands at 17 while the total cases are 3,150.

– Total cases in Iraq have increased to eight while cases in Lebanon stand at four.

– A man who arrived in Israel from Italy has tested positive for Covid-19, bringing the total to seven in the country.

– Finland has reported that the country’s total now stands at three confirmed cases.

– Bahrain confirmed two cases of coronavirus, of which one is from Saudi Arabia. The total in Bahrain stands at 38.

Death toll increases to more than 2,900

– The death toll due to has increased to more than 2,900, as of the end of 28 February.

– The number of confirmed cases around the world have increased to more than 85,000, while recoveries stand at 39,000.

South Korea reports additional cases; three deaths

– South Korea reported another 594 cases, increasing the total cases to 2,931. Death toll reached 16, as per KCDC 29 February morning reports.

Singapore reports two additional cases

The total number of cases in Singapore has increased to 98, including the two new cases reported today.

28 Feb:

– WHO has raised global coronavirus outbreak risk to ‘Very High’

Iran death toll reaches 34

– The Covid-19 death toll in Iran has increased to 34, a Health Ministry spokeswoman said. The total number of cases also inreased to 388.

US reports two cases of community spread

– The states of Oregon and California reported additional cases of community spread, which brings the total cases to 62.

France, Italy confirm additional cases

– France has confirmed additional 19 cases, taking the total to 57 cases, with two deaths so far.

– The total number of cases in Italy have increased to 888. The country also reported four new deaths, increasing the country’s death toll to 21.

Diamond Princess update: sixth death reported

– Another passenger, a man from the UK, who was on the Diamond Princess cruise ship has died. This is sixth Diamond Princess death.

UK reports one additional case

– England has announced an additional case. The total cases in the UK, including Northern Ireland and Wales, stand at 20.

South Korea reports 315 additional cases

– KCDC has announced 2,337 cases in the country, including 315 newly reported cases. The country’s death toll stands at 13.

Greece reports additional case

– Greece has reported an additional case of Covid-19, bringing the total to four. The patient is a 36-year-old Greek woman who arrived from northern Italy.

Cases in Croatia rise to five

– Two additional people in Croatia tested positive for coronavirus, taking the total to five. The newly infected were in close contact with the initial cases, noted the country’s health minister.

Kuwait confirms two new cases; total 45

– Kuwait has recorded two new cases in people who previously came into contact with Iran citizens. The total number of infections in the country now stands at 45.

The Netherlands reports second case

– The country has reported the second case in its capital Amsterdam. This patient is said to have no link to the first case.

UK cases rise to 19

– Wales has confirmed its first case in a patient who arrived from Northern Italy and England has reported two more, taking UK’s total to 19.

Dog tests positive for coronavirus in HK

– A Pomeranian has tested positive for the coronavirus in Hong Kong. The dog is said to have contracted the virus from its infected owner.

– The dog did not exhibit any symptoms and tested ‘weak positive’. It is currently under quarantine for 14 days.

Fifth Diamond Princess passenger dies

– Another passenger from the Diamond Princess cruise ship has died due to coronavirus.

– The patient was a Japanese woman in her 70s who tested positive on 6 February and confirmed to have pneumonia on 12 February.

Japan reports fifth death

– Japanese Ministry of Health, Labor and Welfare has announced the fifth death in the country due to coronavirus. The patient was a Japanese man in his 70s who was hospitalised on 6 February due to fever.

Malaysia reports two new cases; total 25

– The country confirmed two additional cases to total 25. Malaysia government imposed temporary restrictions on visitors from Korea.

Thailand reports one additional case

– Thailand health offical has stated that the country has reported its 41st coronvirus case. The patient had arrived from South Korea and was daignosed on 24 February.

UAE reports six additional cases

– The total cases in UAE have increased to 19, with six newly reported cases. Of the six cases, four are from Iran, one from Bahrain and one from China.

– The Iranians are said to have entered the country before UAE banned flights to and from Iran.

Western Australia registers second case

– A woman from the Diamond Princess cruise ship, who was evacuated last week has tested positive for Covid-19. This is the second case in WA and 24th in Australia.

Lithuania and Belarus report first case

– A woman returing from Verona in Italy has tested positive for coronavirus in Lithuania. This is the country’s first positive case.

– Belarus has also registered its first case of Covid-19.

NZ confirms first case; temporarily bans Iran travel

– New Zealand has announced the first case of Covid-19 in a person who arrived from Iran via Bali. NZ’s Ministry of Health has asked people on the same flight, to contact health authorities.

– NZ has restricted travel to Iran in light of increasing cases and deaths in the Middle Eastern country.

Nigeria reports first case

– An Italian man who arrived in Lagos, Nigeria this week, has tested positive for Covid-19, marking its first case in the country and Sub-Saharan region.

South Korea confirms 256 additional cases

– KCDC has reported 256 additional cases, taking the total to 2,022. The number of deaths in the country stand at 13, with no additional deaths, as of 28 February morning reports.

Death toll increases to more than 2,850 globally

– The Covid-19 death toll has increased to more than 2,850, as of the end of 27 February.

– The total number of infections has risen to around 83,300, with around 78,000 infections in Mainland China. Recoveries worldwide has crossed 36,000.

27 Feb:

Japan reports fourth death

– Japanese Ministry of Health, Labor and Welfare has announced the fourth death in the country due to Covid-19. The patient was a Japanese man in his 80s who tested positive on 22 February.

– The ministry added that the cause of death is under confirmation.

UN to provide sanction exceptions to N Korea

– UN panel monitoring the sanctions in North Korea has permitted WHO to supply medical equipment into North Korea to aid in its efforts to prevent and control the spread of Covid-19.

Swiss cases rise to nine

– Reuters has reported that the number of cases in Switerland has increased to nine, including the latest case in a woman who travelled from Milan.

– The woman works in a daycare facility and following her positive test result, the childern have been put into a 14-day quarantine.

Oman reports sixth case

– Oman has reported its sixth case in a person who returned from Iran.

Cases rise in Spain, Greece, Sweden and France

– Spain has reported a increase in cases, taking the total to 15 in the country.

– Greece has announced two more cases of coronavirus, bringing the total to three. Both the patients have history of travelling to northern Italy. The country has cancelled public events to stop the spread of virus.

– Sweden has announced five new Covid-19 cases with which the total now stands at seven.

– French Health Minister has stated that there are 38 confirmed cases in the country, with 20 new confirmed cases.

Northern Ireland reports first case

– Northern Ireland’s Public Health Agency has confirmed that a woman has tested presumptive positive for Covid-19. This is the first case in the region. The total cases in the UK currently stand at 16.

Lebanon reports third case

– News agency NNA reported that a man returning from Iran has tested positive. Lebanon has so far reported three coronavirus cases.

Iran VP tests positive for Covid-19

– Iran’s VP for Women and Family Affairs Masoumeh Ebtekar has tested positive for the Covid-19 coronavirus.

The Netherlands and San Marino report first cases

– The Netherlands has reported its first case. The patient had a history of travel to Italy’s Lombary region.

– San Marino in Europe has also recorded its first case of the coronavirus. Health authorities have started to search people who were in contact with the patient and are monitoring the general practitioner.

Cases and deaths in Italy rise

– Italy’s Health Ministry has reported additional new cases in the country, bringing the total to 655. The death toll in the country has also increased to 17 while the total recoveries stand at 45.

South Korea reports new cases and death

– South Korea has reported 171 new cases, which rise the total to 1,766. With one new fatality, Covid-19 deaths in the country reach 13.

Malaysia reports one new case; total 23

– Malaysia reported its 23rd case in a national who recently travelled to Japan.

Kuwait confirms 43 cases

– In a press conference, Kuwaiti Ministry of Health stated that the number of Covid-19 cases in the country has risen to 43.

Iran reports four new deaths, 106 new cases

– Iran has announced that four additional people have died, which brings the country’s death toll to 26. The number of infected people increased to 245.

Switzerland announces three new cases

– Swiss health authorities have announced three new cases of coronavirus, taking the country’s total to four.

Australia says pandemic inevitable

– At a press conference, Australia Prime Minister Scott Morrison said that ‘the world will soon enter a pandemic phase of the coronavirus.’

– In an effort to be prepared for the prediction, the country implented its Emergency Response Plan/coronavirus pandemic preparedness plan.

– Australia also extended China travel ban to 7 March.

UK reports two new cases; total 15

– The UK government confirmed two new cases in England, taking the nation’s total to 15.

– England chief medical officer Chris Whitty said that the new patients contracted the virus in Italy and Tenerife, Spain.

Iran death toll rises to 22

– Iran has confirmed four more deaths, bringing the total to 22. The country confirmed 141 cases so far.

South Korea reports additional death

– KCDC has reported an additional death, bringing the total to 13, with 1,595 confirmed cases.

Iraq confirms sixth case

– Iraq confirmed its sixth case, which marks the first one in its capital, Baghdad. The new patient is a male who returned from Iran.

– Iraq suspended public gatherings and banned travel to and from a total of nine countries, including Kuwait and Bahrain.

Estonia, Denmark report first cases

– Estonia’s first case has been confirmed in a man with a recent travel history to Iran, according to Russian news agencies TASS and Interfax.

– Health authority in Denmark has confirmed the country’s first positive case, who is said to be a man returned from a holiday in northern Italy. The patient is under isolation in his home.

Chinese city to offer $1,400 to people who self-report

– Qianjiang in Hubei Province has announced 10,000 yuan ($1,425.96) reward for people with Covid-19 symptoms who report themselves to the authorities. The reward will be provided to confirmed cases.

Japanese woman tests positive for second time

– A Japanese woman from Osaka has tested positive for the coronavirus for the second time.

– She first tested positive in late January and recovered on 1 February.

Saudi Arabia suspends Mecca pilgrimage

– The Kingdom of Saudi Arabia has temporarily banned all religious visits to Mecca and Medina, the Islamic holy sites, in a bid to prevent the spread of coronavirus from other infected Arab countries.

US confirms first case of unknown source

– The US has confirmed one new case suspected to be a result of ‘community spread’, when the source of infection is not known.

– This brings the total in the country to 60 cases, including 42 repatriated from the Diamond Princess cruise ship and three Wuhan evacuees.

India evacuates citizens on Diamond Princess and Wuhan

– India has evacuated 119 Indian citizens along with two Sri Lankans, one Nepalese, one South African, and one Peruvian from the quarantined Diamond Princess cruise ship.

– The Indian Air Force relief aircraft has repartiated 76 Indians and 36 foreign nationals from Wuhan. The aircraft left for China with 15t of medical supplies to Wuhan after which it evacuated the 112 passengers.

South Korea reports new cases

-South Korea has reported 334 new cases and no new deaths. The total cases now stand at 1,595 and 12 deaths so far.

Finland and Lebanon report second cases

– Finland has confirmed a second coronavirus case in Finland – a female national who had recently visited Milan, Italy.

– Lebanon’s health ministry also reported the country’s second case in a person who returned from a trip to Iran.

Death toll touches 2,800

– The death toll due to coronavirus has increased to 2,800 with around 2,640 deaths in Hubei Province in China as of the end of 26 February.

– The confirmed cases around the world are more than 82,000 while recoveries also increased to 32,000.

26 Feb:

Croatia confirms third case

– Croatia confirmed its third case – a man who had been working in Italy – in Rijeka city.  The first two cases were earlier reported in the country’s capital, Zagreb.

Romania reports first case

– Romania confirmed its first Covid-19 case in a man who was in contact with an Italian diagnosed with the virus. The Italian, who visited Romania between 18 and 22 February, was diagnosed after returning to Italy.

US-South Korea postpone military training

Republic of Korea (ROK)-US Alliance has postponed combined command post training after the ROK government declared the highest alert level on Covid-19.

Diamond Princess cases rise to 705

– The Japanese Ministry of Health, Labour and Welfare has announced that the total cases associated with the Diamond Princess cruise ship has increased to 705. Authorities tested 4,061 people.

Italy reports new cases

– Italy has reported that the total number of cases has risen to 400 in the country. It has not reported any new deaths which currently stand at 12.

First cases in Pakistan, Norway, Georgia and North Macedonia

– Pakistan has reported its first two cases. The infected had a history of travelling to Iran. The patients are reported to be stable.

– Norway recorded its first case of Covid-19 in a person who returned from China. Local media stated that the patient is stable and shows no symptoms.

– A Georgian national tested positive, the first in the country. The man came from Azerbaijan and was travelling from Iran. The man’s travel companions tested negative for the virus, but are under quarantine.

– North Macedonia also reported its first case. The woman travelled to the country from Italy.

Italy reports one new death; 52 new cases

– Italy’s Ministry of Health has reported 374  infections in the country of which 12 people have died. One person has recovered.

Japan reports one new death

– With one new death in Japan, the nation’s death toll rised to six, including four fatalities from the Diamond Princess ship.

– The latest casualty, which occurred in Tokyo, is said to be a male in his 80s.

Greece confirms first case

– Greece has reported its first case in a 38-year-old national who visited northern Italy, according to health ministry representative Sotiris Tsiodras.

Iran death toll reaches 19; Kuwait reports six new cases

– With three new reported deaths, Iran’s death toll climbs up to 19 with 139 confirmed cases.

– Kuwait confirms six additonal positive cases, bringing the total to 18 cases.

France reports second death

– French health authorities have reported second death. The fatality, a 60-year-old French man in Paris, is one of the new cases reported in the country. The total infections in France stands at 18.

– UAE National Emergency Crisis and Disasters Management Authority told Reuters that it is well-prepared to tackle the ‘worst case scenario’ of the coronavirus outbreak.

Bahrain confirms nine cases

– Bahrain has confirmed nine new cases to the previous 17, taking the total to 26. The country has started screening passengers arriving from affected countries. People who have visited Iran in February have been asked to get tested.

– KCDC reported an additional 115 cases and one death, taking the total to 1,261 confirmed cases and 12 deaths.

– A second evacuation flight sent by Malaysia repatriated 66 citizens from Wuhan. The plane landed today at the Kuala Lumpur International Airport.

– Thailand confirmed three new cases, taking total infections to 40. Health ministry said that two of the new cases had returned from holidays in Japan and came into contact with the third.

– Kuwait reported new coronavirus infections, which increase the total in the country to 12.

– US Forces Korea stated that a US service member stationed in South Korea tested positive.

Death toll passes 2,750; recoveries rise

– The number of deaths due to coronavirus has increased to more than 2,750 as of the end of 25 February.

– The number of infected cases has risen to around 81,000 while the recovered cases exceeded 30,000.

South Korea reports new cases

– KCDC has reported an additional 169 new cases, taking the total to 1,146. With new deaths reported, the total number of deaths in the country stands at 11.

25 Feb:

Algeria reports first case; second African country with confirmed cases

– Algeria reported its first positive case – an Italian adult who arrived in the African country on 17 February. This represents the second case in Africa.

– Jamaica and the Cayman Islands denied entry to Meraviglia cruise ship as it carried a sick crew member who travelled to countries with confirmed coronavirus cases.

– Switzerland confirmed its first Covid-19 case in canton of Ticino. Swiss health ministry noted the man was in Italy approximately ten days ago when he attended an event near Milan.

– Italy has reported 322 confirmed cases and 11 deaths with one recovery, as of the end of 25 February.

– Brazil reports its first case of the coronavirus.

– El Salvador bans visitors from Italy and South Korea. Salvadoran citizens arriving from these countries will face 30-day quarantine.

Iran Deputy Health Minister tests positive; one more death reported

– Iranian Deputy Health Minister Iraj Harirchi has tested positive for the coronavirus, confirmed health ministry spokesman.

– The country has reported 95 confirmed cases of the virus with 16 deaths so far. The Health Ministry has asked citizens to stay at home.

– Austria has announced its first two cases of the Covid-19 in Tyrol province that shares a border with Italy.

– Croatia has reported its first case of the coronavirus in the country. The patient is a young person and has mild symptoms who was in Milan from 19 to 21 February.

– Bahrain’s Ministry of Health confirmed a total of eight cases, including six new cases – two Bahraini and four Saudi citizens who arrived from Iran via Dubai.

– With three new confirmations, Kuwait’s total Covid-19 cases increased to eight. KUNA  news agency noted that all the three new cases had returned from Iran.

– Iran has reported three additional deaths due to Covid-19, taking the death toll to 15 with 61 confirmed cases.

– Iraq has announced four new positive cases in Kirkuk province, bringing the total to five. The cases were identified in a Iraqi family who travelled to Iran.

– South Italy has recorded its first positive case of the coronavirus. The woman, who was on a holiday in Sicily, was sent to the hospital and her husband and friends were put under a 15-day quarantine.

– With 84 new cases in South Korea, the country’s total surged to 977. Two additional deaths are also confirmed, rising the total to ten.

– Thailand health officials confirmed two new coronavirus Covid-19 cases, which rise the total to 37. Both of the new cases are said to be Thai citizens.

Diamond Princess update: Japan reports fourth death; Philippines and India to send flights

– NHK reported that another passenger from the Diamond Princess has died, taking the total deaths from the ship to four. The deceased was around 80 years old and from Japan.

– Japan asked schools to temporarily close, even if there are no confirmed cases in the school.

– The Philippines’ Department of Foreign Affairs has sent two flights to repatriate approximately 400 citizens who were on the Diamond Princess cruise.

– India has also started arrangements for a charter flight to evacuate around 120 citizens on the ship.

Death toll nears 2,700; recoveries exceed 27,000

– The number of deaths due to Covid-19 has neared 2,700, as of the end of 24 February.

– The number of positive cases has exceeded 80,000 worldwide and the number of recoveries stands at more than 27,000.

South Korea reports 60 new cases and one new death

– South Korea has reported 60 additional cases, the smallest increase in its confirmed cases so far. There are now 893 positive cases in South Korea.

– The KCDC also announced one more death in the country, taking the total to eight.

24 Feb:

– Spain confirms third case in an Italian male who was on a holiday in Tenerife.

– Italy reported seven deaths in total with 229 total confirmed cases in the country, as of the end of 24 February.

– Oman’s Ministry of Health confirmed first coronavirus cases in two women who returned from Iran.

– Kuwait and Bahrain report additional cases, increasing the total to five and two, respectively. The new patients in Kuwait are said to have arrived from Mashhad, Iran.

US CDC confirms 53 cases of coronavirus

– The US Centers for Disease Control and Prevention (CDC) stated that there are 53 cases of the Covid-19 in the country, as of 24 February.

– Of the 53 cases, 14 are in the country, including two new cases in California. The remaining 39 are citizens repatriated from Diamond Princess cruise ship.

– Iraq confirmed its first coronavirus Covid-19 case in Najaf city.

– Italy reported two more deaths, rising the total to five. The government has put nearly 50,000 people in 11 towns in Lombardy and Veneto under quarantine.

– Afghanistan confirmed its first case of Covid-19 coronavirus.

– South Korea reported 70 new additional cases to total 833.

Iran official states 50 deaths in the country; govt denies claims

– ILNA news agency has quoted a Qom official Ahmad Amiriabadi Farahani as saying that the death toll in the country stood at 50 on 13 February.

– However, the officials have stated on 24 February that death toll has increased 12, including four additional deaths reported today.

– Iran’s Deputy Health Minister Iraj Harirchi has rejected the claims of cover-up. He stated that it was ‘not the time for political confrontations’.

– Farahani denied to retract his statement.

Kuwait, Bahrain confirm first cases

– The Ministry of Health in Bahrain has reported the first coronavirus case – a citizen who returned from Iran.

– Three cases have been confirmed in Kuwait, reported local news agency KUNA, which said that the individuals just returned from Iran.

Diamond Princess update: one more death reported

– Another Japanese passenger, a man in his 80s has died from the Covid-19 coronavirus. The total cases on Diamond Princess is 691 with three deaths.

Iran’s neighbours close borders

– Saudi Arabia, Kuwait, Iraq, Turkey and Afghanistan imposed travel and immigration restrictions on Iran, which was the first to report deaths in the Middle East region.

– Turkey, Pakistan, Afghanistan and Armenia also closed their borders with Iran.

Death toll exceeds 2,600; South Korea reports 161 new cases

– Death toll due to Covid-19 coronavirus increased to more than 2,600, as of the end of 23 February.

– The number of confirmed cases rises to more than 79,000, with the cases in Mainland China crossing 77,000.

– South Korea has announced 161 new positive cases of the coronavirus, bringing its total to 763, with seven deaths in the country. The government raised infectious disease alert to the highest.

Italy reports third death and new cases

– Italy has now become the most affected country in Europe with more than 150 Covid-19 cases. The country also reported third death from the new virus.

– Coronavirus ‘hotspot’ towns have been sealed to control the spread. The country also halted public gatherings, including suspension of the Venice carnival.

Israel confirms second case

– An Israeli who returned from the Diamond Princess cruise ship has tested positive, said Sheba Medical Center. This increases the country’s total to two.

23 Feb:

UK reports four new cases; total 13

– The UK

Iran reports two more deaths

– Two additional deaths have occurred in Iran, taking the total to eight, according to the country’s health minister. The total number of cases in the nation reached 43.

South Korea reports fifth death, new cases

– The KCDC in South Korea has reported one additional death, taking the total to five. Also, with 46 new cases, the total number of infections reach 602.

Singapore reports new cases

– Singapore authorities have confirmed a total of 89 cases to date. The country’s health ministry also reported a total of 51 recoveries.

Four more Indian passengers on Diamond Princess test positive

– Four additional Indian passengers aboard the Diamond Princess cruise ship quarantine in Japan have tested positive. This rises the number of Indian cases on the ship to 12.

Cases and deaths rise in South Korea

– The total number of cases in South Korea have increased to 556. Majority of the new cases are linked to the Shincheonji church or Cheongdo Daenam hospital cluster.

– The country also reported two new deaths, which increase the total to four.

Italy records cases surge

The number of infections in Italy have surged to 79, representing nearly four times growth from the last count of 20.

Death toll rises to 2,458; Iran reports sixth death

– Death toll has increased to 2,458, including 2,443 deaths in China, as of the end of 22 February. The total number of cases climbed to more than 78,600.

– One new death has occurred in Iran on 22 February, taking the total to six, reported the country’s media.

22 Feb:

– The US, UAE, Israel and Lebanon have reported additional cases.

Death toll rises to 2,360; Iran reports two deaths

– The death toll due to Covid-19 has reached 2,360, including two more deaths confirmed in Iran as of the end of 21 February. The total number of deaths in Iran is now four.

– The total number of confirmed cases around the world increased to 77,659 with 76,288 cases in Mainland China. The number of recoveries also increases to more than 20,000.

Italy reports one death

– Italy announced one death in the country in Padova in the Veneto region. The deceased was a 78-year-old man.

– The country has also reported 16 additional cases, bringing the total to 20.

21 Feb:

Italy confirms one new case

– Italy has confirmed one new case of Covid-19, bringing the total to four cases in the country. Previously, two Chinese nationals and one Italian were tested positive.

– The positive case was confirmed in a 38-year-old man in the Lombardy region, who is now admitted in a hospital in Codogno.

Cases in South Korea rise to 204

– The total confirmed cases in South Korea have surged to 204, most of which were found in the Daegu city.

– Officials have banned downtown rallies and closed a park, in a bid to contain the spread of the virus.

Diamond Princess update

– The flight carrying around 200 Canadian citizens has taken off from Tokyo airport. After landing in Ontario, Canada, the passengers will undergo additional 14 days of quarantine.

– Flight to evacuate Britons from the cruise ship will take off on 21 February, one day after the previously announced date.

China reports more than 200 cases in prisons

– China has reported more than 200 positive cases in two prisons outside of Hubei province, the epicentre of the outbreak.

Young doctor in Wuhan dies

– Covid-19 has claimed the life of a 29-year-old doctor who worked at First People’s Hospital in Wuhan.

– Named Peng Yinhua, the doctor, who delayed his wedding to continue working, was admitted to hospital on 25 January and succumbed to the coronavirus disease on 20 January.

US reports one new case; total 16

– A new case has been reported in Humboldt County, California, increasing the number of cases in the country to 16.

Cases in South Korea rise to 156

– With 52 new infections reported in South Korea, the country’s total surged to 156 cases. Of the new cases, 39 were traced to the Shincheonji church cluster.

– Government has strengthened measures to control the spread, and declared Daegu and Cheongdo cities as ‘special care zones’.

Death toll reaches 2,247

– The deaths due to Covid-19 have reached 2,247, with majority of the deaths in Mainland China, as of the end of 20 February.

– The total number of confirmed cases increased to more than 76,000, with more than 75,400 in mainland China. The number of recoveries stands at around 18,200.

Two Australian evacuees from Diamond Princess test positive

– Two Diamond Princess passengers tested positive for the Covid-19 coronavirus in Australia after around 170 Australians were evacuated from the ship on 20 February. The total number of cases on the ship reached 634.

Ukraine protesters attack China evacuee buses

– Protesters in a Ukrainian town have attacked buses carrying evacuees from China. The evacuees were being transported to a hospital in Novi Sanzhary.

– All evacuees tested negative during official screening. The protest comes after a fake email, which was claimed to be from the Ministry of Health, said some evacuees had contracted the virus.

– Ukraine’s security service (SSU) said that the false email is being investigated. According to media reports, nine police and one civilian were hospitalised, while more than ten protesters were detained.

20 Feb:

Iran reports three new cases

– As of the end of 20 February, Iran has confirmed three new Covid-19 cases a day after the death of two elderly citizens in the country.

India plans to limit drug exports

– India plans to restrict export of antibiotics and vitamins as supply from China is disrupted due to coronavirus Covid-19.

One death reported in South Korea

– The KCDC reported the death of a coronavirus patient linked to the Cheongdon Daenam hospital cluster.

– The agency also confirmed 22 new cases since the last count, taking the total to 104. Out of 21 new cases, five were related to Shincheonji Church of Jesus cluster, 13 with Cheongdo Daenam hospital and one with Saeronan oriental hospital.

South Korea confirms 31 new cases to total 82

– The KCDC in South Korea has confirmed 31 new cases taking the total to 82. Of the new cases, 23 have been traced to the 31st case who attended Shincheonji Church of Jesus in Daegu.

Diamond Princess updates

– Two Japanese passengers from the Diamond Princess cruise ship have died from the novel coronavirus. Both the patients were in their 80s with underlying health conditions, reported local media. This increases Covid-19 deaths to 2,128.

– Approximately 180 Australians repatriated from the cruise have landed in Darwin and will be subjected to a second 14-day quarantine period.

Death toll reaches 2,126; Iran reports two deaths

– Covid-19 deaths have reached 2,126, including two deaths in Iran, as of the end of 19 February. The deceased in Iran were two elderly citizens in Qom city, said Alireza Vahabzadeh, an adviser to the country’s health minister.

– The total number of cases rose to more than 75,700, including 74,576 in mainland China. The number of recoveries also increased to approximately 16,300.

19 Feb:

– The Japanese ministry announced that the number of cases on Diamond Princess has increased to 621 of the 3,011 people tested. This represents an increase of 79 cases from the last count.

– Hong Kong reported its second Covid-19 death – a 70-year-old man, who had underlying illnesses and was receiving treatment at Princess Margaret Hospital.

Passengers on Diamond Princess disembark

– Passengers who have tested negative started disembarking from the cruise ship after a 14-day quarantine period.

South Korea reports 19 new cases to total 51

– The Korea Centers for Disease Control and Prevention (KCDC) has reported 19 new cases, which increase the total number of confirmed cases in the country to 51.

– Epidemiological investigation revealed that 11 of the new cases are contacts of the 31st case.

Death toll passes 2,000; New recoveries exceed new infections

– Deaths from the new coronavirus have increased to more than 2,000, including 2,004 in mainland China, as of the end of 18 February.

– For the first time, the number of newly recovered patients exceeded that of new confirmed cases in China. In mainland China, 1,749 new cases were confirmed on 18 February, while 1,824 patients newly recovered.

– The total number of infections climbed to more than 75,000.

18 Feb:

– Singapore health ministry confirmed four new Covid-19 cases, which rise the total to 81. The ministry also reported a total of 29 recoveries to date.

– The Centre for Health Protection in Hong Kong reported two new cases to total 62.

– The Japanese Ministry of Health, Labor and Welfare confirmed that the number of cases on Diamond Princess has reached 542 of the 2,404 people tested.

– Taiwan announced plans to fly back its nationals who are onboard the cruise. Of more than 20 Taiwanese on the vessel, four have tested positive.

–  The Korea Centers for Disease Control and Prevention (KCDC) has reported the country’s 31st case –  a 61-year-old South Korean woman currently in isolation.

UK and South Korea plan Diamond Princess evacuations

– South Korea is set to send an aircraft to Japan to bring back five passengers onboard the quarantined Diamond Princess cruise ship. The aircraft will take off today at Seoul Air Base in Seongnam, Seoul.

– The UK government is also planning to send a flight to Japan to evacuate its citizens from the ship.

Deaths increase to 1,873; infections rate drops

– Covid-19 death toll has increased to 1,873, with 98 new deaths in China, as of the end of 17 February. The total number of infection cases has exceeded 73,000, including 72,436 cases in mainland China.

– Chinese authorities have reported that new coronavirus confirmed cases outside the Hubei province recorded a drop for 14 consecutive days since 3 February.

17 Feb:

Aggiornare: More than 200 Australian evacuees return home

– More than 200 Australian evacuees from Wuhan return home after 14 days of quarantine on Christmas Island. None of the evacuees tested positive during the quarantine period.

Singapore confirms two new cases to total 77

– Singapore ministry of health confirmed two new cases – a one year-old male evacuee from Wuhan and a 35 year-old male with no recent travel history to China. These new cases take the country’s total Covid-19 cases to 77.

Diamond Princess – cases rise to 454; 14 new US passengers test positive; Australia plans repatriation

– The Japanese Ministry of Health, Labor and Welfare announced that the number of cases on the cruise ship has further risen to 454 of the 1,723 people tested.

– The US Departments of State and Health and Human Services announced that after citizens disembarked the ship, 14 passengers, who underwent tests two to three days earlier, had tested positive. These patients were asymptomatic and have been isolated in a special containment area on the evacuation aircraft.

– Australia Prime Minister Scott Morrison confirmed that the country will repatriate more than 200 Australians and New Zealanders onboard the cruise ship.  An aircraft will be sent to Japan on 19 February.

Thailand reports 35th case

– Thailand has reported a new Covid-19 case, which increases the nation’s total to 35. The new patient is a 60-year-old Chinese woman whose family members were diagnosed earlier.

New cases on Diamond Princess

– The total number of cases on the Diamond Princess cruise ship in Japan has increased to 355, including three Israelis and two new Indian nationals taking the country’s total onboard to five.

– Israel is considering sending a flight to fly back the remaining Israelis, who have not tested positive, from Japan.

– The Philippines authorities have confirmed 16 new cases onboard the ship, taking the total number of infected Filipinos on the cruise to 27.

Death toll reaches 1,775; Taiwan reports first death

– The coronavirus Covid-19 death toll has reached 1,775 with 105 new deaths in China and one in Taiwan, as of the end of 16 February.

– In Taiwan, a 61-year-old man with a history of diabetes and hepatitis B had died after contracting Covid-19, marking the first novel coronavirus-related death in the country.

– The total number of infection cases has increased to more than 71,000, including 70,548 in mainland China.

16 Feb:

Update: UAE reports ninth case; Germany releases 100 from quarantine

– The Ministry of Health and Prevention in the UAE reported the ninth novel coronavirus case in the country. The new patient is a 37-year old Chinese who was diagnosed during a routine check-up.

– At a military base near Frankfurt airport, 100 German evacuees from Wuhan, China were released from their two-week quarantine after none of them tested positive.

South Korea confirms 29th Covid-19 case

– The South Korean government reported a new coronavirus Covid-19 case  on Sunday, which marks the country’s 29th case.

– The Korea Centers for Disease Control and Prevention (KCDC) said that the new patient, aged 82-years, contracted virus with no history of overseas travel or contact with any confirmed patients.

Covid-19 deaths climb to 1,669

– The coronavirus Covid-19 deaths have claimed further to 1,669 with 142 new deaths in China and one in France as of the end of 15 February. The total number of deaths in mainland China reached 1,665.

– The total number of positive cases surged to 69,186 with 68,500 cases in Mainland China.

– The severe cases are said to be 11,273, while total recoveries stand at 9,600.

15 Feb:

France reports first covid-19 death; Malaysia, Tailandia report new cases

– France reported its first covid-19 death today, which also marks the first death outside Asia.

– French Health Minister Agnes Buzyn confirmed the death of an 80-year old Chinese tourist, who travelled to France from the Hubei province on January 16.

– Malaysia has reported two new coronavirus covid-19 cases on Saturday, taking the total infected cases in the country to 21, while Thailand has reported a new case taking the country’s total to 34.

US to airlift Americans on board Diamond Princess; India making efforts

– US is planing to airlift its nationals from the quarantined Japanese cruise ship Diamond Princess.

– US embassy in Japan has informed all the American passengers and crew on board about this decision in an email.

– Diamond Princess has recorded the highest number of coronavirus infections outside China so far.

– Indian Embassy in Japan also said on Saturday that it is making efforts to evacuate all the Indians on board the cruise ship.

Death toll touches 1,526; Egypt reports first case

– Covid-19 death toll has increased to 1,526, with 143 new deaths reported, as of the end of 13 February.

– The number of new cases increased to more than more than 67,000 of which 66,492 infections are reported in Mainland China.

– Egypt has confirmed its first case of the Covid-19 and has stated that the affected is a ‘foreigner’ who was asymptomatic.

14 Feb:

Facebook, IBM cancel conference plans over coronavirus fears

– Facebook announced the cancellation of its Global Marketing Summit scheduled to take place from 9 March to 15 March in San Francisco, US.

– IBM pulled out of the annual RSA cybersecurity conference, which is set start on 24 February in San Francisco.

Passengers on Westerdam cruise ship disembark

– Westerdam cruise ship, which docked in Cambodia after being turned away by five countries over the fear of the coronavirus, has received permission to disembark its guests after 20 samples taken onboard tested negative.

Death toll rises to 1,383

– Deaths from the new coronavirus Covid-19 increased to 1,383, including the latest one in Japan. The total number of deaths in mainland China is 1,380. The total number of infections reached 64,429, including 63,911 in China, Hong Kong and Macau

13 Feb:

Japan reports first Covid-19 death

– Japan health minister Katsunobu Kato confirmed the first Covid-19 death in the country – a woman in her 80s whose infection was reported to have been confirmed after death.

– The total number of cases in Japan reached 248, including 218 from the quarantined cruise ship and 30 in the country.

New cases in US, Malaysia, Vietnam and Hong Kong

– The US CDC announced 15th case in the country – a recent evacuee quarantined at JBSA-Lackland in Texas.

– Malaysia health director-general has confirmed the nation’s 19th case, a 39-year-old woman who returned from Wuhan, China. The woman is reported to be related to 14th and 16th Covid-19 cases confirmed in the country.

– The number of cases in Vietnam has increased to 16, after a 50-year old man tested positive in Son Loi town. Local authorities have put Son Loi, which recorded a total of eight cases, on lockdown for 20 days.

– Hong Kong authorities have reported a new case, which takes the total to 51.

Deaths increase to 1,369; Hubei sees infections surge

– Covid-19 death toll has increased to 1,369, indicating 254 new deaths, as of the end of 12 February.

– The number of new cases saw a surge of about 15,200, from approximately 45,100 to more than 60,300. This jump is due to 14,840 new cases confirmed in Hubei Province alone.

– Japanese health minister confirmed 44 new cases on the Diamond Princess cruise ship, increasing the total to 219, including a quarantine officer.

12 Feb:

Mobile World Congress cancelled

– The largest global mobile event, Mobile World Congress, has been cancelled over coronavirus fears.

– The decision is said to be based on ‘the global concern regarding the coronavirus outbreak, travel concern and other circumstances’.

– This comes after various exhibitors, including Facebook, Amazon, Sony, Nokia and LG said that they would be pulling out of the event.

UK reports ninth case; US confirms second case among evacuees

– England chief medical officer has comfirmed that the number of coronavirus cases in the country had increased to nine.

– The US CDC confirmed a second case among evacuees quarantined in California, rising the total cases in the country to 14.

DBS evacuates 300 after one is infected

– Singapore’s DBS bank has evacuated 300 employees after one employee was confirmed to have contracted the coronavirus. With three new cases reported, the total cases in Singapore touched 50, one of the highest outside China.

Japan cruise cases increase to 174

– The total confirmed cases on the Diamond Princess cruise ship, quarantined in Japan, have surged to 174, in addition to the positive case of a quarantine officer.

Death toll reaches 1,115; recoveries rise

– Deaths from the new coronavirus have reached 1,115, while the total number of cases exceeded 45,100, including 44,653 reported in mainland China by authorities as of the end of 11 February.

– According to NHC official Mi Feng, the proportion of recovered patients in China increased to 8.2% as of 10 February, from 1.3% on 27 January.

11 Feb:

WHO gives name to new coronavirus disease

– The WHO has officially named the disease caused by the new coronavirus as ‘Covid-19’.

– Ukraine is screening five of its citizens for the novel coronavirus, Health Minister Zoriana Skaletska said at a press briefing on 11 February.

– According to Skaletska, three of the five suspected patients returned from China while the remaining two were in contact with them.

– Germany confirmed two new cases of coronavirus in Bavaria, raising the total cases in the country to 16.

– The Centre for Health Protection in Hong Kong has reported seven new coronavirus infection cases, taking the toal to 49.

– After two cases were confirmed in the same building, Hong Kong government evacuated all of its more than 100 residents to control the spread of the infection. The confirmed cases were residing on different floors of the building.

– Vietnam’s health ministry confirmed a new case, who is a three-month-old baby thought to be infected by her grandparent. The total number of cases in the country stand at 15.

– With 108 new deaths in China, the total toll has reached 1,018. NHC report shows 42,638 confirmed coronavirus cases in mainland China, as of the end of 10 February, which takes the number of global cases to around 43,000.

10 Feb:

UAE, US report new cases; Infections on cruise nearly double

– Eighth case has been confirmed in the UAE, an Indian national who had contact with a recently diagnosed person.

– The US CDC reported a new case in California, who was one of the evacuees from Wuhan. This rises the total cases in the country to 13.

– The number of cases on the Diamond Princess cruise quarantined in Japan have nearly doubled, with 135 total cases on board. As of 9 February, 70 cases were confirmed on the Diamond Princess.

UK declares imminent threat as four more cases confirmed

– The UK government has declared the coronavirus outbreak a ‘serious and imminent threat to public health’.

– Four new cases have been diagnosed in the UK, doubling the total confirmed cases to eight.

– WHO has noted that cases of the new coronavirus among people who have not travelled to China could be the ‘tip of the iceberg’. The agency has sent members of its international expert mission team to help China deal with the outbreak.

Death toll surges to 910; Malaysia confirms sixth citizen case

– Death toll from the Wuhan coronavirus epidemic has surged to 910, as of the end of 09 February, including 97 new deaths from the day before.

– The total number of cases stands at ‭40,547 globally, of which 40,171 are in mainland China. NHC report shows a total of 3,281 recoveries in the region.

– Malaysia health director confirmed the sixth citizen case of coronavirus infection, a 31-year-old man who worked in Macau, China and returned to Malaysia on  1 February. This takes the total coronavirus cases in the country to 18.

09 Feb:

– UK has reported its fourth coronavirus case on Sunday.

– England’s chief medical officer professor Chris Whitty said in a statement that the new patient is a known contact of one of UK’s existing cases and has reportedly contracted virus in France.

– The patient has now been moved to NHS centre at The Royal Free Hospital, and being treated using robust infection control measures to contain further spread of the virus.

– The number of coronavirus deaths reached 813 globally as of the end of 8 February, overtaking the Severe Acute Respiratory Syndrome (SARS) epidemic in 2002-2003 that claimed 774 lives.

– Of the total fatalities, 811 were reported in mainland China and one each in Hong Kong and the Philippines.

– New cases have now touched 37,549 worldwide, of which 37,198 represent mainland China.

– China’s National Health Commission reported 2,656 new confirmed cases, 3,916 new suspected cases, 87 serious cases, and 89 deaths on Saturday alone.

– NHC also reported 600 new recovered cases on Saturday, taking the overall cured cases in mainland China to 2,649 as of Saturday.

08 Feb:

France reports five new cases; UAE confirms two

– France and UAE have confirmed two new cases today, taking their respective totals to 11 and seven.

– France health minister said Saturday that five British nationals in the country have been tested positive for coronavirus. The new cases, including a child, were staying in the same ski chalet and reportedly contracted virus after coming into contact with a Brit, who recently travelled to Singapore.

– The United Arab Emirates too reported two new cases on Saturday. The UAE’s Ministry of Health and Prevention added that the two patients, a Chinese and a Filipino national, are under observation.

– China has opened a second prefabricated hospital  with 1,600 beds in Wuhan to treat patients infected with coronavirus.

US and Japanese citizens die in Wuhan

– US embassy has confirmed that an American citizen diagnosed with coronavirus died in Wuhan on 06 February. This is the first known death of a US national due to the new coronavirus.

– A 60-year-old Japanese man with suspected coronavirus infection also died in Wuhan today.

Death toll passes 700; Hong Kong enforces quarantine

– Coronavirus deaths have gone past 700 as of the end of 07 February, with China reporting 86 new deaths. Death toll now stands at 724, while a total of 34,881 cases have been confirmed. Of the 34,546 cases in mainland China, 6,101 are serious.

– Hong Kong began imposing a two-week quarantine for anyone arriving from mainland China. Visitors must quarantine themselves in hotel rooms or government-run centres, while returning nationals must stay inside their homes.

07 Feb:

Death toll hits 638; Chinese whistleblower doctor dies

– Death toll from the new coronavirus stands at 638, as of the end of 06 February. A total of ‭31,428‬ infection cases have been confirmed, including 31,161 in mainland China.

– The Chinese doctor who had reportedly tried to issue an early warning about the coronavirus outbreak has died after contracting the virus while working at a hospital in Wuhan.

– Japan reported 41 new cases of coronavirus infection on a cruise ship quarantined in Yokohama harbour. This raises the total positive cases on the ship to 61.

– The Central Epidemic Command Center (CECC) in Taiwan has confirmed three new imported cornavirus cases, taking the nation’s total to 16.

06 Feb:

Third case confirmed in the UK; India evacuees test negative

– England’s chief medical officer Professor Chris Witty has confirmed a third case of coronavirus in the UK.

– As of the end of 05 February, the coronavirus has led to 565 deaths, including 73 new deaths compared to 4 February in mainland China. The total number of confirmed cases is 28,275. Of the 28,049 confirmed cases in China, 3,859 are reported to be severe cases. So far, 1,153 patients have recovered in mainland China.

– Indian authorities confirmed that all 645 of the country’s evacuees from Wuhan tested negative for the coronavirus.

– Japanese health officials said ten more passengers on the Diamond Princess cruise ship have tested positive for the new coronavirus.

– Two new cases on Vietnam increase its total to 12, while the number of cases in Singapore reached 30.

05 Feb:

Death toll reaches 492; Japan confirms ten cases on cruise

– With 65 new deaths in China, the toll has reached 492, while the number of infected cases has surged to nearly 24,527, as of the end of 04 February, said Chinese authorities. Of the 24,324 confirmed cases in mainland China, 3,219 cases are in serious condition.

– After screening passengers on a cruise ship, named Diamond Princess, the Japanese authorities confirmed ten positive cases. These patients include three Japanese, two Australians, three from Hong Kong, one from the US and a Filipino crewmember.

– Health authorities confirmed that two Malaysian evacuees, a 45-year-old man and his nine-year-old son, from Wuhan have tested positive for the new coronavirus. This increases the number of cases in the country to 12 – nine Chinese nationals and three Malaysians.

– US confirmed a new case in Wisconsin, an adult who travelled to Beijing, China. This brings the total number of cases in the country to 12.

04 Feb:

Malaysia reports first citizen infected; Belgium confirms first case

– A 41-year-old man, who travelled to Singapore for a conference, has become the first Malaysian to be infected by coronavirus. The Malaysian is one of the two new cases confirmed while the other being a Chinese national aged 61. This brings the total number of coronavirus cases in the country to ten, including nine Chinese nationals.

– Belgium has confirmed its first coronavirus case after one of the nine individuals repatriated from Wuhan tested positive for the virus.

– Deaths from the Wuhan coronavirus have surged to 427, as of the end of 03 February. The number of confirmed cases reached 20,623, while 646 infected patients have recovered.

– Hong Kong has reported its first death case, marking the second one outside mainland China, following the Philippines. A 39-year-old man who travelled from Wuhan died on Tuesday in Hong Kong.

– Medical staff strike in Hong Kong continues, while the city closed more cross-boundary control points to China and left two only points open.

03 Feb:

Australia brings back 243 citizens; Hong Kong medical staff on strike

– A Qantas aircraft carrying 243 Australian citizens and permanent residents, including 89 individuals aged under 16, from Wuhan has landed at RAAF base Learmonth in Western Australia.

– Hundreds of hopsital workers in Hong Kong have gone on strike, demanding the closure of the city’s border with China to minimise the risk of coronavirus spreading.

– The 1000-bed Huoshenshan hospital built within ten days for coronavirus patients in Wuhan is now ready.

– Novel coronavirus has claimed 362 lives so far, including one in the Philippines, as of the end of 02 February. A total of 17,386 cases have been recorded globally. Of the 17,238 cases reported in China, 2,296 are severe.

– India reported a new coronavirus case on Monday, taking the total confirmed cases in the country to three – all from the southern state of Kerala.

– US confirmed two new cases late on 2 February, rising the nation’s total to 11.

02 Feb:

Death toll soars to 305; First coronavirus patient outside China dies in Philippines

– Coronavirus deaths have gone past 300 as of the end of 01 February, with China reporting 304 deaths and the Philippines confirming its first death of a 44-year old  Chinese man from Wuhan city.

– The Philippines case also marked the first death outside China, since it first broke out in Wuhan city on 31 December 2019.

– Coronavirus infected cases have soared on Saturday with over 3,000 new cases, taking the total to an alarming 14,413, according to Chinese health authorities.

– Suspected cases are nearing 20,000 mark, standing at 19,544 as of 01 February.

– Chinese government called for culling of chickens in Shaoyang city following an H5N1 bird flu outbreak in Hunan province.

01 Feb:

Death toll hits 259; Coronavirus reaches Russia, Spain, Sweden

– With 46 new deaths in China, the toll has reached 259, while the number of infected cases has touched 11,374 across a total of 26 countries.

– Spreading its roots further, coronavirus reached three more countries as of 01 February. Russia reported two first cases while Spain and Sweden reported one each.

– US denies entry to foreign nationals who have visited China in the last two weeks.

– No deaths are reported outside mainland China.

– Australia on Saturday announced that it would bar entry to non-citizens coming from China.

– In a sigh of relief, Chinese health authorities announced on 01 February that 243 coronavirus had been discharged from hospitals after recovery by the end of Friday.

31 Jan:

Death toll hits 213; WHO declares global emergency; UK confirms first cases

– Death toll from the virus has touched 213 and the number of infected cases increased to 9,776, as of the end of Thursday.

– First coronavirus suspect in New Zealand announced.

– NHS England chief medical officer Professor Chris Whitty confirmed the first two cases of coronavirus in the UK.

– Thailand reported its first case of domestic transmission, while China sent flights to bring back Wuhan citizens from Thailand and Malaysia.

– Mongolia and Singapore closed their borders to China to contain the virus.

– WHO emergency committee has declared the outbreak as a public health emergency of international concern.

30 Jan:

Russia closes 2,700 mile border; US reports first domestic case

– Russia has reported first suspected case, Prime Minister Mikhail Mishustin has signed an order to immediately close 2,700 mile border with China.

– The Centers for Disease Control and Prevention (CDC) in the US has confirmed its first case of person-to-person transmission.

– The number of deaths from the virus have reached 170 as of late 29 January, with a total of 7,783 people infected, of which 7,678 are in mainland China.

– India and the Philippines have confirmed their first cases, while Italy confirmed two cases.

– The number of affected countries so far is 23, including China.

– A plane has taken off from Portugal to evacuate people from various European countries from Wuhan. The UK Secretary of State for Foreign and Commonwealth Affairs Dominic Raab confirmed UK citizens will be evacuated tomorrow morning – Spanish nationals will also be simultaneously repatriated as part of a joint operation between the two countries.

29 Jan:

Death toll touches 132; UAE and Germany confirm four cases

– As of the end of Tuesday, China has confirmed 132 deaths and a total of 5,974 infected cases, including 1,459 new cases. At least 86 cases are reported in other countries.

– Finland has confirmed its first case.

– Four members of the same Chinese family in the UAE have been infected with coronavirus, while Germany confirms three more cases taking its total to four.

– US evacuates nationals from Wuhan, India to send plane tonight to airlift 250 citizens from Wuhan.

– Australia has confirmed a second case in Victoria and a first in Queensland bringing the confirmed Australian cases to seven.

– New Zealand will join Australia to evacuate their nationals from Wuhan in China.

– Australian researchers have become the first to recreate new coronavirus outside of China.

– UK plans to evacuate its citizens from Wuhan. British Airways has suspended all direct flights to and from mainland China.

28 Jan:

Japan, Taiwan and Germany report first domestic transmission

– Japan, Taiwan and Germany confirm their first cases of domestic transmission of coronavirus.

– Japan sends a chartered flight to Wuhan to evacuate its citizens.

– Germany and Cambodia have reported their first cases late Monday, marking a further spread of the deadly virus to newer regions.

–  China has issued the latest coronavirus update, confirming 107 deaths so far, followed by 4,515 confirmed and 6,973 suspected cases.

– In an attempt to limit the spread of virus, Hong Kong plans to limit the transport with mainland China from 30 January.

– Chinese researchers are exploring the use of natural products and their traditional medicines to combat coronavirus.

– China has suspended trading on its two major stock exchanges, Shanghai and Shenzhen, until next Monday to prevent panic selling as coronavirus fears grow.

– Air Canada and Finnair have cancelled some flights to China.

– White House may suspend flights to China.

– Sri Lanka suspends visa on arrival for Chinese nationals.

27 Jan:

Sri Lanka reports first coronavirus case; More countries look to evacuate nationals

– Sri Lanka has reported its first coronavirus case of a 40-year old woman tourist from Hubei province in China, a senior Sri Lankan health official confirmed on Monday.

– Spain and Portugal are the two new countries after the US and France that are looking to evacuate their nationals from Wuhan city.

– US, Taiwan and Singapore have announced their respective fifth cases of the deadly coronavirus, while South Korea reported its fourth.

– Malaysia has imposed a temporary ban on Chinese visitors from the city of Wuhan and its surrounding Hubei province.

– The death toll has increased to 81 and the confirmed cases in China to 2,744, with about half of them from Hubei province.

26 Jan:

US, France to evacuate nationals from Wuhan; WHO changes risk to ‘high; Mexico confirms first case

– The US government has announced a special flight between Wuhan and San Francisco to evacuate all American citizens from the stricken city on 28 Jan.

– The US has also confirmed its third case in Orange county, California, while Shanghai reported its first death of an 88-year old man from the deadly virus.

– Mexico reports its first confirmed case, while Ivory Coast is dealing with a suspected case of coronavirus.

– France is preparing to evacuate hundreds of its citizens from Wuhan by air, as the country already reported three confirmed coronavirus cases.

– Hong Kong and Taiwan have tightened restrictions against visitors from Hubei province.

– The World Health Organization revised its previous report on China virus saying that the global risk from the virus is “high” and not “moderate”.

– China’s National Health Commission said on Sunday morning that the country has reported 15 more fatalities on 25-Jan, taking the toll to 56 and reported cases to 1975 thereby raising alarm across the globe.

25 Jan:

Hong Kong announces health emergency; Canada, Nepal report first cases

-Hong Kong’s Chief Executive Carrie Lam has declared a health emergency in the city over coronavirus and announced the extension of school break until 17 Feb. Hong Kong cancelled all official visits to China, as the city reported five confirmed cases as of Saturday.

– Canada has reported its first “presumptive” coronavirus case of a 50-year old man who returned from Wuhan, China on 22 Jan, while a Nepali student returned from China tested positive for the new coronavirus.

– Death toll rose to 41 while confirmed cases touched 1320 globally, according to WHO. Of these, 1297 cases were reported in Greater China and 23 were reported outside China.

-China  bans wild animal trade until the coronavirus outbreak eases.

-Hong Kong Mass Transit Railway (MTR) increased the preventive measures at the railway stations and train compartments.

-Airports Council International (ACI) World issued guidelines ‘Advisory Bulletin: Transmission of Communicable Diseases’ for airports to adopt necessary measures against the virus.

-Cruise operators including Royal Caribbean and MSC, have suspended cruises to China.

24 Jan:

China implements further travel restrictions; Starts building temporary hospital

-China has imposed travel restrictions on some more cities such as Chibi, Zhijiang, Huangshi, Xiantao, Enshi, Qianjiang and Xianning, according to the People’s Daily newspaper.

-Chinese authorities have initiated construction on a new temporary 1000-bed hospital in Wuhan’s Caidian district with a plan to complete it in a record time of just six days. With high level of safety and protection in place, the new hospital will treat patients of the deadly virus in isolation.

-Toll has increased to 830 confirmed cases in China with 95 patients remaining in critical condition.

Restaurant chains Starbucks and McDonald’s have announced shut down their stores in China’s Hubei province.

Airports in Malaysia, Canada, Thailand and Uganda implemented different measures to screen passengers who may be infected

Thailand has suspended flights from Chiang Mai Airport to Wuhan until 4 February.

Singapore’s Maritime and Port Authority has started temperature screening at all checkpoints on 24 January.

23 Jan:

China implements travel bans; Singapore confirms first case

–China has suspended travel to and from Wuhan city.  Hours later, authorities have put two more cities, Huanggang and Ezhou, under a travel ban.

-Doctors used a robot to treat the first US coronavirus patient.

-WHO met again and postponed decision on international health emergency declaration of the deadly virus.

–Several US companies have announced plans to develop drugs and vaccines to combat the virus.

-Beijing cancelled Chinese New Year celebrations.

22 Jan:

WHO hold on declaring international health emergency

-The virus has infected over 500 people and led to the deaths of 17 people.

-Airports across the world step up screening of passengers coming from Wuhan.

-WHO officials met in Geneva to discuss the need for declaring coronavirus as an international health emergency and decided to wait further.

-Central China’s Henan Province imposed a ban on sale of live poultry to prevent the coronavirus outbreak from spreading. The virus was first identified at Huanan Seafood Market in Wuhan, the capital of neighbouring Hubei province.

21 Jan:

US confirms first coronavirus case

–US has confirmed its first coronavirus case. The victim, said to be in his 30s, has been admitted at a hospital in Washington upon his return from China.

-China has increased the number of coronavirus infected people to 300 people.

-The virus reached Australia, which announced its coronavirus case. The victim, living in Brisbane, was tested positive with coronavirus after returning from Wuhan city.

-Scientists at the National Institutes of Health (NIH) in the US have already started working towards a vaccine against the new, deadly coronavirus.

20 Jan:

First case detected in South Korea

-Airports in several countries across the world have begun screening of patients showing symptoms of coronavirus.

-China has announced the third death from the deadly virus and over 100 new cases, raising concerns ahead of the Chinese (Lunar) New Year holiday, which begins on 25 January.

-A total of more than 200 cases have been reported in various cities of China.

-A Chinese person who arrived by plane from Wuhan to South Korea was detected with the virus.

-Chinese President Xi Jinping has announced that the virus has to be contained.

-Chinese health experts have confirmed that human-to-human transmission is affirmative.

-One British tourist in Thailand is feared to be infected with coronavirus.

17 Jan:

China reports second coronavirus death

-China has reported the second fatality, with the virus claiming the life of a 69-year-old man in Wuhan.

-US has initiated screening of passengers arriving from Wuhan at San Francisco, JFK and Los Angeles airports.

15 Jan:

First confirmed coronavirus case in Japan

Japan has confirmed its first case of the coronavirus in a person who stayed in Wuhan.

13 Jan:

First confirmed coronavirus case in Thailand

Coronavirus has spread beyond China, with Thailand reporting the first case of a Chinese woman, returning from a visit to Wuhan, and diagnosed with flu-like symptoms.

11 Jan:

First coronavirus death reported

A 61-year-old man, who was admitted to hospital on December 27 with suspected fever, dies from the virus in Wuhan. China revises the number of people infected with the virus down to 41.

9 Jan:

Coronavirus genome sequence released

Chinese Center for Disease Control and Prevention (CDC) has reported that 2019-nCoV is the agent and made the genome sequence available to the world. The new virus is associated to the SARS-CoV group.

8 Jan:

First suspected coronavirus cases in Thailand

Four suspected flu-like cases have been detected at Chiang Mai International Airport.

7 Jan:

Virus identified as coronavirus 2019n-CoV

Chinese authorities have identified the virus, called Coronavirus, which is a family of viruses including the common cold, SARS and MERS. Temporarily, this new virus is named as 2019-nCoV.

6 Jan:

SARS, MERS and bird flu ruled out

Initial investigations into the outbreak ruled out bird flu, seasonal flu, SARS and MERS. The Chinese authorities have reported that the number of suspected cases touched nearly 60 with seven being in critical condition. Human-to-human transmission has not been confirmed yet by the health officials.

5 Jan:

WHO advises against travel restrictions

WHO has issued a statement that advised against applying any restrictions of travel or trade with China based on the information available.

3 Jan:

Passengers screened at Wuhan Airport

Passengers arriving from Wuhan airport to Changi airport were put through temperature screening following the flu-like outbreak.

1 Jan:

Wuhan market identified as outbreak hub

The US Centers for Disease Control and Prevention has identified a seafood market in Wuhan as the suspected hub of the outbreak and the market remained closed since then.

31 Dec:

First cases detected

China has alerted the World Health Organization (WHO) of several flu-like cases in Wuhan, the capital of Central China’s Hubei province with 11 million population. Patients have been quarantined and health authorities commenced work on tracing the source of the flu.

This story is developing. Please check in for updates.

Psorilax:Per gli studenti |crema mani e piedi secchi psoriasi

0

Psorilax: prezzo, funziona, recensioni, opinioni, originale

Astratto

L'assunzione giornaliera di AF del 5% di americani di età pari o superiore a 50 anni e in uno studio su donne americane psoriasiche è di circa 1 mg. Un paziente con psoriasi a placche con 10 mg di lisinopril non ha migliorato le sole vitamine B12 e B6. Quando sono stati aggiunti 5 mg di acido folico al giorno, la PASI è migliorata del 50%. Tre casi di psoriasi a placche divamparono quando somministrati 1-2 mg di acido folico (FA), 100 mg di vitamina B6 e 1000 mcg di B12 al giorno. Quando la FA giornaliera è stata aumentata da 4 a 7 mg al giorno, tutti e tre i casi hanno migliorato la loro malattia.

introduzione

L'omocisteina (Hcy) influenza l'attività dei neutrofili aumentando il rilascio di superossido, IL-8 mRNA e oncogene alfa legato alla crescita causando una riduzione dell'apoptosi dei neutrofili spontanea (1). Hcy aumenta anche la produzione intracellulare di H2O2 da parte dei neutrofili e della migrazione dei neutrofili (2,3). L'Hcy riduce la sintasi dell'ossido nitrico endoteliale causando disfunzione endoteliale (4,5). Cinque mg di acido folico settimana 1 seguiti da 1 mg per le successive 3 settimane somministrate a pazienti con Hcy plasmatica superiore a 15 umol / L riducono le chemochine da cellule mononucleate (6). Il plasma Hcy si correla direttamente e i livelli di FA inversamente con l'area della psoriasi e l'indice di gravità (PASI) (7). I livelli di acido folico nel plasma sono inversamente correlati alla PASI (8).

L'omocisteina può essere ridotta di 1 mg di acido folico 500 mcg di vitamina B12 e di un minimo di 10 mg di vitamina B6 al giorno per un periodo di 12 settimane (9). Altri studi tuttavia usano la vitamina B6 a 100 mg al giorno (10).

Uno studio passato non ha mostrato alcun beneficio nel trattamento della psoriasi con 6 settimane di FA 5 milligrammi (mg) due volte al giorno e 1-2000 microgrammi (mcg) B12 (7). Tuttavia, abbiamo pubblicato casi clinici in cui la FA (5-6 mg al giorno) con vitamine B6 (100 mg al giorno) e B12 (1000 mcg al giorno) migliora la psoriasi in due alcolisti e cancella la pustolosi plantare palmare, un disturbo geneticamente correlato ad alcune psoriasi attraverso il gene CARD14 (11,12). Le mutazioni CARD14 sono associate alla psoriasi plantare palmare attraverso l'attivazione di solito di NF-Kappa B. La CARD 14 si trova sui cheratinociti epidermici e sulle cellule cutanee (13,14). Dosi antinfiammatorie di acido folico riducono NF-kappaB (15).

Nel nostro studio in cui 12 settimane di approvazione della farmacopea degli Stati Uniti (USP) o della certificazione NSF International (16,17) di 5 mg giornalieri di FA, B6 e B12 sono state aggiunte a pazienti già in 16 settimane di adalimumab 4 su 7 soggetti hanno continuato a migliorare, ma La psoriasi di 2 pazienti su 7 è peggiorata e 1 non è cambiata. Entrambi i pazienti che sono peggiorati inizialmente hanno livelli sierici endoteliali di ossido nitrico endoteliale molto elevati (18).

Presento un paziente con psoriasi con lisinopril 10 mg al giorno che non ha risposto alle vitamine B12 e B12 ma che è stato migliorato quando è stato aggiunto acido folico. A tre pazienti affetti da psoriasi viene quindi presentato un elevato livello di omocisteina che si è infiammata con FA 1-2 mg al giorno. Questi tre successivamente sono migliorati con acido folico giornaliero 4-7 mg, più vitamina B12 1000 mcg e vitamina B6 100 mg.

Segnalazioni di casi

Caso 1

L'auto-sperimentazione può portare a interpretazioni distorte (19), ma quando il bene e il male provengono da tale esperienza, la distorsione dovrebbe essere bilanciata se non minimizzata.

Un uomo di 55 anni pesava 87 chilogrammi (kg) e aveva una malattia renale cronica di stadio 3. La sua psoriasi apparve inizialmente all'età di 23 anni. Non era stata controllata con unguento al clobetasol e crema al calcipotriene (Figura 1). L'omocisteina plasmatica a digiuno era di 15,8 micromoli per litro (umol / L) (normale 4-14umol / L). Si è ritenuto possibile ridurre l'omocisteina con almeno 0,8 mg di FA più B6 e B12 (21). Quattro settimane di USP FA 1-2 mg al giorno, 100 mg B6 più 100 mcg B12 hanno portato all'elevazione di Hcy a 16,2 e PASI 7,6, aumentando a 16,9 e PASI 11,3 tra le settimane 4 e 9 (Figura 2).

Figura 1. Paziente 1 prima di acido folico, vitamina B6 e vitamina B12.

Figura 2. Paziente 1 dopo settimana 4 acido folico 1-2 mg, B6 e B12.

In seguito fu scoperto che erano necessari cinque mg di FA per abbassare l'iperomocisteinemia nei pazienti con insufficienza renale cronica predialysis (21). La FA orale è stata aumentata da 5 a 7-8 mg con B6 100 mg, B12 1000 mcg al giorno e, per 2 settimane, il resveratrolo a 10-37,5 mg o 4 once di vino rosso di Muscadine al giorno (da allora il resveratrolo orale è stato screditato come un trattamento) (22,23). La riduzione della PASI ha raggiunto il 78% entro la settimana 10 di questo regime (Figura 3). Hcy è sceso a 13,5 umol / L.

Figura 3 Paziente 1 settimana 10 acido folico 5-8 mg FA, vitamina B6 e B12.

È andato via da vitamine, ha sofferto di infarto miocardico della parete inferiore 14 settimane dopo e poi la sindrome dell'arteria coronaria è stata riparata usando un triplo bypass coronarico.

I 3 B sono stati riavviati (FA 5 mg al giorno) per Hcy che a quel punto aveva raggiunto 18 umol / L. Sette mesi e mezzo dopo, durante l'assunzione del farmaco scolpito con 3,125 mg due volte al giorno, le fosse sono state rilevate solo all'estremità delle unghie e sono scomparse un mese dopo (Figure 4 e 5). Si è leggermente infiammato quando sono stati aggiunti 2,5 mg di lisinopril al giorno. Il controllo è stato ripreso quando la dose di acido folico è stata aumentata a 7 mg al giorno e poi mantenuta a 6 mg al giorno (Figure 6 e 7).

Figura 4 Unghie 6 ½ mesi con FA 5mg. B6 e B12.

Figura 5 Chiodi 7 mesi e mezzo su FA 5 mg, B6 e B12.

Figura 6 Dopo 1isinopril 2,5 mg su 5 mg FA, B6 e B12.

Figura 7 Dopo Lisinopril 2,5 mg su 7 mg FA, B6 e B12.

Caso 2

81 kg di 90 anni. maschio bianco con psoriasi ha una storia di melanoma maligno in situ, altri tumori della pelle e uno stent cardiaco. La sua omocisteina era leggermente elevata (12,1 umol / L). Era in trattamento con Lisinopril 10 mg al giorno. Non ha avuto risposta ai soli farmaci topici. Durante il periodo successivo di 8 settimane e ancora su 10 mg. ogni giorno Lisinopril aggiungendo 5 mg di acido folico a vitamina B12 e vitamina B6l ha portato alla settimana 3 BSA il 7,7% a scendere alla settimana 11 BSA al 4,5% con un miglioramento dello spessore e della scala della lesione (PASI 50) (Figure 8 e 9). Questa risposta non è stata notata dal paziente se non che il prurito è stato ridotto.

Figura 8. Paziente 2. Prima delle vitamine.

Figura 9 Paziente 2 su vitamine.

Caso 3

Un uomo di 40 kg di 60 anni con psoriasi era in fototerapia di mantenimento con oltre 18 trattamenti di fototerapia a banda stretta ultravioletta B (nb-UVB) e calcipotriene 0,005% -betametasone dipropionato unguento allo 0,064%. Hcy era 15,1 umol / L (normale da 4 a 14 umol / L). Il suo coinvolgimento nella superficie corporea (BSA) era dell'1,5 percento (%). Sempre su nb-UVB, gli fu detto di assumere le 3 vitamine del gruppo B, ma prese 1 mg di FA al giorno più B6 (100 mg) e B12 (1000 mcg). La sua psoriasi è divampata 10 settimane dopo (5% BSA).

Nelle successive 6 settimane con 4 mg di FA il suo BSA è migliorato del 22%.

Caso 4

Quest'uomo aveva 56 anni, pesava 104 kg ed era alto 67 pollici. Aveva una psoriasi a placche diffusa nonostante una sperimentazione di NB-UVB e poi alefacept. Alla settimana 13 di Alefacept con Hcy 17 umol / L (normale 4-14 umol / L) è stato iniziato con FA 1 mg al giorno, B6 (100 mg) e B12 (1000 mcg). Era anche su calcipotriene allo 0,005% – betametasone dipropionato allo 0,064% unguento e tacrolimus allo 0,1% unguento. Dopo 16 settimane di alefacept, la sua BSA era ancora del 15-20%. Sette settimane di pausa, ma ancora con le 3 vitamine del gruppo B, la sua BSA era del 28%.

Etanercept 50 mg due volte a settimana è stato iniziato con l'aggiunta giornaliera di FA 1 mg, B6 e B12. Quattro mesi dopo la sua psoriasi BSA era del 4,8%. Aveva bisogno di aspirina 325 mg tre volte al giorno per dolori articolari. Dieci mesi dopo aver iniziato etanercept e aspirina e ancora assumendo 50 mg una volta alla settimana e per l'anno successivo ha avuto l'1% di BSA coinvolto. Il suo peso era aumentato a 250 libbre. Sei mesi dopo il suo dolore alle articolazioni è peggiorato e la sua psoriasi è aumentata al 3% di BSA. Poco dopo ebbe una infezione respiratoria con etanercept trattenuto per 1 mese, ricominciato un mese dopo e poi trattenuto per 3 mesi. Quando etanercept è stato nuovamente avviato, è stata avviata anche l'unguento topico clobetasol. Le sue gambe e glutei avevano placche più grandi con tronco sparso e placche anche sul braccio. Il suo peso era di 247 sterline. Visto due mesi dopo, l'ibuprofene da 800 mg al giorno a due volte al giorno era stato aggiunto insieme alla colchicina da 0,6 mg per il dolore articolare ripensato come secondario alla gotta. La FA era stata aumentata a 2000 mcg al giorno. La BSA era aumentata al 9% di BSA. Tre settimane dopo, mentre l'ibuprofene e la colchicina continuavano, la sua FA veniva aumentata a 5 mg al giorno. Venti settimane dopo la sua psoriasi era quasi scomparsa (BSA 0,1%) (Figura 10).

Figura 10 Paziente 4 BSA su alefacept e poi su etanercept.

Commento

Le cellule T regolatorie (TReg) che esprimono il fattore di trascrizione forkhead box P3 (Foxp3 + cellule) sono naturalmente presenti nel sistema immunitario. Sono indispensabili per il mantenimento dell'autotolleranza dominante e dell'omeostasi immunitaria (24). Le celle T della memoria centrale CD4 + possono differenziarsi in cellule T Foxp3 + (25). I recettori dei folati si trovano sulle cellule T della memoria nella psoriasi (26). Pertanto, l'acido folico può promuovere l'attività del proprio metodo di controllo dell'infiammazione eccessiva.

In uno studio la FA è stata incubata su cellule endoteliali in 0,5 e in 5 umoli. Il rapporto dimero ossido nitrico sintasi endoteliale rispetto al rapporto monomero è aumentato da 1,5 a 1 nei controlli, da circa 1,7 a uno con 0,5 umol FA e da circa 2,25 a uno con 5 umol (27). In questo stesso articolo è stato riportato un rapporto su ottantaquattro pazienti con malattia coronarica che hanno ricevuto 400 mcg o 5 mg di acido folico al giorno per un periodo di trattamento di 6 settimane. Sia 400 mcg / die che 5 mg / die di FA aumentano significativamente il folato plasmatico e diminuiscono l'Hcy plasmatica 5 mg / die – ma non 400 mcg / die di acido folico migliora la funzione delle cellule dei vasi sanguigni nei pazienti con malattia coronarica misurata mediante dilatazione mediata dal flusso (27 . Pertanto, i rapporti eNOS da dimeri (coniugati) a monomerici più elevati hanno proprietà antinfiammatorie non osservate con acido folico inferiore.

In un precedente studio condotto da altri (10), nel Regno Unito è stata eseguita la mancata somministrazione di FA ad alta dose (10 mg al giorno) più 1-2000 mcg settimanali di influenza sulla psoriasi (10). Lì, il dosaggio di FA è stato trovato spesso inaccurato, per lo più troppo basso (28). Tuttavia, abbiamo anche usato la vitamina B6. L'ossido nitrico sintasi inducibile (iNOS) è un locus di suscettibilità alla psoriasi (29).

La pelle con psoriasi cancellata da Etanercept ha l'87% in meno di iNOS (30) La vitamina B6 supplementare abbassa anche iNOS (31). L'espressione dell'RNA Messenger di iNOS è aumentata nella psoriasi (32). I modelli di psoriasi mostrano una maggiore produzione vascolare di perossinitrite accompagnata da una maggiore espressione dell'iNOS e della nicotinamide dinucleotide fosfato (NADPH) ossidasi (33). Il perossinitrito ossida il cofattore NOS essenziale (6R-5,6,7,8-tetraidrobiopterina (BH4). Di conseguenza, la riduzione dell'ossigeno si disaccoppia dalla sintesi NO, trasformando il NOS in un enzima superossido ossido proinfiammatorio (34). L'integrazione BH4 converte il NOS endoteliale (eNOS) torna alla produzione di NO antinfiammatorio (34).

Relativamente ai casi di cui sopra, la dose elevata di FA può migliorare il riciclo di BH4 a causa del ripristino dell'espressione del didrofolato reduttasi (35). La dose elevata di FA aiuta anche a disattivare i radicali derivati ​​dal perossinitrito (36,37).

Uno o due mg di acido folico al giorno sembrano essere pro-infiammatori per la psoriasi. Con una possibile perdita media dei livelli di folati fino al 27% mentre il paziente 3 era in terapia con nb-UVB in 18 trattamenti (38), la psoriasi di questo paziente si infiammava con 1 mg di acido folico al giorno ma si schiariva leggermente quando veniva somministrata 4 mg al giorno.

Le indennità giornaliere raccomandate per il folato negli adulti sono 400 mg di DFE equivalenti di folati nella dieta per uomini e donne adulti a meno che la donna non stia allattando (quando è DFE 500 mg) o incinta (DFE 600 mg). Gli americani di età pari o superiore a 50 anni hanno inutilmente il più alto apporto totale di folati. Il cinque percento di questa popolazione ha un consumo superiore all'UL di 1.000 mcg al giorno. Ciò è dovuto principalmente all'acido folico contenuto negli integratori alimentari (40). Mille mcg al giorno sono considerati eccessivi perché alcuni ma non tutta la letteratura suggerisce che l'acido folico ad alte dosi aumenta il rischio di cancro al colon e alla prostata (39). Tuttavia, uno studio recente suggerisce che 600 mg al giorno di acido folico riducono i biomarcatori del DNA del cancro adiacenti ai siti del polipo del colon (40). Dopo un aggiustamento multivariato, uno studio recentemente pubblicato su infermiere statunitensi ha mostrato un aumento non statisticamente significativo del rischio di psoriasi per il sottogruppo con un basso consumo di folato equivalente (DFE) tra coloro che bevono oltre 5 birre non leggere a settimana rispetto al gruppo DFE alto in questo studio. L'assunzione mediana è stata di 976 ug in questo studio dal 1991-2002 e di 1000 ug nel periodo 2003-2006 (41). Entrambi i gruppi includono tuttavia DFE alla dose giornaliera compresa tra 1000 e 2000 ug in cui il folato nei nostri casi sembra svasare la psoriasi.

Il fattore di crescita endoteliale vascolare (VEGF) è elevato nei modelli di psoriasi (42). Si pensa che i pazienti con psoriasi grave e quelli con insorgenza di psoriasi di età compresa tra 20 e 40 anni abbiano livelli plasmatici elevati di VEGF, alleli VEGF e recettori VEGF (42). Nel nostro studio in cui 5 mg di FA, 100 mg di B6 e 1000 mcg di B12 al giorno sono stati aggiunti ad adalimumab per 16 settimane (18), l'Adalimumab da solo ha indotto tutti i pazienti dello studio a ridurre il loro VEGF. L'aggiunta delle vitamine del gruppo B ha causato un lieve aumento del VEGF. Due dei tre pazienti con VEGF basale elevato (147 e 259 pg / ml) e con BMI di 23 e 24,9 (e quindi meno leptina per stabilizzare le attività antinfiammatorie di eNOS accoppiato) hanno infiammato la loro psoriasi quando 5 mg di FA, B6 e Sono stati aggiunti B12. Uno di questi pazienti ha anche sviluppato anticorpi anti-H. pylori che potrebbero aver impedito la piena ingestione delle vitamine del gruppo B, inducendo il dosaggio a promuovere eNOS disaccoppiato (43). Un paziente in questo stesso studio ha avuto il suo aumento di Hcy durante l'assunzione di vitamine del gruppo B e nonostante il suo alto VEGF iniziale, la sua psoriasi ha continuato a migliorare con adalimumab (12). Hcy in vitro riduce l'espressione di VEGF-A e VEGFR (44). Ridurre l'Hcy con 1-2 mg di FA al giorno può anche aver promosso la psoriasi consentendo all'effetto VEGF di aumentare nei pazienti 1 e 3.

Il paziente 3 è migliorato del 22% con 4 mg di FA, B6 e B12. La dose di 4 mg abbassata ulteriormente dall'NB-UVB sembra una dose troppo bassa per un notevole miglioramento nonostante l'NB-UVB riduca anche il suo VEGF (45). Da quando aveva 40 anni quando si infiammò e il suo indice di massa corporea era basso, il rischio di avere un VEGF elevato era alto (43), probabilmente rendendolo un candidato più povero per gli effetti di una dose elevata di AF.

L'attività dei neutrofili è stata aumentata dall'aumento dell'Hcy nel paziente 1 quando è stata somministrata una FA bassa. Quando è stato aggiunto lisinopril, l'effetto VEGF potrebbe aver riaffermato i suoi effetti.

La PASI del paziente 2 ha superato solo il 50%. Stava assumendo 10 mg di lisinopril al giorno; Il paziente 1 è divampato quando sono stati aggiunti 2,5 mg di lisinopril al giorno essendo già su dose ridotta di Carvedilolo, ma è migliorato di nuovo quando l'acido folico è stato aumentato da 5 a 7 mg al giorno. Il paziente 4 è divampato quando è stato aggiunto ibuprofene nonostante fosse su etanercept. Il paziente 4 è stato quasi eliminato con etanercept quando 1 mg di FA è stato aumentato a 5 mg di FA senza interrompere l'ibuprofene. L'ibuprofene e i beta-bloccanti di terza generazione come carvedilolo preservano o promuovono la NOS o il VEGF o entrambi (46-48). Teoricamente, a seconda del tipo di NOS preservato, questi farmaci potrebbero migliorare o peggiorare la psoriasi. L'omocisteina è ridotta dagli ACE-inibitori e dai beta-bloccanti che da soli dovrebbero migliorare la psoriasi (49). Uno studio caso-controllo non ha associato l'uso del beta-bloccante con il flare della psoriasi (501). Tuttavia, uno studio caso-controllo ha tuttavia associato i chiarori della psoriasi all'ACE-inibitore e all'ingestione di farmaci antinfiammatori non steroidei (51). Come gli ACE-inibitori non sono noti per la psoriasi bagliore sconosciuto Wilkin et al., seguito da Coulter ha suggerito che gli ACE-inibitori non solo inibiscono la produzione di angiotensina II, ma inibiscono anche il catabolismo della chinina. Pertanto, gli ACE-inibitori potenziano l'attività delle chinine e quindi possono causare esacerbazione dei disturbi della pelle associati alla chinina (52). Forse rilevante per il caso 4 è che almeno nei topi, dosi di ibuprofene di 1,0 mg / kg o più aumentano i livelli di VEGF (53).

Rilevanti casi futuri sarebbero i tentativi di trattare i pazienti con deficit e mutazioni della metiltetraidrofolato reduttasi. La conversione dell'omocisteina in un altro amminoacido metionina richiede metilenetetraidrofolato reduttasi. Questo enzima converte una molecola chiamata 5,10-methylenetetrahydrofolate in una molecola chiamata 5-methyltetrahydrofolate (54).

I pazienti con grave carenza di MTHFR hanno elevato omocisteina e bassa metionina nel sangue e preimpostati in modo variabile nell'infanzia o in età avanzata con anomalie neurologiche e vascolari. Una carenza MTHFR più lieve, associata a un enzima termolabile, può aumentare la suscettibilità alle malattie cardiovascolari e ai difetti del tubo neurale (55).

La metiltetraidrofolato reduttasi ha due mutazioni comuni. Ad esempio, l'incidenza delle mutazioni MTHFR 677T è compresa tra il 10 e il 36% della popolazione (56). I pazienti con mutazione 677C o 677T mostrano comunemente elevata Hcy totale e basso folato plasmatico. Un'alta dose orale di acido folico può tra il 23% e il 40% dei pazienti, a seconda del genotipo specifico, ridurre la tHcy (57). Ulteriori cause di ridotto metabolismo dell'omocisteina sono le mutazioni MTHFR A1298C (58). L'omocisteina è elevata negli alcolisti. Una moderata assunzione di alcol e una bassa attività di MTHFR e il genotipo MTHFR677 (ma non il genotipo MTHFR1298) hanno effetti avversi su tHcy, ma tali effetti possono essere superati dall'assunzione di folati sufficiente (59,60). L'acido folico ad alte dosi sembra essere un trattamento per almeno alcuni pazienti che necessitano di acido folico che hanno mutazioni MTHFR (61,62).

conclusioni

La dose giornaliera di 1-2 mg può infiammare la psoriasi. Questa daina è comune nella popolazione degli Stati Uniti oltre i 50 anni e nella popolazione della psoriasi.

Quattro o più mg giornalieri di FA sembrano migliorare in modo variabile la psoriasi in questi stessi pazienti. La riduzione o l'interruzione di FA 4-8 mg al giorno può mettere a rischio un paziente per eventi di comorbidità a causa del passaggio attraverso i livelli di FA che promuovono effetti collaterali pro-infiammatori. La sicurezza di interrompere e la sicurezza di continuare questa terapia richiede studio.

Ringraziamenti

L'autore è investigatore in uno studio citato nel manoscritto finanziato da Abbott e ABBVIE (Aronson PJ, Swearingen J, Malick F, Mehregan DA e Mehregan DM. L'acido folico ad alte dosi, più le vitamine B6 e B12 aggiunte ad Adalimumab possono peggiorare la psoriasi in pazienti con basso indice di massa corporea e in altri può causare effetti di elettrocardiogramma imprevisti J Dermatolog Clin Res.2015 3 gennaio 2015 (10): 1039 http://www.jscimedcentral.com/Dermatology/) e parte di un caso faceva parte del Osservare lo studio -5 di Amgen su etanercept di cui abbiamo ricevuto l'autorizzazione a riferire separatamente.

Riferimenti

  1. Glynn PC, Henney E, Hall IP (2002) L'antagonista selettivo CXCR @ SB272844 blocca l'interleuchina-8 e l'inibizione mediata da oncogene-alfa correlata alla crescita dell'apoptosi neutrofila spontanea. Pulm Pharmacol Ther 15: 103-110. (Crossref)
  2. Ubagai T, Tansho S, Ito T, Ono Y (2008) Influenze dell'aflatossina B (1) sulla generazione di specie reattive dell'ossigeno e chemiotassi dei leucociti polimorfonucleati umani. Toxicol In Vitro 22: 1115-11120. (Crossref)
  3. Fuhler GM, Knol GJ, Drayer AL, Vellenga E (2005) La fosforilazione di interleuchina-8 e GROalpha indotta compromessa della chinasi regolata dal segnale extracellulare determina una riduzione della migrazione dei neutrofili dai pazienti con mielodisplasia. J Leukoc Biol 77: 7. (Crossref)
  4. Bechara C, Wang X, Chai H, Lin PH, Yao Q, et al. (2007) L'oncogene-alfa correlato alla crescita induce disfunzione endoteliale attraverso stress ossidativo e downregulation di eNOS nelle arterie coronarie suine. Am J Physiol Heart Circ Physiol 293: H3088-H3095. (Crossref)
  5. Alvarez-Maqueda M, El Bekay R, Monteseirín J, Alba G, Chacón P, et al. (2004) L'aterosclerosi L'omocisteina migliora il rilascio di anione superossido e l'assemblaggio di NADPH ossidasi da parte dei neutrofili umani. Effetti sull'attivazione del MAPK e sulla migrazione dei neutrofili. Aterosclerosi 172: 229-386. (Crossref)
  6. Holven KB, Aukrust P, Holm T, Ose L, Nenseter MS (2002) Il trattamento con acido folico riduce il rilascio di chemochine da cellule mononucleate del sangue periferico in soggetti iperomocisteinemici. Arterioscler Thromb Vasc Biol 22: 699-703. (Crossref)
  7. Malherba M, Gisondi P, Radaeli A, Sala R, Calzavara Pinton PG, et al. (2006) Omocisteina plasmatica e livelli di folati nei pazienti con psoriasi a placche cronica. Br J Dermatol 155: 1165-1169. (Crossref)
  8. Cakmak SK1, Gül U, Kiliç C, Gönül M, Soylu S, et al. (2009) Omocisteina, vitamina B12 e livelli di acido folico nei pazienti con psoriasi. J Eur Acad Dermatol Venereol 23: 300-303. (Crossref)
  9. Ubbink JB, van der Merwe A, Vermaak WJ, Delport R (1993) Iperomocisteinemia e la risposta alla supplementazione vitaminica. Clin Investig 71: 993-998. (Crossref)
  10. Dawson TA, Scott KW, Merrett JD (1978) Prova della terapia con acido folico nella psoriasi. Ulster Med J 47: 100-101. (Crossref)
  11. Aronson PJ, Malick F (2010) Verso un trattamento razionale della psoriasi grave negli alcolisti: rapporto di due casi. J Drugs Dermatol 9: 405-408. (Crossref)
  12. Aronson PJ, Zhang J (2016) Pustolosi plantare palmare che risponde all'acido folico ad alte dosi più vitamine B6 e B12. Rep. Caso JAAD 2: 19-21. (Crossref)
  13. Feng D1, Zhou Y, Xia M, Ma J (2011) L'acido folico inibisce la risposta infiammatoria indotta dai lipopolisaccaridi nei macrofagi RAW264.7 sopprimendo l'attivazione di MAPK e NF-B. Inflamm Res 60: 817-822. (Crossref)
  14. Mössner R, Frambach Y, Wilsmann-Theis D, Löhr S, Jacobi A, et al. (2015) La psoriasi pustolosa palmoplantare è associata a varianti missenso in CARD14, ma non con mutazioni di perdita di funzione in IL36RN in pazienti europei. J Invest Dermatol 135: 2538-2541. (Crossref)
  15. Jordan CT, Cao L, Roberson ED, Duan S, Helms CA, et al. (2012) Varianti rare e comuni in CARD14, che codificano un regolatore epidermico di NF-kappa B, nella psoriasi. Am J Hum Genetics 90: 796-808. (Crossref)
  16. http://www.nist.gov/standardsgov/upload/USP.pdf (consultato il 3/12/2016)
  17. http://www.nsf.org/about-nsf/nsf-mark (consultato il 24 aprile 2016)
  18. Aronson PJ, Swearingen J, Malick F, Mehregan DA, Mehregan DM (2015) L'acido folico ad alte dosi, oltre alle vitamine B6 e B12 aggiunte ad Adalimumab possono peggiorare la psoriasi in pazienti con basso indice di massa corporea e in altri possono causare effetti di ECG imprevisti. J Dermatolog Clin Res 3: 1039.
  19. www.news.harvard.edu/gazette/2004/04.29/11-selfexperiment.html (consultato il 3/12/2016).
  20. Clarke R, Lewington S, Sherliker P, Armitage J (2007) Effetti delle vitamine del gruppo B sulle concentrazioni plasmatiche di omocisteina e sul rischio di malattie cardiovascolari e demenza. Curr Opinioni Clin Nutr Metab Care 10: 32-39.
  21. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, et al. (2000) L'acido folico riduce l'omocisteina plasmatica e migliora la funzione endoteliale nei pazienti con insufficienza renale predialysis? Circolazione 102: 871-875. (Crossref)
  22. Schroecksnadel K, Winkler C, Wirleitner B, Schennach H, Weiss G, et al. (2005) Il resveratrolo composto antinfiammatorio sopprime la formazione di omocisteina in cellule mononucleate di sangue periferico umano stimolato in vitro. Clin Chem Lab Med 43: 1084-1088. (Crossref)
  23. Farris P, Krutmann J, Li YH, McDaniel D, Krol Y (2013) Resveratrolo: un antiossidante unico che offre un approccio multi-meccanicistico per il trattamento dell'invecchiamento della pelle. J Drugs Dermatol 12: 1389-1394. (Crossref)
  24. Sakaguchi S, Miyara M, Costantino CM, David A. Hafler DA (2010) FOXP3 + cellule T regolatorie nel sistema immunitario umano. Nat Rev Immunol 10: 490-500. (Crossref)
  25. Zhang X, Li XC, Xiao X, Sun R, Tian Z, et al. (2013) Le celle T della memoria centrale CD4 + CD62L + possono essere convertite in celle T Foxp3 +. PLoS One 8: e77322. (Crossref)
  26. Walker LS1 (2007) Cellule T regolatorie: recettore dei folati 4: una nuova impugnatura su regolazione e memoria? Immunol Cell Biol 85: 506-507. (Crossref)
  27. Fossato SJ1, Madhavan A, Taylor SY, Payne N, Allen RH, et al. (2006) L'acido folico ad alta ma non bassa dose migliora la funzione endoteliale nella malattia coronarica. Eur J Clin Invest 36: 850-859. (Crossref)
  28. Sculthorpe NF, Davies B, Ashton T, Allison S, McGuire DN, et al. (2001) Integratori di acido folico disponibili in commercio e loro conformità con il test di farmacopea britannica per lo scioglimento. J Public Health Med 23: 195-197. (Crossref)
  29. Suarez-Farinas M, Fuentes-Duculan J, Lowes MA, Krueger JG (2011) Le lesioni della psoriasi risolte mantengono l'espressione di un sottoinsieme di geni correlati alla malattia. J Invest Dermatol 131: 391-400. (Crossref)
  30. Stuart PE, Nair RP, Ellinghaus E, Ding J, Tejasvi T, et al. (2010) L'analisi dell'associazione a livello del genoma identifica tre loci di suscettibilità alla psoriasi. Nat Genet 42: 1000-1004. (Crossref)
  31. Komatsu S1, Yanaka N, Matsubara K, Kato N (2003) Effetto antitumorale della vitamina B6 e dei suoi meccanismi. Biochim Biophys Acta 1647: 127-130. (Crossref)
  32. Sirsjö A, Karlsson M, Gidlöf A, Rollman O, Törmä H (1996) Aumento dell'espressione dell'inducibile ossido nitrico sintasi nella pelle psoriasica e nei cheratinociti coltivati ​​stimolati dalle citochine. Br J Dermatol 134: 643-648. (Crossref)
  33. Karbach S, Croxford AL, Oelze M, et al. (2014) L'interleuchina 17 guida l'infiammazione vascolare, la disfunzione endoteliale e l'ipertensione arteriosa nella malattia della pelle simile alla psoriasi. Arterioscler Thromb Vasc Biol 34: 2658-2668. (Crossref)
  34. Schmidt TS, Alp NJ (2007) Meccanismi per il ruolo della tetraidrobiopterina nella funzione endoteliale e nelle malattie vascolari. Clin Sci (Lond) 113: 47-63. (Crossref)
  35. Förstermann U (2006) Ruolo affrontato da Janus della sintasi endoteliale NO nelle malattie vascolari: disaccoppiamento della riduzione dell'ossigeno dalla sintesi di NO e sua inversione farmacologica. Biol Chem 387: 1521-1533. (Crossref)
  36. Chalupsky K, Kracun D, ​​Kanchev I, Bertram K, Görlach A (2015) L'acido folico promuove il riciclaggio della tetraidrobiopterina e protegge dall'ipertensione polmonare indotta dall'ipossia attraverso il ricostituzione della sintesi dell'ossido nitrico endoteliale. Segnale redox antiossidante 23: 1076-1091. (Crossref)
  37. McCarty MF, Barroso-Aranda J, Contreras F (2009) I folati ad alto dosaggio e le purine dietetiche promuovono l'eliminazione del potenziale clinico dei radicali derivati ​​dal perossinitrite nei disturbi infiammatori. Ipotesi Med 73: 824-834. (Crossref)
  38. El-Saie LT1, Rabie AR, Kamel MI, Seddeik AK, Elsaie ML (2011) Effetto della fototerapia a banda stretta ultravioletta B sui livelli sierici di acido folico in pazienti con psoriasi. Lasers Med Sci 26: 481-485. (Crossref)
  39. https://ods.od.nih.gov/factsheets/Folate-HealthProfessional/ (consultato il 24 maggio 2017)
  40. O'Reilly SL, McGlynn AP, McNulty H, Reynolds J, Wasson GR, et al. (2016) Supplemento di acido folico in pazienti postpolipectomici in una sperimentazione controllata randomizzata aumenta le concentrazioni di folati tissutali e riduce i biomarcatori di DNA aberrante nei tessuti del colon adiacente al precedente sito di polipo. J Nutr 146: 933-939. (Crossref)
  41. Qureshi AA1, Dominguez PL, Choi HK, Han J, Curhan G (2010) Assunzione di alcol e rischio di psoriasi incidente nelle donne statunitensi: uno studio prospettico. Arch Dermatol 146: 1364-1369. (Crossref)
  42. Canavese M, Altruda F, Ruzicka T, Schauber J (2010) Fattore di crescita endoteliale vascolare (VEGF) nella patogenesi della psoriasi – un possibile bersaglio per nuove terapie? J Dermatol Sci 58: 171-176. (Crossref)
  43. Young HS, Summers AM, Bhushan M, Brenchley PE, Griffiths CE (2004) Polimorfismi a singolo nucleotide del fattore di crescita endoteliale vascolare nella psoriasi a esordio precoce. J Invest Dermatol 122: 209-215. (Crossref)
  44. Chen HQ, Li X, Tang R (2015) Effetti dell'ultravioletto B a banda stretta sui livelli sierici di fattore di crescita endoteliale vascolare e interleuchina-8 in pazienti con psoriasi. Am J Ther 23: e655-e662. (Crossref)
  45. Zhang Q, Li Q, Chen Y, Huang X, Yang IH, et al. (2012) L'angiogenesi compromessa dall'omocisteina è associata all'inibizione di VEGF / VEGFR. Front Biosci (Elite Ed) 4: 2525-2535. (Crossref)
  46. de Boer RA, Siebelink HJ, Tio RA, Boomsma F, van Veldhuisen DJ (2001) Carvedilol aumenta il fattore di crescita endoteliale vascolare plasmatica (VEGF) in pazienti con insufficienza cardiaca cronica. Eur J Heart Fail 3: 331-333. (Crossref)
  47. Vanhoutte PM1, Gao Y (2013) Beta bloccanti, ossido nitrico e malattie cardiovascolari. Curr Opin Pharmacol 13: 265-273. (Crossref)
  48. Li W, Xu RJ, Lin ZY, Zhuo GC, Zhang HH (2009) Effetti di un inibitore selettivo della cicloossigenasi-1 in un modello murino di carcinoma ovarico, somministrato da solo o in combinazione con ibuprofene, un inibitore non selettivo della cicloossigenasi. Med Oncol 26: 170-177. (Crossref)
  49. Poduri A, Kaur J, Thakur JS, Kumari S, Jain S, et al. (2008) Effetto di ACE-inibitori e beta-bloccanti sui livelli di omocisteina nell'ipertensione essenziale. J Hum Hypertens 22: 289–294. (Crossref)
  50. Brauchli YB, Jick SS, Curtin F, Meier CR (2008) Associazione tra beta-bloccanti, altri farmaci antiipertensivi e psoriasi: studio caso-controllo basato sulla popolazione. The Br J Dermatol 158: 1299-1300. (Crossref)
  51. Cohen AD, Bonneh DY, Reuveni H, Vardy DA, Naggan L, et al. (2005) Esposizione ai farmaci e psoriasi vulgaris: studi caso-controllo e caso-crossover. Acta Derm Venereol 85: 299-303. (Crossref)
  52. www.lareb.nl/Signalen/Signals_2015_ACE_inhibitors_psoriasis.aspx (consultato a maggio 28,2017).
  53. Beharry KD1, Modanlou HD, Hasan J, Gharraee Z, Abad-Santos P, et al. (2006) Effetti comparativi dell'ibuprofene postnatale precoce e dell'indometacina su VEGF, IGF-I e GH durante lo sviluppo oculare del ratto. Invest Ophthalmol Vis Sci 47: 3036-3043. (Crossref)
  54. https://ghr.nlm.nih.gov/gene/MTHFR (accesso 21 maggio 2017).
  55. Goyette P1, Christensen B, Rosenblatt DS, Rozen R (1996) Mutazioni gravi e lievi in ​​cis per il gene metilenetetraidrofolato reduttasi (MTHFR) e descrizione di cinque nuove mutazioni in MTHFR. Am J Hum Genet 59: 1268-1275. (Crossref)
  56. Isotalo PA, Wells GA, Donnelly JG (2000) Polimorfismi genetici metilenetetraidrofolato reduttasi neonatale e fetale: un esame delle mutazioni C677T e A1298C. Am J Hum Genet 67: 986-990. (Crossref)
  57. Il polimorfismo del metilenetetraidrofolato reduttasi di Liu CS, Chiang HC, Chen HW (2004) determina l'effetto di riduzione dell'omocisteina nel plasma dell'integrazione di acido folico ad alte dosi in pazienti con malattie cardiovascolari. Nutrizione 20: 974-978. (Crossref)
  58. Pawlak AL, Strauss E (2001) Polimorfismo del gene metilenetetraidrofolato reduttasi (MTHFR) e incidenza di malattie correlate all'iperomocisteinemia. Postepy Hig Med Dosw 55: 233-256. (Crossref)
  59. Chiuve SE, Giovannucci EL, Hankinson SE, Hunter DJ, Stampfer MJ, et al. (2005) L'assunzione di alcol e il polimorfismo della metilenetetraidrofolato reduttasi modificano la relazione tra assunzione di folati e omocisteina plasmatica. Am J Clin Nutr 82: 155-162. (Crossref)
  60. http://pubs.niaaa.nih.gov/publications/arcr351/25-35.htm (consultato il 25 luglio 2016)
  61. Lynn B. Bailey LR, Gregory JFIII (1999) Polimorfismi del metilenetetraidrofolato reduttasi e altri enzimi: significato metabolico, rischi e impatto sul requisito dei folati. J Nutr 129: 919-922. (Crossref)
  62. Weisberg I, Pamela Tran P, Christensen B, Sibani S, Rima Rozen (1998) Secondo polimorfismo genetico nel metilenetetraidrofolato reduttasi (MTHFR) associato ad una ridotta attività enzimatica. Metabolismo. Mol Genet Metab 64: 169-172. (Crossref)

Psorilax:Trova |crema calendula psoriasi

0

Psorilax: prezzo, funziona, recensioni, opinioni, composizione

Un ragazzo di 14 anni è morto dopo essersi ammalato di coronavirus in Portogallo.

La morte dell'adolescente segue quella di una studentessa francese di 16 anni che è stata descritta venerdì come la più giovane vittima per il coronavirus in Europa dopo essere morta in un ospedale di Parigi.

Il giovane portoghese di Ovar, a mezz'ora di macchina a sud di Porto, ha perso la sua battaglia per la vita nelle prime ore di questa mattina dopo essere stato ricoverato all'ospedale Sao Sebastiao nella vicina Santa Maria da Feira.

Si dice che i medici abbiano deciso di non trasferirlo in un ospedale con un'unità pediatrica di pronto soccorso a Porto, la seconda città più grande del Portogallo, a causa della gravità delle sue condizioni.



L'adolescente è morta all'ospedale Sao Sebastiao di Santa Maria da Feira

Rapporti locali hanno detto che soffriva di psoriasi, una malattia della pelle che può influenzare il sistema immunitario.

È stato confermato come la persona più giovane del Portogallo affetta da coronavirus a morire finora.

La ragazza descritta all'inizio di questa settimana come la più giovane vittima del coronavirus d'Europa, di nome Julie Alliot, è stata portata d'urgenza dal suo medico locale a Longjumeau, a sud di Parigi, martedì prima di essere trasferita all'ospedale Necker nella capitale francese.

È morta il giorno seguente.

Sua sorella Manon le ha reso omaggio dopo che la notizia della sua morte è diventata pubblica, dicendo che era “brillante e molto amata” e “amava ballare, cantare e far ridere la gente”.



Il ragazzo di 14 anni si è ammalato in Portogallo

Il numero di morti per coronavirus in Portogallo è stato di 119 oggi all'ora di pranzo.

Quasi 6.000 sono stati infettati dal virus e altri 5.500 erano in attesa dei risultati dei test secondo i dati del Ministero della Salute.

Oggi è emerso che un uomo britannico è morto in Algarve dopo essersi ammalato di coronavirus.

L'OAP, che era sulla settantina, ha perso la sua lotta per la vita di due settimane ieri / sabato al Faro Hospital.

Viveva a Benagil, una zona balneare vicino a Lagoa, nota per la sua spettacolare grotta.

Il sindaco di Lagoa Luis Encarnacao ha confermato la morte, la seconda della città dall'inizio della crisi del coronavirus.

Il primo era un insegnante di 60 anni che viveva a Carvoeiro ed è stato chiamato Manuel Magalhaes.

Il signor Encarnacao ha detto di aver parlato alle famiglie di entrambi gli uomini per porgere loro le sue condoglianze.

L'espatriato britannico non è stato nominato.